Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof

ABSTRACT

The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK).

FIELD OF THE INVENTION

The present invention relates to a Rho-associated protein kinase inhibitor, a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

BACKGROUND OF THE INVENTION

Rho-associated protein kinase (ROCK) is a serine/threonine kinase from the AGC kinase family, and comprises two isoforms, ROCK1 and ROCK2. ROCK1 and ROCK2 are expressed and regulated differently in specific tissues. For example, ROCK1 is ubiquitously expressed at a relatively high level, while ROCK2 is preferentially expressed in heart, brain and skeletal muscle. ROCK is the first downstream effector of the Rho protein discovered, and its biological function is achieved by phosphorylating the downstream effector proteins (MLC, Lin-11, Isl-1, LIMK, ERM, MARCKS, CRMP-2, etc). Studies have shown that various diseases (e.g., pulmonary fibrosis, cardiac-cerebral vascular disease, neurological disease and cancer etc) are related to the pathways mediated by ROCK. As such, ROCK is considered as an important target in the development of novel drugs.

However, at present, only Fasudil is approved as a ROCK inhibitor for the treatment of cerebral vasospasm and ischemia in Japan. Although various small molecule ROCK inhibitors have been reported by now, most of them are for topical ophthalmic application, and no small molecule ROCK inhibitor suitable for systemic administration is available.

SUMMARY OF THE INVENTION

The present invention provides a compound for use as a ROCK (preferably ROCK2) inhibitor, it has superior properties, such as excellent inhibitory activity on ROCK (preferably ROCk2), good selectivity (higher selectivity towards ROCK2 as compared with ROCK1), better physicochemical properties (e.g., solubility, physical and/or chemical stability), improved pharmacokinetic properties (e.g., improved bioavailability, proper half-life and duration of action), improved safety (low toxicity and/or less side effects, wide therapeutic window), and the like.

According to an aspect of the present invention, a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof is provided, wherein the compound has the structure of Formula (I):

wherein:

X and Y are each independently selected from the group consisting of a direct bond, C(═O), O, S(═O)_(i) and NR;

R is selected from the group consisting of H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, saturated or partially unsaturated C₃₋₁₀ cyclic hydrocarbyl, saturated or partially unsaturated 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl, and at most 2 ring members in the cyclic hydrocarbyl and heterocyclyl are C(═O);

ring A and ring B are each independently selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O); provided that when ring B is a heterocycle containing a nitrogen atom, ring B is not attached to X via the nitrogen atom;

ring C is selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O);

ring D is absent, or is selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and

ring E is selected from the group consisting of

ring F is selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O);

R¹ is selected from the group consisting of H, —NH₂, C₁₋₆ alkyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, N-methylpyrrolidinyl, N-methylpiperidinyl,

acetyl,

—C(═O)—(C₁₋₆ alkylene)_(n)-CF₃, —C(═O)—(C₁₋₆ alkylene)_(n)-CN, —C(═O)-(saturated or partially unsaturated C₃₋₁₀ cyclic hydrocarbyl), —NHC(═O)-(saturated or partially unsaturated C₃₋₁₀ cyclic hydrocarbyl), —C(═O)-(saturated or partially unsaturated 3- to 10-membered heterocyclyl), —C(═O)—C₁₋₆ alkylene-(saturated or partially unsaturated 3- to 10-membered heterocyclyl), —C(═O)-(5- to 14-membered heteroaryl), —C(═O)—C₁₋₆ alkylene-NH(C₁₋₆ alkyl), —C(═O)—C₁₋₆ alkylene-N(C₁₋₆ alkyl)₂, N-methylpiperazine substituted acetyl, —S(═O)₂R^(1a), —P(═O)R^(1a)R^(1b),

when one of R¹ and R¹⁰ is C₁₋₆ alkyl, and the other is H or C₃₋₁₀ cyclic hydrocarbyl, at least one of X and Y is a direct bond, and ring C is not a 5-membered heteroaromatic ring; when one of R¹ and R¹⁰ is H, and the other is

ring C is not a 5-membered heteroaromatic ring; when both R¹ and R¹⁰ are H, ring A contains at least one nitrogen atom, and is not a 5- or 6-membered ring; when one of R¹ and R¹⁰ is H, and the other is

ring C is not a 5-membered heteroaromatic ring; and when one of R¹ and R¹⁰ is H, and the other is H or acetyl, ring D is absent;

R^(1a) and R^(1b) are each independently selected from the group consisting of H, halogen, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶, —C₁₋₆ alkylene-OR⁵ and —O—C₁₋₆ alkylene-NR⁵R⁶, provided that when one of R^(1a) and R^(1b) is n-propyl, the other is not H; or R^(1a) and R^(1b) together with the atom to which they are attached form a 3-to 12-membered heterocycle or heteroaromatic ring;

R², R³, R⁴, R⁷, R⁸, R⁹ and R¹⁰, at each occurrence, are each independently selected from the group consisting of H, halogen, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶, —C₁₋₆ alkylene- O(P═O)(OH)₂ and —O—C₁₋₆ alkylene-NR⁵R⁶;

the above alkyl, alkylene, alkenyl, alkynyl, cyclic hydrocarbyl, hydrocarbon ring, heterocyclyl, heterocycle, aryl, aromatic ring, heteroaryl, heteroaromatic ring and aralkyl, at each occurrence, are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, oxo, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, ═N—OR⁵, —C(═NH)NH₂, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶ and —O—C₁₋₆ alkylene-NR⁵R⁶, and the alkyl, cyclic hydrocarbyl, heterocyclyl, aryl, heteroaryl and aralkyl are further optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, oxo, amino, cyano, nitro, C₁₋₆ alkyl, C₃₋₆ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl;

R⁵ and R⁶, at each occurrence, are each independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl;

m, at each occurrence, is each independently an integer of 0, 1, 2 or 3;

n is an integer of 0, 1 or 2;

i is an integer of 0, 1 or 2; and

g is an integer of 0, 1, 2, 3 or 4.

According to another aspect of the invention, a pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof and one or more pharmaceutically acceptable carriers is provided, and the pharmaceutical composition is preferably in the form of a solid, semi-solid, liquid, or gas preparation.

According to another aspect of the invention, use of the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof or the pharmaceutical composition of the present invention in the preparation of a medicament for use as a Rho-associated protein kinase (ROCK) inhibitor, preferably a selective ROCK2 inhibitor, is provided.

According to another aspect of the invention, the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof or the pharmaceutical composition of the present invention for use as a Rho-associated protein kinase (ROCK) inhibitor, preferably a selective ROCK2 inhibitor, is provided.

According to another aspect of the invention, a method for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK) is provided, wherein the method comprises administering to a subject in need thereof an effective amount of the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof or the pharmaceutical composition of the present invention.

According to another aspect of the invention, a method for the preparation of the compound of the present invention is provided.

DETAILED DESCRIPTION OF THE INVENTION Definition

Unless otherwise defined in the context, all technical and scientific terms used herein are intended to have the same meaning as commonly understood by a person skilled in the art. References to techniques employed herein are intended to refer to the techniques as commonly understood in the art, including variations on those techniques or substitutions of equivalent techniques which would be apparent to a person skilled in the art. While it is believed that the following terms will be readily understood by a person skilled in the art, the following definitions are nevertheless put forth to better illustrate the present invention.

The terms “contain”, “include”, “comprise”, “have”, or “relate to”, as well as other variations used herein are inclusive or open-ended, and do not exclude additional, unrecited elements or method steps.

As used herein, the term “alkylene” refers to a saturated divalent hydrocarbyl, preferably refers to a saturated divalent hydrocarbyl having 1, 2, 3, 4, 5 or 6 carbon atoms, e.g., methylene, ethylene, propylene or butylene.

As used herein, the term “alkyl” is defined as a linear or branched saturated aliphatic hydrocarbon. In some embodiments, alkyl has 1-12, e.g., 1-6, carbon atoms. For example, as used herein, the term “C₁₋₆ alkyl” refers to a linear or branched group having 1-6 carbon atoms (such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl), which is optionally substituted with one or more (e.g., 1 to 3) suitable substituents such as halogen (in which case the group may be referred to as “haloalkyl”) (e.g., CH₂F, CHF₂, CF₃, CCl₃, C₂F₅, C₂Cl₅, CH₂CF₃, CH₂Cl or —CH₂CH₂CF₃ etc). The term “C₁₋₄ alkyl” refers to a linear or branched aliphatic hydrocarbon chain having 1-4 carbon atoms (i.e., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).

As used herein, the term “alkenyl” refers to a linear or branched monovalent hydrocarbyl having a double bond and 2-6 carbon atoms (“C₂₋₆ alkenyl”). The alkenyl is e.g., vinyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl and 4-methyl-3-pentenyl. When the compound of the present invention contains an alkenylene group, the compound may exist as the pure E (entgegen) form, the pure Z (zusammen) form, or any mixture thereof.

As used herein, the term “alkynyl” refers to a monovalent hydrocarbyl containing one or more triple bond, and preferably having 2, 3, 4, 5 or 6 carbon atoms, e.g., ethynyl or propynyl.

As used herein, the term “cycloalkyl” refers to a saturated monocyclic or polycyclic (e.g., bicyclic) hydrocarbon ring (e.g., monocyclic, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or cyclononyl, or bicyclic, including spiro, fused or bridged cyclic system (such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl or bicyclo[5.2.0]nonyl, or decahydronaphthalene etc)), which is optionally substituted with one or more (e.g., 1 to 3) suitable substituents. The cycloalkyl has 3 to 15 carbon atoms. For example, the term “C₃₋₆ cycloalkyl” refers to a saturated monocyclic or polycyclic (e.g., bicyclic) hydrocarbon ring having 3 to 6 ring forming carbon atoms (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), which is optionally substituted with one or more (e.g., 1 to 3) suitable substituents, e.g., methyl substituted cyclopropyl.

As used herein, the terms “cyclic hydrocarbylene”, “cyclic hydrocarbyl” and “hydrocarbon ring” refer to a saturated (i.e., “cycloalkylene” and “cycloalkyl”) or unsaturated (i.e., having one or more double and/or triple bonds in the ring) monocyclic or polycyclic hydrocarbon ring having e.g., 3-10 (suitably having 3-8, and more suitably having 3-6) ring carbon atoms, including but not limited to cyclopropyl(ene) (ring), cyclobutyl(ene) (ring), cyclopentyl(ene) (ring), cyclohexyl(ene) (ring), cycloheptyl(ene) (ring), cyclooctyl(ene) (ring), cyclononyl(ene) (ring), cyclohexenyl(ene) (ring), and the like.

As used herein, the terms “heterocyclyl”, “heterocyclylene” and “heterocycle” refer to a saturated (i.e., heterocycloalkyl) or partially unsaturated (i.e., having one or more double and/or triple bonds in the ring) cyclic group having e.g. 3-10 (suitably having 3-8, and more suitably having 3-6) ring atoms, wherein at least one ring atom is a heteroatom selected from the group consisting of N, O and S, and the remaining ring atoms are C. For example, “3- to 10-membered heterocyclyl(ene)” of “3- to 10-membered heterocycle” refers to saturated or partially unsaturated heterocyclyl(ene) or heterocycle having 2-9 (e.g., 2, 3, 4, 5, 6, 7, 8 or 9) ring carbon atoms and one or more (e.g., 1, 2, 3, or 4) heteroatoms independently selected from the group consisting of N, O and S. Examples of heterocyclylene, heterocyclyl and heterocycle include, but are not limited to oxiranyl(ene), aziridinyl(ene), azetidinyl(ene), oxetanyl(ene), tetrahydrofuranyl(ene), dioxolinyl(ene), pyrrolidinyl(ene), pyrrolidonyl(ene), imidazolidinyl(ene), pyrazolidinyl(ene), pyrrolinyl(ene), tetrahydropyranyl(ene), piperidinyl(ene), morpholinyl(ene), dithianyl(ene), thiomorpholinyl(ene), piperazinyl(ene) or trithianyl(ene). Said group also encompasses a bicyclic system, including a spiro, fused, or bridged system (e.g., 8-azaspiro[4.5]decane, 3,9-diazaspiro[5.5]undecane, 2-azabicyclo[2.2.2]octane, etch. Heterocyclylene, heterocyclyl and heterocycle may optionally be substituted with one or more (e.g. 1, 2, 3 or 4) suitable substituents.

As used herein, the terms “aryl(ene)” and “aromatic ring” refer to an all-carbon monocyclic or fused-ring polycyclic aromatic group having a conjugated % electron system. For example, as used herein, the terms “C₆₋₁₀ aryl(ene)” and “C₆₋₁₀ aromatic ring” refer to an aromatic group containing 6 to 10 carbon atoms, such as phenyl(ene) (benzene ring) or naphthyl(ene) (naphthalene ring). Aryl(ene) or aromatic ring is optionally substituted with one or more (such as 1 to 3) suitable substituents (e.g., halogen, —OH, —CN, —NO₂, and C₁₋₆ alkyl, etch.

As used herein, the terms “heteroaryl(ene)” and “heteroaromatic ring” refer to a monocyclic, bicyclic or tricyclic aromatic ring system having 5, 6, 8, 9, 10, 11, 12, 13 or 14 ring atoms, particularly 1 or 2 or 3 or 4 or 5 or 6 or 9 or 10 carbon atoms, and containing at least one heteroatom (such as O, N, or S), which can be same to different. Moreover, in each case, it can be benzo-fused. In particular, “heteroaryl(ene)” or “heteroaromatic ring” is selected from the group consisting of thienyl(ene), furyl(ene), pyrrolyl(ene), oxazolyl(ene), thiazolyl(ene), imidazolyl(ene), pyrazolyl(ene), isoxazolyl(ene), isothiazolyl(ene), oxadiazolyl(ene), triazolyl(ene), thiadiazolyl(ene) etc., and benzo derivatives thereof; or pyridinyl(ene), pyridazinyl(ene), pyrimidinyl(ene), pyrazinyl(ene), triazinyl(ene), etc., and benzo derivatives thereof.

As used herein, the term “aralkyl” preferably means aryl or heteroaryl substituted alkyl, wherein aryl, heteroaryl and alkyl are as defined herein. Normally, the aryl group may have 6-14 carbon atoms, the heteroaryl group may have 5-14 ring atoms, and the alkyl group may have 1-6 carbon atoms. Exemplary aralkyl group includes, but is not limited to, benzyl, phenylethyl, phenylpropyl, phenylbutyl.

As used herein, the term “halo” or “halogen” are defined to include F, Cl, Br, or I.

As used herein, the term “nitrogen containing heterocycle” refers to a saturated or unsaturated monocyclic or bicyclic group having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 carbon atoms and at least one nitrogen atom in the ring, which may further optionally comprise one or more (e.g., one, two, three or four) ring members selected from the group consisting of N, O, C═O, S, S═O and S(═O)2. The nitrogen containing heterocycle is attached to the rest of the molecule through the nitrogen atom and any other ring atom in said nitrogen containing heterocycle. The nitrogen containing heterocycle is optionally benzo-fused, and is preferably attached to the rest of the molecule through the nitrogen atom in said nitrogen containing heterocycle and any carbon atom in the fused benzene ring.

The term “substituted” means that one or more (e.g., one, two, three, or four) hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

If a substituent is described as being “optionally substituted,” the substituent may be either (1) not substituted, or (2) substituted. If a carbon of a substituent is described as being optionally substituted with one or more of a list of substituents, one or more of the hydrogens on the carbon (to the extent there are any) may separately and/or together be replaced with an independently selected optional substituent. If a nitrogen of a substituent is described as being optionally substituted with one or more of a list of substituents, one or more of the hydrogens on the nitrogen (to the extent there are any) may each be replaced with an independently selected optional substituent.

If substituents are described as being “independently selected” from a group, each substituent is selected independent of the other(s). Each substituent therefore may be identical to or different from the other substituent(s).

As used herein, the term “one or more” means one or more than one (e.g., 2, 3, 4, 5 or 10) as reasonable.

As used herein, unless specified, the point of attachment of a substituent can be from any suitable position of the substituent.

When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any of the ring-forming atoms in that ring that are substitutable.

The present invention also includes all pharmaceutically acceptable isotopically labeled compounds, which are identical to those of the present invention except that one or more atoms are replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature. Examples of isotopes suitable for inclusion in the compound of the present invention include, but are not limited to, isotopes of hydrogen, such as ²H, ³H; carbon, such as ¹¹C, ¹³C, and ¹⁴C; chlorine, such as ³⁶Cl; fluorine, such as ¹⁸F; iodine, such as ¹²³I and ¹²⁵I; nitrogen, such as ¹³N and ¹⁵N; oxygen, such as ¹⁵O, ¹⁷O, and ¹⁸O; phosphorus, such as ³²P; and sulfur, such as ³⁵ S. Certain isotopically labeled compounds of the present invention, for example those incorporating a radioactive isotope, are useful in drag and/or substrate tissue distribution studies (e.g., assays). The radioactive isotopes tritium, i.e., ³H, and carbon-14, i.e., ¹⁴C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with positron-emitting isotopes, such as ¹¹C, ¹⁸F, ¹⁵O and ¹³N, can be useful in positron emission tomography (PET) studies for examining substrate receptor occupancy. Isotopically labeled compounds of the present invention can generally be prepared by processes analogous to those described in the accompanying Schemes and/or in the Examples and Preparations, by using an appropriate isotopically labeled reagent in place of the non-labeled reagent previously employed. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g., D₂O, acetone-d₆, or DMSO-d₆.

The term “stereoisomer” refers to isomers with at least one asymmetric center. A compound having one or more (e.g., one, two, three or four) asymmetric centers can give rise to a racemic mixture, single enantiomer, diastereomer mixture and individual diastereomer. Certain individual molecules may exist as geometric isomers (cis/trans). Similarly, the compound of the present invention may exist as a mixture of two or more structurally different forms in rapid equilibrium (generally referred to as tautomer). Typical examples of a tautomer include a keto-enol tautomer, phenol-keto tautomer, nitroso-oxime tautomer, imine-enamine tautomer and the like. It is to be understood that all such isomers and mixtures thereof in any proportion (such as 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, and 99%) are encompassed within the scope of the present invention.

The chemical bonds of the compound of the present invention may be depicted herein using a solid line (

), a solid wedge (

), or a dotted wedge (

). The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers (e.g., specific enantiomers, racemic mixtures, etc) at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that the stereoisomer shown is present. When present in racemic compounds, solid and dotted wedges are used to define relative stereochemistry, rather than absolute stereochemistry. Unless stated otherwise, it is intended that the compound of the present invention can exist as stereoisomers, which include cis and trans isomers, optical isomers such as R and S enantiomers, diastereomers, geometric isomers, rotational isomers, conformational isomers, atropisomers, and mixtures thereof. The compound of the present invention may exhibit more than one type of isomerism, and consist of mixtures thereof (such as racemates and diastereomeric pairs).

The present invention includes all possible crystalline forms or polymorphs of the compound of the present invention, either as a single polymorph, or as a mixture of more than one polymorphs, in any ratio.

It also should be understood that, certain compounds of the present invention can be used for the treatment in a free from, or where appropriate, in a form of a pharmaceutically acceptable derivative. In the present invention, the pharmaceutically acceptable derivative includes, but is not limited to a pharmaceutically acceptable salt, ester, solvate, N-oxide, metabolite or prodrug, which can directly or indirectly provide the compound of the present invention or a metabolite or residue thereof after being administered to a patient in need thereof. Therefore, “the compound of the present invention” mentioned herein also means to encompass various derivative forms of the compound as mentioned above.

A pharmaceutically acceptable salt of the compound of the present invention includes an acid addition salt and a base addition salt thereof.

A suitable acid addition salt is formed from an acid which forms a pharmaceutically acceptable salt. Specific examples include acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate/sulfate, borate, camphorsulfonate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate salts.

A suitable base addition salt is formed from a base which forms a pharmaceutically acceptable salt. Specific examples include aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.

For a review on suitable salts, see “Hand book of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, 2002). The method for preparing a pharmaceutically acceptable salt of the compound of the present invention is known to a person skilled in the art.

As used herein, the term “ester” refers to those derived from the compounds of the various formulae in the present application, which include physiologically-hydrolyzable esters (which may be hydrolyzed under physiological conditions to release the compounds of the present invention in the form of free acids or alcohols). The compound of the present invention itself may be an ester as well.

The compound of the present invention can exist as a solvate (preferably a hydrate), wherein the compound of the present invention contains a polar solvent, in particular water, methanol or ethanol for example, as a structural element of the crystal lattice of the compound. The amount of the polar solvent, in particular water, may exist in a stoichiometric or non-stoichiometric ratio.

As can be appreciated by a person skilled in the art, not all nitrogen containing heterocycles can form N-oxides since the nitrogen requires an available lone-pair electron for oxidation to the oxide; a person skilled in the art will recognize those nitrogen containing heterocycles which can form N-oxides. A person skilled in the art will also recognize that tertiary amines can form N-oxides. Synthetic methods for the preparation of N-oxides of heterocycles and tertiary amines are well known to a person skilled in the art, and they include the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic acid and m-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for the preparation of N-oxides have been extensively described and reviewed in literatures, see e.g., T. L. Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp 748-750; A. R. Katritzky and A. J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G. Werstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press.

The metabolite of the compound of the present invention, namely a substance formed in vivo upon administration of the compound of the present invention, is also included within the scope of the present invention. Such a product may result e.g., from the oxidation, reduction, hydrolysis, amidation, de-amidation, esterification, enzymolysis, and the like, of the administered compound. Accordingly, the present invention encompasses the metabolite of the compound of the present invention, including a compound produced by a method comprising contacting the compound of the present invention with a mammal for a period of time sufficient to result in a metabolic product thereof.

Also within the scope of the present invention is a prodrug of the compound of the invention, which is certain derivative of the compound of the invention that may have little or no pharmacological activity itself, but can, when administered into or onto the body, be converted into the compound of the invention having the desired activity, for example, by hydrolytic cleavage. In general, such prodrug will be a functional derivative of the compound which is readily converted in vivo into the compound with desired therapeutic activity. Further information on the use of the prodrug may be found in “Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and V. Stella). The prodrug in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compound of the present invention with certain moieties known to those skilled in the art as “pro-moieties” as described, for example, in “Design of Prodrugs” by H. Bundgaard (Elsevier, 1985).

The present invention further encompasses the compound of the present invention having a protecting group. During any of the processes for preparation of the compound of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned, thereby resulting in the chemically protected form of the compound of the present invention. This may be achieved by means of conventional protecting groups, e.g., those described in T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which is incorporated herein by reference. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The term “about” refers to a range within ±10%, preferably within ±5%, and more preferably within ±2% of the specified value.

Compound

In some embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the compound has the structure of Formula (I):

wherein:

X and Y are each independently selected from the group consisting of a direct bond, C(═O), O, S(═O)_(i) and NR;

R is selected from the group consisting of H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, saturated or partially unsaturated C₃₋₁₀ cyclic hydrocarbyl, saturated or partially unsaturated 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl, and at most 2 ring members in the cyclic hydrocarbyl and heterocyclyl are C(═O);

ring A and ring B are each independently selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O); provided that when ring B is a heterocycle containing a nitrogen atom, ring B is not attached to X via the nitrogen atom;

ring C is selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O);

ring D is absent, or is selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O);

ring E is selected from the group consisting of

ring F is selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O);

R¹ is selected from the group consisting of H, —NH₂, C₁₋₆ alkyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, N-methylpyrrolidinyl, N-methylpiperidinyl,

acetyl,

—C(═O)—(C₁₋₆ alkylene)_(n)-CF₃, —C(═O)—(C₁₋₆ alkylene)_(n)-CN, —C(═O)-(saturated or partially unsaturated C₃₋₁₀ cyclic hydrocarbyl), —NHC(═O)-(saturated or partially unsaturated C₃₋₁₀ cyclic hydrocarbyl), —C(═O)-(saturated or partially unsaturated 3- to 10-membered heterocyclyl), —C(═O)—C₁₋₆ alkylene-(saturated or partially unsaturated 3- to 10-membered heterocyclyl), —C(═O)-(5- to 14-membered heteroaryl), —C(═O)—C₁₋₆ alkylene-NH(C₁₋₆ alkyl), —C(═O)—C₁₋₆ alkylene-N(C₁₋₆ alkyl)₂, N-methylpiperazine substituted acetyl, —S(═O)₂R^(1a), —P(═O)R^(1a)R^(1b),

provided that when one of R¹ and R¹⁰ is C₁₋₆ alkyl, and the other is H or C₃₋₁₀ cyclic hydrocarbyl, at least one of X and Y is a direct bond, and ring C is not a 5-membered heteroaromatic ring; when one of R¹ and R¹⁰ is H, and the other is

ring C is not a 5-membered heteroaromatic ring; when both R¹ and R¹⁰ are H, ring A contains at least one nitrogen atom, and is not a 5- or 6-membered ring; when one of R¹ and R¹⁰ is H, and the other is

ring C is not a 5-membered heteroaromatic ring; and when one of R¹ and R¹⁰ is H, and the other is H or acetyl, ring D is absent;

R^(1a) and R^(1b) are each independently selected from the group consisting of H, halogen, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶, —C₁₋₆ alkylene-OR⁵ and —O—C₁₋₆ alkylene-NR⁵R⁶, provided that when one of R^(1a) and R^(1b) is n-propyl, the other is not H; or R^(1a) and R^(1b) together with the atom to which they are attached form a 3-to 12-membered heterocycle or heteroaromatic ring;

R², R³, R⁴, R⁷, R⁸, R⁹ and R¹⁰, at each occurrence, are each independently selected from the group consisting of H, halogen, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶, —C₁₋₆ alkylene- O(P═O)(OH)₂ and —O—C₁₋₆ alkylene-NR⁵R⁶;

the above alkyl, alkylene, alkenyl, alkynyl, cyclic hydrocarbyl, hydrocarbon ring, heterocyclyl, heterocycle, aryl, aromatic ring, heteroaryl, heteroaromatic ring and aralkyl, at each occurrence, are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, oxo, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, ═N—OR⁵, —C(═NH)NH₂, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶ and —O—C₁₋₆ alkylene-NR⁵R⁶, and the alkyl, cyclic hydrocarbyl, heterocyclyl, aryl, heteroaryl and aralkyl are further optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, oxo, amino, cyano, nitro, C₁₋₆ alkyl, C₃₋₆ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl;

R⁵ and R⁶, at each occurrence, are each independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl;

m, at each occurrence, is each independently an integer of 0, 1, 2 or 3;

n is an integer of 0, 1 or 2;

i is an integer of 0, 1 or 2; and

g is an integer of 0, 1, 2, 3 or 4.

In some embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein X and Y are each independently selected from the group consisting of a direct bond, C(═O), O, S, S(═O), S(═O)₂, NH and NCH₃, and preferably, at least one of X and Y is a direct bond.

In some embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein at least one of ring A and ring B is selected from the group consisting of saturated or partially unsaturated 3- to 10-membered heterocycle and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the heterocycle are C(═O).

In some embodiments,

preferably

the above group is attached to X at either of the two positions labeled # or ##, and is attached to R¹ at the other position,

wherein:

represents either a single or a double bond, and the adjacent bonds are not double bonds simultaneously;

Z¹, Z², Z³, Z⁴, Z⁵, Z⁶, Z⁷, Z⁸ and Z⁹, at each occurrence, are each independently selected from the group consisting of C, CR⁹, C(R⁹)₂, CR¹⁰, C(R¹⁰)₂, C(═O), N, NR⁹, NR¹⁰, O and S; preferably, Z¹, Z², Z³, Z⁴, Z⁵, Z⁶, Z⁷, Z⁸ and Z⁹, at each occurrence, are each independently selected from the group consisting of C, CH, CF, CCl, CCH₃, CH₂, C(CH₃)₂, C—OCH₃, C(═O), N, NH, NCH₃, NCH₂CH₃, NCH(CH₃)₂, NCH═CH₂, NCH₂F, NCHF₂, NCH₂CHF₂, NC(═O)CH₃, NCH₂OH, NCH₂OMe, NCH₂CH₂OMe, NCH₂—O(P═O)(OH)₂,

NCH₂CH₂—N(CH₃)₂, O and S; and

j is 0, 1, 2, 3 or 4;

provided that at most two groups among Z¹-Z⁹ are simultaneously C(═O), and the atom attached to X is not a nitrogen atom.

In more preferred embodiments,

wherein ring A′ and ring B′ are each independently selected from the group consisting of saturated or partially unsaturated 3- to 10-membered heterocycle and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the heterocycle are C(═O); provided that when ring B′ is a heterocycle containing a nitrogen atom, ring B′ is not attached to X via the nitrogen atom.

In some embodiments,

is preferably

is preferably

In preferred embodiments, R⁹ and R¹⁰, at each occurrence, are each independently selected from the group consisting of halogen (e.g., F, Cl, or Br), methyl, ethyl, propyl (e.g., n-propyl or isopropyl), vinyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, monofluoromethyl, difluoromethyl, trifluoromethyl, —CH₂CHF₂, acetyl, —OCH₃, —CH₂OH, —CH₂OCH₃, —CH₂CH₂OCH₃, —CH₂—O(P═O)(OH)₂,

and —CH₂CH₂—N(CH₃)₂.

In the most preferred embodiments,

is selected from the group consisting of

the above group is attached to X at either of the two positions labeled # or ##, and is attached to R¹ at the other position, provided that the atom attached to X is not a nitrogen atom.

In some embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein

more preferably

and more preferably

the above group is attached to Y at either of the two positions labeled * or **, and is attached to X at the other position,

wherein:

represents either a single or a double bond, and the adjacent bonds are not double bonds simultaneously;

V¹, V², V³, V⁴, V⁵, V⁵, V⁶, V⁷, V₈, and V⁹, at each occurrence, are each independently selected from the group consisting of C, CR⁷, C(R⁷)₂, CR⁸, C(R⁸)₂, C(═O), N, NR⁷, NR⁸, O and S; preferably, V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸ and V⁹, at each occurrence, are each independently selected from the group consisting of C, CH, CF, CCl, CCN, CCH₃, C—OCH₃, CCF₃, C—CH₂-Ph, C—NH-Ph, C—O-Ph, C—CH₂OCH₃, C—CH₂—NHCH₃, C—N(CH₃)₂, C—CH₂NH₂, C—C(═O)OH, C—C(═O)OCH₂CH₃, C—C(═O)NH₂, —CO—CH₂CH₂—N(CH₃)₂, CH₂, C(═O), N, NH, NCH₃, N—C(═O)CH₃, N-Ph, —N—CH₂CH₂—N(CH₃)₂, O and S; and

k is 0, 1, 2, 3 or 4;

provided that at most two groups among V¹-V⁹ are simultaneously C(═O).

In preferred embodiments,

more preferably

In preferred embodiments, R⁷ and R⁸, at each occurrence, are each independently selected from the group consisting of F, Cl, Br, I, cyano, —N(CH₃)₂, methyl, ethyl, propyl, methoxy, trifluoromethyl, phenyl, —CH₂-Ph, —NH-Ph, —O-Ph, —CH₂OCH₃, —CH₂NH₂, —CH₂—NHCH₃, —C(═O)CH₃, —C(═O)OH, —C(═O)OCH₂CH₃, —C(═O)NH₂, —O—CH₂CH₂—N(CH₃)₂ and —CH₂CH₂—N(CH₃)₂.

In the most preferred embodiments,

the above group is attached to Y at either of the two positions labeled * or **, and is attached to X at the other position.

In some embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein ring E is

preferably

In some embodiments, R³ and R⁴, at each occurrence, are each independently selected from the group consisting of H, F, Cl, Br, I, —OH, methyl, ethyl, propyl, methoxy, —NH₂, —N(CH₃)₂, —O-ethylene-N(CH₃)₂.

In preferred embodiments, ring E is

In some embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein R¹ is methyl, —CH₂OH,

—C(═O)CF₃, —C(═O)CH₂CF₃, —C(═O)CH₂CN, —C(═O)OCH₃, —C(═O)OC(CH₃)₃,

—S(═O)₂CH₂CH₃,

—C(═O)CH₂N(CH₃)₂;

more preferably

wherein R¹¹ is H, halogen, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶ or —O—C₁₋₆ alkylene-NR⁵R⁶.

In some embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein R^(1a) and R^(1b) are each independently selected from the group consisting of H, methyl, —CF₃, ethyl, —CH₂CF₃, —CH₂CH₂CF₃, —CH(CH₃)CF₃, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -ethylene-O-methyl, —CH₂CN, —CH₂CH₂CN, —CH₂CH₂OH,

or R^(1a) and R^(1b) together with the atom to which they are attached form the following group:

In some embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the compound has the structure of any of the following formulae:

wherein:

Z is selected from the group consisting of O, S(═O)_(i) and NR;

each of the remaining groups is as defined above.

In preferred embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the compound has the structure of formula (XVII) or formula (XVIF):

wherein:

R is selected from the group consisting of H and C₁₋₆ alkyl;

ring D is saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aryl or 5- to 10-membered heteroaromatic ring, preferably

phenyl ring, N-methylpyrrole ring, furan ring or thiophene ring;

R² is selected from the group consisting of H and C₁₋₆ alkyl;

R³, R⁴, R⁷, R^(7′) and R⁸, at each occurrence, are each independently selected from the group consisting of H, halogen, —NH₂, —OH, C₁₋₆ alkyl and —OR⁵;

R⁹ and R¹⁰, at each occurrence, are each independently selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵ and —C₁₋₆ alkylene-O(P═O)(OH)₂;

the above alkyl, alkenyl, cyclic hydrocarbyl, heterocyclyl, aryl, heteroaryl, heteroaromatic ring and aralkyl, at each occurrence, are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl and —OR⁵;

R⁵ and R⁶, at each occurrence, are each independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl;

m, at each occurrence, is each independently an integer of 0, 1, 2 or 3; and

n is an integer of 0, 1 or 2.

In preferred embodiments, R⁵ and R⁶, at each occurrence, are each independently selected from the group consisting of H, methyl and ethyl.

In preferred embodiments, R³, R⁴, R⁷, R^(7′) and R⁸, at each occurrence, are each independently selected from the group consisting of H, F, Cl, Br, —NH₂, —OH, methyl, trifluoromethyl, —CH₂-Ph, methoxy, ethoxy and —CH₂OCH₃.

In preferred embodiments, R⁹ and R¹⁰, at each occurrence, are each independently selected from the group consisting of H, F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, vinyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, monofluoromethyl, difluoromethyl, trifluoromethyl, acetyl, —CH₂CHF₂, —CH₂CH₂OCH₃, —CH₂CH₂OCH₃, —CH₂—O(P═O)(OH)₂,

The compound obtained by any combination of the various embodiments is encompassed by the invention.

In some embodiments, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein the structure and characterization data of the compound is as follows:

MS m/z (ESI): No. Structural Formula [M + H] TDI01102

413.2 TDI01103

431.2 TDI01104

429.3 TDI01105

413.2 TDI01106

429.2 TDI01107

429.3 TDI01108

412.2 TDI01109

401.1 TDI01110

415.1 TDI01111

427.2 TDI01112

469.1 TDI01113

457.0 TDI01114

484.3 TDI01115

464.2 TDI01116

465.1 TDI01117

428.2 TDI01118

444.1 TDI01119

469.1 TDI01120

485.1 TDI01121

516.2 TDI01122

539.1 TDI01127

412.1 TDI01128

462.2 TDI01129

410.2 TDI01130

504.1 TDI01131

544.2 TDI01132

532.2 TDI01133

467.1 TDI01134

450.2 TDI01135

469.1 TDI01136

485.1 TDI01139

435.1 TDI01140

474.1 TDI01141

468.2 TDI01142

468.1 TDI01143

451.1 TDI01144

451.2 TDI01145

453.2 TDI01146

453.2 TDI01147

418.1 TDI01148

469.1 TDI01149

469.1 TDI01150

469.1 TDI01151

410.2 TDI01152

448.2 TDI01153

447.1 TDI01154

454.1 TDI01155

398.1 TDI01156

437.1 TDI01157

437.1 TDI01158

454.1 TDI01159

454.1 TDI01160

448.2 TDI01161

448.1 TDI01162

448.2 TDI01163

449.2 TDI01164

487.1 TDI01165

502.2 TDI01166

488.2 TDI01167

449.3 TDI01168

473.2 TDI01169

498.1 TDI01171

447.1 TDI01172

462.2 TDI01173

448.2 TDI01174

474.1 TDI01175

504.1 TDI01176

428.2 TDI01177

385.2 TDI01178

462.1 TDI01179

482.1 TDI01180

482.1 TDI01181

482.2 TDI01182

486.1 TDI01183

463.2 TDI01184

463.2 TDI01185

498.2 TDI01186

464.2 TDI01187

448.2 TDI01188

448.2 TDI01189

449.1 TDI01190

449.2 TDI01191

448.2 TDI01192

449.2 TDI01193

449.0 TDI01194

466.1 TDI01195

450.1 TDI01196

449.2 TDI01197

450.1 TDI01198

451.2 TDI01199

436.1 TDI01200

536.1 TDI01201

462.2 TDI01209

439.1 TDI01211

448.2 TDI01212

449.1 TDI01213

466.1 TDI01214

466.1 TDI01215

446.1 TDI01216

516.1 TDI01217

546.2 TDI01218

544.2 TDI01219

403.2 TDI01220

399.2 TDI01221

490.1 TDI01222

489.2 TDI01223

478.2 TDI01224

478.2 TDI01225

478.2 TDI01226

462.2 TDI01227

546.2 TDI01228

466.1 TDI01229

369.3 TDI01230

467.3 TDI01231

516.2 TDI01232

476.3 TDI01233

538.1 TDI01234

451.3 TDI01235

519.2 TDI01236

460.3 TDI01237

450.2 TDI01238

464.3 TDI01239

478.2 TDI01240

478.2 TDI01241

474.2 TDI01242

482.1 TDI01243

396.1 TDI01244

494.2 TDI01245

396.2 TDI01246

434.2 TDI01247

454.1 TDI01248

586.2 TDI01249

448.0 TDI01250

462.3 TDI01251

462.1 TDI01253

444.2 TDI01254

456.2 TDI01255

456.2 TDI01256

483.1 TDI01257

508.2 TDI01258

486.2 TDI01259

485.2 TDI01260

400.2 TDI01261

462.1 TDI01262

507.3 TDI01263

403.2 TDI01264

359.2 TDI01265

372.1 TDI01266

442.1 TDI01267

416.2 TDI01268

428.2 TDI01271

484.2 TDI01272

460.2 TDI01273

412.2 TDI01274

508.2 TDI01275

462.2 TDI01276

462.2 TDI01277

466.1 TDI01278

516.2 TDI01280

438.3 TDI01281

460.2 TDI01282

476.3 TDI01283

436.2 TDI01285

412.3 TDI01286

426.2 TDI01287

398.2 TDI01288

343.2 TDI01289

490.2 TDI01290

481.1 TDI01291

454.3 TDI01292

414.2 TDI01294

424.2 TDI01295

416.2 TDI01296

410.2 TDI01297

545.2 TDI01298

444.2 TDI01299

439.2 TDI01300

462.2 TDI01310

398.2 TDI01311

447.2 TDI01312

414.2 TDI01314

467.2 TDI01315

477.2 TDI01316

533.2 TDI01317

550.3 TDI01318

550.3 TDI01319

536.3 TDI01320

521.3 TDI01321

521.3 TDI01322

333.1 TDI01323

412.2 TDI01324

436.2 TDI01325

497.2 TDI01326

469.2 TDI01327

424.2 TDI01328

410.1 TDI01329

438.2 TDI01330

436.2 TDI01331

466.2 TDI01332

452.2 TDI01333

441.1 TDI01334

480.2 TDI01335

466.2 TDI01336

512.2 TDI01337

466.2 TDI01338

480.2 TDI01339

479.2 TDI01340

454.2 TDI01341

442.2 TDI01342

468.2 TDI01343

479.2 TDI01344

466.2 TDI01345

479.2 TDI01346

482.2 TDI01347

462.2 TDI01348

458.1 TDI01348P-2

445.1 TDI01350

438.4 TDI01351

452.2 TDI01353

398.1 TDI01354

507.3 TDI01355

492.1 TDI01356

449.1 TDI01357

412.3 TDI01358

471.3 TDI01360

507.3 TDI01360P-1

607.5 TDI01361

480.1 TDI01362

426.2 TDI01363

473.2 TDI01364

414.2 TDI01365

428.1 TDI01366

426.1 TDI01367

509.2 TDI01368

480.3 TDI01369

477.1 TDI01370

494.2 TDI01371

422.1 TDI01372

498.1 TDI01373

497.1 TDI01374

483.1 TDI01375

455.2 TDI01376

483.1 TDI01379

466.1 TDI01380

536.3 TDI01381

494.2 TDI01382

470.1 TDI01383

457.2 TDI01384

447.1 TDI01385

522.4 TDI01386

461.1 TDI01387

461.1 TDI01388

475.2 TDI01389

357.1 TDI01390

537.3 TDI01391

455.1 TDI01392

471.1 TDI01393

490.2 TDI01394

465.2 TDI01395

515.0 TDI01396

483.1 TDI01397

473.1 TDI01398

461.2 TDI01399

455.1 TDI01400

529.3 TDI01402

438.2 TDI01344-2A

484.2 TDI01403

449.1 TDI01404

563.2 TDI01405

440.3 TDI01406

454.1 TDI01407

468.1 TDI01408

424.2 TDI01410

492.0 TDI01411

426.5 TDI01415

468.1 TDI01416

454.2 TDI01417

443.2 TDI01418

480.3 TDI01419

480.2 TDI01420

464.2 TDI01421

487.2 TDI01422

480.3 TDI01423

522.2 TDI01424

506.3 TDI01425

533.3 TDI01426

510.2 TDI01427

492.2 TDI01428

509.2 TDI01429

492.2 TDI01430

449.2 TDI01431

480.3 TDI01432

506.2 TDI01433

504.2 TDI01434

472.0 TDI01435

486.2 TDI01436

520.2 TDI01437

452.2 TDI01438

466.1 TDI01439

511.1 TDI01440

560.2 TDI01441

468.2 TDI01442

463.2 TDI01443

506.2 TDI01444

518.3 TDI01445

489.2 TDI01446

442.1 TDI01447

562.4 TDI01448

475.2 TDI01449

468.1 TDI01450

522.2 TDI01451

508.3 TDI01452

506.1 TDI01453

442.1 TDI01454

513.1 TDI01455

454.2 TDI01456

495.1 TDI01457

506.2 TDI01458

480.2 TDI01459

480.1 TDI01460

450.1 TDI01461

475.3 TDI01462

466.3 TDI01463

486.1 TDI01464

505.3 TDI01465

514.3 TDI01466

480.2 TDI01467

474.3 TDI01468

519.3 TDI01469

562.2 TDI01470

486.2 TDI01471

489.1 TDI01472

528.1 TDI01473

468.2 TDI01474

446.1 TDI01475

481.1 TDI01476

481.1 TDI01477

486.3 TDI01478

486.2 TDI01479

516.1 TDI01480

465.1 TDI01481

451.0 TDI01482

471.1 TDI01483

413.1 TDI01484

482.1 TDI01485

500.2 TDI01486

512.2 TDI01487

524.2 TDI01488

542.1 TDI01489

529.3 TDI01490

498.2 TDI01491

482.1 TDI01492

500.1 TDI01493

502.1 TDI01494

484.1 TDI01495

448.2 TDI01496

468.1 TDI01497

514.2 TDI01498

465.2 TDI01499

494.1 TDI01500

478.1 TDI01501

517.0 TDI01502

463.1 TDI01503

500.1 TDI01504

532.3 TDI01505

548.2 TDI01506

532.2 TDI01507

500.3 TDI01508

542.2 TDI01509

506.1 TDI01510

477.1 TDI01511

498.1 TDI01512

512.2 TDI01513

526.2 TDI01514

500.2 TDI01515

487.2 TDI01516

471.4 TDI01517

492.3 TDI01518

498.2 TDI01519

560.2 TDI01520

498.2 TDI01521

532.1 TDI01522

532.1 TDI01523

534.3 TDI01524

500.3 TDI01525

545.1 TDI01526

473.1 TDI01529

516.1 TDI01530

504.1 TDI01531

452.3 TDI01532

487.2 TDI01533

525.3 TDI01534

475.2 TDI01535

475.2 TDI01536

473.8 TDI01537

514.0 TDI01538

518.3 TDI01543

449.6 TDI01544

434.2 TDI01545

434.2 TDI01546

505.8 TDI01547

541.1 TDI01550

502.6 TDI01551

467.8 TDI01552

482.0 TDI01553

451.7 TDI01554

482.8 TDI01555

522.8 TDI01556

521.1 TDI01557

354.7 TDI01557B

455.0 TDI01558

447.1 TDI01559

489.0 TDI01560

466.8 TDI01561

452.8 TDI01562

489.0 TDI01563

521.8 TDI01564

511.6 TDI01565

512.1 TDI01566

467.7 TDI01567

515.8 TDI01567B

545.0 TDI01567C

516.7 TDI01569

559.5 TDI01570

486.6 TDI01571

501.1 TDI01571B

482.8 TDI01572

502.1 TDI01573

501.1 TDI01574

472.1 TDI01575

460.7 TDI01578

502.5 TDI01579

500.1 TDI01580

462.6 TDI01581

472.7 TDI01582

489.6 TDI01583

471.1 TDI01584

528.5 TDI01585

504.5 TDI01586

484.6 TDI01587

556.2 TDI01588

422.1 TDI01589

464.7 TDI01590

491.1 TDI01591

485.1 TDI01592

516.1 TDI01593

491.1 TDI01594

458.7 TDI01594B

544.5 TDI01596

504.7 TDI01596B

486.6 TDI01597

485.1 TDI01597B

466.8 TDI01598

509.1 TDI01609

506.5 TDI01611

504.6 TDI01613

480.7 TDI01615

504.1 TDI01617

533.6 TDI01618A

491.1 TDI01620

521.8 TDI01621

503.1 TDI01622

477.1 TDI01623

544.1 TDI01628

505.0 TDI01633

556.5 TDI01634

493.9 TDI01653

474.1 TDI01654

488.1 TDI01655

518.6 TDI01656

531.1 TDI01657

533.1 TDI01658

532.6 TDI01659

505.1 TDI01662

519.1 TDI01665

520.6 TDI01666

544.1 TDI01667

524.7 TDI01668

530.1 TDI01670

509.1 TDI01672

506.5 TDI01673

483.1 TDI01674

440.8 TDI01675

507.0 TDI01676

500.8 TDI01678

535.5 TDI01681

553.7 TDI01682

460.7 TDI01683

460.7 TDI01684

451.1 TDI01689

501.1 TDI01690

516.6 TDI01691

506.2 TDI01692

492.0 TDI01693

493.1 TDI01694

479.1 TDI01695

457.1 TDI01698

500.1 TDI01706

500.7 TDI01708

487.1 TDI01709

502.1 TDI01710

419.1 TDI01712

473.1 TDI01714

487.1 TDI01715

484.1 TDI01721

493.1 TDI01801

478.2 TDI01802

478.1 TDI01803

494.9 TDI01804

482.8 TDI01806

456.0 TDI01807

411.9 TDI01808

552.3 TDI01809

491.1 TDI01810

491.1 TDI01811

490.7 TDI01812

491.1 TDI01813

477.9 TDI01814

529.9 TDI01815

515.9 TDI01816

443.7 TDI01816B

470.2 TDI01818

396.0 TDI01819

444.0 TDI01820

457.8 TDI01821

443.8 TDI01822

457.7 TDI01823

482.0 TDI01824

481.9 TDI01825

462.1 TDI01825B

440.0 TDI01825C

466.0 TDI01826

436.2 TDI01827

420.1 TDI01829

472.1 TDI01829B

498.0 TDI01829C

598.8 TDI01830

428.1 TDI01831

428.1 TDI01832

454.2 TDI01833

430.9 TDI01834

479.1 TDI01835

495.1 TDI01836

467.2 TDI01837

425.2 TDI01838

425.2 TDI01839

515.1 TDI01840

530.0 TDI01841

494.8 TDI01842

442.2 TDI01842B

489.9 TDI01843

342.1 TDI01844

481.9 TDI01845

522.7 TDI01846

429.2 TDI01847

563.6 TDI01847B

589.8 TDI01848

442.9 TDI01849

475.0 TDI01849B

500.9 TDI01850

508.1 TDI01851

543.9 TDI01852

496.0 TDI01853

495.7 TDI01854

463.2 TDI01855

453.0 TDI01856

452.8 TDI01861

479.9 TDI01862

488.0 TDI01863

438.1 TDI01864

478.0 TDI01865

524.8 TDI01867

468.2 TDI01868

522.2 TDI01869

429.9 TDI01870

430.7 TDI01871

466.0 TDI01872

479.2 TDI01873

418.9 TDI01874

432.9 TDI01875

417.9 TDI01876

419.1 TDI01876B

433.1 TDI01877

435.9 TDI01878

562.9 TDI01879

466.0 TDI01880

548.6 TDI01881

460.0 TDI01882

556.0 TDI01883

541.2 TDI01884

606.9 TDI01885

575.8 TDI01886

453.9 TDI01887

442.9 TDI01888

393.9 TDI01890

429.9 TDI01891

430.9 TDI01892

453.9 TDI01893

430.9 TDI01894

493.9 TDI01898

501.6 TDI01898B

575.8 TDI01899

504.0 TDI01900

503.0 TDI01901

341.1 TDI01902

454.9 TDI01903

499.2 TDI01904

504.1 TDI01905

503.5 TDI01906

460.0 TDI01907

514.2 TDI01908

453.9 TDI01909

484.0 TDI01910

516.2 TDI01911

604.0 TDI01912

465.6 TDI01913

507.9 TDI01914

501.6 TDI01915

516.0 TDI01916

525.6 TDI01917

521.1 TDI01918

535.9 TDI01919

449.9 TDI01920

516.6 TDI01921

529.6 TDI01923

498.0 TDI01924

514.1 TDI01925

512.2 TDI01926

528.2 TDI01927

526.2 TDI01928

556.2 TDI01929

542.2 TDI01930

562.2 TDI01931

555.2 TDI01932

504.0 TDI01933

490.2 TDI01934

504.2 TDI01935

582.1 TDI01936

486.6 TDI01937B

486.6 TDI01938

501.9 TDI01939

437.0 TDI01940

437.0 TDI01941

475.6 TDI01942

472.9 TDI01943

501.6 TDI01944

472.5 TDI01945

538.5 TDI01946

525.9 TDI01947

541.9 TDI01948

524.9 TDI01949

519.9 TDI01950

499.2 TDI01951

487.8 TDI01952

527.6 TDI01953

526.6 TDI01954

540.5 TDI01955

500.0 TDI01956

503.9 TDI01957

487.6 TDI01958

486.6 TDI01959

488.1 TDI01960

526.0 TDI01962

527.6 TDI01965

459.6 TDI01966

459.6 TDI01967

447.0 TDI01968A

466.1 TDI01968B

465.7 TDI01969

452.0 TDI01972

465.9 TDI01973

535.1 TDI01974

466.0 TDI01975

472.0 TDI01976

512.6 TDI01978

490.9 TDI01979

474.0 TDI01989

426.9 TDI01990

472.0 TDI01991

472.6 TDI01995

521.0 TDI01996

507.1 TDI01998

535.0 TDI01999

513.6

In some embodiments, the present invention provides a method for the preparation of a compound of Formula (II), wherein the method comprises the following steps:

wherein:

R² is H;

Hal¹ and Hal² are same or different halogens, e.g., F, Cl, Br or I;

PG¹ is a carboxy protecting group, preferably C₁₋₆ alkyl;

PG² is H or an amino protecting group, preferably tert-butyloxycarbonyl (Boc);

R^(a) and R^(a′), at each occurrence, are each independently selected from the group consisting of H and C₁₋₆ alkyl; or R^(a) and R^(a′) together with the group to which they are attached form a 5- to 10-membered ring system;

the remaining groups are as defined above;

the reaction conditions for each step are as follows:

step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound b-1;

step 2: reacting compound b-1 with compound REG-1 under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound c-1; and

step 3: reacting compound c-1 with compound REG-2 (preferably in the presence of an appropriate condensation agent and an appropriate base), to obtain the compound of Formula (II);

alternatively, the method comprises the following steps:

wherein each of the groups is as defined above;

the reaction conditions for each step are as follows:

step 1: reacting compound a-2 with compound REG-2 (preferably in the presence of an appropriate condensation agent and an appropriate base), to obtain compound b-2;

step 2: reacting compound b-2 with a boric acid or borate under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound c-2; and

step 3: reacting compound c-2 with compound REG-1 under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain the compound of Formula (II);

alternatively, the method comprises the following steps:

wherein each of the groups is as defined above;

the reaction conditions for each step are as follows:

step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound b-1;

step 2: deprotecting compound b-1 under a condition corresponding to PG¹, to obtain compound c-3;

step 3: reacting compound c-3 with compound REG-2 (preferably in the presence of an appropriate condensation agent and an appropriate base), to obtain compound d-3; and

step 4: reacting compound d-3 with compound REG-1 under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain the compound of Formula (II);

In some embodiments, the present invention provides a method for the preparation of a compound of Formula (XII), wherein the method comprises the following steps:

wherein:

R² is H;

Hal¹ and Hal² are same or different halogens, e.g., F, Cl, Br or I;

PG¹ is a carboxy protecting group, preferably C₁₋₆ alkyl;

PG² is H or an amino protecting group, preferably tert-butyloxycarbonyl (Boc);

R^(a) and R^(a′), at each occurrence, are each independently selected from the group consisting of H and C₁₋₆ alkyl; or R^(a) and R^(a′) together with the group to which they are attached form a 5- to 10-membered ring system;

the remaining groups are as defined above;

the reaction conditions for each step are as follows:

step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound b-1;

step 2: reacting compound b-1 with compound REG-1′ under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound c-1′; and

step 3: reacting compound c-1′ with compound REG-2′ (preferably in the presence of an appropriate condensation agent and an appropriate base), to obtain the compound of Formula (XII).

In some embodiments, the present invention provides a method for the preparation of a compound of Formula (XIII), wherein the method comprises the following steps:

wherein:

R² is H;

Hal¹ and Hal² are same or different halogens, e.g., F, Cl, Br or I;

PG¹ is a carboxy protecting group, preferably C₁₋₆ alkyl;

PG² is H or an amino protecting group, preferably tert-butyloxycarbonyl (Boc);

R^(a) and R^(a′), at each occurrence, are each independently selected from the group consisting of H and C₁₋₆ alkyl; or R^(a) and R^(a′) together with the group to which they are attached form a 5- to 10-membered ring system;

the remaining groups are as defined above;

the reaction conditions for each step are as follows:

step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound b-1;

step 2: reacting compound b-1 with compound REG-1 under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound c-1; and

step 3: reacting compound c-1 with compound REG-2′ (preferably in the presence of an appropriate condensation agent and an appropriate base), to obtain the compound of Formula (XIII).

In some embodiments, the present invention provides a method for the preparation of a compound of Formula (XIV), wherein the method comprises the following steps:

wherein:

R² is H;

Hal¹ and Hal² are same or different halogens, e.g., F, Cl, Br or I;

PG¹ is a carboxy protecting group, preferably C₁₋₆ alkyl;

PG² is H or an amino protecting group, preferably tert-butyloxycarbonyl (Boc);

R^(a) and R^(a′), at each occurrence, are each independently selected from the group consisting of H and C₁₋₆ alkyl; or R^(a) and R^(a′) together with the group to which they are attached form a 5- to 10-membered ring system;

the remaining groups are as defined above;

the reaction conditions for each step are as follows:

step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound b-1;

step 2: reacting compound b-1 with compound REG-1′ under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound c-1′; and

step 3: reacting compound c-1′ with compound REG-2 (preferably in the presence of an appropriate condensation agent and an appropriate base), to obtain the compound of Formula (XIV);

alternatively, the method comprises the following steps:

wherein each of the groups is as defined above;

the reaction conditions for each step are as follows:

step 1: reacting compound a-2 with compound REG-2 (preferably in the presence of an appropriate condensation agent and an appropriate base), to obtain compound b-2;

step 2: reacting compound b-2 with a boric acid or borate under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound c-2; and

step 3: reacting compound c-2 with compound REG-1′ under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain the compound of Formula (XIV);

alternatively, the method comprises the following steps:

wherein each of the groups is as defined above;

the reaction conditions for each step are as follows:

step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain compound b-1;

step 2: deprotecting compound b-1 under a condition corresponding to PG¹, to obtain compound c-3;

step 3: reacting compound c-3 with compound REG-2 (preferably in the presence of an appropriate condensation agent and an appropriate base), to obtain compound d-3; and

step 4: reacting compound d-3 with compound REG-1′ under the catalysis of a palladium catalyst (preferably in the presence of a base), to obtain the compound of Formula (XIV).

In preferred embodiments, the boric acid or borate is e.g., bis(pinacolato)diboron.

In preferred embodiments, the palladium catalyst is e.g., Pd(dppf)Cl₂, Pd(PPh₃)₄, Pd(OAc)₂ or Pd(PPh₃)₂C₁₋₂.

In preferred embodiments, the condensation agent is e.g., DCC, EDCI, HATU, PyBOP.

In preferred embodiments, the appropriate base is e.g., diisopropylethylamine, triethylamine, pyridine, sodium carbonate, potassium acetate, potassium carbonate, potassium hydroxide, cesium carbonate.

Pharmaceutical composition and therapeutic method

In some embodiments, the present invention provides a pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof and one or more pharmaceutically acceptable carriers, and the pharmaceutical composition is preferably in the form of a solid, semi-solid, liquid, or gas preparation. In some embodiments, the pharmaceutical composition can further comprise one or more additional therapeutic agents.

In some embodiments, the present invention provides use of the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof or the pharmaceutical composition of the present invention in the preparation of a medicament for use as a Rho-associated protein kinase (ROCK) inhibitor, preferably a selective ROCK2 inhibitor.

In some embodiments, the present invention provides the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof or the pharmaceutical composition of the present invention for use as a Rho-associated protein kinase (ROCK) inhibitor, preferably a selective ROCK2 inhibitor.

In some embodiments, the present invention provides a method for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK), wherein the method comprises administering to a subject in need thereof an effective amount of the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof or the pharmaceutical composition of the present invention.

In some embodiments, the disease mediated by the Rho-associated protein kinase (ROCK) includes an autoimmune disorder (comprising rheumatoid arthritis, systemic lupus erythematosus (SLE; lupus), psoriasis, Crohn's disease, atopic dermatitis, eczema, or graft-versus-host disease (GVHD)); a cardiovascular disorder (comprising hypertension, atherosclerosis, restenosis, cardiac hypertrophy, cerebral ischemia, cerebral vasospasm, or erectile dysfunction); inflammation (comprising asthma, cardiovascular inflammation, ulcerative colitis, or renal inflammation); a central nervous system disorder (comprising neuronal degeneration or spinal cord injury; and the central nervous system disorder is preferably Huntington's disease, Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), or multiple sclerosis); an arterial thrombotic disorder (comprising platelet aggregation, or leukocyte aggregation); a fibrotic disorder (comprising liver fibrosis, lung fibrosis, or kidney fibrosis); a neoplastic disease (comprising a lymphoma, carcinoma (e.g., squamous cell cancer, small-cell lung cancer, pituitary cancer, esophageal cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, liver cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, prostate cancer, vulval cancer, thyroid cancer, brain cancer, endometrial cancer, testis cancer, cholangiocarcinoma, gallbladder carcinoma, gastric cancer, melanoma, or head and neck cancer), leukemia, astrocytoma, soft tissue sarcoma, sarcoma, or blastoma); a metabolic syndrome; insulin resistance; hyperinsulinemia; type 2 diabetes; glucose intolerance; osteoporosis; an ocular disorder (comprising ocular hypertension, age related macular degeneration (AMD), choroidal neovascularization (CNV), diabetic macular edema (DME), iris neovascularization, uveitis, glaucoma (comprising primary open-angle glaucoma, acute angle-closure glaucoma, pigmentary glaucoma, congenital glaucoma, normal tension glaucoma, secondary glaucoma or neo vascular glaucoma), or retinitis of prematurity (ROP)).

In some embodiments, the disease mediated by the Rho-associated protein kinase (ROCK) includes lupus nephritis, atherosclerosis, rheumatoid arthritis (RA), hemangioma, angiofibroma, lung fibrosis, psoriasis, corneal graft rejection, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, Chron's disease, autoimmune nephritis, primary biliary cirrhosis, acute pancreatitis, allograph rejection, allergic inflammation, contact dermatitis, delayed hypersensitivity, inflammatory bowel disease, septic shock, osteoporosis, osteoarthritis, neuronal inflammation, Osier-Weber syndrome, restenosis, fungal infection, parasitic infection, and viral infection.

The term “pharmaceutically acceptable carrier” in the present invention refers to a diluent, auxiliary material, excipient, or vehicle with which a therapeutic is administered, and it is, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The pharmaceutically acceptable carrier which can be employed in the pharmaceutical composition of the present invention includes, but is not limited to sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is an exemplary carrier when the pharmaceutical composition is administered intravenously. Physiological salines as well as aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, maltose, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. The pharmaceutical composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in e.g. Remington's Pharmaceutical Sciences (1990).

The pharmaceutical composition of the present invention can act systemically and/or topically. To this end, it can be administered through a suitable route, such as through injection, (intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection, including dripping), or transdermal administration, or administered via oral, buccal, nasal, transmucosal, topical, as an ophthalmic formulation, or via inhalation.

For these routes of administration, the pharmaceutical composition of the present invention can be administered in a suitable dosage form.

Such dosage forms include, but are not limited to tablets, capsules, lozenges, hard candies, powders, sprays, creams, salves, suppositories, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, and syrups.

As used herein, the term “effective amount” refers to the amount of a compound being administered which will relieve to some extent one or more of the symptoms of the disorder being treated.

Dosage regimens may be adjusted to provide the optimum desired response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the composition.

The amount of the compound of the present invention administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. Generally, an effective dosage is in the range of about 0.0001 to about 50 mg per kg body weight per day, for example about 0.01 to about 10 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.007 mg to about 3500 mg/day, for example about 0.7 mg to about 700 mg/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases, still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

The content or dosage of the compound of the present invention in the pharmaceutical composition is about 0.01 mg to about 1000 mg, suitably 0.1-500 mg, preferably 0.5-300 mg, more preferably 1-150 mg, particularly preferably 1-50 mg, e.g., 1.5 mg, 2 mg, 4 mg, 10 mg, 25 mg, etc.

Unless otherwise indicated, the term “treating” or “treatment”, as used herein, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.

As used herein, the term “subject” includes a human or non-human animal. An exemplary human subject includes a human subject having a disease (such as one described herein) (referred to as a patient), or a normal subject. The term “non-human animal” as used herein includes all vertebrates, such as non-mammals (e.g. birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and/or domesticated animals (such as sheep, dog, cat, cow, pig and the like).

In some embodiments, the pharmaceutical composition of the present invention can further comprise one or more additional therapeutic agents or prophylactic agents.

EXAMPLES

The present invention is further described with reference to the following examples, which are not provided to limit the scope of the present invention.

The structure of the compound was confirmed by nuclear magnetic resonance spectrum (¹H NMR) or mass spectrum (MS).

Chemical shifts (b) are expressed in parts per million (ppm). ¹HNMR was recorded on a Bruker BioSpin GmbH 400 spectrometer, the test solvent was deuterated methanol (CD₃OD), deuterated chloroform (CDCl₃) or hexadeuterated dimethyl sulfoxide (DMSO-d₆), and the internal standard was tetramethylsilane (TMS).

The LC-MS assay was conducted on Shimadzu LC-MS-2020 liquid chromatography-mass spectrometer (Manufacturer: Shimadzu, Model: Shimadzu LC-MS-2020).

Preparative high-performance liquid chromatography was conducted on Waters 2767 (waters sunfire, C18, 19×250 mm 10 um chromatographic column).

Thin layer chromatography (TLC) was performed with Huanghai HSGF 254 (5×20 cm) silica gel plates, and preparative thin layer chromatography was performed with GF 254 (0.4˜0.5 nm) silica gel plates produced in Yantai.

The reaction was monitored by thin layer chromatography (TLC) or LC-MS, the developing solvent system included dichloromethane and methanol system, hexane and ethyl acetate system, as well as petroleum ether and ethyl acetate system, and was adjusted (by adjusting the volume ratio the solvents, or by adding triethylamine, etc.) according to the polarity of the compound to be separated.

The microwave reaction was conducted by BiotageInitiator+(400 W, RT ˜300° C.) microwave reactor.

Silica gel (200˜300 mesh) produced by Yucheng Chemical Co., Ltd was normally employed as a stationary phase in column chromatography. The eluent system included dichloromethane and methanol system, as well as hexane and ethyl acetate system, and was adjusted (by adjusting the volume ratio the solvents, or by adding triethylamine, etc.) according to the polarity of the compound to be separated.

In the following examples, unless otherwise specified, the reaction temperature was room temperature (20° C.˜30° C.).

The reagents employed in the Examples were purchased from companies such as Acros Organics, Aldrich Chemical Company, or Bide Pharmatech Ltd. etc.

The abbreviations as used in the present invention have the following meanings:

Abbreviation Meaning ACN acetonitrile AcOH acetic acid AcOK/KOAc potassium acetate aq. aqueous solution BINAP (±)-2,2′-B is(diphenylphosphino)-1,1′-binaphthalene Boc₂O Di-teri-butyl dicarbonate Cs₂CO₃ cesium carbonate Cu(AcO)₂ copper acetate CuCN cuprous cyanide DCC Dicyclo hexylcarbodiimide DCE 1,2-dichloroethane DCM dichloromethane DIAD diisopropyl azodiformate DIEA/DIPEA N,N-diisopropylethylamine DMAP dimethylaminopyridine DMF N,N-dimethylformamide DMSO dimethyl sulfoxide DNPC bis(4-nitrophenyl)carbonate EA ethyl acetate EDCI 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride Et₃N triethylamine EtOH ethanol HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′- tetramethyluronium hexafluorophosphate HCl hydrochloric acid H₂O water IPA isopropanol K₂CO₃ potassium carbonate KMnO₄ potassium permanganate KOH potassium hydroxide KTB potassium tert-butoxide LiAlH₄ lithium aluminium hydride LiOH•H₂O lithium hydroxide monohydrate m-CPBA metachloroperbenzoic acid MeCN acetonitrile MeOH methanol MgCl₂ magnesium chloride Mg₂SO₄ magnesium sulfate MnO₂ manganese dioxide MsCl methylsulfonyl chloride MTBE methyl tert-butyl ether NaBH₄ sodium borohydride NaBH(OAc)₃ sodium triacetoxyborohyride Na₂CO₃ sodium carbonate NaH sodium hydride NaOH sodium hydroxide NBS N-bromosuccinimide NH₄Cl ammonium chloride N₂H₄•H₂O hydrazine hydrate NMP N-methylpyrrolidone O₂ oxygen Pd/C palladium/carbon Pd₂(dba)₃ tris(dibenzylideneacetone)dipalladium Pd(dppf)Cl₂ [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium Pd(OAc)₂ palladium acetate Pd(PPh₃)₄ tetrakis(triphenylphosphine)palladium Pd(PPh₃)₂Cl₂ dichlorobis(triphenylphosphine)palladium PE petroleum ether Pin₂B₂ bis(pinacolato)diboron POCl₃ phosphorus oxychloride PPh₃ triphenylphosphine PyBOP Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate SOCl₂ thionyl chloride t-BuXPhos 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl TEA triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TsCl 4-toluenesulfonyl chloride Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene Zn zinc

Preparation of Intermediates

Intermediate Example 1

Step 1:

Compound Reg-1-1-a (26 g, 159.38 mmol) and tetrahydrofuran (400 mL) were added to a 1 L flask, and ethylamine (45 mL, 324.6 mmol) and 4-dimethylaminopyridine (2.92 g, 23.91 mmol) were added, followed by slowly dropwise addition of Boc₂O (41.74 g, 191.25 mmol). The reaction was performed overnight at room temperature. Thin layer chromatography (petroleum ether:ethyl acetate=3:1) indicated the reaction was complete. The reaction mixture was concentrated to obtain a crude product, which was dissolved in dichloromethane (400 mL), and the organic phase was washed three times with 0.5M dilute hydrochloric acid. The organic phase was then washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to afford compound Reg-1-1-b (39 g, brown solid, yield: 92.95%).

¹H NMR (400 MHz, CDCl₃) δ 8.70 (d, J=2.1 Hz, 1H), 8.42 (dd, J=9.1, 2.1 Hz, 1H), 8.34 (d, J=9.6 Hz, 2H), 1.75 (s, 9H). MS m/z (ESI): 164.2 [M-Boc+H].

Step 2:

Compound Reg-1-1-b (38 g, 144.35 mmol) was dissolved in methanol (700 mL), Pd/C (3.8 g, 10% water) was added, purge with hydrogen was performed for three times, and the reaction was performed under a hydrogen atmosphere overnight. Thin layer chromatography (petroleum ether:ethyl acetate=3:1) indicated the reaction was complete. The reaction solution was filtered through Celite to afford compound Reg-1-1-c (33.2 g, brown solid, yield: 98.60%).

¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, J=10.8 Hz, 2H), 7.00-6.87 (m, 2H), 3.74 (s, 2H), 1.71 (s, 9H).

Step 3:

Compound Reg-1-1-c (4 g, 17.14 mmol) and 2,4-dichloropyrimidine (5.1 g, 34.28 mmol) were dissolved in N,N-dimethylformamide (60 mL), diisopropylethylamine (11.08 g, 85.8 mmol) was added, and the reaction was placed in an oil bath at 80° C., and allowed to proceed overnight. Thin layer chromatography (petroleum ether:ethyl acetate=2:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure to give a crude product, which was separated through preparative chromatography (petroleum ether:ethyl acetate=100:1˜1.5:1) to afford compound Reg-1-1 (3 g, yellow solid, yield: 50.60%).

¹H NMR (400 MHz, CDCl₃) δ 9.50-9.23 (m, 1H), 8.52-7.91 (m, 4H), 7.89-7.45 (m, 1H), 7.28-6.51 (m, 1H), 1.73 (s, 9H). MS m/z (ESI): 346.1 [M+H].

The following intermediates were prepared according to methods similar to that described in Intermediate Example 1:

No. Structure of Intermediate Characterization Data Reg-1-2

¹H NMR (400 MHz, CDCl₃) δ 8.41 (s, 1H), 8.24-8.22 (m, 2H), 7.91-7.87 (m, 2H), 7.86-7.82 (m, 1H), 7.74 (s, 1H), 7.67 (d, J = 8.8 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 1.75 (s, 9H). Reg-1-3

¹H NMR (400 MHz, CDCl₃) δ 8.28 (s, 1H), 8.21 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 2.0 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.27 (s, 1H), 6.87 (d, J = 2.0 Hz, 1H), 1.74 (s, 9H). Reg-1-4

¹H NMR (400 MHz, CDCl₃) δ 10.35 (s, 1H), 8.48 (s, 1H), 8.28 (d, J = 5.2 Hz, 1H), 8.22 (s, 1H), 8.11 (d, J = 9.2 Hz, 1H), 7.83 (d, J = 9.2 Hz, 1H), 7.43 (d, J = 5.2 Hz, 1H), 1.67 (s, 9H). MS m/z (ESI): 402.1 [M + H]. Reg-1-5

MS m/z (ESI): 402.1 [M + H]. Reg-1-6

¹H NMR 1H NMR (400 MHz, DMSO-d₆) δ 11.99 (s, 1H), 10.06 (s, 1H), 8.46-8.41 (m, 2H), 8.06 (d, J = 8.0 Hz, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.24 (s, 1H), 6.86 (s, 1H). MS m/z (ESI): 385.2 [M + H]. Reg-1-7

¹H NMR (400 MHz, DMSO-d₆) δ 10.84 (s, 1H), 9.42 (s, 1H), 8.49 (s, 1H), 8.33 (d, J = 1.2 Hz, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.97 (dd, J = 8.8, 1.6 Hz, 1H), 1.67 (s, 9H). Reg-1-8

¹H NMR (400 MHz, DMSO-d₆) δ 10.08 (s, 1H), 8.49 (s, 1H), 8.34 (s, 1H), 8.24 (d, J = 1.5 Hz, 1H), 8.14-8.11 (m, 1H), 7.87 (dd, J = 9.0, 1.9 Hz, 1H), 7.64 (d, J = 0.9 Hz, 1H), 7.14 (s, 1H), 1.67 (s, 10H). MS m/z (ESI): 385.0 [M + H]. Reg-1-9

¹H NMR (400 MHz, CDCl₃) δ 8.21 (s, 1H), 8.19 (s, 1H), 8.04 (s, 1H), 7.56 (dd, J = 8.9, 1.8 Hz, 1H), 7.26 (s, 2H), 7.21 (s, 1H), 6.97 (d, J = 3.6 Hz, 1H), 5.81 (d, J = 2.9 Hz, 1H), 4.30 (t, J = 6.4 Hz, 2H), 2.33 (s, 6H), 1.73 (d, J = 13.8 Hz, 9H). MS m/z (ESI): 454.1 [M − H]. Reg-1-10*

¹H NMR (400 MHz, CD₃OD) δ 8.13 (d, J = 3.7 Hz, 1H), 8.05 (s, 1H), 7.86 (d, J = 8.9 Hz, 1H), 7.51 (m, 6H), 7.04 (m, 3H), 6.65 (d, J = 9.0 Hz, 1H). MS m/z (ESI): 361.1 [M + H]. Reg-1-11

¹H NMR (400 MHz, CDCl₃) δ 8.49 (d, J = 24.0 Hz, 1H), 8.21- 8.03 (m, 3H), 7.69 (d, J = 40.0 Hz, 1H), 7.46 (dd, J = 8.8, 4.0 Hz, 1H), 1.66 (s, 9H). MS m/z (ESI): 347.1 [M + H], Reg-1-12

¹H NMR (400 MHz, DMSO-d₆) δ 10.20 (s, 1H), 8.47 (s, 1H), 8.35 (d, J = 3.6 Hz, 1H), 8.21 (d, J = 1.2 Hz, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.82 (dd, J = 8.8, 2.0 Hz, 1H), 1.66 (s, 9H). Reg-1-15

¹H NMR (400 MHz, DMSO-d₆) δ 10.07 (s, 1H), 8.44 (s, 1H), 8.16 (s, 1H), 8.05 (d, J = 9.2 Hz, 1H), 7.63 (d, J = 8.8 Hz, 1H), 6.61 (s, 1H), 2.29 (s, 3H), 1.66 (s, 9H). MS m/z (ESI): 360.0 [M + H]. Reg-1-30

¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, J = 8.8 Hz, 1H), 8.20 (s, 1H), 7.76 (s, 1H), 7.54 (s, 1H), 7.43 (d, J = 8.8 Hz, 1H), 6.48 (s, 1H), 1.73 (s, 9H). Reg-1-53

¹H NMR (400 MHz, DMSO-d₆) δ 10.12 (s, 1H), 8.45 (d, J = 11.3 Hz, 1H), 8.18 (s, 1H), 8.03 (d, J = 9.1 Hz, 1H), 7.63 (t, J = 8.9 Hz, 1H), 7.33 (dt, J = 17.3, 8.3 Hz, 4H), 6.53 (d, J = 12.4 Hz, 1H), 3.94 (s, 2H), 1.66 (s, 9H). MS m/z (ESI): 436.0 [M + H]. Reg-1-55

¹H NMR (400 MHz, DMSO-d₆) δ 7.49 (s, 1H), 7.35 (s, 1H), 7.20 (d, J = 8.9 Hz, 1H), 6.89 (d, J = 8.9 Hz, 1H), 6.77 (d, J = 7.6 Hz, 2H), 6.51 (s, 2H), 6.30 (m, 1H), 5.40 (s, 1H), 0.92 (s, 9H). MS m/z (ESI): 436.6, 438.7 [M + H]. Reg-1-80

¹H NMR (400 MHz, DMSO-d₆) δ 9.52 (s, 1H), 8.44 (s, 1H), 8.25 (s, 1H), 8.02 (d, J = 9.0 Hz, 1H), 7.96 (s, 1H), 7.85 (d, J = 9.0 Hz, 1H), 3.96 (s, 3H), 1.66 (s, 9H). MS m/z (ESI): 375.9 [M + H]. Reg-1-81

MS m/z (ESI): 379.9, 381.8 [M + H]. Reg-1-83

¹H NMR (400 MHz, DMSO-d₆) δ 12.85 (s, 1H), 9.40 (s, 1H), 8.16 (s, 1H), 7.97 (s, 1H), 7.56 (dd, J = 9.0, 1.4 Hz, 1H), 7.44 (d, J = 8.9 Hz, 1H), 6.14 (s, 1H), 2.70 (s, 6H). MS m/z (ESI): 289.1 [M + H].

The reagent employed in step 3 for the preparation of Reg-1-10 was prepared according to the following reaction:

Compound Reg-1-10-1 (1.0 g, 5.32 mmol), phenylboronic acid (972.79 mg, 7.98 mmol) and pyridine (2.52 g, 31.86 mmol) were dissolved in dichloromethane (30 mL), followed by addition of copper acetate (0.966 g, 4.99 mmol) and molecular sieve (0.5 g), and then the reaction was performed under an oxygen atmosphere for 12 h. LC-MS indicated the reaction was complete. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to give a crude product, which was separated and purified through a medium pressure preparative column (petroleum ether:ethyl acetate=100:1˜3:1) to afford compound Reg-1-10-2 (0.9 g, white solid, yield: 64.07%). MS m/z (ESI): 264.0 [M+H].

Intermediate Example 2

Step 1:

Compound Reg-1-16-a (4.5 g, 2.58 mmol) and dichloromethane (200 mL) were added to a 100 mL flask, diisopropylethylamine (5.99 g, 46.38 mmol) and 4-dimethylaminopyridine (424 mg, 3.48 mmol) were added, followed by slow dropwise addition of Boc₂O (7.59 g, 34.79 mmol). The reaction was performed overnight at room temperature. Thin layer chromatography (petroleum ether:ethyl acetate=3:1) indicated the reaction was complete. The reaction solution was concentrated to give a crude product, which was dissolved in dichloromethane (100 mL), and the organic phase was then washed three times with 0.5M dilute hydrochloric acid. The organic phase was further washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain Reg-1-16-b (6.8 g, colorless oil, yield: 99.68%). MS m/z (ESI): 195.2 [M-Boc+H].

Step 2:

Compound Reg-1-16-b (6.8 g, 23.12 mmol) and 1-bromo-4-nitrobenzene (7.0 g, 34.68 mmol) were dissolved in a mixture of 1,4-dioxane/water (4:1) (200 mL), followed by addition of potassium carbonate (9.58 g, 69.35 mmol) and Pd(dppf)Cl₂ (0.9 g, 1.16 mmol). Purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 80° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, and concentrated under reduced pressure to afford compound Reg-1-16-c (12 g, brown solid). The crude was used directly in the next reaction. MS m/z (ESI): 190.1 [M+H].

Step 3:

Compound Reg-1-16-c (4.5 g, 2.58 mmol) and dichloromethane (200 mL) were added to a 250 mL flask, and diisopropylethylamine (8.54 mL, 52.86 mmol) and 4-dimethylaminopyridine (484 mg, 3.96 mmol) were added, followed by slow dropwise addition of BOC₂O (8.65 g, 39.65 mmol). The reaction was performed overnight at room temperature. Thin layer chromatography (petroleum ether:ethyl acetate=3:1) indicated the reaction was complete. The reaction solution was concentrated to give a crude product, which was purified through flash column chromatography (petroleum ether:ethyl acetate=100:1 to 1.5:1) to afford compound Reg-1-16-d (6 g, light yellow oil, yield: 78.47%).

¹H NMR (400 MHz, CDCl₃) δ 8.44 (s, 1H), 8.27 (d, J=8.8 Hz, 2H), 8.06 (s, 1H), 7.69 (d, J=8.8 Hz, 2H), 1.34-1.12 (m, 9H). MS m/z (ESI): 190.2 [M-Boc+H].

Step 4:

Compound Reg-1-16-d (6 g, 20 mmol) was dissolved in methanol (100 mL), Pd/C (10% water) was added, and purge with hydrogen was performed for 3 times. The reaction was performed under a hydrogen atmosphere overnight. LC-MS indicated the reaction was complete. The reaction solution was filtered through Celite, and concentrated to afford compound Reg-1-16-e (5 g, white solid, yield: 92.97%).

¹H NMR (400 MHz, CDCl₃) δ 7.74 (s, 1H), 7.49 (s, 1H), 6.89-6.82 (m, 2H), 6.25 (d, J=8.8 Hz, 2H), 1.43-1.08 (m, 9H). MS m/z (ESI): 260.2 [M+H].

Step 5:

Compound Reg-1-16-e (3.8 g, 14.65 mmol) and 2,4-dichloropyrimidine (4.37 g, 29.31 mmol) were dissolved in N,N-dimethylformamide (30 mL), diisopropylethylamine (7.22 mL, 43.98 mmol) was added, and the reaction was performed in an oil bath at 80° C. for 8 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and concentrated under reduced pressure to afford a crude product, which was separated through preparative chromatography (dichloromethane/methanol=100:1˜100:5) to afford compound Reg-1-16 (2.2 g, yellow solid, yield: 54.80%).

¹H NMR (400 MHz, CDCl₃) δ 8.31 (s, 1H), 8.16 (d, J=5.9 Hz, 1H), 7.99 (s, 1H), 7.57 (d, J=8.4 Hz, 2H), 7.38 (d, J=8.4 Hz, 2H), 6.98 (s, 1H), 6.62 (d, J=5.9 Hz, 1H), 1.69 (s, 9H). MS m/z (ESI): 372.1 [M+H].

The following intermediates were prepared according to methods similar to that described in Intermediate Example 2:

No. Structure of Intermediate Characterization Data Reg-1-33

¹H NMR (400 MHz, DMSO-d₆) δ 10.22 (s, 1H), 8.73 (s, 1H), 8.32 (s, 1H), 8.30 (d, J = 5.6 Hz, 1H), 7.80 (s, 1H), 7.76 (s, 1H), 7.66 (s, 1H), 7.43 (d, J = 5.6 Hz, 1H), 1.62 (s, 9H). MS m/z (ESI): 428.3 [M + H]. Reg-1-34

¹H NMR (400 MHz, DMSO-d₆) δ 9.56 (s, 1H), 8.72 (s, 1H), 8.39 (s, 1H), 8.31 (s, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H), 1.61 (s, 9H). MS m/z (ESI): 404.1 [M − H]. Reg-1-36

¹H NMR (400 MHz, DMSO-d₆) δ 9.52 (s, 1H), 8.44 (s, 1H), 8.25 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.96 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 3.96 (s, 3H), 1.66 (s, 9H). MS m/z (ESI): 375.9 [M − H]. Reg-1-70

MS m/z (ESI): 311.1 [M + H].

Intermediate Example 3

Compound Reg-1-17-a (650 mg, 4.30 mmol) and 2,4-dichloropyrimidine (1.28 g, 8.60 mmol) were dissolved in N,N-dimethylformamide (20 mL), diisopropylethylamine (2.22 g, 17.2 mmol) was added, and the reaction was performed in an oil bath at 80° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=1:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, diluted with ethyl acetate (80 mL.), and was successively washed with a saturated aqueous solution of ammonium chloride (80 mL×2) and saturated brine (100 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude was separated and purified by column chromatography (petroleum ether:ethyl acetate=10:1, 4:1 to 2:1) to afford compound Reg-1-17 (480 mg, yellow solid, yield: 42.5%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.20 (s, 11H), 9.75 (s, 11H), 8.21-8.06 (m, 2H), 7.98 (d, J=7.6 Hz, 11H), 7.50 (d, J=12.0 Hz, 11H), 6.67 (s, 11H).

The following intermediates were prepared according to methods similar to that described in Intermediate Example 3.

No. Structure of Intermediate Characterization Data Reg-1-13

¹H NMR (400 MHz, DMSO-d₆) δ 8.81 (s, 1H), 8.06 (s, 1H), 7.85 (s, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 8.8 Hz, 1H), 2.32 (s, 3H), 2.16 (s, 3H). MS m/z (ESI): 274.0 [M + H]. Reg-1-14

¹H NMR (400 MHz, DMSO-d₆) δ 13.07 (s, 1H), 8.92 (s, 1H), 8.08 (s, 1H), 8.00 (s, 1H), 7.93 (s, 1H), 7.56 (d, J = 8.8 Hz, 1H), 7.49 (dd, J = 8.9, 1.4 Hz, 1H), 2.18 (s, 3H). MS m/z (ESI): 260.1 [M + H]. Reg-1-19

¹H NMR (400 MHz, DMSO-d₆) δ 13.20 (s, 1H), 9.75 (s, 1H), 8.21- 8.06 (m, 2H), 7.98 (d, J = 7.6 Hz, 1H), 7.50 (d, J = 12.0 Hz, 1H), 6.67 (s, 1H). Reg-1-20

¹H NMR (400 MHz, DMSO-(d₆) δ 12.72 (s, 1H), 10.14 (s, 1H), 8.14 (d, J = 5.9 Hz, 1H), 8.00 (s, 1H), 7.93 (s, 1H), 7.52 (d, J,= 8.8 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 2.51 (s, 3H). MS m/z (ESI): 260.1 [M + H]. Reg-1-21

¹H NMR (400 MHz, DMSO-d₆) δ 13.10 (s, 1H), 9.99 (s, 1H), 8.13- 8.06 (m, 2H), 7.99 (s, 1H), 7.57 (d, J = 8.8 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 6.70 (d, J = 5.8 Hz, 1H). Reg-1-22

¹H NMR (400 MHz, DMSO-d₆) δ 12.98 (s, 1H), 9.69 (s, 1H), 8.20 (s, 1H), 8.01 (s, 1H), 7.50 (d, J = 15.6 Hz, 2H), 2.42 (s, 3H), 2.19 (s, 3H). MS m/z (ESI): 274.0 [M + H]. Reg-1-26

¹H NMR (400 MHz, DMSO-d₆) δ 13.11 (s, 1H), 9.59 (s, 1H), 8.17 (s, 1H), 8.03 (d, J = 5.5 Hz, 1H), 7.41 (d, J = 8.6 Hz, 1H), 7.20 (d, J = 8.6 Hz, 1H), 2.40 (s, 3H). MS m/z (ESI): 260.1 [M + H]. Reg-1-28

MS m/z (ESI): 302.1 [M + H]. Reg-1-88

¹H NMR (400 MHz, DMSO-d₆) δ 12.95 (s, 1H), 9.43 (s, 1H), 8.22 (t, t, J = 13.4 Hz, 1H), 7.99 (s, 1H), 7.77 (s, 1H), 7.07 (s, 1H), 3.84 (s, 3H). MS m/z (ESI): 293.8 [M + H].

Intermediate Example 4

Compound Reg-3-a (3 g, 15.63 mmol), 2-(dimethylamino)ethanol (1.7 g, 19.11 mmol) and triphenylphosphine (5.01 g 19.11 mmol) were dissolved in tetrahydrofuran (200 mL), diisopropyl azodiformate (4.83 g, 23.89 mmol) was added at 0° C., purge with argon was performed for 3 times, and the reaction was performed at room temperature for 6 hours. LC-MS indicated the reaction was complete. 200 mL ethyl acetate was added to the reaction solution; the organic phase was washed with water (100 mL×3), dried, concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane:methanol=100:1˜20:1) to afford compound Reg-3 (3 g, brown solid, yield: 72.55%). MS m/z (ESI): 259.0 [M+H].

Intermediate Example 5

Compound 2,4-dichloro-5-(trifluoromethyl)pyrimidine (3 g, 13.825 mmol) and N,N-diisopropylethylamine (2.14 g, 16.59 mmol) were dissolved in isopropanol (100 mL), compound Reg-1-1-c (3.2 g, 13.825 mmol) was then added to the aforementioned solution in portions. The reaction was performed at room temperature for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was filtered, and the filter cake was rinsed once with isopropanol to afford compound Reg-1-24 (2.3 g, pink solid, yield: 40.19%); the filtrate was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated to dryness, to afford compound Reg-1-23 (1.84 g, dark red solid, yield: 32.15%). Characterization data of the compound are as follows:

No. Structure of Intermediate Characterization Data Reg-1-23

¹H NMR (400 MHz, CDCl₃): δ 8.46 (s, 1H), 8.21 (m, 2H), 8.08 (d, 1H), 7.53 (dd, 1H), 7.20 (s, 1H), 1.74 (s, 9H). MS m/z (ESI): 414.1 [M + H]. Reg-1-24

¹H NMR (400 MHz, CDCl₃) δ 8.59 (s, 1H), 8.20 (m, 3H), 7.71 (s, 1H), 7.53 (dd, 1H), 1.73 (s, 9H). MS m/z (ESI): 414.1 [M + H].

Intermediate Example 6

Compound Reg-1-20 (0.8 g, 3.09 mmol) was dissolved in dichloromethane (100 mL), DIEA (1.59 g, 12.36 mmol) and DMAP (188 mg, 1.55 mmol) were added, and Boc₂O (2.02 g, 9.27 mmol) was added after stir at room temperature for 10 minutes, the reaction was performed at room temperature for 3 hours. Thin layer chromatography (petroleum ether:ethyl acetate=2:1) indicated the reaction was complete. The reaction solution was dissolved in dichloromethane (400 mL), and successively washed with water (250 mL×3) and saturated brine (250 mL), the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was separated and purified by column chromatography (petroleum ether:ethyl acetate=1:0 to 5:1), to afford compound Reg-1-25 (2.01 g, white solid).

¹H NMR (400 MHz, CDCl₃) δ 8.45 (d, J=5.6 Hz, 1H), 8.15 (d, J=8.8 Hz, 1H), 7.96 (d, J=5.6 Hz, 1H), 7.41 (d, J=1.6 Hz, 1H), 7.29 (d, J=1.6 Hz, 1H), 2.59 (s, 3H), 1.74 (s, 9H), 1.41 (s, 9H). MS m/z (ESI): 460.3 [M+H].

The following intermediate was prepared according to a method similar to that described in Intermediate Example 6:

No. Structure of Intermediate Characterization Data Reg-1-27

¹H NMR (400 MHz, DMSO-d₆) δ 8.63 (d, J = 6.0 Hz, 1H), 8.45 (s, 1H), 8.13 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 6.0 Hz, 1H), 7.82 (d, J = 2.0 Hz, 1H), 7.50 (dd, J = 8.8, 2.0 Hz, 1H), 1.67 (s, 9H), 1.36 (s, 9H).

Intermediate Example 7

Step 1:

A solution of Reg-1-29-a (6.7 g, 30.612 mmol) and Reg-1-16-b (6.0 g, 20.408 mmol) dissolved in a mixture of dioxane and water (4:1) (84 mL) was added to a 250 mL single neck flask, potassium carbonate (11.28 g, 81.59 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (833 mg, 1.020 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 70° C. for 3 hours. The reaction was cooled to room temperature, water (50 mL) was added, and the solution was extracted three times with ethyl acetate (150 mL). The organic phase was dried over sodium sulfate, filtered, dried by rotary evaporation, and the residue was directly used in the next reaction. MS m/z (ESI): 208.2 [M+H].

Step 2:

Reg-1-29-b (4.58 g, 22.126 mmol) was dissolved in dichloromethane (50 mL), DMAP (270 mg, 2.213 mmol) and DIEA (5.7 g, 44.251 mmol) were added, followed by slow dropwise addition of Boc₂O (5.79 g, 26.551 mmol). The reaction was performed overnight at room temperature. After the reaction was complete, the reaction solution was concentrated under reduced pressure to afford a crude product, which was separated by medium pressure preparative chromatography to afford Reg-1-29-c (3.6 g, yellow solid, yield: 53.04%).

¹H NMR (400 MHz, CDCl₃) δ 8.44 (s, 1H), 8.17-8.10 (m, 1H), 8.03 (s, 1H), 7.43 (dt, J=6.5, 2.1 Hz, 2H), 1.69 (s, 9H). MS m/z (ESI): 206.1 [M-Boc-H].

Step 3:

Reg-1-29-c (3.6 g, 11.726 mmol) and methanol (100 mL) were added to a 250 mL single neck flask, and then Pd/C (10 wt %, 360 mg) was added. The reaction was performed under a hydrogen atmosphere overnight. After thin layer chromatography indicated completion of the reaction, the reaction solution was filtered through Celite to afford Reg-1-29-d (3.0 g, brown oil, yield: 92.36%).

¹H NMR (400 MHz, CDCl₃) δ 8.17 (s, 1H), 7.89 (s, 1H), 7.18-7.08 (m, 2H), 6.82-6.75 (m, 1H), 1.67 (s, 9H). MS m/z (ESI): 178.3 [M-Boc+H].

Step 4:

Reg-1-29-d (3.3 g, 12.74 mmol) and 2,4-dichloropyrimidine (3.8 g, 25.48 mmol) were dissolved in DMF (60 mL), DIEA (4.93 g, 38.22 mmol) was added, and the reaction was performed in an oil bath at 120° C. overnight. Thin layer chromatography indicated the reaction was complete. The reaction solution was cooled to room temperature, followed by addition of water (30 mL), and extraction with ethyl acetate (150 mL). The organic phase was dried over sodium sulfate, filtered, and dried by rotary evaporation to afford a crude product, which was separated by column chromatography to afford Reg-1-29 (1 g, yellow solid, yield: 29.52%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.04 (s, 1H), 9.78 (s, 1H), 8.33-7.96 (m, 3H), 7.79-7.57 (m, 2H), 7.48 (dd, J=8.3, 1.5 Hz, 1H), 6.75 (d, J=5.3 Hz, 1H). MS m/z (ESI): 290.0 [M+H].

The following intermediates were prepared according to methods similar to that described in Intermediate Example 7:

No. Structure of Intermediate Characterization Data Reg-1-32

¹H NMR (400 MHz, DMSO- d₆) δ 12.99 (s, 1H), 9.48 (s, 1H), 9.23 (s, 1H), 8.53 (s, 1H), 8.17 (d, J = 5.9 Hz, 1H), 7.73 (d, J = 5.2 Hz, 1H), 7.61 (d, J = 5.2 Hz, 1H), 7.49 (dd, J = 8.2, 1.7 Hz, 1H), 7.28 (dd, J = 8.2, 1.7 Hz, 1H), 3.94 (s, 3H). MS m/z (ESI): 302.3 [M + H]. Reg-1-37

¹H NMR (400 MHz, DMSO- d₆) δ 12.89 (s, 1H), 9.30 (s, 1H), 8.02 (s, 1H), 7.94 (s, 1H), 7.73 (d, J,= 8.0 Hz, 2H), 7.58 (d, J = 8.0 Hz, 2H), 3.95 (s, 3H). MS m/z (ESI): 302.0 [M + H].

Intermediate Example 8

Compound Reg-1-30 (2.0 g, 5.26 mmol) was dissolved in anhydrous ethanol (20 mL), and dimethylaminoethanol (468 mg, 5.26 mmol) and DIPEA (905 mg, 5.26 mmol) were added. The obtained mixture was heated to 90° C., at which temperature the reaction was performed overnight. LC-MS indicated the starting material underwent complete reaction. The reaction solution was concentrated under reduced pressure, and ethyl acetate (40 mL) and water (40 mL) were added to the residue. The organic layer was separated, and Reg-1-31 was obtained after evaporation under reduced pressure to remove solvents. MS m/z (ESI): 432.9 [M+H].

The following intermediates were prepared according to methods similar to that described in Intermediate Example 8:

No. Structure of Intermediate Characterization Data Reg-1-54

MS m/z (ESI): 437.7 [M + H]. Reg-1-82

¹H NMR (400 MHz, DMSO- d₆) δ 13.06 (s, 1H), 9.93 (s, 1H), 8.14-8.01 (m, 2H), 7.53 (d, J = 8.8 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 3.86 (s, 3H).

Intermediate Example 9

Step 1:

TDI01314-1-a (8.00 g, 37.20 mmol) and 2-(chloromethyl)oxirane (6.88 g, 74.40 mmol) were dissolved in acetonitrile (200 mL), potassium carbonate (15.42 g, 111.60 mmol) was added, and the reaction was performed at 80° C. overnight. Thin layer chromatography indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was separated and purified by flash column chromatography to afford TDI01314-1-b (6 g, white solid, yield: 59.49%). MS m/z (ESI): 271.1; 273.1 [M+H].

Step 2:

TDI01314-1-b (6 g, 22.13 mmol) was dissolved in dichloromethane (100 mL), m-chloroperbenzoic acid (7.64 g, 44.26 mmol) was added, and the reaction was performed at 40° C. for 8 hours. Thin layer chromatography indicated the reaction was complete. The reaction solution was cooled to room temperature, and stirred for half an hour after addition of a saturated solution of sodium sulfite. The precipitated white solid was filtered, the organic phase was concentrated, and the crude product was separated and purified by column chromatography to afford TDI01314-1-c (3 g, white solid, yield: 47.21%). MS m/z (ESI): 287.1; 289.1 [M+H].

Step 3:

TDI01314-1-c (3 g, 10.45 mmol) was dissolved in tetrahydrofuran (100 mL) and water (10 mL), sodium hydroxide (835.85 mg, 20.90 mmol) was added, and the reaction was performed at ambient temperature overnight. Thin layer chromatography indicated the reaction was complete. The reaction solution was extracted with ethyl acetate, concentrated under reduced pressure, and the residue was separated and purified by column chromatography to afford TDI01314-1-d (2 g, colorless oil, yield: 78.1%).

¹H NMR (400 MHz, CDCl₃) δ 7.06 (dd, J=11.2, 2.3 Hz, 1H), 6.95 (dd, J=8.6, 2.3 Hz, 1H), 6.75 (d, J=8.6 Hz, 1H), 4.33-4.22 (m, 2H), 4.14-4.05 (m, 1H), 3.95-3.79 (m, 2H).

Step 4:

TDI01314-1-d (2 g, 8.16 mmol) was added to water (100 mL), followed by addition of potassium carbonate (2.26 g, 16.32 mmol) and potassium permanganate (2.58 g, 16.32 mmol), and the reaction was performed at ambient temperature for 12 hours. LC-MS assay indicated the reaction was complete. The reaction solution was filtered, and the filtrate was concentrated to give a crude product, which was then separated and purified by column chromatography to afford TDI01314-1 (1 g, white solid, yield: 47.3%).

¹H NMR (400 MHz, CDCl₃) δ 7.16 (d, J=2.3 Hz, 1H), 6.99 (dd, J=8.7, 2.3 Hz, 1H), 6.76 (d, J=8.6 Hz, 1H), 4.88 (dd, J=4.3, 3.0 Hz, 1H), 4.44 (dd, J=11.5, 4.4 Hz, 1H), 4.36 (dd, J=11.5, 2.9 Hz, 1H).

Intermediate Example 10

Compound Reg-1-38-a (320 mg, 1.24 mmol) and 2,4-dichloropyrimidine (221 mg, 1.48 mmol) were dissolved in N,N-dimethylformamide (20 mL), diisopropylethylamine (638 mg, 4.94 mmol) was added, and the reaction solution was slowly warmed to 80° C., and kept at this temperature for 16 hours. Thin layer chromatography (petroleum ether/ethyl acetate=2:1) indicated the reaction was complete. The reaction solution was dissolved in ethyl acetate (250 mL), and successively washed with water (250 mL×2) and saturated brine (250 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated, and the crude product was directly used in the next reaction.

The crude product obtained from the last step was dissolved in dichloromethane (20 mL), diisopropylethylamine (417 mg, 3.24 mmol) and 4-dimethylaminopyridine (99 mg, 0.81 mmol) were added, and the reaction was stirred at room temperature for 10 minutes. Di-tert-butyl dicarbonate (705 mg, 3.24 mmol) was then added, and the reaction was performed at room temperature for 3 hours. Thin layer chromatography (petroleum ether/ethyl acetate=2:1) indicated the reaction was complete. The reaction solution was dissolved in dichloromethane (400 mL), and successively washed with water (250 mL×32) and saturated brine (250 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was separated and purified by column chromatography (petroleum ether:dichloromethane=100:1 to 0:1) to afford compound Reg-1-38 (400 mg, light yellow oil).

¹H NMR (400 MHz, CDCl₃) δ 8.44 (d, J=5.6 Hz, 1H), 8.31 (s, 1H), 7.99 (s, 1H), 7.90 (d, J=5.6 Hz, 1H), 7.73 (dd, J=5.6, 3.2 Hz, 1H), 7.53 (dd, J=5.6, 3.2 Hz, 3H), 7.08 (d, J=7.6 Hz, 1H), 1.68 (s, 9H), 1.43 (s, 9H). MS m/z (ESI): 472.3 [M+H].

Intermediate Example 11

Step 1:

Compound Reg-1-39-1 (15 g, 68 mmol), 3-fluoro-4-bromonitrobenzene (24.2 g, 82 mmol) and potassium carbonate (28 g, 204 mmol) were mixed in mixed solvents of 1,4-dioxane (500 mL) and water (50 mL), the flask was purged with N₂ 3 times, followed by addition of Pd(dppf)Cl₂ (10 g, 13.6 mmol). The flask was purged with N₂ 3 times again, and then the reaction solution was heated to reflux for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered to remove salt impurities, the filtrate was concentrated under reduced pressure, and the crude product was separated through column chromatography on silica gel (petroleum ether:ethyl acetate=3:1˜1:3) to afford compound Reg-1-39-2 (10 g, brown solid, yield: 71.7%).

¹H NMR (300 MHz, DMSO-d₆) δ 13.40 (s, 1H), 8.42 (s, 1H), 8.29-7.95 (m, 4H). MS m/z (ESI): 207.8 [M+H].

Step 2:

Compound Reg-1-39-2 (10 g, 48 mmol) and Pd/C (10 g, 10%) were mixed in isopropanol (50 mL) and tetrahydrofuran (50 mL), the flask was purged with hydrogen 3 times, and the reaction was placed at room temperature under an atmosphere of hydrogen overnight. LC-MS indicated the reaction was complete. The reaction was filtered, the filter cake was washed repeatedly with tetrahydrofuran (200 mL), and the filtrates were combined and concentrated under reduced pressure to afford compound Reg-1-39-3 (8 g, brown solid, yield: 94%).

¹H NMR (301 MHz, DMSO-d₆) δ 12.84 (s, 1H), 7.89 (s, 1H), 7.73 (s, 1H), 7.32 (t, J=8.8 Hz, 1H), 6.38 (t, J=9.2 Hz, 2H), 5.35 (s, 2H). MS m/z (ESI): 178.0 [M+H].

Step 3:

Compound Reg-1-39-3 (8 g, 45 mmol), 2,4-dichloropyrimidine (6.69 g, 45 mmol) and DIPEA (17.42 g, 135 mmol) were dissolved in DMF (160 mL) and heated to 80° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the crude product was separated through column chromatography on silica gel (petroleum ether:ethyl acetate=3:1˜1:3) to afford compound Reg-1-39-4 (4.8 g, yellow solid, yield: 36.9%).

¹H NMR (301 MHz, DMSO-d₆) δ 10.22 (s, 1H), 8.20 (d, J=5.9 Hz, 1H), 8.01 (s, 2H), 7.73-7.66 (m, 2H), 7.36 (dd, J=8.5, 2.1 Hz, 1H), 6.80 (d, J=5.9 Hz, 1H). MS m/z (ESI): 289.8, 291.7 [M+H, Cl].

Step 4:

Compound Reg-1-39-4 (4.8 g, 16.6 mmol) and Boc₂O (5.07 g, 23 mmol) were dissolved in DMF (50 mL), DIPEA (6.4 g, 49.8 mmol) and DMAP (0.203 g, 1.66 mmol) were added, and the reaction was stirred at room temperature overnight. LC-MS indicated the reaction was complete. The reaction was concentrated under reduced pressure, and the crude product was separated by flash chromatography (petroleum ether ethyl acetate=3:1˜1:3) to afford compound Reg-1-39 (4.6 g, yellow solid, yield: 71.3%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.30 (s, 1H), 8.54 (d, J=1.1 Hz, 1H), 8.27-8.22 (m, 2H), 7.85 (t, J=8.7 Hz, 1H), 7.75 (dd, J=13.7, 1.9 Hz, 1H), 7.41 (dd, J=8.6, 2.0 Hz, 1H), 6.82 (d, J=5.9 Hz, 1H), 1.61 (s, 9H). MS m/z (ESI): 389.6, 391.6 [M+H, Cl].

The following intermediates were prepared according to methods similar to that described in Intermediate Example 11:

No. Structure of Intermediate Characterization Data Reg-1-40

¹H NMR (300 MHz, DMSO- d₆) δ 10.03 (s, 1H), 8.68 (d, J = 3.6 Hz, 1H), 8.30 (m, 2H), 7.72 (m, 4H), 1.60 (d, J = 3.5 Hz, 9H). MS m/z (ESI): 390.0, 391.9 [M + H]. Reg-1-41

MS m/z (ESI): 372.8 [M + H]. Reg-1-42

MS m/z (ESI): 401.9 [M + H]. Reg-1-43

¹H NMR (400 MHz, DMSO- d₆) δ 8.62 (t, J = 2.9 Hz, 2H), 8.35 (s, 1H), 7.88 (d, J = 5.9 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.07 (s, 1H), 6.90 (d, J = 8.2 Hz, 1H), 3.87 (s, 3H), 1.61 (s, 9H), 1.41 (s, 9H). MS m/z (ESI): 501.5 [M + H]. Reg-1-44

¹H NMR (400 MHz, DMSO- d₆) δ 10.43 (s, 1H), 8.71 (s, 1H), 8.43 (d, J = 2.0 Hz, 1H), 8.31 (s, 1H), 7.80 (q, J = 8.8 Hz, 4H), 7.08 (d, J = 2.0 Hz, 1H), 1.61 (s, 9H). MS m/z (ESI): 411.7 [M + H]. Reg-1-45

¹H NMR (400 MHz, DMSO- d₆) δ 12.95 (s, 1H), 10.21 (s, 1H), 8.58 (d, J = 8.5 Hz, 1H), 8.21 (s, 1H), 7.77 (m, 8H). MS m/z (ESI): 321.9, 323.9 [M + H]. Reg-1-46

¹H NMR (400 MHz, DMSO- d₆) δ 10.33 (s, 1H), 8.81-8.74 (m, 2H), 8.34 (s, 1H), 8.23 (d, J = 8.6 Hz, 1H), 8.13 (dd, J = 8.6, 2.4 Hz, 1H), 7.91 (d, J = 8.6 Hz, 1H), 6.82 (d, J = 5.9 Hz, 1H), 1.61 (s, 9H). Reg-1-56

¹H NMR (400 MHz, DMSO- d₆) δ 9.61 (d, J = 3.1 Hz, 1H), 8.70 (s, 1H), 8.30 (s, 1H), 7.73 (dt, J = 8.8, 6.4 Hz, 4H), 4.49 (dd, J = 28.5, 11.4 Hz, 4H), 1.61 (s, 9H), 1.47 (d, J = 8.0 Hz, 9H). MS m/z (ESI): 512.6, 514.6 [M + H]. Reg-1-57

¹H NMR (400 MHz, DMSO- d₆) δ 12.92 (s, 1H), 9.33 (s, 1H), 8.16 (s, 1H), 7.90 (s, 1H), 7.60 (s, 4, 3.80 (s, 2H), 3.75 (s, 2H), 3.17 (d, J = 5.2 Hz, 3H). MS m/z (ESI): 327.0, 329.0 [M + H]. Reg-1-58

¹H NMR (400 MHz, DMSO- d₆) δ 9.74 (d, J = 52.9 Hz, 1H), 9.47 (s, 1H), 8.84 (s, 1H), 8.39 (s, 1H), 7.79 (dd, J = 9.9, 7.0 Hz, 3H), 4.76 (d, J = 20.6 Hz, 2H), 4.51 (d, J = 33.7 Hz, 2H), 2.66 (s, 3H), 2.07 (d, J = 9.7 Hz, 3H). MS m/z (ESI): 396.6, 398.6 [M + H]. Reg-1-64

MS m/z (ESI): 343.9 [M + H]. Reg-1-65

¹H NMR (300 MHz, DMSO- d₆) δ 10.10 (s, 1H), 8.44 (s, 1H), 8.35 (d, J = 3.1 Hz, 1H), 7.78 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 2.39 (s, 3H), 1.59 (s, 9H). MS m/z (ESI): 348.0. 350.0 [M + H]. Reg-1-70

¹H NMR (400 MHz, DMSO- d₆) δ 10.35 (s, 1H), 8.74 (s, 1H), 8.32 (s, 1H), 7.82 (d, J = 10.7 Hz, 5H), 7.25 (s, 1H), 6.77 (dd, J = 4.0, 2.7 Hz, 1H), 1.61 (s, 9H). MS m/z (ESI): 410.8 [M + H]. Reg-1-71

¹H NMR (300 MHz, DMSO- d₆) δ 8.77 (s, 1H), 8.56 (d, J = 5.9 Hz, 1H), 8.31 (s, 1H), 7.92 (d, J = 5.8 Hz, 1H), 7.49 (s, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.24 (d, J = 8.1 Hz, 1H), 5.24 (s, 2H), 3.18 (s, 3H), 1.60 (s, 9H), 1.36 (s, 9H). MS m/z (ESI): 532.0 [M + H]. Reg-1-72

MS m/z (ESI): 524.5 [M + H]. Reg-1-73

¹H NMR (400 MHz, DMSO- d₆) δ 10.11 (s, 1H), 8.73 (s, 1H), 8.32 (s, 1H), 7.88 (d, J = 6.0 Hz, 1H), 7.82 (s, 4H), 7.76 (d, J = 5.9 Hz, 1H), 1.61 (s, 9H). MS m/z (ESI): 427.9, 429.9 [M + H]. Reg-1-74

¹H NMR (300 MHz, DMSO- d₆) δ 8.89 (s, 1H), 8.68 (s, 1H), 8.28 (s, 1H), 8.04 (s, 1H), 7.76-7.66 (m, 4H), 2.18 (s, 3H), 1.61 (s, 9H). MS m/z (ESI): 386.0 [M + H]. Reg-1-75

¹H NMR (400 MHz, DMSO- d₆) δ 9.63 (s, 1H), 8.70 (s, 1H), 8.30 (s, 1H), 7.95 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.65 (dd, J = 18.4, 8.4 Hz, 2H), 4.98 (s, 2H), 4.85 (s, 2H), 1.61 (s, 9H). MS m/z (ESI): 413.6, 415.6 [M + H]. Reg-1-76

MS m/z (ESI): 386.0 [M + H]. Reg-1-77

¹H NMR (400 MHz, DMSO- d₆) δ 9.17 (s, 1H), 8.69 (d, J = 0.6 Hz, 1H), 8.29 (d, J = 0.6 Hz, 1H), 7.73 (q, J = 9.0 Hz, 4H), 3.33 (s, 4H), 2.81 (s, 2H), 1.61 (s, 9H). MS m/z (ESI): 411.7, 413.7 [M + H]. Reg-1-78

MS m/z (ESI): 522.0 [M + Na]. Reg-1-84

MS m/z (ESI): 461.6 [M + H]. Reg-1-87

MS m/z (ESI): 415.8 [M + H].

Intermediate Example 12

Step 1:

Compound Reg-1-51-1 (50 mg, 0.27 mmol) and 4-(1H-pyrazol-4-yl)aniline (43.4 mg, 0.27 mmol) were dissolved in ethanol (3 mL), N,N-diisopropylethylamine (0.07 mL, 0.4 mmol) was added, and the reaction solution was heated to 90° C. for 16 hours. LC-MS indicated the reaction was complete, the reaction solution was cooled to room temperature, the reaction solvent was removed through rotary evaporation under vacuum to afford the crude compound Reg-1-51-2 (100 mg).

MS m/z (ESI): 305.8 [M+H].

Step 2:

Compound Reg-1-51-2 (100 mg, 0.27 mmol) was dissolved in ethanol (50 mL), 2-(dimethylamino)ethanol (24 mg, 0.27 mmol) was added, and the reaction solution was heated to 90° C. and stirred overnight. LC-MS indicated the reaction was complete, and the reaction solvent was removed through rotary evaporation under vacuum to afford compound Reg-1-51-3 (150 mg, crude product).

MS m/z (ESI): 358.8 [M+H].

Step 3:

Compound Reg-1-51-3 (150 mg, 0.418 mmol) was dissolved in dichloromethane (5 mL), BOC anhydride (228 mg, 1.045 mmol), triethylamine (0.2 mL, 1.254 mmol) and 4-dimethylaminopyridine (5 mg, 0.042 mmol) were respectively added, and the reaction solution was stirred at room temperature for 16 hours. LC-MS indicated the reaction was complete, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified on a preparative silica gel plate (petroleum ether ethyl acetate=1:1) to afford compound Reg-1-51 (80 mg, 41.7% yield).

MS m/z (ESI): 458.7 [M+H].

Intermediate Example 13

Step 1:

Compound Reg-1-52-1 (1.02 g, 5 mmol) and 1-Boc-pyrazol-4-boronic acid pinacol ester (1.47 g, 5 mmol) were dissolved in 1,4-dioxane:water (40:4 mL), potassium carbonate (2.07 g, 15 mmol) was added, and the flask was purged with nitrogen three times. Pd(dppf)Cl₂ (0.366 g, 0.5 mmol) was added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 85° C. for 6 hours. LC-MS indicated the reaction was complete, the reaction solution was cooled to room temperature, filtered, and the filtrate was rotary evaporated under vacuum to remove solvents. The residue was purified by column chromatography (petroleum ether:ethyl acetate=1:2 to ethyl acetate) to afford compound Reg-1-52-2 (0.5 g, 34.5% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 9.16 (s, 1H), 9.13 (d, J=2.1 Hz, 1H), 8.61 (dd, J=8.5, 2.3 Hz, 1H), 8.56 (s, 1H), 8.38 (d, J=8.5 Hz, 1H), 1.62 (s, 9H).

Step 2:

Compound Reg-1-52-2 (0.5 g, 1.71 mmol) was suspended in isopropanol (20 mL), Pd/C (0.5 g) was added, the flask was purged with hydrogen three times, and the reaction was performed overnight under normal pressure at room temperature under hydrogen atmosphere. LC-MS assay indicated the reaction was complete, the reaction solution was filtered, and the filtrate was rotary evaporated under vacuum to remove solvents, to afford compound Reg-1-52-3 (0.4 g, 89% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.54 (s, 1H), 8.32 (d, J=2.1 Hz, 1H), 8.19 (s, 1H), 7.79-7.66 (m, 1H), 6.47 (d, J=8.4 Hz, 1H), 6.05 (s, 2H), 1.59 (s, 9H).

Step 3:

Compound Reg-1-52-3 (52 mg, 0.2 mmol), 2,4-dichloropyrimidine (29.8 mg, 0.2 mmol), cesium carbonate (130 mg, 0.4 mmol), Pd₂(dba)₃ (18.3 mg, 0.02 mmol) and Xantphos (11.6 mg, 0.02 mmol) were mixed in dioxane (2 mL), the reaction was purged with nitrogen three times, and heated to 110° C. for 1 hour. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered to remove insoluble salt impurities, the filtrate was concentrated under reduced pressure, and the crude product was separated through column chromatography on silica gel (dichloromethane/methanol=20/1) to afford compound Reg-1-52 (20 mg, yellow solid, yield: 26.8%). ¹H NMR (400 MHz, DMSO-d₆) δ 10.78 (s, 1H), 8.80 (s, 1H), 8.77 (d, J=2.1 Hz, 1H), 8.36 (d, J=5.9 Hz, 1H), 8.35 (s, 1H), 8.18 (dd, J=8.6, 2.4 Hz, 1H), 7.78 (s, 1H), 7.63 (d, J=8.5 Hz, 1H), 1.61 (s, 9H).

The following intermediates were prepared according to methods similar to that described in Intermediate Example 13:

No. Structure of Intermediate Characterization Data Reg-1-60

¹H NMR (400 MHz, DMSO- d₆) δ 9.47 (s, 1H), 8.63 (s, 1H), 8.26 (s, 1H), 7.69 (d, J = 8.0 Hz, 2H), 7.64 (d, J = 8.0 Hz, 2H), 7.50 (t, J = 8.0 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.83 (d,J = 8.0 Hz, 1H), 1.60 (s, 9H). Reg-1-61

¹H NMR (400 MHz, DMSO- d₆) δ 9.83 (s, 1H), 8.65 (s, 1H), 8.27 (s, 1H), 8.18 (d, J = 6.0 Hz, 2H), 7.74 (d, J = 8.6 Hz, 2H), 7.66 (d, J = 8.6 Hz, 2H), 1.60 (s, 9H).

Intermediate Example 14

Step 1:

A mixture of compound Reg-1-62-1 (200 mg, 1.26 mmol) and tert-butanol (12 mL) was added with 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine (236 mg, 1.26 mmol) and trifluoroacetic acid (716 mg, 5 mmol), and the reaction was heated to 100° C. for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, to afford crude product Reg-1-62-2 (800 mg, yellow solid), which was used directly in the next reaction step. ¹H NMR (400 MHz, DMSO-d₆) δ 12.05 (s, 1H), 10.39 (s, 1H), 8.11 (s, 2H), 7.87 (d, J=8.7 Hz, 2H), 7.74 (t, J=2.9 Hz, 1H), 7.66 (d, J=8.7 Hz, 2H), 6.45 (dd, J=2.9, 2.0 Hz, 1H).

MS m/z (ESI): 310.7 [M+H, Cl].

Step 2:

Compound Reg-1-62-2 (0.8 g, crude product, 1.26 mmol) and BOC anhydride (1.37 g, 6.28 mmol) were dissolved in DCM (20 mL), TEA (0.95 g, 9.42 mmol) and DMAP (0.019 g, 0.157 mmol) were added, and the reaction was stirred at room temperature overnight. LC-MS indicated the reaction was complete. The reaction was concentrated under reduced pressure, and the crude product was separated by flash column chromatography (petroleum ether:ethyl acetate=3:1˜1:3) to afford compound Reg-1-62 (0.63 g, yellow solid, yield: 78%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.80 (s, 1H), 8.72 (s, 1H), 8.31 (s, 1H), 8.07 (d, J=3.8 Hz, 1H), 7.82 (d, J=8.7 Hz, 2H), 7.74 (d, J=8.8 Hz, 2H), 6.73 (d, J=3.8 Hz, 1H), 1.67 (s, 9H), 1.62 (s, 9H). MS m/z (ESI): 510.9 [M+H, Cl].

The following intermediates were prepared according to methods similar to that described in Intermediate Example 14:

No. Structure of Intermediate Characterization Data Reg-1-63

¹H NMR (400 MHz, DMSO- d₆) δ 11.91 (s, 1H), 9.69 (s, 1H), 8.03 (s, 2H), 7.76 (d, J = 8.6 Hz, 2H), 7.63 (t, J = 8.2 Hz, 2H), 7.23 (s, 1H), 6.74 (s, 1H). MS m/z (ESI): 310.7 [M + H]. Reg-1-68

MS m/z (ESI): 407.8 [M + H].

Intermediate Example 15

Compound Reg-1-40 (110 mg, 0.3 mmol) was dissolved in acetonitrile (3 mL), and cesium carbonate (147 mg, 0.45 mmol) and iodomethane (64 mg, 0.45 mmol) were added. The reaction was stirred at room temperature overnight, and LC-MS indicated the reaction was complete. The solvents were evaporated off, and the residue was purified by preparative flash chromatography (EA/PE=0˜25%) to afford a light yellow solid Reg-1-67 (110 mg, yield: 90.9%). 1H NMR (400 MHz, DMSO-d₆) δ 8.78 (s, 1H), 8.33 (s, 1H), 8.19 (d, J=5.3 Hz, 1H), 7.80 (d, J=8.2 Hz, 2H), 7.41 (d, J=8.2 Hz, 2H), 3.44 (s, 3H), 1.61 (s, 9H).

Intermediate Example 16

Step 1:

Metallic sodium (3.9 g, 170 mmol) was added portionwise to ethanol (250 mL) under stirring, and the reaction was continually stirred until a clear solution was obtained. Urea (10.2 g, 170 mmol) was added in one portion, the mixture was heated to reflux for 15 minutes, and then slowly cooled to room temperature. Dimethyl 2-methoxymalonate (25 g, 154 mmol) was added to result in a pink precipitate, and the reaction solution was heated to 100° C. for 48 hours. LC-MS indicated the reaction was complete, the reaction solvent was removed through rotary evaporation under vacuum. The residue was added with water (200 mL), and the pH value was adjusted with concentrated hydrochloric acid to 3-4. The reaction was extracted with ethyl acetate (300 mL×2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated under vacuum to remove solvents, to afford a brown oil (23 g, crude product). MS m/z (ESI): 159.0 [M+H].

Step 2:

Compound Reg-1-69-2 (23 g, crude product, 145 mmol) and phosphorus oxychloride (50 mL) were mixed. The reaction was heated to 100° C., and allowed to proceed overnight. LC-MS assay indicated that the starting materials had disappeared, and the new product had no signal in MS assay. The reaction solution was cooled to room temperature, and phosphorus oxychloride was removed by rotary evaporation under vacumm. The residue was slowly added to a mixture of ice and water (200 mL), extracted with ethyl acetate (200 mL×2), the organic phases were combined, washed with saturated sodium bicarbonate (100 mL). The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated under vacuum to remove solvents. The residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1), to afford compound Reg-1-69-3 (13 g, white solid, 42% yield).

Step 3:

Compound Reg-1-69-3 (13.7 g, 64 mol) and methyl 2-hydroxyacetate (6.93 g, 77 mmol) were dissolved in tetrahydrofuran (300 mL), and cooled to −5° C.-0° C. under protection of nitrogen. NaH (3.08 g, 77 mmol) was added portionwise, and the reaction solution was allowed to warm to room temperature, and stirred 16 hours. LC-MS indicated the reaction was complete, the reaction solution was added with water (300 mL), and extracted with ethyl acetate (300 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated under vacuum to remove solvents. The residue was purified by column chromatography (petroleum ether:ethyl acetate=8:1), to afford compound Reg-1-69-4 (15.6 g, colourless oil, 91.3% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 5.15 (s, 2H), 3.90 (s, 3H), 3.73 (s, 2H). MS m/z (ESI): 266.8 [M+H].

Step 4:

Compound Reg-1-69-4 (14.6 g, 54.7 mmol) were dissolved in methanol (146 mL), sodium borohydride (6.2 g, 164 mmol) was added portionwise, and the reaction solution was stirred at room temperature for 16 hours. LC-MS indicated the reaction was complete, and the reaction was quenched by addition of water (10 mL). The reaction solvent was removed through rotary evaporation under vacuum to afford the crude compound Reg-1-69-5 (41 g, crude product). MS m/z (ESI): 238.7 [M+H].

Step 5:

Compound Reg-1-69-5 (41 g, crude product, 54.7 mmol) was dissolved in dichloromethane (300 mL), and cooled to −50° C. under protection of nitrogen. Boron tribromide (54.7 mL, 109.4 mmol) was slowly dropwise added, and the reaction solution was allowed to warm to room temperature, and stirred for 16 hours. LC-MS assay indicated that the reaction was substantially complete, the reaction solution was added with water (500 mL), and extracted with ethyl acetate (300 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was rotary evaporated under vacuum to remove solvents. The residue was purified by column chromatography (ethyl acetate), to afford compound Reg-1-69-6 (5.6 g).

¹H NMR (400 MHz, DMSO-d₆) δ 10.73 (s, 1H), 4.85 (s, 1H), 4.41 (t, J=4.9 Hz, 2H), 3.75 (t, J=4.9 Hz, 2H). MS m/z (ESI): 224.8 [M+H].

Step 6:

Compound Reg-1-69-6 (5.45 g, 24.2 mmol) and triphenylphosphine (7.63 g, 29.1 mmol) were dissolved in tetrahydrofuran (270 mL), diisopropyl azodiformate (5.88 g, 29.1 mmol) was added at room temperature under protection of nitrogen, and the reaction solution was stirred at room temperature for 16 h. LC-MS indicated the reaction was complete, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (petroleum ether:ethyl acetate=4:1 to 1:1), to afford compound Reg-1-69-7 (6.7 g, 53% purity).

¹H NMR (400 MHz, DMSO-d₆) δ 4.64-4.60 (m, 2H), 4.48-4.43 (m, 2H). MS m/z (ESI): 206.8 [M+H].

Step 7:

Compound Reg-1-69-7 (960 mg, 53% purity, 2.46 mmol) and 4-(1H-pyrazol-4-yl)aniline (390 mg, 2.46 mmol) were dissolved in N-methylpyrrolidinone (10 mL), N,N-diisopropylethylamine (1.3 mL, 7.38 mmol) was added, and the reaction solution was performed at 200° C. in the microwave for 2 hours. LC-MS assay indicated that the reaction was substantially complete, the reaction solution was added with water (80 mL), extracted with ethyl acetate (50 mL×2), and the organic phases were combined, and rotary evaporated under vacuum to remove solvents. The residue was purified by column chromatography (dichloromethane methanol=30:1) to afford compound Reg-1-69-8 (600 mg, 74% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 12.89 (s, 1H), 9.22 (s, 1H), 8.02 (d, J=28.9 Hz, 2H), 7.66 (d, J=8.5 Hz, 2H), 7.56 (d, J=8.6 Hz, 2H), 4.52 (s, 2H), 4.38 (s, 2H). MS m/z (ESI): 329.8 [M+H].

Step 8:

Compound Reg-1-69-8 (600 mg, 1.82 mmol) was dissolved in tetrahydrofuran (15 mL), BOC anhydride (834 mg, 3.82 mmol), triethylamine (0.76 mL, 5.46 mmol) and 4-dimethylaminopyridine (22 mg, 0.182 mmol) were respectively added, and the reaction solution was stirred at room temperature for 16 hours. LC-MS indicated the reaction was complete, the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (petroleum ether:ethyl acetate=4:1 to 1:1) to afford compound Reg-1-69 (350 mg, 36.3% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 8.74 (s, 1H), 8.30 (s, 1H), 7.73 (d, J=8.5 Hz, 2H), 7.21 (d, J=8.5 Hz, 2H), 4.63 (s, 2H), 4.44 (s, 2H), 1.60 (s, 9H), 1.42 (s, 9H). MS m/z (ESI): 552.0 [M+Na].

Intermediate Example 17

Compound Reg-1-84-1 (1.1 g, 6.0 mmol) was dissolved in tetrahydrofuran (20 mL), and cooled to −78° C. under protection of nitrogen. Benzylmagnesium chloride (6.0 mL, 6.0 mmol) was dropwise added, after which the reaction was allowed to warm to room temperature and proceed overnight. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, the residue was added with dichloromethane (30 mL) and water (30 mL), and extracted. The organic phase was washed with a concentrated salt solution (30 mL), dried over anhydrous sodium sulfate, and rotary evaporated under reduced pressure to afford the crude compound Reg-1-84-2 (1.5 g, oil).

¹H NMR (400 MHz, DMSO-d₆) δ 7.35 (d, J=8.0 Hz, 1H), 7.29-7.15 (m, 5H), 4.12 (s, 2H). MS m/z (ESI): 238.8 [M+H].

Intermediate Example 18

Compound Reg-1-16-e (0.3 g, 1.158 mmol) and 2,4-dichloro-5-(trifluoromethyl)pyrimidine (0.25 g, 1.158 mmol) were dissolved in N,N-dimethylformamide (20 mL), diisopropylethylamine (449 mg, 3.47 mmol) was added, and the reaction was performed in an ice-salt bath. LC-MS indicated the reaction was complete. The reaction solution was diluted with water (20 mL), and extracted with dichloromethane (30 mL×3). The organic phase was combined, dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford a residue, which was separated by flash column chromatography (petroleum ether/ethyl acetate=5:1˜1:5) to afford a mixture of compound Reg-1-85 and Reg-1-86 (396 mg, colourless oil, yield: 78%).

MS m/z (ESI): 439.9 [M+H](t_(R)=1.701 min), 439.9 [M+H](t_(R)=1.784 mi).

Preparation of Final Products

Example 1: preparation of 6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-N-(tetrahydrofuran-3-yl)benzo[b]thiophene-2-carboxamide (TDI01113)

Step 1:

Compound TDI01113-1 (500 mg, 1.95 mmol) was dissolved in anhydrous methanol (20 mL), thionyl chloride (4 mL) was slowly added, and the reaction was performed at 70° C. for 2 hours. Thin layer chromatography (petroleum ether:ethyl acetate=5:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, and concentrated under reduced pressure. The crude product was dissolved in dichloromethane (40 mL), and successively washed with saturated aqueous sodium carbonate (50 mL×2) and saturated brine (50 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound TDI01113-2 (550 mg, yellow solid, crude product).

¹H NMR (400 MHz, CDCl₃) δ 8.01 (s, 2H), 7.73 (d, J=8.4 Hz, 1H), 7.51 (d, J=8.4 Hz, 1H), 3.95 (s, 3H).

Step 2:

Compound TDI01113-2 (550 mg, 2.04 mmol) and bis(pinacolato)diboron (621 mg, 2.44 mmol) were dissolved in 1,4-dioxane (20 mL), potassium acetate (600 mg, 6.12 mmol) and Pd(dppf)Cl₂ (140 mg, 0.20 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 80° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=10:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (petroleum ether:ethyl acetate=20:1) to afford compound TDI01113-3 (600 mg, white solid, yield: 92.3%).

¹H NMR (400 MHz, CDCl₃) δ 8.35 (s, 1H), 8.06 (s, 1H), 7.87 (d, J=8.0 Hz, 1H), 7.80 (d, J=8.0 Hz, 1H), 3.95 (s, 3H), 1.38 (s, 12H).

Step 3:

Compound TDI01113-3 (600 mg, 1.90 mmol) and Reg-1-1 (546 mg, 1.58 mmol) were dissolved in a mixture of ethanol/water (10:1) (55 mL), sodium carbonate (335 mg, 3.16 mmol) and Pd(PPh₃)₂Cl₂ (112 mg, 0.16 mmol) were added, purge with argon was performed for 3 times, and the reaction mixture was placed in an oil bath at 110° C. overnight. Thin layer chromatography (ethyl acetate) indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was dissolved in water (40 mL), extracted with ethyl acetate (50 mL×2). The pH of the aqueous phase was adjusted to 2 with 4N HCl, the precipitated solid was filtered, dissolved in methanol, and then concentrated to afford compound TDI01113-4 (700 mg, yellow solid, crude product).

¹H NMR (400 MHz, DMSO-d₆) δ 11.90 (s, 1H), 9.06 (s, 1H), 8.37 (d, J=6.4 Hz, 2H), 8.25-8.18 (m, 4H), 7.68 (d, J=8.0 Hz, 2H), 7.51 (d, J=7.6 Hz, 1H), 7.20 (s, 1H). MS m/z (ESI): 388.1 [M+H].

Step 4:

Compound TDI01113-4 (200 mg, 0.52 mmol) and tetrahydrofuran-3-amine (54.6 mg, 0.62 mmol) were dissolved in N,N-dimethylformamide (10 mL), HATU (236 mg, 0.62 mmol) and diisopropylethylamine (268 mg, 2.08 mmol) were added, and the reaction was performed at room temperature overnight. Thin layer chromatography (dichloromethane/methanol=10:1) indicated the reaction was complete. Water (60 mL) was slowly added to the reaction solution, a large amount of solid precipitated and was filtered after being stirred for 30 minutes. The solid was purified by high-performance liquid chromatography to afford compound TDI01113 (56.2 mg, yellow solid, yield: 23.7%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.05 (s, 1H), 9.67 (s, 1H), 8.93 (s, 1H), 8.90 (d, J=6.4 Hz, 1H), 8.42 (dd, J=8.4, 1.2 Hz, 1H), 8.39 (d, J=6.0 Hz, 1H), 8.23 (s, 1H), 8.18 (s, 1H), 8.10 (s, 1H), 8.06 (d, J=8.4 Hz, 1H), 7.59 (s, 2H), 6.71 (d, J=6.0 Hz, 1H), 4.51-4.45 (m, 1H), 3.91-3.85 (m, 2H), 3.77-3.71 (m, 1H), 3.66-3.63 (m, 1H), 2.24-2.15 (m, 1H), 1.99-1.92 (m, 1H). MS m/z (ESI): 457.0 [M+H].

The compounds in Table 1 were prepared according to methods similar to that described in Example 1.

TABLE 1 Compound Starting material or regent different from that in Characterization No. Compound Structure Name Example 1 Data TDI- 01116

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)benzo [b]thio- phene-2- carboxamide

in step 4 of Example 1 was replaced with

¹H NMR (400 MHz, DMSO- d₆) δ 13.16 (s, 1H), 11.28 (s, 1H), 10.18 (s, 1H), 9.56 (s, 1H), 9.18 (d, J = 4.0 Hz, 1H), 8.98 (s, 1H), 8.53 (s, 1H), 8.41 (d, J = 4.0 Hz, 2H), 8.24 (d, J = 8.0 Hz, 1H), 8.17 (s, 2H), 8.14 (s, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.60 (s, 1H), 6.80 (d, J = 8.0 Hz, 1H). MS m/z (ESI): 465.1 [M + H]. TDI- 01121

6-(4-((1H- indazol-5- yl)amino)- 6-(2- (dimethyl- amino) ethoxy) pyrimidin- 2-yl)-N- isopropyl- benzo [b] thiophene-2- carboxamide

in step 3 of Example 1 was replaced with

(Reg-1-31); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 9.82 (s, 1H), 9.65 (s, 1H), 8.71 (s, 1H), 8.61 (d, J = 8.0 Hz, 1H), 8.18 (s, 1H), 8.14 (s, 1H), 8.05 d J = 6.0 Hz 2H), 8.01 (d J = 8.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.05 (s, 1H), 4.76-4.73 (m, 2H), 4.14-4.05 (m, 1H), 3.60 (s, 2H), 2.90 (s, 3H), 2.89 (s, 3H), 1.20 (d, J = 6.0 Hz, 6H). MS m/z (ESI): 516.2 [M + H]. TDI- 01127

2-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- isopropyl- 1H- indole-6- carboxamide

in step 3 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO- d₆) δ 11.88 (s, 1H), 10.22 (s, 1H), 8.34 (d, J = 6.3 Hz, 1H), 8.27 (s, 1H), 8.20 (d, J = 7.9 Hz, 1H), 8.16 (s, 1H), 8.05 (s, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.67-7.54 (m, 2H), 7.41 (s, 1H) 6.74 (d, J = 6.4 Hz, 1H), 4.17-4.11 (m, 1H), 1.19 (d, J = 6.6 Hz, 6H). MS m/z (ESI): 412.1 [M + H]. TDI- 01130

methyl 4-(6-(4- ((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indole-2- carbox- amido) benzoate

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.05 (s, 1H), 12.17 (s, 1H), 10.61 (s, 1H), 9.62 (s, 1H), 8.58 (s, 1H), 8.37 (d, J = 5.9 Hz, 1H), 8.30 (s, 1H), 8.24-8.11 (m, 2H), 8.01 (s, 4H), 7.80 (d, J = 8.6 Hz, 1H), 7.58 (d, J = 20.9 Hz, 3H), 6.68 (d, J = 5.9 Hz, 1H), 3.86 (s, 3H). MS m/z (ESI): 504.1 [M + H]. TDI- 01131

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (4-(4- methyl- piperazin- 1-yl) phenyl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.03 (s, 1H), 12.03 (s, 1H), 10.11 (s, 1H), 9.60 (s, 1H), 8.55 (s, 1H), 8.35 (d, J = 4.0 Hz, 1H), 8.30 (s, 1H), 8.16 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.59 (s, 2H), 7.42 (s, 1H), 6.96 (d, J = 16.0 Hz, 2H), 6.66 (d, J = 8.0 Hz, 1H), 3.12 (s, 4H), 2.46 (s, 4H), 2.23 (s, 3H). MS m/z (ESI): 544.2 [M + H]. TDI- 01132

methyl (6-(4- ((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indole-2- carbonyl) phenyl- alaninate

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.23 (s, 1H), 12.27 (s, 1H), 11.08 (s, 1H), 9.09 (d, J = 8.0 Hz, 1H), 8.35 (s, 1H), 8.30 (d, J = 4.0 Hz, 1H), 8.20 (s, 1H), 7.90 (s, 2H), 7.69- 7.62 (m, 2H), 7.33 (d, J = 8.0 Hz, 3H), 7.27 (t, J = 8.0 Hz, 2H), 7.19 (t, J = 8.0 Hz, 1H), 6.87 (s, 1H), 4.78-4.72 (m, 1H), 3.67 (s, 3H), 3.24-3.20 (m, 1H), 3.15-3.09 (m, 1H). MS m/z (ESI): 532.2 [M + H]. TDI- 01134

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)- N-(1- methyl- 1H- pyrazol- 4-yl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.23 (s, 1H), 12.41 (s, 1H), 10.83 (s, 1H), 8.50 (s, 1H), 8.32 (d, J = 6.7 Hz, 1H), 8.21 (s, 1H), 8.15- 8.03 (m, 2H), 7.86 (d, J = 8.5 Hz, 1H), 7.66 (d, J = 7.6 Hz, 2H), 7.43 (d, J = 2.5 Hz, 1H), 7.32 (s, 1H), 7.19 (s, 1H), 6.97 (s, 1H), 3.86 (s, 3H). MS m/z (ESI): 450.2 [M + H]. TDI- 01140

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (1-phenyl- ethyl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.17 (s, 1H), 12.18 (s, 1H), 10.77 (s, 1H), 8.98 (d, J = 8.0 Hz, 1H), 8.40 (s, 1H), 8.31 (d, J = 4.0 Hz, 1H), 8.19 (s, 2H), 7.94 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.67-7.62 (m, 2H), 7.44-7.33 (m, 5H), 7.24 (t, J = 8.0 Hz, 1H), 6.83 (d, J = 4.0 Hz, 1H), 5.26-5.22 (m, 1H), 1.53 (d, J = 8.0 Hz, 3H). MS m/z (ESI): 474.1 [M + H]. TDI- 01151

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- cyclo- propyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.36- 8.16 (m, 4H), 7.83 (s, 2H), 7.70 (s, 2H), 7.15 (s, 1H), 6.88 (br, 1H), 2.88 (s, 1H), 0.85-0.84 (d, J = 4.0 Hz, 2H), 0.68 (s, 2H). MS m/z (ESI): 410.2 [M + H]. TDI- 01152

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 9.60 (s, 1H), 9.27 (s, 1H), 8.83 (s, 1H), 8.54 (s, 1H), 8.35 (d, J = 5.6 Hz, 1H), 8.30 (s, 1H), 8.19-8.09 (m, 2H), 8.05-8.04 (m, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.64- 7.58 (m, 2H), 7.21 (s, 1H), 6.65 (d, J = 5.6 Hz, 1H). MS m/z (ESI): 448.2 [M + H]. TDI- 01153

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridin- 4-yl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.66 (d, J = 6.1 Hz, 2H), 8.47-8.34 (t, 3H), 8.27-8.12 (t, 3H), 7.94 (q, J = 8.8 Hz, 2H), 7.73-7.56 (m, 3H), 6.89 (d, J = 6.9 Hz, 1H). MS m/z (ESI): 447.1 [M + H]. TDI- 01156

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (isoxazol- 4-yl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.21 (s, 1H), 12.44 (s, 1H), 10.99 (s, 1H), 10.76 (s, 1H), 9.30 (s, 1H), 8.81 (s, 1H), 8.41 (d, J = 43.7 Hz, 2H), 8.20 (s, 2H), 7.96 (d, J = 28.6 Hz, 2H), 7.66 (s, 2H), 7.42 (s, 1H), 6.85 (s, 1H). MS m/z (ESI): 437.1 [M + H]. TDI- 01161

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyrimidin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.12 (s, 1H), 12.28 (s, 1H), 11.39 (s, 1H), 9.98 (s, 1H), 9.01 (s, 1H), 8.79 (s, 1H), 8.53 (s, 1H), 8.36 (d, J = 6.0 Hz, 1H), 8.29 (d, J = 5.2 Hz, 2H), 8.17 (s, 1H), 8.13 (d, J = 8.4 Hz, 1H),7.81 (d, J = 9.2 Hz, 2H), 7.62 (s, 2H), 6.74 (d, J = 6.0 Hz, 1H). MS m/z (ESI): 448.1 [M + H]. TDI- 01164

6-(7-((1H- indazol-5- yl)amino) imidazo [1,2- c]pyrimidin- 5- yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-8); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.24 (s, 1H), 12.33 (s, 1H), 10.97 (s, 1H), 10.31 (s, 1H), 9.59 (s, 1H), 9.14 (d, J = 5.8 Hz, 1H), 8.54 (s, 1H), 8.26 (s, 1H), 8.23 (s, 1H), 8.20- 8.16 (m, 2H), 8.10 (s, 1H), 7.87 (s, 2H), 7.81 (d, J = 8.9 Hz, 1H), 7.77-7.71 (m, 2H), 7.59 (s, 1H). MS m/z (ESI): 487.1 [M + H]. TDI- 01167

6-(4-((1H- indazol-5- yl)amino)- 1,3,5- triazin-2- yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-11); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.26- 12.93 (m, 1H), 12.41 (s, 1H), 11.03 (s, 1H), 10.30 (s, 1H), 9.60 (s, 1H), 9.16 (d, J = 5.2 Hz, 1H), 8.81 (s, 1H), 8.64 (s, 1H), 8.21 (s, 4H), 7.89 (d, J = 8.4 Hz, 1H), 7.63 (s, 3H). MS m/z (ESI): 449.3 [M + H]. TDI- 01169

6-(4-((1H- indazol-5- yl)amino) quinazolin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-2); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.54 (s, 1H), 11.15-11.07 (m, 2H), 9.60 (s, 1H), 9.16 (d, J = 4.8 Hz, 1H), 8.73 (d, J = 7.6 Hz, 1H), 8.48 (s, 1H), 8.24-8.22 (m, 3H), 8.06 (br.s, 3H), 7.86-7.73 (m, 4H), 7.64 (s, 1H). MS m/z (ESI): 498.1 [M + H]. TDI- 01171

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridin- 3-yl)- 1H- indole-2- carboxamide in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.52 (s, 1H), 10.90 (s, 1H), 10.85 (s, 1H), 9.17 (s, 1H), 8.52- 8.49 (m, 2H), 8.45- 8.39 (m, 2H), 8.26 (s, 2H), 8.05-7.98 (m, 2H), 7.74-7.64 (m, 4H), 6.92 (d, J = 6.4 Hz, 1H). MS m/z (ESI): 447.1 [M + H]. TDI- 01174

6-(4-((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin-2- yl)-N- (pyridazin-4- yl)-1H- indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-16) was used to replace

(Reg-1-1) in step 3; and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.52 (s, 1H), 11.14 (s, 1H), 10.60 (s, 1H), 9.61 (s, 1H), 9.19 (d, J = 5.9 Hz, 1H), 8.52 (s, 1H), 8.39 (d, J = 6.5 Hz, 1H), 8.26 (dd, J = 5.9, 2.5 Hz, 1H), 8.09 (s, 2H), 8.05 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.81 (d, J = 7.6 Hz, 2H), 7.72 (d, J = 8.5 Hz, 2H), 7.66 (s, 1H), 6.86 (d, J = 6.5 Hz, 1H). MS m/z (ESI): 474.1 [M + H]. TDI- 01175

6-(4-((1H- indazol-5- yl)amino) thieno [3,2- d]pyrimidin- 2- yl)-N- (pyridazin- 4- yl)-1H- indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-4); and

in step 4 was replaced

¹H NMR (400 MHz, DMSO-d₆) δ 12.39 (s, 1H), 11.15 (s, 1H), 10.32 (s, 1H), 9.62 (s, 1H), 9.20 (d, J = 5.6 Hz, 1H), 8.56 (s, 1H), 8.30- 8.26 (m, 2H), 8.19- 9.17 (m, 3H), 7.88 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.38-7.64 (m, 2H), 7.56 (d, J = 5.4 Hz, 1H). MS m/z (ESI): 504.1 [M + H]. TDI- 01176

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(1- hydroxy- propan- 2-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.38 (s, 1H), 8.24-8.09 (m, 3H), 7.84 (d, J = 8.5 Hz, 2H), 7.67 (t, J = 11.5 Hz, 2H), 7.22 (s, 1H), 6.85 (d, J = 7.0 Hz, 1H), 4.22 (dd, J = 12.6, 6.1 Hz, 1H), 3.65- 3.60 (m, 2H), 1.28 (d, J = 6.8 Hz, 4H). MS m/z (ESI): 428.2 [M + H]. TDI- 01177

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(4- (1H- pyrazol-4- yl)phenyl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

(Reg-1-16-e). ¹H NMR (400 MHz, CD₃OD) δ 7.99 (s, 2H) 7.80 (t, J = 6.9 Hz, 3H) 7.67 (d, J = 8.1 Hz, 2H), 7.37- 7.25 (m, 1H), 6.96 (s, 2H), 6.38 (d, J = 7.3 Hz, 1H), 5.01 (d, J = 16.9 Hz, 2H), 4.82 (s, 2H), 3.82 (s, 3H). MS m/z (ESI): 385.2 [M + H]. TDI- 01178

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin-4- ylmethyl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.38 (s, 1H), 11.11 (s, 1H), 9.41 (t, J = 5.9 Hz, 1H) 9.28-9.15 (m, 2H), 8.30 (m, J = 40.4, 33.4 Hz, 5H), 7.91 (s, 2H), 7.72- 7.60 (m, 3H), 7.34 (s, 1H), 6.89 (s, 1H), 4.62 (d, J = 5.8 Hz, 2H). MS m/z (ESI): 462.1 [M + H]. TDI- 01180

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(3- chloro- pyridazin- 4-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

1H NMR (400 MHz, CD₃OD) δ 9.07 (d, J = 5.4 Hz, 1H), 8.61 (d, J = 5.4 Hz, 1H), 8.41 (s, 1H), 8.35- 8.04 (m, 3H), 7.96 (d, J = 8.3 Hz, 1H), 7.90 (s, 1H), 7.70 (d, J = 7.5 Hz, 2H), 7.51 (s, 1H), 6.91 (s, 1H). MS m/z (ESI): 482.1 [M + H]. TDI- 01181

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(5- chloro- pyridazin- 4-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.2- 13.10 (m, 1H), 12.49 (s, 1H), 10.66 (s, 1H), 9.64 (s, 1H), 9.44 (s, 1H), 8.49 (s, 1H), 8.35 (d, J = 6.4 Hz, 1H), 8.18 (s, 1H), 8.06 (d, J = 7.4 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.63 (s, 3H), 6.80 (s, 1H). MS m/z (ESI): 482.2 [M + H]. TDI- 01182

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (1H- indazol-5- yl)-1H- indole- 2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.18 (s, 2H), 12.41 (s, 1H), 10.94 (s, 1H), 10.44 (s, 1H), 8.45 (s, 1H), 8.35 (d, J = 6.8 Hz, 1H), 8.29 (s, 1H), 8.16 (d, J = 42.0 Hz, 3H), 7.95 (m, J = 17.1, 8.5 Hz, 2H), 7.74-7.61 (m, 3H), 7.58 (d, J = 12.7 Hz, 2H), 6.87 (d, J = 6.3 Hz, 1H). MS m/z (ESI): 486.1 [M + H]. TDI- 01187

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 3- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 9.55 (s, 1H), 9.23 (d, J = 5.0 Hz, 1H), 8.78 (d, J = 4.7 Hz, 1H), 8.58 (s, 1H), 8.50 (d, J = 8.5 Hz, 1H), 8.41 (s, 1H), 8.22 (d, J = 7.2 Hz, 2H), 8.16 (s, 1H), 8.04 (dd, J = 3.5, 1.4 Hz, 1H), 7.86-7.57 (m, 2H), 6.92 (s, 1H). MS m/z (ESI): 448.2 [M + H]. TDI- 01188

5-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.23 (s, 1H), 12.46 (s, 1H), 11.09 (s, 1H), 10.93 (s, 1H), 9.60 (d, J = 1.6 Hz, 1H), 9.17 (d, J = 6.0 Hz, 1H), 8.70 (s, 1H), 8.36 (d, J = 6.8 Hz, 1H), 8.21 (dt, J = 22.4, 7.2 Hz, 4H), 7.68 (dd, J = 28.8, 19.2 Hz, 4H), 6.86 (d, J = 6.4 Hz, 1H). MS m/z (ESI): 448.2 [M + H]. TDI- 01189

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)-1H- pyrrolo [3,2-b] pyridine- 2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹NMR (400 MHz, DMSO-d₆) δ 13.08 (s, 2H), 12.78 (s, 1H), 11.14 (s, 1H), 10.07 (s, 1H), 9.61 (s, 1H), 9.46 (s, 1H), 9.18 (d, J = 6.0 Hz, 1H), 8.83 (s, 1H), 8.40 (d, J = 6.1 Hz, 1H), 8.21 (d, J = 3.3 Hz, 1H), 8.15 (s, 1H), 7.76 (s, 1H), 7.61 (t, J = 8.4 Hz, 2H), 6.78 (d, J = 6.1 Hz, 1H). MS m/z (ESI): 449.1 [M + H]. TDI- 01191

5-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 3- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 9.58 (s, 1H), 9.33 (s, 1H), 9.23 (d, J = 5.2 Hz, 1H), 8.59 (s, 1H), 8.54 (d, J = 4.8 Hz, 1H), 8.41 (s, 1H), 8.27-8.25 (m, 2H), 8.15 (d, J = 8.8 Hz, 1H), 7.78 (d, J = 8.8 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.63 (s, 1H), 6.93 (d, J = 6.0 Hz, 1H). MS m/z (ESI): 448.2 [M + H] TDI- 01193

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)-1H- benzo[d] imidazole- 2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 9.68 (d, J = 2.3 Hz, 1H), 9.21 (d, J = 6.2 Hz, 1H), 8.68 (s, 1H), 8.54 (dd, J = 6.1, 2.6 Hz, 1H), 8.24 (m, 4H), 7.95 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 8.3 Hz, 1H), 7.65 (s, 1H), 6.94 (d, J = 6.2 Hz, 1H). MS m/z (ESI): 449.0 [M + H]. TDI- 01199

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (1H- pyrazol-4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.23 (s, 1H), 12.40 (s, 1H), 11.02 (s, 1H), 10.66 (s, 1H), 8.42 (s, 1H), 8.33 (d, J = 6.8 Hz, 1H), 8.21 (s, 2H), 7.95-7.92 (m, 2H), 7.88 (s, 2H), 7.70-7.64 (m, 2H), 7.40 (s, 1H), 6.87 (d, J = 5.2 Hz, 1H). MS m/z (ESI): 436.1 [M + H]. TDI- 01200

tert-butyl 4-(6- (4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indole-2- carbox- amido)- 1H- pyrazole-1- carboxylate

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.58 (s, 1H), 8.54 (s, 1H), 8.30 (d, J = 6.0 Hz, 1H), 8.25 (s, 1H), 8.19-8.09 (m, 2H), 7.99 (s, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.66-7.60 (m, 2H), 7.29 (s, 1H), 6.66 (d, J = 6.0 Hz, 1H), 1.66 (s, 9H). MS m/z (ESI): 536.1 [M + H]. TDI- 01201

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1- methyl-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide The preparation started from step 3 of Example 1,

in step 3 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 11.24 (s, 1H), 10.97 (s, 1H), 9.57 (s, 1H), 9.19 (d, J = 5.6 Hz, 1H), 8.54 (s, 1H), 8.40 (d, J = 6.4 Hz, 1H), 8.24 (s, 2H), 8.17 (s, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.61-7.57 (m, 2H), 6.89 (d, J = 6.0 Hz, 1H), 4.11 (s, 3H). MS m/z (ESI): 462.2 [M + H]. TDI- 01213

6-(4-((1H- indazol-5- yl)amino)- 5- fluoro- pyrimidin- 2-yl)-N- (pyridazin- 4- yl)-1H- indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-12); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD + DMSO- d₆) δ 9.64 (s, 1H), 9.19 (s, 1H), 8.53- 8.47 (m, 2H), 8.41 (d, J = 3.6 Hz, 1H), 8.36 (s, 1H), 8.22 (s, 1H), 8.16 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 8.8 Hz, 1H), 7.57 (s, 1H). MS m/z (ESI): 466.1 [M + H]. TDI- 01214

6-(4- ((6-fluoro- 1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-17); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.35 (s, 1H), 11.02 (s, 1H), 9.91 (s, 1H), 9.60 (s, 1H), 9.14 (d, J = 5.2 Hz, 1H), 8.43 (s, 1H), 8.39 (d, J = 6.0 Hz, 1H), 8.27- 8.14 (m, 3H), 8.02 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.60 (s, 1H), 7.55 (d, J = 10.8 Hz, 1H), 6.78 (d, J = 3.6 Hz, 1H). MS m/z (ESI): 466.1 [M + H]. TDI- 01215

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- phenyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.22 (s, 1H), 12.40 (s, 1H), 10.85 (s, 1H), 10.39 (s, 1H), 8.45 (s, 1H), 8.34 (d, J = 6.8 Hz, 1H), 8.20 (s, 2H), 7.98 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 7.6 Hz, 2H), 7.66 (t, J = 9.2 Hz, 2H), 7.56 (s, 1H), 7.40 (t, J = 7.6 Hz, 2H), 7.14 (t, J = 7.2 Hz, 1H), 6.86 (d, J = 5.6 Hz, 1H). MS m/z (ESI): 446.1 [M + H]. TDI- 01221

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)- N-(6- (dimethyl- amino) pyridin- 3-yl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.21 (s, 1H), 12.41 (s, 1H), 10.76 (s, 2H), 10.52 (s, 1H), 8.56 (s, 1H), 8.45 (s, 1H), 8.34 (d, J = 6.7 Hz, 1H), 8.20 (s, 2H), 8.11 (s, 1H), 8.00 (d, J = 8.3 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.66 (d, J = 8.8 Hz, 2H), 7.62 (s, 1H), 7.49 (s, 1H), 7.11 (s, 1H), 6.84 (s, 1H), 3.15 (s, 7H). MS m/z (ESI): 490.1 [M + H]. TDI- 01231

6-(4-((1H- indazol-5- yl)amino)- 5- (trifluoro- methyl) pyrimidin- 2- yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-23); and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 13.16 (s, 1H), 12.31 (s, 1H), 11.06 (s, 1H), 9.58 (d, 1H), 9.17 (m, 2H), 8.75 (s, 1H), 8.45 (s, 1H), 8.26 (dd, 1H), 8.14 (s, 1H), 7.95 (dd, 1H), 7.88 (s, 1H), 7.76 (d, 1H), 7.60 (m, 3H). MS m/z (ESI): 516.2 [M + H]. TDI- 01232

6-(4-((1H- indazol-5- yl)amino)- 5,6- dimethyl- pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-13); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.16 (s, 1H), 12.45 (s, 1H), 10.98 (s, 1H), 9.58 (s, 2H), 9.14 (s, 1H), 8.29 (s, 1H), 8.17 (s, 2H), 8.00 (s, 1H), 7.89 (d, J = 8.4 Hz, 2H), 7.64 (s, 2H), 7.59 (s, 1H), 2.58 (s, 3H), 2.31 (s, 3H). MS m/z (ESI): 476.3 [M + H]. TDI- 01248

tert-butyl 5-(6- (4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indole-2- carbox- amido)- 1H- indazole-1- carboxylate

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, CDCl₃ + CD₃OD) δ 8.46 (s, 1H), 8.36 (s, 1H), 8.26-8.20 (t, 2H), 8.13 (d, J = 9.5 Hz, 2H), 8.07 (d, J = 9.0 Hz, 2H), 7.82 (t, J = 8.9 Hz, 2H), 7.63 (d, J = 8.8 Hz, 1H), 7.58 (d, J = 8.9 Hz, 1H), 7.47 (s, 1H), 7.40 (s, 1H), 6.69 (d, J = 6.1 Hz, 1H), 1.76 (s, 9H). MS m/z (ESI): 586.2 [M + H]. TDI- 01250

6-(4-((1H- indazol-5- yl)amino)- 5- methyl- pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-14); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.17 (br, 1H), 12.52 (s, 1H), 11.04 (s, 1H), 9.95 (br, 1H), 9.59 (d, J = 4.0 Hz, 1H), 9.16 (d, J = 8.0 Hz, 1H), 8.31 (d, J = 5.2 Hz, 2H), 8.22-8.18 (m, 2H), 8.05 (s, 1H), 7.91 (d, J = 8.6 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.68 (s, 2H), 7.61 (s, 1H), 2.36 (s, 3H). MS m/z (ESI): 462.3 [M + H]. TDI- 01251

6-(4-((1H- indazol-5- yl)amino)- 6- methyl- pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-15); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.20 (s, 1H), 12.55 (s, 1H), 11.11 (s, 1H), 10.78 (s, 1H), 9.62 (d, J = 2.0 Hz, 1H), 9.18 (d, J = 6.0 Hz, 1H), 8.43 (s, 1H), 8.20 (dt, J = 40.4, 13.2 Hz, 3H), 7.97 (d, J = 8.8 Hz, 2H), 7.71- 7.47 (m, 3H), 6.71 (s, 1H), 2.54 (s, 3H). MS m/z (ESI): 462.1 [M + H]. TDI- 01258

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (1H- pyrrolo [2,3- b]pyridin- 5-yl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.14 (s, 1H), 12.41 (s, 1H), 11.64 (s, 1H), 10.91 (s, 1H), 10.46 (s, 1H), 8.52 (d, J = 2.3 Hz, 1H), 8.44 (s, 1H), 8.35 (dd, J = 16.0, 4.5 Hz, 2H), 8.20 (s, 1H), 7.94 (dd, J = 8.8 Hz, 2H), 7.72-7.48 (m, 5H), 6.87 (s, 1H), 6.49 (dd, J = 3.3, 1.8 Hz, 1H). MS m/z (ESI): 486.2 [M + H]. TDI- 01275

6-(4-((3- methyl-1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-25); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.82- 12.59 (m, 1H), 12.43 (s, 1H), 10.99 (s, 1H), 10.37 (s, 1H), 9.60 (s, 1H), 9.14 (d, J = 5.6 Hz, 1H), 8.50 (s, 1H), 8.35 (d, J = 6.4 Hz, 1H), 8.18 (d, J = 3.6 Hz, 2H), 8.09 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.62 (s, 1H), 7.55 (s, 1H), 6.78 (d, J = 5.6 Hz, 1H), 2.54 (s, 3H). MS m/z (ESI): 462.2 [M + H]. TDI- 01276

6-(4-((4- methyl-1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-26); and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 13.22 (s, 1H), 12.48 (s, 1H), 11.00 (s, 1H), 9.59 (d, J = 2.3 Hz, 1H), 9.15 (d, J = 6.0 Hz, 1H), 8.34 (s, 1H), 8.29 (d, J = 6.7 Hz, 1H), 8.24 (s, 1H), 8.20-8.16 (m, 1H), 7.90 (s, 2H), 7.61 (s, 1H), 7.50 (d, J = 8.7 Hz, 1H), 7.39 (s, d, J = 8.2 Hz, 1H), 2.50 (s, 3H). MS m/z (ESI): 462.2 [M + H]. TDI- 01278

6-(2-((1H- indazol-5- yl)amino)- 5- (trifluoro- methyl) pyrimidin- 4- yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-24); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.98 (s, 1H), 12.26 (s, 1H), 11.04 (s, 1H), 10.34 (s, 1H), 9.59 (d, 1H), 9.17 (d, 1H), 8.86 (s, 1H), 8.24 (m, 2H), 8.03 (s, 1H), 7.88 (d, 1H), 7.76 (s, 1H), 7.63 (s, 2H), 7.50 (d, 1H), 7.34 (d, 1H). MS m/z (ESI): 516.2 [M + H]. TDI- 01282

6-(2-((1H- indazol-5- yl)amino)- 5,6- dimethyl- pyrimidin- 4-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-22); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 10.13 (s, 2H), 9.70 (s, 1H), 8.96 (s, 1H), 8.82 (s, 1H), 8.50 (s, 1H), 8.40-8.23 (m, 3H), 8.10 (d, J = 12.0 Hz, 3H), 7.93 (dd, J = 34.6, 8.8 Hz, 3H), 3.02 (s, 3H), 2.75 (s, 3H). MS m/z (ESI): 476.3 [M + H]. TDI- 01285

5-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- isopropyl- 1H- indole-3- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.17 (s, 1H), 11.97 (s, 1H), 10.96 (s, 1H), 9.33 (s, 1H), 8.52 (s, 1H), 8.36 (s, 1H), 8.30 (d, J = 6.8 Hz, 1H), 8.21 (d, J = 2.4 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 7.6 Hz, 1H), 7.67-7.63 (m, 2H), 7.54 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 5.2 Hz, 1H), 4.25-4.17 (m, 1H), 1.23 (d, J = 6.4 Hz, 6H). MS m/z (ESI): 412.3 [M + H]. TDI- 01289

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(3- (dimethyl- amino) pyridin- 4-yl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 13.17 (s, 1H), 12.57 (s, 1H), 10.49 (s, 1H), 10.08 (s, 1H), 8.63 (s, 1H), 8.57-8.52 (m, 2H), 8.50 (s, 1H), 8.36 (d, J = 6.4 Hz, 1H), 8.23 (s, 1H), 8.18 (s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.66-7.61 (m, 3H), 6.81 (d, J = 6.4 Hz, 1H), 2.86 (s, 6H). MS m/z (ESI): 490.2 [M + H]. TDI- 01290

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(3- chloro- pyridin- 4-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.16 (s, 1H), 12.48 (s, 1H), 10.65 (s, 1H), 10.24 (s, 1H), 8.73 (s, 1H), 8.56 (d, J = 5.3 Hz, 1H), 8.46 (s, 1H), 8.34 (d, J = 6.6 Hz, 1H), 8.19 (s, 2H), 8.01 (d, J = 8.3 Hz, 1H), 7.92 (t, J = 6.0 Hz, 2H), 7.65 (t, J = 9.0 Hz, 2H), 7.59 (s, 1H), 6.83 (s, 1H). MS m/z (ESI): 481.1 [M + H]. TDI- 01291

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (tetrahydro- 2H- pyran- 4-yl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 10.84 (br, 1H), 8.51 (d, J = 7.7 Hz, 1H), 8.41 (s, 1H), 8.33 (d, J = 6.8 Hz, 1H), 8.20 (s, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.5 Hz, 1H), 7.68-7.61 (m, 2H), 7.30 (s, 1H), 6.85 (d, J = 6.1 Hz, 1H), 3.92 (d, J = 8.0 Hz, 3H), 3.43 (t, J = 12.0 Hz, 2H), 1.81 (d, J = 12.0 Hz, 2H), 1.62 (dt, J = 11.8, 7.8 Hz, 2H). MS m/z (ESI): 454.3 [M + H]. TDI- 01292

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- isopropyl- indoline- 2- carboxamide

in step 2 of Example 1 was replaced with

in step 4 was replaced with isopropylamine. 1H NMR (400 MHz, DMSO-d₆) δ 13.19 (s, 1H), 10.34 (s, 1H), 9.88 (s, 1H), 8.30 (d, J = 6.4 Hz, 1H), 8.17 (d, J = 25.2 Hz, 2H), 7.95 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.56 (dd, J = 35.6, 28.5 Hz, 3H), 7.25-7.14 (m, 1H), 6.77 (s, 1H), 4.26 (d, J = 9.2 Hz, 1H), 3.89 (d, J = 7.2 Hz, 1H), 2.89 (s, 2H), 1.24 (s, 3H), 1.14- 1.04 (m, 3H). MS m/z (ESI): 414.2 [M + H]. TDI- 01294

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N,N- dimethyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-16) was used to replace

(Reg-1-1) in step 3; and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.11 (s, 1H), 10.61 (s, 1H), 8.46 (s, 1H), 8.36 (d, J = 6.4 Hz, 1H), 8.08 (s, 2H), 7.99 (d, J = 8.8 Hz, 1H), 7.84-7.78 (m, 3H), 7.72 (d, J = 8.8 Hz, 2H), 7.00 (s, 1H), 6.85 (d, J = 6.4 Hz, 1H), 3.10 (s, 6H). MS m/z (ESI): 424.2 [M + H]. TDI- 01296

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- methyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-16) was used to replace

(Reg-1-1) in step 3; and

in step 4 was replaced with methylamine hydrochloride ¹H NMR (400 MHz, DMSO-d₆) δ 12.15 (s, 1H), 10.57 (s, 1H), 8.62 (d, J = 4.6 Hz, 1H), 8.46 (s, 1H), 8.35 (d, J = 6.6 Hz, 1H), 8.08 (s, 2H), 7.98 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 8.4 Hz, 3H), 7.71 (d, J = 8.5 Hz, 2H), 7.17 (s, 1H), 6.83 (d, J = 6.5 Hz, 1H), 2.85 (d, J = 4.5 Hz, 3H). MS m/z (ESI): 410.2 [M + H]. TDI- 01299

isopropyl 6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)- 1H-indole- 2- carboxylate

in step 1 of Example 1 was replaced with

(Reg-1-16) was used to replace

(Reg-1-1) in step 3; and

in step 4 was replaced with isopropanol. ¹H NMR (400 MHz, CD₃OD) δ 8.46 (s, 1H), 8.24 (d, J = 7.3 Hz, 1H), 8.06 (s, 2H), 7.92 (s, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.78 (s, 4H), 7.28 (s, 1H), 6.94 (d, J = 7.2 Hz, 1H), 5.34-5.25 (m, 1H), 1.44 (d, J = 6.2 Hz, 6H). MS m/z (ESI): 439.2 [M + H]. TDI- 01314

7-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)-2,3- dihydro- benzo[b] [1,4] dioxine- 2- carboxamide

in step 1 of Example 1 was replaced with

(TDI01314-1); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 9.40 (s, 1H), 9.15 (d, J = 6.1 Hz, 1H), 8.57 (d, J = 7.1 Hz, 1H), 8.47 (d, J = 3.1 Hz, 1H), 8.35 (d, J = 3.7 Hz, 1H), 8.18 (d, J = 7.2 Hz, 1H), 8.13 (s, 1H), 7.92 (s, 1H), 7.74 (s, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.87 (s, 1H), 5.16 (s, 1H), 4.60 (d, J = 3.8 Hz, 2H). MS m/z (ESI): 467.2 [M + H]. TDI- 01315

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(6- methoxy- pyridin- 3-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.16 (s, 1H), 12.37 (s, 1H), 10.67 (s, 1H), 10.45 (s, 1H), 8.58 (d, J = 2.4 Hz, 1H), 8.45 (s, 1H), 8.34 (d, J = 6.4 Hz, 1H), 8.20 (d, J = 6.4 Hz, 2H), 8.08 (dd, J = 8.8, 2.4 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.65 (t, J = 8.8 Hz, 2H), 7.50 (s, 1H), 6.89 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 6.4 Hz, 1H), 3.86 (s, 3H). MS m/z (ESI): 477.2 [M + H]. TDI- 01316

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(1- (1- methyl- piperidin- 4-yl)-1H- pyrazol- 4-yl)- 1H-indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.02 (s, 1H), 12.01 (s, 1H), 10.51 (s, 1H), 9.58 (s, 1H), 8.55 (s, 1H), 8.35 (d, 1H), 8.30 (s, 1H), 8.15 (t, 2H), 8.06 (s, 1H), 7.75 (d, 1H), 7.65 (s, 1H), 7.59 (s, 2H), 7.32 (s, 1H), 6.65 (d, 1H), 4.13 (m, 1H), 2.86 (d, 2H), 2.21 (s, 3H), 2.00 (m, 6H). MS m/z (ESI): 533.2 [M + H]. TDI- 01317

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (1′-methyl- [1,4′- bipiperidin]- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

1H NMR (400 MHz, CD₃OD) δ 8.45 (s, 1H), 8.26 (d, J = 6.0 Hz, 1H), 8.22 (s, 1H), 8.12-8.06 (m, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.65- 7.57 (m, 2H), 7.16 (s, 1H), 6.63 (d, J = 6.0 Hz, 1H), 3.95-3.90 (m, 1H), 3.11-3.01 (m, 4H), 2.45-2.40 (m, 2H), 2.39 (s, 3H), 2.30-2.19 (m, 2H), 2.04-1.94 (m, 4H), 1.72-1.64 (m, 5H). MS m/z (ESI): 550.3 [M + H]. TDI- 01318

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- (1′-methyl- [1,4′- bipiperidin]- 3- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.23 (s, 1H), 9.90 (s, 2H), 8.78 (d, J = 6.6 Hz, 1H), 8.43 (s, 1H), 8.34 (d, J = 6.6 Hz, 1H), 8.24 (s, 1H), 8.18 (s, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.64 (t, J = 10.5 Hz, 2H), 7.30 (s, 1H), 6.82 (d, J = 6.0 Hz, 1H), 4.30 (s, 1H), 2.99 (s, 6H), 2.79 (s, 3H), 2.33 (s, 2H), 1.95 (dd, J = 36.5, 12.4 Hz, 8H). MS m/z (ESI): 550.3 [M + H]. TDI- 01319

(6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indol-2- yl)(4- (4- methyl- piperazin- 1- yl) piperidin-1- yl) methanone

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.45 (s, 1H), 8.26 (d, J = 6.0 Hz, 1H), 8.22 (s, 1H), 8.08 (dd, J = 5.8, 2.6 Hz, 2H), 7.72 (d, J = 8.5 Hz, 1H), 7.61 (q, J = 8.9 Hz, 2H), 6.89 (s, 1H), 6.66 (d, J = 6.1 Hz, 1H), 4.97 (s, 6H), 4.56 (s, 3H), 3.96 (s, 4H), 2.76 (s, 4H), 2.50 (s, 3H). MS m/z (ESI): 536.3 [M + H]. TDI- 01320

(6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indol-2-yl) (9- methyl-3,9- diazaspiro [5.5] undecan-3- yl) methanone

in step 1 of Example 1 was replaced with

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 12.18 (s, 1H), 9.27 (s, 2H), 8.40 (s, 1H), 8.33 (d, J = 6.8 Hz, 1H), 8.19 (s, 2H), 7.95 (s, 2H), 7.81 (d, J = 8.6 Hz, 1H), 7.66 (d, J = 8.9 Hz, 1H), 7.62-7.56 (m, 1H), 6.86 (s, 2H), 3.29 (s, 2H), 3.09 (s, 2H), 2.79 (d, J = 4.5 Hz, 3H), 1.94 (d, J = 14.2 Hz, 2H), 1.71 (s, 2H), 1.49 (d, J = 26.0 Hz, 4H). MS m/z (ESI): 521.3 [M + H]. TDI- 01324

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- cyclopropyl- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-16) was used to replace

(Reg-1-1) in step 3; and

in step 4 was replaced with cyclopropylamine. ¹H NMR (400 MHz, DMSO-d₆) δ 12.09 (s, 1H), 10.55-10.29 (br, 1H), 8.61 (d, J = 4.0 Hz, 1H), 8.47 (s, 1H), 8.35 (d, J = 6.4 Hz, 1H), 8.07 (s, 2H), 7.98 (s, 1H), 7.79 (d, J = 8.0 Hz, 3H), 7.70 (d, J = 8.5 Hz, 2H), 7.19 (s, 1H), 6.81 (d, J = 6.8 Hz, 1H), 2.89 (d, J = 3.9 Hz, 1H), 0.75 (q, J = 7.0 Hz, 2H), 0.64-0.59 (m, 2H). MS m/z (ESI): 436.2 [M + H]. TDI- 01329

6-(4- ((3-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- isopropyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-38); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.07 (s, 1H) 10.46 (s, 1H), 8.45 (s, 1H), 8.38 (dd, J = 7.2, 3.6 Hz, 2H), 8.12-8.00 (m, 3H), 7.97 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.65 (s, 1H), 7.50-7.41 (m, 2H), 7.25 (s, 1H), 6.83 (d, J = 6.4 Hz, 1H), 4.18-4.13 (m, 1H), 1.21 (d, J = 6.4 Hz, 6H). MS m/z (ESI): 438.2 [M + H]. TDI- 01330

(6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-1H- indol-2- yl) (azetidin-1- yl) methanone

in step 1 of Example 1 was replaced with

(Reg-1-16) was used to replace

(Reg-1-1) in step 3; and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 12.19 (s, 1H), 10.77 (s, 1H), 8.48 (s, 1H), 8.35 (d, J = 6.7 Hz, 1H), 8.08 (s, 2H), 7.98 (d, J = 8.5 Hz, 1H), 7.88-7.76 (m, 3H), 7.72 (d, J = 8.5 Hz, 2H), 6.96-6.84 (m, 2H), 4.57 (s, 2H), 4.13 (s, 2H), 2.42- 2.33 (m, 2H). MS m/z (ESI): 436.2 [M + H]. TDI- 01331

(6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-1H- indol-2- yl) (morpholino) methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.41 (s, 1H), 8.20 (d, J = 7.2 Hz, 1H), 8.05 (s, 2H), 7.87 (s, 2H), 7.83 (d, J = 13.2 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 6.95 (s, 1H), 6.91 (d, J = 7.2 Hz, 1H), 3.86 (s, 4H), 3.76 (d, J = 4.4 Hz, 4H). MS m/z (ESI): 466.2 [M + H]. TDI- 01332

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N,N- diethyl-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.18 (s, 1H), 10.89-10.62 (br, 1H), 8.45 (s, 1H), 8.36 (s, 1H), 8.10 (d, J = 3.6 Hz, 2H), 7.96 (s, 1H), 7.91-7.75 (m, 3H), 7.73 (d, J = 7.9 Hz, 2H), 6.91 (s, 2H), 1.24 (s, 6H). MS m/z (ESI): 452.2 [M + H]. TDI- 01333

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N,N- dimethyl- benzo [b] thiophene- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-25); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 9.87 (s, 1H), 8.93 (s, 1H), 8.44-8.39 (m, 2H), 8.06 (t, J = 4.1 Hz, 2H), 7.89 (s, 1H), 7.79 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.5 Hz, 2H), 6.78 (d, J = 6.0 Hz, 1H), 3.27 (s, 3H), 3.09 (s, 3H). MS m/z (ESI): 441.1 [M + H]. TDI- 01334

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) thieno[3,2- d] pyrimidin- 2- yl)-N,N- dimethyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-33); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 11.92 (s, 1H), 10.09 (s, 1H), 8.56 (s, 1H), 8.29 (d, J = 5.2 Hz, 1H), 8.14 (d, J = 8.0 Hz, 1H), 8.09 (s, 2H), 7.92 (d, J = 8.0 Hz, 2H), 7.75-7.71 (m, 4H), 7.56 (d, J = 5.2 Hz, 1H), 6.95 (s, 1H), 2.54 (s, 6H). MS m/z (ESI): 480.2 [M + H]. TDI- 01335

(6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-1H- indol-2- yl)(3- methoxy- azetidin- 1- yl) methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.16 (s, 1H), 10.46 (s, 1H), 8.49 (s, 1H), 8.36 (d, J = 6.5 Hz, 1H), 8.07 (s, 2H), 8.01 (d, J = 8.7 Hz, 1H), 7.81 (d, J = 8.5 Hz, 3H), 7.71 (d, J = 8.5 Hz, 2H), 6.96 (s, 1H), 6.82 (d, J = 6.4 Hz, 1H), 4.73 (s, 1H), 4.44-4.27 (m, 4H), 3.92 (d, J = 7.5 Hz, 1H), 3.28 (s, 3H). MS m/z (ESI): 466.2 [M + H]. TDI- 01336

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)- N,N-bis(2- methoxy- ethyl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹NMR (400 MHz, DMSO-d₆) δ 12.00 (s, 1H), 10.27 (s, 1H), 8.49 (s, 1H), 8.36 (d, J = 6.3 Hz, 1H), 8.09-8.01 (m, 3H), 7.79 (dd, J = 17.6, 8.4 Hz, 3H), 7.69 (d, J = 8.5 Hz, 2H), 6.93 (s, 1H), 6.79 (d, J = 6.3 Hz, 1H), 3.61 (s, 8H), 3.29 (s, 6H). MS m/z (ESI): .2 [M + H]. TDI- 01337

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- (tetrahydro- furan- 3-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-16) was used to replace

(Reg-1-1) in step 3. ¹H NMR (400 MHz, CD₃OD) δ 8.40 (s, 1H), 8.19 (d, J = 6.8 Hz, 1H), 8.03 (s, 2H), 7.89-7.82 (m, 3H), 7.79-7.68 (m, 3H), 7.25 (s, 1H), 6.90 (d, J = 6.8 Hz, 1H), 4.63-4.59 (m, 1H), 4.02- 3.96 (m, 2H), 3.88- 3.82 (m, 1H), 3.78- 3.76 (m, 1H), 2.38- 2.28 (m, 1H), 2.07-2.00 (m, 1H). MS m/z (ESI): 466.2 [M + H]. TDI- 01338

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- (tetrahydro- 2H- pyran-4-yl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 12.23 (s, 1H), 10.89 (s, 1H), 8.52 (d, J = 7.8 Hz, 1H), 8.44 (s, 1H), 8.34 (d, J = 6.8 Hz, 1H), 8.09 (s, 2H), 7.94 (d, J = 8.7 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.79 (d, J = 7.5 Hz, 2H), 7.74 (d, J = 8.5 Hz, 2H), 7.31 (s, 1H), 6.89 (d, J = 6.8 Hz, 1H), 3.92 (s, 1H), 3.89 (s, 1H), 3.45- 3.39 (m, 3H), 1.81 (d, J = 12.6 Hz, 2H), 1.67-1.62 (m, 1H), 1.62-1.56 (m, 1H). MS m/z (ESI): 480.2 [M + H] TDI- 01339

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(1- methyl- pyrrolidin- 3-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-16) was used to replace

(Reg-1-1) in step 3; and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.07 (s, 1H), 10.31 (s, 1H), 10.15 (s, 1H), 8.90 (d, J = 52.4 Hz, 1H), 8.51 (s, 1H), 8.36 (d, J = 5.6 Hz, 1H), 8.06 (d, J = 12.0 Hz, 3H), 7.93- 7.73 (m, 2H), 7.68 (d, J = 7.6 Hz, 1H), 7.27 (s, 1H), 6.78 (d, J = 5.6 Hz, 1H), 4.71 (s, 2H), 3.09- 3.02 (m, 1H), 2.91 (d, J = 12.4 Hz, 3H), 2.77 (s, 1H), 2.33 (s, 3H), 2.11 (s, 2H). MS m/z (ESI): 479.2 [M + H]. TDI- 01340

6-(4-((2- methoxy- 4- (1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N,N- dimethyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-32); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.17 (d, J = 7.3 Hz, 1H), 8.09 (s, 2H), 7.86-7.82 (m, 2H), 7.41-7.32 (m, 2H), 7.01 (s, 1H), 3.98 (s, 3H), 3.30 (s, 6H). MS m/z (ESI): 454.2 [M + H]. TDI- 01341

6-(4- ((2-fluoro- 4-(1H- pyrazol- 4- yl)phenyl) amino) pyrimidin- 2- yl)-N,N- dimethyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-29); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 11.96 (s, 1H), 9.96 (s, 1H), 8.46-8.36 (m, 2H), 8.15 (s, 2H), 8.09-7.94 (m, 2H), 7.73 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 12.5 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 6.94 (s, 1H), 6.86 (s, 1H), 3.08 (s, 6H). MS m/z (ESI): 442.2 [M + H]. TDI- 01342

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(2- methoxy- ethyl)- N-methyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆ + D₂O) δ 8.42 (s, 1H), 8.30 (d, J = 7.2 Hz, 1H), 8.10 (s, 2H), 7.90 (s, 2H), 7.77 (s, 4H), 7.61 (t, J = 10.0 Hz, 1H), 7.05 (s, 1H), 6.93 (d, J = 7.2 Hz, 1H), 3.60 (t, J = 5.6 Hz, 2H), 3.37 (s, 1H), 3.29 (s, 3H), 3.07 (s, 3H), 2.78 (s, 1H). MS m/z (ESI): 468.2 [M + H]. TDI- 01343

(6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-1H- indol-2- yl)(4- methyl- piperazin- 1- yl) methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.14 (s, 1H), 10.34 (s, 1H), 10.06 (s, 1H), 8.49 (s, 1H), 8.37 (d, J = 6.4 Hz, 1H), 8.06 (s, 2H), 8.04 (s, 1H), 7.80 (d, J = 8.0 Hz, 3H), 7.69 (d, J = 8.4 Hz, 2H), 7.02 (s, 1H), 6.81 (d, J = 6.0 Hz, 1H), 4.61 (s, 2H), 3.52 (s, 4H), 3.16 (s, 2H), 2.88 (s, 3H). MS m/z (ESI): 479.2 [M + H]. TDI- 01344

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- methyl- N- (oxetan-3- yl)-1H- indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD + DMSO- d₆) δ 8.56 (s, 1H), 8.34 (d, J = 5.8 Hz, 1H), 8.17 (d, J = 8.5 Hz, 1H), 8.03 (s, 2H), 7.84 (d, J = 8.5 Hz, 2H), 7.75 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 6.92 (s, 1H), 6.68 (d, J = 5.9 Hz, 2H), 4.85 (dt, J = 17.3, 6.9 Hz, 4H), 4.12 (s, 1H), 3.40 (s, 3H). MS m/z (ESI): 466.2 [M + H]. TDI- 01344- 2A

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(1,3- dihydroxy- propan- 2-yl)-N- methyl-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 12.40 (s, 1H), 10.40 (s, 1H), 8.81 (s, 2H), 8.51 (s, 1H), 8.38 (d, J = 6.4 Hz, 1H), 8.07 (s, 2H), 7.87 (d, J = 8.5 Hz, 1H), 7.79 (d, J = 8.3 Hz, 2H), 7.70 (d, J = 8.5 Hz, 2H), 7.43 (s, 1H), 6.83 (d, J = 6.4 Hz, 1H), 5.70-5.40 (m, 2H), 4.56 (dd, J = 12.9, 5.0 Hz, 2H), 3.81 (dd, J = 13.0, 4.9 Hz, 2H), 3.59 (d, J = 4.9 Hz, 1H), 2.73 (S, 3H). MS m/z (ESI): 484.2 [M + H]. TDI- 01345

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- methyl- N- (pyrrolidin- 3-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.02 (s, 1H), 8.89 (s, 1H), 8.79 (s, 1H), 8.51 (s, 1H), 8.37 (d, 1H), 8.06 (d, 3H), 7.79 (q, 3H), 7.68 (d, 2H), 7.00 (s, 1H), 6.77 (d, 1H), 5.17 (m, 1H), 3.47 (m, 1H), 3.23 (dd, 4H), 2.25 (m, 2H), 2.11 (m, 2H). MS m/z (ESI): 479.2 [M + H]. TDI- 01346

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(1- methoxy- propan- 2-yl)-N- methyl-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.40 (s, 1H), 8.20 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.87-7.73 (m, 6H), 6.98 (d, J = 16.0 Hz, 1H), 6.90 (d, J = 7.2 Hz, 1H), 3.67-3.54 (m, 1H), 3.35 (s, 3H), 3.30 (s, 3H), 3.00 (s, 2H), 1.26 (d, J = 6.8 Hz, 3H). MS m/z (ESI): 482.2 [M + H]. TDI- 01347

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N- methyl-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.33 (s, 1H), 10.61 (s, 1H), 9.28 (d, J = 2.1 Hz, 1H), 9.23 (d, J = 5.7 Hz, 1H), 8.43 (s, 1H), 8.34 (d, J = 6.5 Hz, 1H), 8.19 (d, J = 13.4 Hz, 2H), 7.95 (d, J = 8.6 Hz, 1H), 7.78 (dd, J = 5.7, 2.7 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.63 (q, J = 8.8 Hz, 2H), 6.82 (d, J = 6.5 Hz, 1H), 6.39 (s, 1H), 3.59 (s, 3H). MS m/z (ESI): 462.2 [M + H]. TDI- 01348

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino)- 5- chloro- pyrimidin- 2-yl)-N,N- dimethyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-34); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 11.85 (s, 1H), 9.45 (s, 1H), 9.09 (s, 1H), 8.53 (s, 1H), 8.46 (s, 1H), 8.08 (s, 2H), 8.02 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.68 (dd, J = 8.8, 4.0 Hz, 3H), 6.92 (s, 1H), 2.77 (d, J = 4.8 Hz, 6H). MS m/z (ESI): 458.1 [M + H]. TDI- 01348 P-2

methyl 6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino)- 5- chloro- pyrimidin- 2-yl)-1H- indole-2- carboxylate

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-34); and step 4 was performed according to the esterification reaction in step 1. ¹H NMR (400 MHz, DMSO-d₆) δ 12.24 (s, 1H), 9.15 (s, 1H), 8.55 (s, 1H), 8.46 (s, 1H), 8.09 (s, 2H), 8.05 (d, J = 8.8 Hz, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.71 (dd, J = 16.8, 8.8 Hz, 3H), 7.20 (s, 1H), 3.90 (s, 3H). MS m/z (ESI): 445.1 [M + H]. TDI- 01350

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)- N,N,1- trimethyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.40 (s, 1H), 8.23 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.95 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 7.6 Hz, 3H), 6.91 (d, J = 7.2 Hz, 1H), 6.83 (s, 1H), 3.91 (s, 3H), 3.19 (s, 6H). MS m/z (ESI): 438.4 [M + H]. TDI- 01353

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N,N- dimethyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.17 (s, 1H), 10.91 (s, 1H), 8.41 (s, 1H), 8.33 (d, J = 6.7 Hz, 1H), 8.20 (s, 2H), 7.94 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.66 (t, J = 10.1 Hz, 2H), 6.99 (s, 1H), 6.87 (d, J = 6.5 Hz, 1H), 3.32 (s, 3H), 3.10 (s, 3H). MS m/z (ESI): 398.1 [M + H]. TDI- 01354

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(3- chloro- pyridin- 4-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.66 (s, 1H), 8.47 (s, 2H), 8.40 (d, J = 5.5 Hz, 1H), 8.23 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.98 (d, J = 8.6 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.76 (s, 4H), 7.50 (s, 1H), 6.93 (d, J = 7.2 Hz, 1H). MS m/z (ESI): 507.3 [M + H]. TDI- 01355

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)- N-methyl- N-(2,2,2- trifluoro- ethyl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.10 (s, 1H), 10.07 (s, 1H), 8.52 (s, 1H), 8.37 (d, J = 6.4 Hz, 1H), 8.18-7.99 (m, 3H), 7.93-7.76 (m, 3H), 7.68 (d, J = 8.0 Hz, 2H), 7.11 (s, 1H), 6.76 (d, J = 5.6 Hz, 1H), 2.77 (d, J = 4.8 Hz, 2H), 2.55 (s, 3H). MS m/z (ESI): 492.1 [M + H]. TDI- 01357

N,N- dimethyl- 6-(4-((3- methyl-1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-20); and

in step 4 was replaced with dimethylamine hydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δ 12.71 (s, 1H), 12.08 (s, 1H), 10.67-10.44 (m, 1H), 8.43 (s, 1H), 8.32 (d, J = 6.4 Hz, 1H), 8.21 (s, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.54 (s, 2H), 6.79 (s, 1H), 3.32 (s, 3H), 3.09 (s, 3H), 2.53 (s, 3H). MS m/z (ESI): 412.3 [M + H]. TDI- 01360

(6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indol-2-yl) (3,9- diazaspiro [5.5] undecan-3- yl) methanone

in step 1 of Example 1 was replaced with

in step 4 was replaced with

and then the product was obtained by removal of Boc protection using TFA. ¹H NMR (400 MHz, DMSO-d₆) δ 12.34 (s, 1H), 11.74 (s, 1H), 8.92 (s, 2H), 8.44 (s, 1H), 8.30 (d, J = 7.0 Hz, 2H), 8.22 (s, 1H), 8.02 (d, J = 8.5 Hz, 1H), 7.85 (d, J = 8.5 Hz, 1H), 7.75 (s, 1H), 7.69 (d, J = 8.6 Hz, 2H), 7.15 (s, 1H), 6.88 (s, 1H), 3.72 (s, 4H), 3.05 (s, 4H), 1.71 (s, 4H), 1.57 (s, 4H). MS m/z (ESI): 507.3 [M + H]. TDI- 01360 P-1

tert-butyl 9-(6- (4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indole-2- carbonyl)- 3,9- diazaspiro [5.5] undecan-3- carboxylate

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 1H), 8.26 (d, J =0 6.0 Hz, 1H), 8.21 (s, 1H), 8.08 (s, 2H), 7.70 (d, J = 8.6 Hz, 1H), 7.59 (s, 2H), 6.83 (s, 1H), 6.63 (d, J = 6.0 Hz, 1H), 3.84 (s, 4H), 3.45 (s, 4H), 1.63 (s, 4H), 1.55 (s, 4H), 1.46 (s, 9H). MS m/z (ESI): 607.5 [M + H]. TDI- 01363

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)- N-(pyridin- 4-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.38 (s, 1H), 11.40 (s, 1H), 9.96 (s, 1H), 8.75 (d, 2H), 8.58 (s, 1H), 8.39 (d, 1H), 8.28 (d, 2H), 8.15 (d, 1H), 8.05 (s, 2H), 7.89 (d, 1H), 7.83 (d, 2H), 7.68 (d, 3H), 6.76 (d, 1H). MS m/z (ESI): 473.2 [M + H]. TDI- 01368

(6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indol-2- yl) (hexahydro- pyrrolo [3,4- c]pyrrol-2 (1H)- yl) methanone

in step 1 of Example 1 was replaced with

in step 4 was replaced with

and then the product was obtained by removal of Boc using TFA. ¹H NMR (400 MHz, DMSO-d₆ + CD₃OD) δ 8.43 (s, 1H), 8.31 (d, J = 7.1 Hz, 2H), 8.21 (s, 1H), 7.91 (s, 2H), 7.70 (d, J = 7.5 Hz, 2H), 7.10 (s, 1H), 7.03 (s, 1H), 3.82 (d, J = 75.6 Hz, 4H), 3.46 (d, J = 12.0 Hz, 3H), 3.18 (d, J = 10.2 Hz, 3H). MS m/z (ESI): 480.3 [M + H]. TDI- 01369

(6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-1H- indol-2- yl)(2,6- diazaspiro [3.3] heptan-2- yl) methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

and then the product was obtained by removal of Boc using TFA. ¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 1H), 8.22 (d, J = 7.0 Hz, 1H), 8.02 (s, 2H), 7.90 (s, 2H), 7.75 (s, 4H), 6.99 (s, 1H), 6.91 (d, J = 7.2 Hz, 1H), 4.35 (s, 4H), 1.40-1.27 (m, 4H). MS m/z (ESI): 477.1 [M + H]. TDI- 01370

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) thieno[3,2- d] pyrimidin- 2- yl)-N- isopropyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-33); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.45 (s, 1H), 8.35 (d, J = 5.6 Hz, 1H), 8.06 (s, 2H), 7.96 (d, J = 8.8 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.8 Hz, 4H), 7.57 (d, J = 5.6 Hz, 1H), 7.19 (s, 1H), 4.29-4.22 (m, 1H), 1.29 (d, J = 6.4 Hz, 6H). MS m/z (ESI): 494.2 [M + H]. TDI- 01372

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(3- chloro- pyridin- 4- yl)benzo [b]thio- phene-2- carboxamide

in step 4 of Example 1 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 10.59 (s, 1H), 10.46 (s, 1H), 8.95 (s, 1H), 8.74 (s, 1H), 8.56 (d, J = 5.2 Hz, 1H), 8.52 (s, 1H), 8.41 (d, J = 6.4 Hz, 1H), 8.36 (d, J = 8.5 Hz, 1H), 8.23 (d, J = 8.5 Hz, 1H), 8.15 (s, 2H), 7.89 (d, J = 5.3 Hz, 1H), 7.63 (dd, J = 21.8, 8.8 Hz, 2H), 6.85 (d, J = 6.4 Hz, 1H). MS m/z (ESI): 498.1 [M + H]. TDI- 01379

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) thieno[3,2- d] pyrimidin-2- yl)-N- methyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-33); and

in step 4 was replaced with methylamine hydrochloride. ¹H NMR (400 MHz, CD₃OD) δ 8.46 (s, 1H), 8.35 (d, J = 5.6 Hz, 1H), 8.06 (s, 2H), 7.98 (dd, J = 8.8, 1.2 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.82-7.75 (m, 4H), 7.57 (d, J = 5.6 Hz, 1H), 7.11 (s, 1H), 2.96 (s, 3H). MS m/z (ESI): 466.1 [M + H]. TDI- 01380

(6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indol-2- yl)(3- (4- methyl- piperazin- 1- yl) piperidin-1- yl)methanone

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.21 (s, 1H), 10.86 (s, 1H), 8.41 (s, 1H), 8.34 (d, J = 6.7 Hz, 1H), 8.20 (s, 2H), 7.96 (d, J = 8.3 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.65 (t, J = 12.0 Hz, 2H), 6.87 (d, J = 11.1 Hz, 2H), 4.39 (s, 2H), 4.22 (s, 2H), 3.15 (s, 7H), 2.78 (s, 3H), 2.66 (s, 2H), 1.97 (s, 1H), 1.82 (s, 1H), 1.65- 1.46 (m, 2H). MS m/z (ESI): 536.3 [M + H]. TDI- 01385

methyl (6-(4- ((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indole-2- carbonyl) histidinate

in step 1 of Example 1 was replaced with

in step 4 was replaced with methyl histidinate. ¹H NMR (400 MHz, DMSO-d₆ + D₂O) δ 8.89 (d, J = 5.2 Hz, 1H), 8.33 (s, 1H), 8.25-8.14 (m, 3H), 7.89-7.87 (m, 2H), 7.69 (d, J = 8.4 Hz, 1H), 7.62 (s, 1H), 7.40 (s, 1H), 7.27 (s, 1H), 6.89 (d, J = 4.4 Hz, 1H), 4.92- 4.83 (m, 1H), 3.68 (s, 3H), 3.35- 3.30 (m, 1H), 3.26- 3.18 (m, 1H). MS m/z (ESI): 522.4 [M + H]. TDI- 01388

1-(6- (4-((4- (1H- pyrazol- 4- yl)phenyl) amino) pyrimidin-2- yl)-1H- indole- 2- carbonyl) pyrrol- idine-2- carbonitrile

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.17 (s, 1H), 10.14 (s, 1H), 9.80 (s, 1H), 8.55 (s, 1H), 8.38 (d, J = 5.6 Hz, 1H), 8.06 (dd, J = 19.2, 11.2 Hz, 3H), 7.82 (t, J = 8.0 Hz, 3H), 7.69 (d, J = 8.0 Hz, 2H), 7.17 (s, 1H), 6.79 (d, J = 5.6 Hz, 1H), 5.03 (s, 1H), 4.71 (d, J = 7.2 Hz, 1H), 4.05 (s, 1H), 2.34 (s, 1H), 2.14 (s, 2H), 1.99 (s, 1H). MS m/z (ESI): 475.2 [M + H]. TDI- 01390

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(1- (tetrahydro- 2H- pyran-4- yl) piperidin-3- yl)-1H- indole- 2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.21 (s, 1H), 10.53 (s, 1H), 9.70 (s, 1H), 8.76 (d, J = 7.6 Hz, 1H), 8.44 (s, 1H), 8.34 (d, J = 6.5 Hz, 1H), 8.24 (s, 1H), 8.18 (s, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.63 (q, J = 8.8 Hz, 2H), 7.29 (s, 1H), 6.81 (d, J = 6.5 Hz, 1H), 4.30 (s, 1H), 3.99 (d, J = 10.9 Hz, 2H), 3.38-3.28 (m, 4H), 2.92-2.77 (m, 2H), 2.00 (d, J = 8.4 Hz, 4H), 1.85- 1.58 (m, 4H), 1.31- 1.19 (m, 1H). MS m/z (ESI): 537.3 [M + H]. TDI- 01393

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- (pyridin- 4- yl)benzo [b]thio- phene-2- carboxamide

in step 3 of Example 1 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 11.74 (s, 1H), 9.95 (s, 1H), 9.03 (s, 1H), 8.79 (d, J = 6.8 Hz, 2H), 8.61 (s, 1H), 8.46 (dd, J = 12.2, 7.6 Hz, 2H), 8.27 (dd, J = 17.7, 7.7 Hz, 3H), 8.06 (s, 2H), 7.79 (d, J = 8.3 Hz, 2H), 7.69 (s, 2H), 6.81 (d, J = 6.0 Hz, 1H). MS m/z (ESI): 490.2 [M + H]. TDI- 01397

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- (pyridin- 3-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.35 (s, 1H), 10.69 (s, 1H), 10.37 (s, 1H), 9.08 (s, 1H), 8.53 (s, 1H), 8.45-8.31 (m, 3H), 8.07 (s, 3H), 7.90 (d, J = 8.2 Hz, 1H), 7.82 (d, J = 7.5 Hz, 2H), 7.71 (d, J = 7.9 Hz, 2H), 7.57 (s, 2H), 6.82 (d, J = 6.1 Hz, 1H). MS m/z (ESI): 473.1 [M + H]. TDI- 01398

1-(6- (4-((4- (1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)- 1H-indole- 2- carbonyl) azetidine- 3- carbonitrile

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.43 (s, 1H), 8.21 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.88- 7.86 (m, 1H), 7.81- 7.73 (m, 4H), 7.00 (s, 1H), 6.92 (d, J = 7.2 Hz, 1H), 4.55 (s, 2H), 4.39 (s, 2H), 3.91-3.85 (m, 1H). MS m/z (ESI): 461.2 [M + H]. TDI- 01402

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- ethyl-N- methyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 12.16 (s, 1H), 10.79 (s, 1H), 8.44 (s, 1H), 8.35 (d, J = 6.7 Hz, 1H), 8.09 (s, 2H), 7.96 (d, J = 8.5 Hz, 1H), 7.81 (dd, J = 17.7, 7.6 Hz, 3H), 7.73 (d, J = 8.5 Hz, 2H), 6.98 (s, 1H), 6.87 (d, J = 6.6 Hz, 1H), 3.61 (s, 3H), 3.31 (s, 2H), 1.23 (s, 3H). MS m/z (ESI): 438.2 [M + H]. TDI- 01404

(6-(4- ((1H- indazol-5- yl)amino) thieno [3,2- d] pyrimidin- 2- yl)-1H- indol-2- yl)(3,9- diazaspiro [5.5] undecan-3- yl) methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-4); and

in step 4 was replaced with

and then the product was obtained by deprotection with HCl. ¹H NMR (400 MHz, CDCl₃) δ 9.28 (s, 1H), 8.57 (s, 1H), 8.31 (d, J = 8.4 Hz, 1H), 8.14 (s, 1H), 8.01 (s, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.67 (d, J = 5.6 Hz, 1H), 7.61 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.49 (d, J = 5.6 Hz, 1H), 6.80 (s, 1H), 3.95- 3.79 (m, 4H), 3.46- 3.41 (m, 4H), 1.57- 1.52 (m, 8H), 1.47 (s, 9H). MS m/z (ESI): 563.2 [M + H]. TDI- 01405

6-(4-((1H- indazol-5- yl)amino) thieno [3,2- d] pyrimidin- 2- yl)-N- methyl- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-4); and

in step 4 was replaced with methylamine hydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δ 13.16 (s, 1H), 11.95 (s, 1H), 10.07 (s, 1H), 8.60-8.49 (m, 2H), 8.28-8.08 (m, 4H), 7.73 (dd, J = 15.3, 8.8 Hz, 2H), 7.65 (d, J = 8.8 Hz, 1H), 7.52 (d, J = 5.4 Hz, 1H), 7.12 (s, 1H), 2.84 (d, J = 4.4 Hz, 3H). MS m/z (ESI): 440.3 [M + H]. TDI- 01406

6-(4-((1H- indazol-5- yl)amino) thieno [3,2- d] pyrimidin- 2- yl)-N,N- dimethyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-4);

in step 4 was replaced with dimethylamine hydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δ 13.17 (s, 1H), 11.94 (s, 1H), 8.51 (s, 1H), 8.18 (m, 3H), 7.88-7.41 (m, 4H), 6.94 (s, 1H), 3.09 (s, 6H). MS m/z (ESI): 454.1 [M + H]. TDI- 01415

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- ethyl-N- (2- hydroxy- ethyl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

1H NMR (400 MHz, CD₃OD) δ 8.40 (s, 1H), 8.20 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.87 (s, 2H), 7.75 (s, 4H), 7.04 (s, 1H), 6.90 (d, J = 7.2 Hz, 1H), 3.84 (d, J = 5.0 Hz, 2H), 3.77 (s, 4H), 1.32 (s, 3H). MS m/z (ESI): 468.1 [M + H]. TDI- 01417

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N,N- diethyl- benzo[b] thiophene- 2- carboxamide

in step 4 of Example 1 was replaced with diethylamine. ¹H NMR (400 MHz, DMSO-d₆) δ 13.12 (s, 1H), 10.31 (s, 2H), 8.89 (s, 1H), 8.39 (d, J = 6.3 Hz, 1H), 8.33 (d, J = 8.4 Hz, 1H), 8.12 (dd, J = 14.6, 9.1 Hz, 3H), 7.80 (s, 1H), 7.61 (d, J = 13.3 Hz, 2H), 6.80 (d, J = 6.2 Hz, 1H), 3.54-3.52 (m, 4H), 1.22-1.20 (m, 6H). MS m/z (ESI): 443.2 [M + H]. TDI- 01421

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin-2- yl)-N- methyl- N- (pyridin-4- yl)-1H- indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.35 (s, 1H), 10.42 (s, 1H), 8.68 (d, J = 6.6 Hz, 2H), 8.48 (s, 1H), 8.36 (d, J = 6.4 Hz, 1H), 8.07 (s, 2H), 7.98 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.3 Hz, 2H), 7.71 (dd, J = 10.2, 5.5 Hz, 5H), 6.82 (d, J = 6.5 Hz, 1H), 6.58 (s, 1H), 3.62 (s, 3H). MS m/z (ESI): 487.2 [M + H]. TDI- 01422

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) thieno[3,2- d] pyrimidin-2- yl)-N- ethyl-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-33); and

in step 4 was replaced with ethylamine hydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δ 11.96 (s, 1H), 10.12 (s, 1H), 8.65-8.52 (m, 2H), 8.30 (d, J = 5.2 Hz, 1H), 8.20- 8.06 (m, 3H), 7.98- 7.88 (m, 2H), 7.74 (t, J = 7.9 Hz, 3H), 7.57 (d, J = 5.3 Hz, 1H), 7.17 (s, 1H), 3.35 (d, J = 6.6 Hz, 2H), 1.17 (t, J = 7.1 Hz, 3H). MS m/z (ESI): 480.3 [M + H]. TDI- 01423

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) thieno[3,2- d] pyrimidin- 2- yl)-N- (tetrahydro- furan- 3-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-33). 1H NMR (400 MHz, CD₃OD) δ 8.41 (s, 1H), 8.36 (d, J = 4.4 Hz, 1H), 8.05 (s, 2H), 7.92 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.80- 7.72 (m, 4H), 7.56 (d, J = 4.8 Hz, 1H), 7.21 (s, 1H), 4.63- 4.61 (m, 1H), 4.05- 3.95 (m, 2H), 3.87- 3.85 (m, 1H), 3.80- 3.73 (m, 1H), 2.38-2.28 (m, 1H), 2.05-2.03 (m, 1H). MS m/z (ESI): 522.2 [M + H]. TDI- 01424

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) thieno[3,2- d] pyrimidin- 2- yl)-N- cyclobutyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-33); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.46 (s, 1H), 8.40 (s, 1H), 8.08 (br.s, 2H), 7.96 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.80-7.72 (m, 4H), 7.61 (d, J = 4.8 Hz, 1H), 7.22 (s, 1H), 4.58-4.51 (m, 1H), 2.39-2.37 (m, 2H), 2.21- 2.12 (m, 2H), 1.85- 1.76 (m, 2H). MS m/z (ESI): 506.3 [M + H]. TDI- 01425

(6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-1H- indol-2- yl)(3,9- diazaspiro [5.5] undecan-3- yl)methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16);

in step 4 was replaced with

and then the product was obtained by removal of Boc using TFA. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H), 8.18 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.84 (s, 2H), 7.71 (d, J = 7.9 Hz, 4H), 6.94-6.83 (m, 2H), 3.84 (s, 4H), 3.22 (s, 4H), 1.91- 1.75 (m, 4H), 1.69 (s, 4H). MS m/z (ESI): 533.3 [M + H]. TDI- 01428

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)- N-methyl- N-(2,2,2- trifluoro- ethyl) benzo[b] thiophene- 2- carboxamide

(Reg-1-1) in step 3 of Example 1 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 9.89 (s, 1H), 8.96 (s, 1H), 8.42 (d, J = 6.3 Hz, 2H), 8.08 (d, J = 16.4 Hz, 3H), 7.78 (d, J = 6.6 Hz, 2H), 7.68 (d, J = 7.6 Hz, 2H), 6.78 (d, J = 5.6 Hz, 1H), 4.47 (d, J = 9.1 Hz, 2H), 3.41 (s, 3H). MS m/z (ESI): 509.2 [M + H]. TDI- 01439

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) thieno [3,2- d] pyrimidin- 2- yl)-N- isopropyl- benzo [b] thiophene- 2- carboxamide

(Reg-1-1) in step 3 of Example 1 was replaced with

(Reg-1-33); and

in step 4 was replaced with isopropylamine. 1H NMR (400 MHz, DMSO-d₆) δ 9.99 (s, 1H), 8.97 (s, 1H), 8.59 (d, J = 7.2 Hz, 1H), 8.46 (d, J = 8.8 Hz, 1H), 8.30 (d, J = 5.6 Hz, 1H), 8.18 (s, 1H), 8.15- 8.02 (m, 3H), 7.88 (d, J = 8.8 Hz, 2H), 7.72 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 5.6 Hz, 1H), 4.13- 4.08 (m, 1H), 1.21 (d, J = 6.4 Hz, 6H). MS m/z (ESI): 511.1 [M + H]. TDI- 01456

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)- N-(2,2,2- trifluoro- ethyl) benzo[b] thiophene- 2- carboxamide

(Reg-1-1) in step 3 of Example 1 was replaced with

(Reg-1-16); and

in step 4 was replaced with trifluoroethylamine. ¹H NMR (400 MHz, DMSO-d₆) δ 9.93 (s, 1H), 9.49 (t, J = 6.3 Hz, 1H), 8.96 (s, 1H), 8.42 (dd, J = 6.6, 3.6 Hz, 2H), 8.29 (s, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.07 (s, 2H), 7.78 (d, J = 8.5 Hz, 2H), 7.68 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 6.0 Hz, 1H), 4.17-4.11 (m, 2H). MS m/z (ESI): 495.1 [M + H]. TDI- 01471

(6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)benzo [b]thio- phen-2-yl) (3,3- difluoro- azetidin- 1- yl) methanone

(Reg-1-1) in step 3 of Example 1 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 8.91 (s, 1H), 8.41-8.34 (m, 2H), 8.20 (d, J = 8.4 Hz, 1H), 8.11 (s, 2H), 8.01 (s, 1H), 7.80-7.76 (m, 4H), 6.96 (d, J = 6.8 Hz, 1H), 5.07 (s, 4H). MS m/z (ESI): 489.1 [M + H]. TDI- 01500

1-(6- (4-((4- (1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)benzo [b]thio- phene-2- carbonyl) azetidine-3- carbonitrile

(Reg-1-1) in step 3 of Example 1 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 9.86 (s, 1H), 8.95 (s, 1H), 8.44-8.40 (m, 2H) 8.11-8.03 (m, 3H), 7.96 (s, 1H), 7.78 (d, J = 8.2 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 6.78 (d, J = 5.9 Hz, 1H), 4.86 (s, 2H), 4.41 (s, 1H), 4.27 (s, 1H), 3.97 (d, J = 7.4 Hz, 1H). MS m/z (ESI): 478.1 [M + H]. TDI- 01525

(6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) thieno[3,2- d]pyrimidin- 2- yl)benzo [b]thio- phen-2-yl) (3,3- difluoro- azetidin- 1- yl) methanone

(Reg-1-1) in step 3 of Example 1 was replaced with

(Reg-1-33); and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 9.85 (s, 1H), 9.01 (s, 1H), 8.52 (dd, J = 8.5, 1.4 Hz, 1H), 8.44 (s, 2H), 8.27 (d, J = 5.4 Hz, 1H), 8.07 (d, J = 8.5 Hz, 1H), 8.00 (s, 1H), 7.89 (d, J = 8.6 Hz, 2H), 7.71 (d, J = 8.6 Hz, 1H), 7.56 (d, J = 5.4 Hz, 1H), 5.08 (s, 2H), 4.60 (s, 2H). MS m/z (ESI): 545.1 [M + H]. TDI- 01801

6-(4-((1H- indazol-5- yl)amino)- 6- methoxy pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-82); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.29 (s, 1H), 11.10 (s, 1H), 9.91 (s, 1H), 9.60 (s, 1H), 9.20 (d, J = 6.0 Hz, 1H), 8.30 (s, 1H), 8.22 (s, 1H), 8.18 (s, 1H), 8.07 (s, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.61 (s, 1H), 7.55 (t, J = 8.7 Hz, 2H), 6.93 (s, 1H), 4.01 (s, 3H). MS m/z (ESI): 478.2 [M + H]. TDI- 01803

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-4- methoxy-N- (pyridazin- 4- yl)benzo [b]thio- phene-2- carboxamide The synthesis started from step 2 of Example 1.

in step 2 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.04 (s, 1H), 11.06 (s, 1H), 9.72 (s, 1H), 9.55 (s, 1H), 9.11 (d, J = 5.8 Hz, 1H), 8.61 (d, J = 6.3 Hz, 2H), 8.57 (d, J = 3.9 Hz, 1H), 8.40 (d, J = 5.8 Hz, 1H), 8.31 (s, 1H), 8.10 (dd, J = 5.9, 2.6 Hz, 1H), 8.06 (s, 1H), 8.01 (s, 1H), 7.78 (t, J = 7.6 Hz, 1H), 7.58 (dd, J = 16.2, 8.8 Hz, 2H), 7.40-7.37 (m, 1H), 6.73 (d, J = 5.9 Hz, 1H), 4.12 (s, 3H). MS m/z (ESI): 494.9 [M + H]. TDI- 01804

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-4- fluoro-N- (pyridazin- 4- yl)benzo [b]thio- phene-2- carboxamide The synthesis started from step 2 of Example 1.

in step 2 of Example 1 was replaced with

and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 13.06 (s, 1H), 11.12 (s, 1H), 9.73 (s, 1H), 9.53 (s, 1H), 9.13 (d, J = 5.9 Hz, 1H), 8.86 (s, 1H), 8.58 (s, 1H), 8.39 (d, J = 5.8 Hz, 1H), 8.11 (dd, J = 14.1, 9.3 Hz, 4H), 7.59 (dd, J = 17.7, 8.8 Hz, 2H), 6.73 (d, J = 5.8 Hz, 1H). MS m/z (ESI): 482.8 [M + H]. TDI- 01808

6-(4-((1H- indazol-5- yl)amino)- 6-(2- (dimethyl- amino) ethoxy) pyrimidin- 2-yl)-N- (pyridazin- 4- yl)benzo [b]thio- phene-2- carboxamide

(Reg-1-1) in step 3 of Example 1 was replaced with

(Reg-1-31); and

in step 4 was replaced with

¹H NMR (400 MHz, CD₃OD) δ 9.60 (s, 1H), 9.27 (d, J = 5.9 Hz, 1H), 8.68 (s, 2H), 8.43 (s, 1H), 8.18-8.04 (m, 4H), 7.58 (dd, J = 27.2, 8.7 Hz, 2H), 6.99 (s, 1H), 3.79-3.71 (m, 1H), 3.67 (s, 2H), 3.27-3.22 (m, 1H), 3.03 (s, 6H). MS m/z (ESI): 552.3 [M + H]. TDI- 01811

6-(4-((1H- indazol-5- yl)amino)- 6- (dimethyl- amino) pyrimidin- 2- yl)-N- (pyridazin- 4- yl)-1H- indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-83); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.08 (s, 1H), 12.50 (s, 1H), 11.04 (s, 1H), 9.62 (s, 1H), 9.14 (d, J = 6.0 Hz, 1H), 8.22-8.07 (m, 4H), 7.97 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.65 (s, 1H), 7.58 (s, 2H), 6.80 (s, 1H), 3.27 (s, 6H). MS m/z (ESI): 490.7 [M + H]. TDI- 01813

6-(4-((1H- indazol-5- yl)amino)- 5- methoxy- pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-80); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.22 (s, 1H), 12.50 (s, 1H), 11.18 (s, 1H), 10.27 (s, 1H), 9.59 (s, 1H), 9.23 (s, 1H), 8.31 (s, 2H), 8.19 (s, 2H), 8.09 (s, 1H), 7.91 (d, J = 11.8 Hz, 2H), 7.76 (d, J = 8.9 Hz, 1H), 7.64 (d, J = 8.7 Hz, 2H), 4.10 (s, 3H). MS m/z (ESI): 477.9 [M + H]. TDI- 01814

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)- N-(1- (pyridin-4- yl)piperidin- 4- yl)-1H- indole- 2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 13.35 (s, 1H), 12.20 (s, 1H), 10.70 (s, 1H), 8.51 (d, J = 7.9 Hz, 1H), 8.42 (s, 1H), 8.33 (d, J = 6.5 Hz, 1H), 8.30-8.17 (m, 4H), 7.96 (d, J = 8.8 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.64- 7.62 (m, 2H), 7.28- 7.26 (m, 3H), 6.82 (d, J = 6.4 Hz, 1H), 4.29-4.26 (m, 3H), 3.42-3.36 (m, 2H), 2.05-2.02 (m, 2H), 1.63-1.60 (m, 2H). MS m/z (ESI): 529.9 [M + H]. TDI- 01815

(6-(4- ((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indol-2-yl) (4- (pyridin-4- yl) piperazin- 1- yl) methanone

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.42 (s, 1H), 12.15 (s, 1H), 8.47 (s, 1H), 8.36- 8.24 (m, 4H), 8.17 (s, 1H), 8.04 (d, J = 7.5 Hz, 1H), 7.80 (d, J = 8.6 Hz, 1H), 7.65-7.60 (m, 2H), 7.18 (d, J = 7.3 Hz, 2H), 7.00 (s, 1H), 6.76 (s, 1H), 4.02 (s, 2H), 3.88 (s, 2H). MS m/z (ESI): 515.9 [M + H]. TDI- 01818

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with a solution of ammonia in methanol. ¹H NMR (400 MHz, CD₃OD) δ 8.45 (s, 1H), 8.24 (d, J = 6.8 Hz, 1H), 8.01 (s, 2H), 7.94 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.77 (s, 2H), 7.72 (d, J = 8.0 Hz, 2H), 7.20 (s, 1H), 6.83 (d, J = 6.8 Hz, 1H). MS m/z (ESI): 396.0 [M + H]. TDI- 01819

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-3- chloro-N- methyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with methylamine hydrochloride. ¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 1H), 8.25 (d, J = 6.9 Hz, 1H), 8.02 (s, 2H), 8.00 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.78- 7.71 (m, 4H), 6.89 (d, J = 6.9 Hz, 1H). MS m/z (ESI): 444.0 [M + H]. TDI- 01820

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-3- chloro- N,N- dimethyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

1H NMR (400 MHz, CD₃OD) δ 8.39 (s, 1H), 8.23 (d, J = 8.0 Hz, 1H), 8.03 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.80- 7.70 (m, 4H), 6.93 (d, J = 8.0 Hz, 1H), 5.35 (s, 1H), 3.17 (s, 6H). MS m/z (ESI): 457.8 [M + H]. TDI- 01821

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-5- chloro-N- methyl- 1H- indole-2- carboxamide The synthesis started from step 2 of Example 1.

in step 2 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with MeNH₂. ¹H NMR (400 MHz, DMSO-d₆) δ 12.23 (s, 1H), 10.99 (s, 1H), 8.70 (s, 1H), 8.45 (d, J = 6.8 Hz, 1H), 8.05 (s, 2H), 7.99 (s, 1H), 7.84 (s, 1H), 7.67 (m, J = 14.1 Hz, 4H), 7.17 (s, 1H), 6.98 (s, 1H), 2.85 (d, J = 4.5 Hz, 3H). MS m/z (ESI): 443.8 [M + H]. TDI- 01822

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-5- chloro- N,N- dimethyl- 1H-indole- 2- carboxamide The synthesis started from step 2 of Example 1.

in step 2 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.20 (s, 1H), 11.10 (s, 1H), 8.46 (d, J = 6.9 Hz, 1H), 8.06 (s, 2H), 7.95 (s, 1H), 7.87 (s, 1H), 7.67 (m, J = 12.8 Hz, 4H), 7.03- 6.97 (m, 2H), 3.31 (d, J = 14.5 Hz, 3H), 3.08 (s, 3H). MS m/z (ESI): 457.7 [M + H]. TDI- 01823

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino)- 5- methoxy- pyrimidin- 2-yl)-N,N- diethyl-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-36);

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 11.97 (s, 1H), 8.37 (s, 1H), 8.12 (s, 1H), 8.07 (s, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 6.85 (s, 1H), 4.05 (s, 3H), 3.56 (s, 4H), 1.24 (s, 6H). MS m/z (ESI): 482.0 [M + H]. TDI- 01824

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-3- chloro-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.16 (d, J = 25.7 Hz, 1H), 12.69 (s, 1H), 10.92 (s, 1H), 10.38 (s, 1H), 9.51 (s, 1H), 9.18 (s, 1H), 8.49 (s, 1H), 8.37 (d, J = 6.4 Hz, 1H), 8.15 (d, J = 20.0 Hz, 4H), 7.85 (s, 1H), 7.62 (d, J = 8.6 Hz, 2H), 6.80 (s, 1H). MS m/z (ESI): 481.9 [M + H]. TDI- 01829 C

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(3- iodopyridin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.42 (s, 1H), 11.71 (s, 1H), 10.04 (s, 1H), 8.99 (s, 1H), 8.58 (dd, J = 28.0, 22.8 Hz, 2H), 8.38 (d, J = 6.3 Hz, 1H), 8.07 (s, 2H), 7.90 (dd, J = 22.7, 14.4 Hz, 2H), 7.81 (d, J = 4.8 Hz, 2H), 7.67 (dd, J = 26.4, 7.9 Hz, 2H), 7.52 (s, 1H), 7.20 (m, 1H), 6.82 (s, 1H). MS m/z (ESI): 598.8 [M + H]. TDI- 01836

4-(6- (4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-1H- indole-2- carbonyl)- 1,1- dimethyl- piperazin- 1-ium- chloride

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.18 (s, 1H), 12.20 (s, 1H), 10.02 (s, 1H), 8.46 (s, 1H), 8.34 (d, J = 6.3 Hz, 1H), 8.25 (s, 1H), 8.18 (s, 1H), 8.04 (s, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.62 (t, J = 9.7 Hz, 2H), 7.02 (s, 1H), 6.79 (s, 1H), 4.62 (s, 2H), 4.15 (s, 2H), 3.97 (s, 2H), 3.54 (s, 6H), 3.23 (s, 1H), 2.87 (s, 1H). MS m/z (ESI): 467.2 [M − Cl]. TDI- 01840

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(1- (pyridin-4- yl) piperidin-3- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.30 (s, 1H), 12.11 (s, 1H), 10.40-10.24 (m, 1H), 8.64 (d, J = 7.0 Hz, 1H), 8.46 (s, 1H), 8.33 (d, J = 6.3 Hz, 1H), 8.21 (d, J = 29.1 Hz, 3H), 8.03 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.62 (t, J = 8.2 Hz, 2H), 7.27 (s, 3H), 6.76 (s, 1H), 4.24 (d, J = 11.7 Hz, 1H), 4.14 (d, J = 13.2 Hz, 1H), 3.97 (s, 1H), 3.31- 3.30 (m, 1H), 3.28 (s, 1H), 2.04 (s, 1H), 1.92 (s, 1H), 1.81 (d, J = 11.7 Hz, 1H), 1.63 (s, 1H). MS m/z (ESI): 530.0 [M − H]. TDI- 01841

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(3- chloro- pyridin- 4-yl)- 1-methyl- 1H- indole-2- carboxamide The synthesis started from step 2 of Example 1.

in step 2 of Example 1 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 10.80 (s, 1H), 10.30 (s, 1H), 8.74 (s, 1H), 8.57 (s, 2H), 8.40 (d, J = 6.2 Hz, 1H), 8.20 (d, J = 23.4 Hz, 2H), 8.07 (d, J = 8.5 Hz, 1H), 7.95 (t, J = 7.1 Hz, 2H), 7.68 (d, J = 8.8 Hz, 1H), 7.61 (s, 1H), 7.54 (s, 1H), 6.87 (d, J = 6.7 Hz, 1H), 5.33 (s, 1H), 4.14 (s, 3H). MS m/z (ESI): 494.8 [M + H]. TDI- 01844

6-(4-((1H- indazol-5- yl)amino)- 5- chloro- pyrimidin- 2-yl)-N- (pyridazin- 4- yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-81); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.12 (d, J = 8.0 Hz, 1H), 12.25 (s, 1H), 10.97 (s, 1H), 9.58 (s, 1H), 9.19 (d, J = 26.2 Hz, 2H), 8.53 (s, 1H), 8.43 (s, 1H), 8.22 (s, 1H), 8.15 (s, 1H), 8.09 (s, 1H), 8.01 (d, J = 8.6 Hz, 1H), 7.75 (dd, J = 19.5, 13.8 Hz, 2H), 7.58 (d, J = 17.9 Hz, 1H). MS m/z (ESI): 481.9 [M + H]. TDI- 01845

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- methyl- N-(2- morpholino- ethyl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.03 (s, 1H), 10.1 (s, 1H), 9.61 (s, 1H), 8.53 (s, 1H), 8.37 (d, J = 6.0 Hz, 1H), 8.05 (s, 2H), 7.81 (t, J = 8.0 Hz, 2H), 7.68 (d, J = 8.0 Hz, 2H), 7.10 (s, 1H), 6.78 (d, J = 6.0 Hz, 1H), 4.02- 3.93 (m, 5H), 3.75- 3.59 (m, 6H), 3.25- 3.10 (m, 4H). MS m/z (ESI): 522.7 [M + H]. TDI- 01847

6-(4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(1- (3- chloro- pyridin- 4-yl) piperidin- 4-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.02 (s, 1H), 11.92 (s, 1H), 9.59 (s, 1H), 8.52 (s, 1H), 8.46 (d, J = 8.0 Hz, 1H), 8.41 (s, 1H), 8.38-8.28 (m, 3H), 8.14 (d, J = 8.5 Hz, 2H), 7.71 (d, J = 8.3 Hz, 1H), 7.59 (s, 1H), 7.24 (s, 1H), 7.10 (d, J = 5.5 Hz, 1H), 6.65 (d, J = 5.9 Hz, 1H), 4.07 (s, 1H), 3.62 (d, J = 12.4 Hz, 2H), 2.94 (t, J = 11.7 Hz, 2H), 1.99 (d, J = 10.6 Hz, 2H), 1.85- 1.73 (m, 2H). MS m/z (ESI): 563.6 [M + H]. TDI- 01847 B

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(1-(3- chloro- pyridin- 4-yl) piperidin- 4-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.05 (s, 1H), 10.11 (s, 1H), 8.52-8.48 (m, 3H), 8.36 (d, J = 6.0 Hz, 2H), 8.13 (s, 1H), 8.06-8.04 (m, 3H), 7.82 (d, J = 8.0 Hz, 2H), 7.77 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.27 (s, 1H), 7.20 (d, J = 8.0 Hz, 1H), 6.76 (d, J = 6.0 Hz, 1H), 4.13 (d, J = 8.0 Hz, 1H), 3.78 (d, J = 12.0 Hz, 2H), 3.07 (t, J = 12.0 Hz, 2H), 2.02-1.99 (m, 2H), 1.82- 1.74 (m, 2H). MS m/z (ESI): 589.8 [M + H]. TDI- 01848

(R)-6- (4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(1- (6- (trifluoro- methyl) pyridin-3- yl)ethyl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.17 (d, J = 14.0 Hz, 1H), 12.18 (s, 1H), 9.15 (s, 1H), 8.85 (s, 1H), 8.41 (s, 1H), 8.32 (d, J = 6.5 Hz, 1H), 8.18 (s, 2H), 8.11 (d, J = 8.0 Hz, 1H), 8.03-7.89 (m, 3H), 7.85 (s, 1H), 7.63 (s, 2H), 7.38 (s, 1H), 6.79 (s, 1H), 5.33 (d, J = 6.9 Hz, 1H), 1.59 (d, J = 6.9 Hz, 3H). MS m/z (ESI): 442.9 [M + H]. TDI- 01849

(R)-6- (4-((1H- indazol-5- yl)amino) pyrimidin- 2-yl)-N-(1- (pyridin-4- yl)ethyl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.14 (s, 1H), 12.17 (s, 1H), 9.17 (d, J = 6.5 Hz, 1H), 8.71 (s, 2H), 8.42 (s, 1H), 8.32 (d, J = 6.5 Hz, 1H), 8.19 (d, J = 13.8 Hz, 2H), 7.98 (s, 1H), 7.86 (d, J = 8.3 Hz, 1H), 7.74 (s, 2H), 7.63 (t, J = 9.2 Hz, 3H), 7.42 (s, 1H), 6.80 (s, 1H), 5.30 (m, 1H), 1.56 (d, J = 6.9 Hz, 3H). MS m/z (ESI): 475.0 [M + H]. TDI- 01849 B

(R)-6- (4-((4- (1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(1- (pyridin-4- yl)ethyl)- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.28 (s, 1H), 10.97 (s, 1H), 9.29 (d, J = 8.0 Hz, 1H), 8.85 (d, J = 8.0 Hz, 2H), 8.41 (s, 1H), 8.34 (d, J = 6.0 Hz, 1H), 8.09 (s, 2H), 8.02 (d, J = 8.0 Hz, 2H), 7.93 (s, 2H), 7.76-7.72 (m, 3H), 7.47 (s, 1H), 6.90 (d, J = 8.0 Hz, 1H), 5.42- 5.34 (m, 1H), 1.59 (d, J = 8.0 Hz, 3H). MS m/z (ESI): 500.9 [M + H]. TDI- 01852

(R)-(6- (4-((4- (1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-1H- indol-2- yl)(2- (hydroxy- methyl) morpholino) methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.27 (s, 1H), 8.42 (s, 1H), 8.34 (d, J = 8.0 Hz, 1H), 8.10 (s, 2H), 7.94 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.77- 7.72 (m, 3H), 6.94 (s, 1H), 6.89 (d, J = 8.0 Hz, 1H), 4.41 (m, 1H), 4.28 (m, 2H), 3.91 (m, 2H), 3.56-3.46 (m, 4H). MS m/z (ESI): 496.0 [M + H]. TDI- 01853

(R)-(6- (4-((4- (1H-pyrazol- 4- yl)phenyl) amino) pyrimidin- 2- yl)-1H- indol-2- yl)(3- (hydroxy- methyl) morpholino) methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.09 (s, 1H), 8.47 (s, 1H), 8.35 (d, J = 8.0 Hz, 1H), 8.07 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.79 (s, 2H), 7.70 (d, J = 8.0 Hz, 1H), 6.97 (s, 1H), 6.81 (d, J = 8.0 Hz, 1H), 4.41 (s, 1H), 4.17 (d, J = 12.0 Hz, 1H), 3.93-3.88 (m, 2H), 3.76- 3.72 (m, 2H), 3.67- 3.64 (m, 4H). MS m/z (ESI): 495.7 [M + H]. TDI- 01854

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- (isoxazol- 4-yl)- 1H-indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.92 (s, 1H), 12.16 (s, 1H), 10.98 (s, 1H), 9.70 (s, 1H), 9.28 (s, 1H), 8.81 (s, 1H), 8.58 (s, 1H), 8.38 (d, J = 5.7 Hz, 1H), 8.16 (d, J = 8.3 Hz, 2H), 7.83 (m, 3H), 7.65 (d, J = 8.3 Hz, 2H), 7.40 (s, 1H), 6.71 (d, J = 5.7 Hz, 1H). MS m/z (ESI): 462.8 [M + H]. TDI- 01855

(R)-6- (4-((4- (1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(1- amino- propan- 2-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 11.99 (s, 1H), 9.64 (s, 1H), 8.56 (s, 2H), 8.37 (d, J = 8.0 Hz, 1H), 8.29 (s, 1H), 8.13 (d, J = 8.0 Hz, 1H), 8.03 (s, 2H), 7.84 (d, J = 8.0 Hz, 2H), 7.71 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.21 (s, 1H), 6.68 (d, J = 8.0 Hz, 1H), 4.27- 4.20 (m 1H), 2.91 (d, J = 8.0 Hz, 2H), 1.22 (d, J = 8.0 Hz, 3H). MS m/z (ESI): 453.0 [M + H]. TDI- 01856

(S)-6- (4-((4- (1H- pyrazol- 4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(1- amino- propan- 2-yl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 12.00 (s, 1H), 9.64 (s, 1H), 8.58 (d, J = 8.0 Hz, 1H), 8.55 (s, 1H), 8.37 (d, J = 8.0 Hz, 1H), 8.32 (s, 1H), 8.12 (d, J = 8.0 Hz, 1H), 8.03 (s, 2H), 7.84 (d, J = 8.0 Hz, 2H), 7.71 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.21 (s, 1H), 6.68 (d, J = 8.0 Hz, 1H), 4.27-4.20 (m 1H), 2.89 (d, J = 8.0 Hz, 2H), 1.23 (d, J = 8.0 Hz, 3H). MS m/z (ESI): 452.8 [M + H]. TDI- 01862

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) quinazolin- 2- yl)-N- isopropyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-45); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.13 (s, 1H), 8.68 (s, 1H), 8.56 (s, 1H), 8.38 (s, 1H), 8.14 (s, 3H), 8.00 (s, 3H), 7.79 (s, 3H), 7.26 (s, 1H), 4.14 (s, 1H), 1.28- 1.18 (m, 6H). MS m/z (ESI): 488.0 [M + H]. TDI- 01867

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino)- 5- methoxy- pyrimidin- 2-yl)-N- isopropyl- 1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-36);

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d6) δ 11.86 (s, 1H), 9.18 (s, 1H), 8.41 (s, 1H), 8.32 (d, J = 7.7 Hz, 1H), 8.15 (s, 1H), 8.02 (dd, J = 16.7, 11.8 Hz, 5H), 7.67 (t, J = 8.8 Hz, 3H), 7.19 (s, 1H), 4.16-4.11 (m, 1H), 4.02 (s, 3H), 1.20 (d, J = 6.5 Hz, 6H). MS m/z (ESI): 468.0 [M + H]. TDI- 01868

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino)- 5- methoxy- pyrimidin- 2-yl)-N- methyl-N- (2,2,2- trifluoro- ethyl)- 1H-indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-36);

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.84 (s, 1H), 11.92 (s, 1H), 8.92 (s, 1H), 8.46 (s, 1H), 8.18 (s, 1H), 8.04 (dd, J = 21.7, 8.6 Hz, 4H), 7.67 (dd, J = 21.6, 8.4 Hz, 3H), 7.07 (s, 1H), 4.49 (d, J = 8.2 Hz, 2H), 4.01 (s, 3H), 3.45 (s, 3H). MS m/z (ESI): 521.9 [M + H]. TDI- 01872

(R)-(6- (4-((4- (1H- pyrazol-4- yl)phenyl) amino) pyrimidin-2- yl)-1H- indol-2- yl)(2- methyl- piperazin- 1- yl) methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

and the final product was obtained by removal of Boc using 4N hydrochloric acid/dioxane solution in the final step. ¹H NMR (400 MHz, DMSO-d₆) δ 12.34 (s, 1H), 11.13 (s, 1H), 9.07 (s, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 8.33 (s, 1H), 8.11 (s, 2H), 7.90 (s, 2H), 7.76 (s, 3H), 7.03 (s, 1H), 6.93 (s, 1H), 4.91 (s, 1H), 4.47 (d, J = 14.1 Hz, 2H), 3.27 (s, 2H), 3.10 (d, J = 10.9 Hz, 2H), 1.41 (d, J = 6.7 Hz, 3H), 1.25 (s, 1H). MS m/z (ESI): 478.9 [M +H]. TDI- 01878

6-(4- ((4-(1H- pyrazol- 4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(3- morpholino- cyclo- hexyl)-1H- indole-2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.23 (s, 1H), 10.78 (s, 1H), 8.67 (s, 1H), 8.47 (s, 1H), 8.37 (d, J = 6.5 Hz, 1H), 8.09 (s, 2H), 7.98 (s, 1H), 7.87-7.79 (m, 2H), 7.73 (d, J = 7.8 Hz, 2H), 7.46- 7.21 (m, 2H), 7.06 (d, J = 51.1 Hz, 1H), 6.87 (s, 1H), 4.41 (s, 1H), 4.01 (d, J = 12.4 Hz, 2H), 3.78- 3.57 (m, 3H), 3.45 (d, J = 12.0 Hz, 2H), 3.12 (dd, J = 21.1, 11.5 Hz, 2H), 2.17 (dd, J = 66.0, 24.1 Hz, 2H), 1.96-1.73 (m, 3H), 1.61 (d, J = 7.8 Hz, 1H), 1.52- 1.35 (m, 2H). MS m/z (ESI): 562.9 [M + H]. TDI- 01880

(6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-1H- indol-2- yl)(3- morpholino- piperidin- 1- yl) methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 12.16 (s, 1H), 9.89 (d, J = 7.3 Hz, 2H), 8.48 (s, 1H), 8.36 (d, J = 6.4 Hz, 1H), 8.11- 7.97 (m, 3H), 7.81 (d, J = 8.0 Hz, 3H), 7.70 (d, J = 8.2 Hz, 3H), 6.98 (s, 1H), 6.82 (d, J = 4.5 Hz, 1H), 4.69 (s, 2H), 4.34 (d, J = 6.2 Hz, 3H), 4.04 (d, J = 11.7 Hz, 3H), 3.71 (s, 3H), 3.49-3.24 (m, 7H), 2.24 (s, 1H), 1.93 (d, J = 12.1 Hz, 1H), 1.79 (d, J = 10.0 Hz, 1H), 1.59 (s, 1H). MS m/z (ESI): 548.6 [M + H]. TDI- 01882

6-(4- ((4-(1H- pyrazol- 4- yl)phenyl) amino) pyrimidin- 2- yl)-N-(1- (pyridin- 4- yl) piperidin-3- yl)-1H- indole- 2- carboxamide

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.28 (s, 1H), 12.18 (s, 1H), 8.68 (s, 1H), 8.48 (s, 1H), 8.36 (s, 1H), 8.24 (s, 2H), 8.04 (d, J = 28.6 Hz, 3H), 7.83 (s, 3H), 7.70 (d, J = 7.9 Hz, 2H), 7.26 (d, J = 23.9 Hz, 3H), 6.81 (s, 1H), 4.26 (s, 1H), 4.14 (d, J = 13.3 Hz, 4H), 1.93 (dd, J = 52.9, 42.3 Hz, 4H). MS m/z (ESI): 556.0 [M + H]. TDI- 01884

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-N- (1-(3- chloro- pyridin- 4-yl) piperidin- 4- yl)benzo [b]thio- phene-2- carboxamide

(Reg-1-1) in step 3 of Example 1 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 10.19 (s, 2H), 8.93 (s, 1H), 8.81 (s, 1H), 8.67 (s, 1H), 8.40 (dd, J = 19.9, 7.4 Hz, 3H), 8.23 (s, 1H), 8.13 (d, J = 8.2 Hz, 1H), 8.08 (s, 1H), 7.78 (d, J = 8.1 Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 7.36 (s, 1H), 6.83 (s, 1H), 4.16 (s, 1H), 4.01 (s, 2H), 3.28 (s, 2H), 2.05 (d, J = 11.6 Hz, 2H), 1.78 (dd, J = 21.7, 10.7 Hz, 2H). MS m/z (ESI): 606.9 [M + H]. TDI- 01885

(6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)- 1H-indol- 2- yl)(4-(3- chloro- pyridin- 4-yl) piperazin- 1-yl) methanone

in step 1 of Example 1 was replaced with

(Reg-1-1) in step 3 was replaced with

(Reg-1-16);

in step 4 was replaced with

1H NMR (400 MHz, DMSO-d₆) δ 12.20 (s, 1H), 10.56 (s, 1H), 8.59 (s, 1H), 8.48 (s, 1H), 8.41 (s, 1H), 8.36 (s, 1H), 8.10 (d, J = 22.4 Hz, 3H), 8.02 (s, 1H), 7.91- 7.77 (m, 3H), 7.72 (s, 1H), 7.23 (s, 1H), 7.00 (s, 1H), 6.84 (s, 1H), 4.00 (s, 4H), 3.54 (s, 4H). MS m/z (ESI): 575.8 [M + H]. TDI- 01675

(6-(4- ((4-(1H- pyrazol- 4- yl)phenyl) amino)- 5- fluoro- pyrimidin- 2- yl)benzo [b]thio- phen-2- yl)(3,3- difluoro- azetidin- 1- yl) methanone

in step 3 of Example 1 was replaced with

(Reg-1-40); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 9.73 (s, 1H), 8.89 (s, 1H), 8.53 (d, J = 2.9 Hz, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.12- 8.04 (m, 3H), 8.00 (s, 1H), 7.90 (d, J = 8.2 Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 5.08 (s, 2H), 4.59 (s, 2H). MS m/z (ESI): 507.0 [M − H]. TDI- 01691

6-(4- ((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2- yl)-1- methyl- N-(1,1,1- trifluoro- propan- 2-yl)-1H- indole-2- carboxamide

in step 3 of Example 1 was replaced with

in step 3 was replaced with

(Reg-1-16); and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 9.05 (d, J = 8.8 Hz, 1H), 8.53 (s, 1H), 8.40 (d, J = 6.4 Hz, 1H), 8.08 (s, 3H), 7.94- 7.67 (m, 5H), 7.33 (s, 1H), 6.83 (s, 1H), 4.90-4.84 (m, 1H), 4.09 (s, 3H), 1.39 (d, J = 7.0 Hz, 3H). MS m/z (ESI): 506.2 [M + H].

Example 2: preparation of 6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-N-isopropylbenzofuran-2-carboxamide (TDI01102)

Step 1:

Compound TDI01102-1 (3.6 g, 17.9 mmol) and tert-butyl 2-bromoacetate (5.38 g, 27.6 mmol) were dissolved in dimethyl sulfoxide (100 mL), cesium carbonate (17.51 g, 53.7 mmol) was added, and the reaction was placed in an oil bath at 100° C., and allowed to proceed for 3 hours. Thin layer chromatography (petroleum ether) indicated the reaction was complete. The reaction solution was cooled to room temperature, extracted with ethyl acetate (100 mL×3) and water, respectively, washed with saturated brine (100 mL×3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford compound TDI01102-2 (4.0 g, brown solid, crude product).

¹H NMR (400 MHz, CDCl₃) δ 7.75 (s, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.41 (m, H), 7.38 (s, 1H), 1.62 (s, 9H).

Step 2:

Compound TDI01102-2 (4.0 g, 13.47 mmol) was dissolved in anhydrous dichloromethane (40 mL), trifluoroacetic acid (10 mL) was added, and the reaction was performed at room temperature for 4 hours. Thin layer chromatography (petroleum ether) indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude was dissolved in dichloromethane, and then concentrated to afford compound TDI01102-3 (3.0 g, yellow solid, crude product).

¹H NMR (400 MHz, DMSO-d₆) δ 13.63 (s, 1H), 8.06 (s, 1H), 7.76 (d, J=8.4 Hz, 1H), 7.69 (s, 1H), 7.53 (m, 1H). MS m/z (ESI): 239.0 [M−H].

Step 3:

Compound TDI01102-3 (400 mg, 1.66 mmol) and isopropylamine (119 mg, 2.0 mmol) were dissolved in N,N-dimethylformamide (10 mL), HATU (762 mg, 2.0 mmol) and diisopropylethylamine (1.07 g, 8.3 mmol) were added, and the reaction was performed at room temperature for 3 hours. Thin layer chromatography (petroleum ether:ethyl acetate=1:1) indicated the reaction was complete. Water (100 mL) was slowly added to the reaction solution, a large amount of solid precipitated, and was stirred for 30 minutes before filtered to afford compound TDI01102-4 (400 mg, yellow solid, crude product). MS m/z (ESI): 282.0/283.0 [M+H].

Step 4:

Compound TDI01102-4 (400 mg, 1.42 mmol) and bis(pinacolato)diboron (440 mg, 1.7 mmol) were dissolved in 1,4-dioxane (50 mL), potassium acetate (424 mg, 4.26 mmol) and Pd(dppf)Cl₂ (52 mg, 0.071 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 90° C., and allowed to proceed for 4 hours. Thin layer chromatography (petroleum ether:ethyl acetate=4:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was separated and purified by column chromatography (petroleum ether:ethyl acetate=5:1 to 2:1), to afford compound TDI01102-5 (360 mg, yellow solid, crude product).

¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H), 7.72 (d, J=7.6 Hz, 1H), 7.66 (d, J=7.6 Hz, 1H), 7.45 (s, 1H), 6.46 (d, J=7.6 Hz, 1H), 4.31 (m, 1H), 1.37 (s, 12H), 1.31 (d, J=6.6 Hz, 6H). MS m/z (ESI): 330.2 [M+H].

Step 5:

Compound Reg-1-1 (300 mg, 0.87 mmol) and TDI01102-5 (360 mg, 1.10 mmol) were dissolved in a mixture of ethanol/water (10:1) (30 mL), sodium carbonate (184 mg, 1.74 mmol) and Pd(PPh₃)₂Cl₂ (63.0 mg, 0.09 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 110° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by preparative liquid chromatography to afford compound TDI01102 (100 mg, yellow solid, yield: 27.9%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.11 (s, 1H), 10.66 (s, 1H), 8.63 (d, J=8.0 Hz, 1H), 8.44 (s, 1H), 8.40 (d, J=8.0 Hz, 1H), 8.24 (d, J=8.0 Hz, 1H), 8.16 (s, 1H), 8.11 (s, 1H), 7.97 (d, J=8.0 Hz, 1H), 7.67-7.60 (m, 3H), 6.86 (d, J=8.0 Hz, 1H), 4.14 (m, 1H), 1.21 (d, J=8.0 Hz, 6H). MS m/z (ESI): 413.2 [M+H].

The compounds in Table 2 were prepared according to methods similar to that described in Example 2.

TABLE 2 Compound No. Compound Structure Name TDI01104

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N- isopropylbenzo [b]thiophene- 2-carboxamide TDI01108

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N-isopropyl- 1H-indole-2- carboxamide TDI01109

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N- methylbenzo [b]thiophene- 2-carboxamide TDI01110

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N,N- dimethylbenzo [b]thiophene- 2-carboxamide TDI01111

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N- cyclopropyl- benzo[b] thiophene-2- carboxamide TDI01112

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N- cyclohexyl- benzo[b] thiophene-2- carboxamide TDI01114

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N-(1-methyl- piperidin-4- yl)benzo[b] thiophene-2- carboxamide TDI01115

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N-(pyridin-3- yl)benzo[b] thiophene-2- carboxamide TDI01122

6-(4-((1H- indazol-5- yl)amino)-7-(2- (dimethylamino) ethyl)- 7H-pyrrolo[2,3- d]pyrimidin- 2-yl)-N- isopropylbenzo [b]thiophene- 2-carboxamide TDI01128

6-(4-((1H- indazol-5- yl)amino) quinazolin-2-yl)- N-isopropyl- 1H-indole-2- carboxamide TDI01135

6-(4-((1H- indazol-5- yl)amino) furo[3,2- d]pyrimidin- 2-yl)-N- isopropylbenzo [b]thiophene- 2-carboxamide TDI01136

6-(4-((1H- indazol-5- yl)amino) thieno[3,2- d]pyrimidin- 2-yl)-N- isopropylbenzo [b]thiophene- 2-carboxamide TDI01141

6-(4-((1H- indazol-5- yl)amino) thieno[3,2- d]pyrimidin- 2-yl)-N- isopropyl-1H- indole-2- carboxamide TDI01142

6-(4-((1H- indazol-5- yl)amino) thieno[2,3- d]pyrimidin- 2-yl)-N- isopropyl-1H- indole-2- caiboxamide TDI01143

6-(4-((1H- indazol-5- yl)amino)-7H- pyrrolo[2,3- d]pyrimidin- 2-yl)-N- isopropyl-1H- indole-2- carboxamide TDI01149

6-(7-((1H- indazol-5- yl)amino) thiazolo[4,5- d]pyrimidin- 5-yl)-N- isopropyl-1H- indole-2- carboxamide TDI01218

6-(4-((1H- indazol-5- yl)amino)-7- phenyl-7H- pyrrolo[2,3-d] pyrimidin-2- yl)-N- isopropylbenzo [b]thiophene- 2-carboxamide TDI01262

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N-{2- (dimethylamino) pyridin-4- yl)benzo[b] thiophene-2- carboxamide TDI01280

6-(4-((4-(1H- pyrazol-4- yl)phenyl) amino) pyrimidin- 2-yl)-N- isopropyl-1H- indole-2- carboxamide TDI01327

7-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N-isopropyl- quinoline-2- carboxamide TDI01392

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N-methyl-N- (tetrahydro- furan-3 yl)benzo[b] thiophene-2- carboxamide TDI01394

6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N-(3- fluoropyridin- 4-yl)- 1H-indole-2- carboxamide TDI01410

6-(4-((4-(1H- pyrazol-4- yl)phenyl) amino)furo[3,2- d]pyrimidin- 2-yl)-N,N- diethyl-1H- indole-2- carboxamide TDI01434

(6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol- 2-yl)(3,3- difluoroazetidin- 1- yl)methanone TDI01434B

(6-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- 1H-indol- 2-yl)(3,3- difluoroazetidin- 1- yl)methanone TDI0126

(6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl) benzofuran-2- yl)(3,3- difluoroazetidin- 1- yl)methanone TDI01581

(6-(4-((4-(1H- pyrazol-4- yl)phenyl) amino)-1,3,5- triazin-2-yl)- 1H-indol-2- yl)(3,3- difluoroazetidin- 1- yl)methanone TDI01582

(6-(4-((4-(1H- pyrazol-4- yl)phenyl) amino)-5- fluoropyrimidin- 2-yl)-1H- indol-2- yl)(3,3- difluoroazetidin- 1- yl)methanone TDI01825B

5-(4-((1H- indazol-5- yl)amino) pyrimidin-2-yl)- N,N-diethyl-3- methyl-1H- indole-2- carboxamide TDI01825C

5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N,N- diethyl-3- methyl-1H- indole-2- carboxamide TDI01832

6-(4-((3- methoxy-4-(1H- pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N,N- dimethyl-1H- indole-2- carboxamide TDI01833

N-(4-(1H- pyrazol-4- yl)phenyl)- 2-(2- (methylsulfonyl)- 1H- indol-6-yl) pyrimidin-4- amine TDI01837

6-(4-((5-(1H- pyrazol-4- yl)pyridin-2- yl)amino) pyrimidin-2-yl)- N,N-dimethyl- 1H-indole- 2-carboxamide TDI01842

6-(4-((3- fluoro-4-(1H- pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N,N- dimethyl-1H- indole-2- carboxamide TDI01842B

(3,3- difluoroazetidin-1- yl)(6-(4-((3- fluoro-4-(1H- pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H- indol-2- yl)methanone TDI01864

6-(4-((4-(1H- pyrazol-4- yl)phenyl) amino)furo[3,2- d]pyrimidin- 2-yl)-N- isopropyl- 1H-indole-2- carboxamide TDI01865

6-(4-((4-(1H- pyrazol-4- yl)phenyl) amino)-6-(2- (dimethylamino) ethoxy) pyrimidin-2-yl)- N-isopropyl- 1H-indole-2- carboxamide TDI01879

6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N,N- diethyl-3- methyl-1H- indole-2- carboxamide TDI01898

6-(4-((1H- indazol-5- yl)amino)-6- benzylpyrimidin- 2-yl)-N- isopropyl- 1H-indole-2- carboxamide TDI01899

6-(4-((1H- indazol-5- yl)amino)-6- phenoxy- pyrimidin-2-yl)- N-isopropyl- 1H-indole-2- carboxamide TDI01900

6-(4-((1H- indazol-5- yl)amino)-6- (phenylamino) pyrimidin- 2-yl)-N- isopropyl-1H- indole-2- carboxamide TDI01901

N-(2-(2-methyl- 1H-indol- 6-yl)pyrimidin- 4-yl)-1H- indazol-5-amine TDI01914

(6-(4-((4-(1H- pyrazol-4- yl)phenyl) amino)-5- methoxy- pyrimidin-2-yl)- 1H-indol- 2-yl)(3,3- difluoroazetidin- 1- yl)methanone Starting material or regent different No. from that in Example 2 Characterization Data TDI01104

¹H NMR (400 MHz, CD₃OD) δ 8.76 (s, 1H), 8.24 (d, J = 7.2 Hz, 1H), 8.19- 8.11 (m, 4H), 8.07 (s, 1H), 7.69 (s, 1H), 7.61 (s, 1H), 6.92 (d, J = 8.0 Hz, 1H), 4.25-4.19 (m, 1H), 1.29 (d, J = 6.4 Hz, 6H). MS m/z (ESI): 429.3 [M + H]. TDI01108

¹H NMR (400 MHz, CD₃OD) δ 8.44 (s. 1H), 8.25 (d. J = 4.0 Hz, 1H), 8.20 (s, 1H), 8.09-8.06 (m, 2H), 7.69 (d, J = 8.0 Hz, 1H), 7.61 (m, 2H), 7.13 (s, 1H), 6.62 (d, J = 4.0 Hz, 1H), 4.28-4.21 (m, 1H), 1.30 (s, 3H), 1.28 (s, 3H). MS m/z (ESI): 412.2 [M + H]. TDI01109

¹H NMR (400 MHz, DMSO-d₆) δ 13.08 (s, 1H), 10.28 (s, 1H), 8.88 (d, J = 19.2 Hz, 2H), 8.39-8.34 (m, 2H), 8.17- 8.11 (m, 3H), 7.61 (d, J = 10.0 Hz, 2H), 7.31-7.06 (m, 1H), 6.81 (s, 1H), 2.83 (s, 3H). MS m/z (ESI): 401.1 [M + H]. TDI01110

¹H NMR (400 MHz, CD₃OD) δ 8.78 (s, 1H), 8.24 (m, 3H), 8.13 (d, J = 4.0 Hz, 2H), 7.82 (s, 1H), 7.69 (d, J = 12 Hz, 1H), 7.62 (s, 1H), 6.88 (d, J = 8.0 Hz, 1H), 3.17 (s, 6H). MS m/z (ESI): 415.1 [M + H]. TDI01111

¹H NMR (400 MHz, DMSO-d₆) δ 13.12 (s, 1H), 10.25 (s, 1H), 8.87 (m, 1H), 8.39 (d, J = 4.0 Hz, 1H), 8.32 (d. J = 8.0 Hz, 1H), 8.13-8.08 (m, 4H), 7.61 (m, 2H), 6.79 (d, J = 4.0 Hz, 1H), 2.87 (s, 1H), 0.75 (d. J = 4.0 Hz, 2H), 0.62 (s, 2H). MS m/z (ESI): 427.2 [M + H]. TDI01112

¹H NMR (400 MHz, DMSO-d₆) δ 13.15 (s, 1H), 10.27 (s, 1H), 8.88 (s, 1H), 8.60 (d, J = 8.0 Hz, 1H), 8.39 (d, J = 4.0 Hz, 1H), 8.31 (s, 1H), 8.21 (s, 1H), 8.13 (s, 2H), 8.10 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.59 (s, 1H), 6.80 (d, J = 4.0 Hz, 1H), 3.77 (s, 1H), 1.87 (s, 2H), 1.76 (s, 2H), 1.65-1.59 (m, 1H), 1.34 (s, 4H), 1.17 (s, 1H). MS m/z (ESI): 469.1 [M + H]. TDI01114

¹H NMR (400 MHz, CD₃OD) δ 8.86 (s, 1H), 8.42-8.35 (m, 1H), 8.29 (d, J = 6.0 Hz, 1H), 8.13 (s, 1H), 8.04 (d, J = 17.2 Hz, 2H), 7.97 (d, J = 8.4 Hz, 1H), 7.59 (s, 2H), 6.66 (d, J = 6.0 Hz, 1H), 3.92-3.87 (m, 1H), 2.97-2.95 (m, 2H), 2.33 (s, 3H), 2.22-2.19 (m, 2H), 2.01-1.98 (m, 2H), 1.78-1.68 (m, 2H). MS m/z (ESI): 484.3 [M + H]. TDI01115

¹H NMR (400 MHz. DMSO-d₆) δ 11.07 (s, 1H), 10.41 (s, 1H), 9.12 (s, 1H), 8.96 (s, 1H), 8.50 (s, 2H), 8.42-8.36 (m, 3H), 8.23 (d, J = 8.4 Hz, 1H), 8.17- 8.15 (m, 2H), 7.68-7.59 (m, 3H), 6.84 (d, J = 6.4 Hz, 1H). MS m/z (ESI): 464.2 [M + H]. TDI01122

¹H NMR (400 MHz, DMSO-d₆) δ 9.62 (s, 1H), 9.57 (s, 1H), 9.00 (s, 1H), 8.58 (d, J = 7.8 Hz, 1H), 8.50 (d, J = 8.5 Hz, 1H), 8.32 (s, 1H), 8.17 (s, 1H), 8.12 (s, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.77 (d, J = 9.1 Hz, 1H), 7.62 (d, J = 8.9 Hz, 1H), 7.40 (d, J = 3.5 Hz, 1H), 6.81 (s, 1H), 4.69 (s, 2H), 4.13-4.07 (m, 1H), 3.67 (d, J = 5.6 Hz, 2H), 2.91 (d, J = 4.2 Hz, 6H), 1.21 (d, J = 6.6 Hz, 6H). MS m/z (ESI): 539.1 [M + H]. TDI01128

¹H NMR (400 MHz, DMSO-d₆) δ 13.09 (s, 1H), 11.82 (s, 1H), 9.87 (s, 1H), 8.58 (d, J = 7.6 Hz, 2H), 8.36 (s, 1H), 8.26 (d, J = 7.6 Hz, 1H), 8.21 (d, J = 8.8 Hz, 2H), 7.96-7.90 (m, 1H), 7.85 (d, J = 3.2 Hz, 2H), 7.67 (dd, J = 8.4, 2.8 Hz, 2H), 7.61-7.54 (m, 1H), 7.18 (s, 1H), 4.17-4.12 (m, 1H), 1.21 (d, J = 6.4 Hz, 6H). MS m/z (ESI): 462.2 [M + H]. TDI01135

¹H NMR (400 MHz, CD₃OD) δ 8.74 (s, 1H), 8.27-8.19 (m, 3H), 8.11 (s, 1H), 8.01 (d, J = 7.6 Hz, 2H), 7.76 (dd, J = 8.8, 1.6 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 4.25- 4.19 (m, 1H), 1.29 (d, J = 6.4 Hz, 6H). MS m/z (ESI): 469.1 [M + H]. TDI01136

¹H NMR (400 MHz, DMSO-d₆) δ 13.25 (s, 1H), 10.25 (s, 1H), 8.94 (s, 1H), 8.61 (d, J = 8.0 Hz, 1H), 8.41 (d, J = 8.0 Hz, 1H), 8.26 (d, J = 4.0 Hz, 1H), 8.18-8.14 (m, 3H), 8.06 (d, J = 8.0 Hz, 1H), 7.71- 7.65 (m, 2H), 7.54 (d, J = 4.0 Hz, 1H), 4.15-4.06 (m, 1H), 1.21 (d, J = 8.0 Hz, 6H). MS m/z (ESI): 485.1 [M + H]. TDI01141

¹H NMR (400 MHz, DMSO-d₆) δ 13.26 (s, 1H), 12.11 (s, 1H), 10.80 (s, 1H), 8.46 (s, 1H), 8.40 (d, J = 7.2 Hz, 1H), 8.33 (d, J = 4.0 Hz, 1H), 8.21 (s, 1H), 8.15 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.70 (s, 2H), 7.56 (d, J = 4.0 Hz, 1H), 7.26 (s, 1H), 4.20-4.12 (m, 1H), 1.22 (d, J = 6.4 Hz, 6H). MS m/z (ESI): 468.2 [M + H]. TDI01142

¹H NMR (400 MHz, DMSO-d₆) δ 11.18 (s, 1H), 9.79 (s, 1H), 8.37 (m, 3H), 8.15 (m, 1H), 8.00-7.86 (m, 2H), 7.67 (s, 2H), 7.20 (s, 1H), 1.22 (s, 6H). MS m/z (ESI): 468.1 [M + H]. TDI01143

¹H NMR (400 MHz, CD₃OD) δ 8.47 (s, 1H), 8.32 (s, 1H), 8.13 (d, J = 9.5 Hz, 2H), 7.84 (d, J = 7.8 Hz, 1H), 7.70- 7.59 (m, 2H), 7.13 (d, 2H), 6.54 (s, 1H), 4.25 (m, J = 12.6, 6.3 Hz, 1H), 1.30 (s, 3H), 1.28 (s, 3H); MS m/z (ESI): 451.1 [M + H]. TDI01149

¹H NMR (400 MHz, DMSO-d₆) δ 13.08 (s, 1H), 11.90 (s, 1H), 10.22 (s, 1H), 9.34 (s, 1H), 8.53 (s, 1H), 8.44 (s, 1H), 8.32 (d, J = 7.6 Hz, 1H), 8.19 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.21 (s, 1H), 4.16-4.13 (m, 1H), 1.21 (d, J = 6.4 Hz, 6H). MS m/z (ESI): 469.1 [M + H]. TDI01218

¹H NMR (400 MHz. CD₃OD) δ 8.94 (s, 1H), 8.85 (d, J = 8.7 Hz, 1H), 8.53 (d, J = 8.4 Hz, 1H), 8.22 (s, 1H), 7.98 (s, 2H), 7.96-7.85 (m, 2H), 7.70 (s, 1H), 7.62 (t, J = 7.5 Hz, 2H), 7.47 (s, 2H), 7.16 (d, J = 8.7 Hz, 1H), 7.10 (s, 1H), 4.23 (s, 1H), 1.30 (d, J = 6.5 Hz, 6H). MS m/z (ESI): 544.2 [M + H]. TDI01262

¹H NMR (400 MHz, DMSO-d₆) δ 13.07 (s, 1H), 10.78 (s, 1H), 9.72 (s, 1H), 8.99 (s, 1H), 8.48 (dd, J = 12.2, 5.8 Hz, 2H), 8.40 (d, J = 5.8 Hz, 1H), 8.15 (dd, J = 18.3, 9.8 Hz, 3H), 8.03 (d, J = 5.8 Hz, 1H), 7.60 (s, 2H), 7.13 (s, 2H), 6.73 (d, J = 5.8 Hz, 1H), 3.08 (s, 5H). MS m/z (ESI): 507.3 [M + H]. TDI01280

¹H NMR (400 MHz, CD₃OD) δ 8.42 (s. 1H), 8.20 (d, J = 7.2 Hz, 1H), 8.04 (s, 2H), 7.86 (s, 4H), 7.76 (s, 2H), 7.22 (s, 1H), 6.91 (d, J = 7.2 Hz, 1H), 4.25 (dt, J = 13.2, 6.5 Hz, 1H), 1.29 (d, J = 6.6 Hz, 7H). MS m/z (ESI): 438.3 [M + H]. TDI01327

¹H NMR (400 MHz, DMSO-d₆) δ 13.12 (s, 1H), 10.03 (s, 1H), 9.16 (s, 1H), 8.68- 8.58 (m, 3H), 8.45 (d, J = 6.1 Hz, 1H), 8.29-8.15 (m, 4H), 7.63 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 9.5 Hz, 1H), 6.81 (d, J = 6.1 Hz, 1H), 4.20 (d, J = 7.9 Hz, 1H), 1.29 (d, J = 6.6 Hz, 6H). MS m/z (ESI): 424.2 [M + H]. TDI01392

¹H NMR (400 MHz, DMSO-d₆) δ 9.69 (s, 1H), 8.94 (s, 1H), 8.43 (d, J = 8.4 Hz, 1H), 8.39 (d, J = 5.6 Hz, 1H), 8.18 (s, 1H), 8.10 (s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.83 (s, 1H), 7.62-7.57 (m, 2H), 6.71 (d, J = 5.6 Hz, 1H), 5.08- 5.02 (m, 1H), 4.03-3.97 (m, 1H), 3.87- 3.83 (m, 1H), 3.77-3.71 (m, 1H), 3.63-3.57 (m, 1H), 3.08 (s, 3H), 2.32- 2.24 (m, 1H), 2.04-1.97 (m, 1H). MS m/z (ESI): 471.1 [M + H]. TDI01394

¹H NMR (400 MHz, DMSO-d₆) δ 13.04 (s, 1H), 12.20 (s, 1H), 10.48 (s, 1H), 9.63 (s, 1H), 8.63 (s, 1H), 8.56 (s, 1H), 8.43 (d, J = 5.2 Hz, 1H), 8.36 (d, J = 5.8 Hz, 1H), 8.29 (s, 1H), 8.23-8.12 (m, 1H), 8.02-7.96 (m, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.59 (d, J = 10.5 Hz, 1H), 6.68 (d, J = 5.9 Hz, 1H). MS m/z (ESI): 465.2 [M + H]. TDI01410

¹H NMR (400 MHz, DMSO-d₆) δ 12.90 (s, 1H), 11.84 (s, 1H), 9.97 (s, 1H), 8.55 (s, 1H), 8.37 (s, 1H), 8.16 (d, J = 8.5 Hz, 2H), 8.02 (d, J = 8.6 Hz, 3H), 7.69 (t, J = 7.6 Hz, 3H), 7.15 (s, 1H), 6.83 (s, 1H), 3.60 (s, 2H), 3.31 (s, 2H), 1.23 (s, 6H). MS m/z (ESI): 492.0 [M + H]. TDI01434

¹H NMR (400 MHz, DMSO-d₆) δ 12.89 (s, 1H), 12.07 (s, 1H), 9.65 (s, 1H), 8.58 (s, 1H), 8.38 (d, J = 5.8 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.92 (s, 1H), 7.83 (d, J = 8.2 Hz, 2H), 7.72 (d, J = 8.5 Hz, 1H), 7.65 (d, J = 8.4 Hz, 2H), 6.97 (s, 1H), 6.69 (d, J = 5.8 Hz, 1H), 5.02 (s, 2H), 4.59 (s, 2H). MS m/z (ESI): 472.0 [M + H]. TDI01434B

¹H NMR (400 MHz, DMSO-d₆) δ 13.04 (s, 1H), 12.09 (s, 1H), 9.69 (s, 1H), 8.53 (s, 1H), 8.35 (d, J = 5.7 Hz, 1H), 8.27 (s, 1H), 8.14 (d, J = 7.2 Hz, 2H), 7.73 (d, J = 8.4 Hz, 1H), 7.60 (s, 1H), 6.98 (s, 1H), 6.68 (d, J = 5.7 Hz, 1H), 5.02 (s, 2H), 4.60 (s, 2H). MS m/z (ESI): 445.9 [M + H]. TDI01526

¹H NMR (400 MHz, DMSO-d₆) δ 10.13 (s, 1H), 8.54 (s, 1H), 8.42 (d, J = 6.4 Hz, 1H), 8.34 (dd, J = 8.4, 1.2 Hz, 1H), 8.08 (s, 2H), 7.94 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 7.73-7.63 (m, 3H), 6.82 (d, J = 6.4 Hz, 1H), 5.11 (s, 2H), 4.56 (s, 2H). MS m/z (ESI): 473.2 [M + H]. TDI01581

¹H NMR (400 MHz, DMSO-d₆) δ 12.21 (s, 1H), 10.28 (s, 1H), 8.82 (s, 1H), 8.64 (s, 1H), 8.17 (d, J = 8.9 Hz, 1H), 8.05 (s, 2H), 7.80 (t, J = 12.1 Hz, 3H), 7.65 (s, 2H), 7.02 (s, 1H), 5.06 (s, 2H), 4.60 (s, 2H). MS m/z (ESI): 472.7 [M + H]. TDI01582

¹H NMR (400 MHz, DMSO-d₆) δ 12.05 (s, 1H), 9.66 (s, 1H), 8.48 (s, 2H), 8.06 (d, J = 6.0 Hz, 3H), 7.94 (d, J = 8.4 Hz, 2H), 7.70 (dd, J = 13.3, 8.6 Hz, 3H), 6.96 (s, 1H), 4.96 (d, J = 16.2 Hz, 2H), 4.57 (s, 2H). MS m/z (ESI): 489.6 [M + H]. TDI01825B

¹H NMR (400 MHz, DMSO-d₆) δ 13.03 (s, 1H), 11.41 (s, 1H), 9.59 (s, 1H), 8.65 (s, 1H), 8.33 (d, J = 4 Hz, 1H), 8.24 (d. J = 12 Hz, 1H), 8.08 (s, 1H), 7.56 (m, 1H), 7.42 (d, J = 8.4 Hz, 2H) 6.63 (d, J = 6 Hz, 1H), 3.44 (s, 4H), 2.31 (s, 3H), 1.13 (s, 6H). MS m/z (ESI): 440.0 [M + H]. TDI01825C

¹H NMR (400 MHz, DMSO-d₆) δ11.42 (s, 1H), 9.62 (s, 1H), 8.64 (s, 1H), 8.37 (s, 1H), 8.25 (s,, 1H) 8.16 (s, 1H), 8.06 (s, 1H), 7.82 (s, 2H), 7.67 (s, 2H) 7.43 (s, 1H) 6.66 (s, 1H) 3.45 (s, 4H), 2.30 (s, 3H), 1.13 (s, 6H). MS m/z (ESI): 466.0 [M + H]. TDI01832

¹H NMR (400 MHz, DMSO-d₆) δ 11.85 (s, 1H), 9.68 (s, 1H), 8.54 (s, 1H), 8.4 (d, J = 5.6 Hz), 8.17 (m, 2H) 8.02 (m, 2H) 7.79 (s, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 9.6 Hz, 1H), 6.93 (s, 1H), 6.71 (d, J = 6 Hz, 1H), 3.96 (s, 3H), 2.55 (s, 6H). MS m/z (ESI): 454.0 [M + H]. TDI01833

¹H NMR (400 MHz, DMSO-d₆) δ 12.73 (s, 1H), 10.29 (s, 1H), 8.52 (s, 1H), 8.39 (d, J = 6.3 Hz, 1H), 8.13 (d, J = 8.0 Hz, 1H), 8.07 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 7.24 (s, 1H), 6.81 (d, J = 6.3 Hz, 1H), 3.39 (s, 3H). MS m/z (ESI): 430.9 [M + H]. TDI01837

¹H NMR (400 MHz, DMSO-d₆) δ 12.08 (s, 1H), 11.03 (s, 1H), 8.72 (s, 1H), 8.58- 8.45 (m, 2H), 8.30-7.96 (m, 5H), 7.82 (d, J = 8.0 Hz, 1H), 7.62 (s, 1H), 6.99 (s, 1H), 3.34 (s, 3H), 3.09 (s, 3H). MS m/z (ESI): 424.7 [M + H]. TDI01842

¹H NMR (400 MHz, DMSO-d₆) δ 13.03 (s, 1H), 11.88 (s, 1H), 9.86 (s, 1H), 8.53 (s, 1H), 8.43 (d, J = 5.7 Hz, 1H), 8.11 (d, J = 8.3 Hz, 1H), 8.03 (s, 2H), 7.91 (d, J = 13.7 Hz, 1H), 7.74 (dd, J = 16.5, 8.3 Hz, 2H), 7.60 (d, J = 8.5 Hz, 1H), 6.94 (s, 1H), 6.72 (d, J = 5.7 Hz, 1H), 3.40 (s, 3H), 3.08 (s, 3H). MS m/z (ESI): 441.8 [M + H]. TDI01842B

¹H NMR (400 MHz, DMSO-d₆) δ 13.04 (s, 1H), 12.10 (s, 1H), 9.92 (s, 1H), 8.55 (s, 1H), 8.43 (d, J = 5.6 Hz, 1H), 8.26- 7.86 (m, 4H), 7.75 (t, J = 8.3 Hz, 2H), 7.61 (d, J = 8.3 Hz, 1H), 6.98 (s, 1H), 6.74 (d, J = 5.6 Hz, 1H), 5.04 (s, 2H), 4.59 (s, 2H). MS m/z (ESI): 489.9 [M + H]. TDI01864

¹H NMR (400 MHz, DMSO-d₆) δ 12.88 (s, 1H), 11.83 (s, 1H), 9.96 (s, 1H), 8.54 (s, 1H), 8.37 (s, 1H), 8.30 (d, J = 7.8 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.02 (d, J = 8.4 Hz, 4H), 7.68 (d, J = 8.4 Hz, 3H), 7.20 (s, 1H), 7.15 (s, 1H), 4.15 (dd, J = 13.5, 6.7 Hz, 1H), 1.21 (d, J = 6.6 Hz, 6H). MS m/z (ESI): 478.0 [M + H]. TDI01865

¹H NMR (400 MHz, DMSO-d₆) δ 11.88 (s, 1H), 9.81 (s, 1H), 9.65 (s, 1H), 8.35 (d, J = 7.8 Hz, 1H), 8.14 (s, 1H), 8.02 (s, 1H), 7.76-7.68 (m, 3H), 7.59 (d, J = 8.3 Hz, 2H), 7.22 (s, 1H), 7.00 (s, 1H), 6.67 (s, 1H), 5.34 (d, J = 4.6 Hz, 1H), 4.72 (s, 2H), 4.15 (d, J = 6.9 Hz, 1H), 3.61 (s, 3H), 2.91 (d, J = 3.7 Hz, 3H), 2.02-1.97 (m, 2H), 1.21 (d, J = 6.6 Hz, 6H). MS m/z (ESI): 524.8 [M + H]. TDI01879

¹H NMR (400 MHz, DMSO-d₆) δ 11.49 (s, 1H), 9.63 (s, 1H), 8.46-8.35 (m, 4H), 8.11 (s, 1H), 7.82 (d, J = 8 Hz 2H), 6.67 (d, J = 5.6 Hz 2H), 3.5 (m, 4H), 2.25 (s, 3H), 1.10 (m, 6H). MS m/z (ESI): 466.0 [M + H]. TDI01898

¹H NMR (400 MHz, DMSO-d₆) δ 13.09 (s, 1H), 12.02 (s, 1H), 8.42 (d, J = 29.2 Hz, 2H), 8.25 (s, 1H), 8.16 (s, 1H), 8.04 (s, 1H), 7.78 (s, 1H), 7.59 (s, 2H), 7.41 (s, 3H), 7.28 (d, J = 25.8 Hz, 2H), 6.43 (s, 1H), 4.16 (dd, J = 13.7, 6.8 Hz, 2H), 3.12-3.07 (m, 1H), 1.20 (dd, J = 17.9, 6.9 Hz, 6H). MS m/z (ESI): 501.6 [M + H]. TDI01899

¹H NMR (400 MHz, DMSO-d₆) δ 11.91 (s, 1H), 9.85 (s, 1H), 8.35 (d, J = 7.8 Hz, 1H), 8.14 (s, 1H), 7.90 (s, 1H), 7.79 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.56 (t, J = 7.8 Hz, 2H), 7.41 (t, J = 8.0 Hz, 2H), 7.30 (dd, J = 17.6, 8.4 Hz, 3H), 7.22 (s, 1H), 7.00 (s, 1H), 5.34 (d, J = 4.2 Hz, 1H), 4.18- 4.13 (m, 1H), 1.23 (d, J = 7.2 Hz, 6H). MS m/z (ESI): 504.0 [M + H]. TDI01900

¹H NMR (400 MHz, DMSO-d₆) δ 13.04 (s, 1H), 12.05 (s, 1H), 8.40 (s, 1H), 8.21 (d, J = 9.9 Hz, 2H), 8.04 (s, 2H), 7.83 (s, 1H), 7.62 (d, J = 57.7 Hz, 6H), 7.34- 7.24 (m, 3H), 7.09 (s, 1H), 6.72 (s, 1H), 4.15 (s, 1H), 1.21 (d, J = 6.5 Hz, 6H). MS m/z (ESI): 503.0 [M + H]. TDI01901

¹H NMR (400 MHz, DMSO-d₆) δ 13.02 (s, 1H), 11.17 (s, 1H), 9.52 (s, 1H), 8.34 (s, 2H), 8.31 (d, J = 5.8 Hz, 1H), 8.19 (s, 1H), 8.14 (s, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.56 (s, 2H), 7.46 (d, J = 8.2 Hz, 1H), 6.60 (d, J = 5.8 Hz, 1H), 6.18 (s, 1H), 2.43 (s, 3H). MS m/z (ESI): 341.1 [M + H]. TDI01914

¹H NMR (400 MHz, DMSO-d₆) δ 12.91 (s, 1H), 11.99 (s, 1H), 9.31 (s, 1H), 8.93 (s, 1H), 8.47 (s, 1H), 8.18 (s, 1H), 8.07 (d, J = 8.5 Hz, 1H), 8.02 (d, J = 8.4 Hz, 2H), 7.93 (s, 1H), 7.67 (dd, J = 16.0, 8.4 Hz, 3H), 6.95 (s, 1H), 5.01 (s, 2H), 4.57 (s, 2H), 4.01 (s, 3H). MS m/z (ESI): 501.6 [M + H].

Example 3: Preparation of 6-(4-((1H-indazol-5-yl)oxy)pyrimidin-2-yl)-N-(pyridazin-4-yl)-1H-indole-2-carboxamide (TDI01212)

Preparation of Intermediate TDI122-b

Intermediate TDI01212-a was prepared according to steps 1 and 2 of Example 1, wherein

in step 1 was replaced with

Intermediate TDI01212-a (3.00 g, 9.97 mmol) was dissolved in a mixture of methanol and water (2:1) (60 mL), lithium hydroxide monohydrate (4.19 g, 99.7 mmol) was added, and the reaction was performed at room temperature overnight. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure to remove methanol, the pH of the aqueous phase was adjusted to 3 with 6N HCl, a large amount of solid precipitated, and was stirred for 30 minutes before filtered to obtain intermediate TDI01212-b (2.1 g, yellow solid, yield: 73.2%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.89 (s, 1H), 7.82 (s, 1H), 7.64 (d, J=8.0 Hz, 1H), 7.34 (d, J=8.0 Hz, 1H), 7.09 (s, 1H), 1.30 (s, 12H).

Step 1:

Compound TDI01212-1 (600 mg, 3.36 mmol), 2,4-dichloropyrimidine (736 mg, 3.70 mmol), TEA (1.36 g, 10 mmol) and anhydrous ethanol (20 mL) were added to a 50 mL flask, and the reaction was warmed to 80° C., and allowed to proceed overnight. Thin layer chromatography (methanol/dichloromethane=1:10) indicated the reaction was complete. The reaction solution was concentrated to give a crude product, and the crude product was added to 20 mL MTBE and 7.5 mL anhydrous ethanol. The mixture was warmed to 50° C., and triturated to afford TDI01212-2 (1.2 g, yellow solid, yield: 87%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.33 (s, 1H), 8.61 (d, J=5.7 Hz, 1H), 8.11 (s, 1H), 7.67-7.63 (m, 2H), 7.25 (dd, J=9.0, 2.0 Hz, 1H), 7.14 (d, J=5.7 Hz, 1H). MS m/z (ESI): 247 [M+H].

Step 2:

Compound TDI01212-2 (1 g, 4 mmol), TDI01212-b (1.44 g, 4.8 mmol), Pd(PPh₃)Cl₂ (0.28 g, 0.4 mmol), Na₂CO₃ (0.85 g, 8 mmol), 40 mL ethanol and 5 mL water were added to a 100 mL flask, purge with argon was performed for 3 times, and the reaction was warmed to 105° C. and allowed to proceed for 4 h. The reaction was cooled to 50° C., 0.32 g sodium hydroxide was added, and the reaction was continued for 1 h. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, the pH was adjusted to 3-4, and the solution was filtered to give a solid (1.5 g). 20 mL MTBE was added to obtain slurry, and the slurry was dried to afford compound TDI01212-3 (0.4 g, yellow solid, yield: 27%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.26 (s, 1H), 12.05 (s, 1H), 8.74 (d, J=5.7 Hz, 1H), 8.38 (s, 1H), 8.13 (s, 1H), 7.92 (d, J=8.6 Hz, 1H), 7.66 (d, J=8.6 Hz, 3H), 7.51 (d, J=6.9 Hz, 2H), 7.34 (d, J=9.2 Hz, 2H), 7.09 (s, 1H), 6.91 (d, J=5.7 Hz, 1H). MS m/z (ESI): 372 [M+H].

Step 3:

Compound TDI01212-3 (200 mg, 0.54 mmol), pyridazin-4-amine (61.6 mg, 0.64 mmol), HATU (244 mg, 0.64 mmol), DIEA (280 mg, 2.16 mmol) and 12 mL DMF were added to a 25 mL flask, and the reaction was performed at room temperature for 3 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and added to 100 mL water. The precipitated solid was filtered and dried before purified by preparative liquid chromatography to afford TDI01212 (50 mg, yellow solid, yield: 13.8%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.28 (s, 1H), 12.27 (s, 1H), 11.08 (s, 1H), 9.58 (d, J=2.0 Hz, 1H), 9.19 (d, J=6.2 Hz, 1H), 8.76 (d, J=5.7 Hz, 1H), 8.41 (s, 1H), 8.28 (dd, J=6.0, 2.5 Hz, 1H), 8.13 (s, 1H), 7.96 (d, J=8.5 Hz, 1H), 7.77 (d, J=8.5 Hz, 1H), 7.72-7.66 (m, 2H), 7.57 (s, 1H), 7.34 (dd, J=8.9, 2.1 Hz, 1H), 6.93 (d, J=5.7 Hz, 1H). MS m/z (ESI): 449.1 [M+H].

Example 4: preparation of 7-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-N-isopropyl-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide (TDI01103)

Step 1:

Compound TDI01103-1 (250 mg, 0.84 mmol) and bis(pinacolato)diboron (254 mg, 1.00 mmol) were dissolved in 1,4-dioxane (15 mL), potassium acetate (247 mg, 2.52 mmol) and Pd(dppf)Cl₂ (61.5 mg, 0.08 mmol) were added, purge with argon was performed for 3 times, and the reaction was allowed to proceed overnight in an oil bath at 80° C. Thin layer chromatography (petroleum ether:ethyl acetate=1:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by preparative chromatography (petroleum ether:ethyl acetate=1:1) to afford compound TDI01103-2 (240 mg, yellow solid, yield: 82.8%).

¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, J=1.2 Hz, 1H), 7.35 (dd, J=8.0, 1.2 Hz, 1H), 6.91 (d, J=8.0 Hz, 1H), 6.40 (s, 1H), 4.63-4.55 (m, 2H), 4.15-4.08 (m, 2H), 1.33 (s, 12H), 1.21 (d, J=6.4 Hz, 3H), 1.14 (d, J=6.4 Hz, 3H). MS m/z (ESI): 348.2 [M+H].

Step 2:

Compound TDI01103-2 (240 mg, 0.68 mmol) and Reg-1-1 (200 mg, 0.57 mmol) were dissolved in a mixture of ethanol/water (10:1) (22 mL), sodium carbonate (120 mg, 1.14 mmol) and Pd(PPh₃)₂Cl₂ (42.1 mg, 0.06 mmol) were added, purge with argon was performed for 3 times, and the reaction was allowed to proceed overnight in an oil bath at 110° C. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography to afford compound TDI01103 (18.5 mg, yellow solid, yield: 9.4%).

¹H NMR (400 MHz, CD₃OD) δ 8.16 (d, J=7.2 Hz, 1H), 8.13 (s, 1H), 7.95 (d, J=7.6 Hz, 1H), 7.86 (s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.67 (d, J=8.8 Hz, 1H), 7.59 (s, 1H), 7.11 (d, J=8.8 Hz, 1H), 6.84 (d, J=6.4 Hz, 1H), 4.80-4.77 (m, 1H), 4.53-4.50 (m, 1H), 4.36-4.31 (m, 1H), 4.07-4.01 (m, 1H), 1.19 (d, J=6.4 Hz, 3H), 1.13 (d, J=6.4 Hz, 3H). MS m/z (ESI): 431.2 [M+H].

Example 5: Preparation of 2-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-N-isopropylbenzo[b]thiophene-6-carboxamide (TDI01106)

Step 1:

Compound TDI01106-1 (2.50 g, 7.04 mmol) and CuCN (1.58 g, 17.6 mmol) were dissolved in N-methylpyrrolidone (25 mL), the reaction was performed under microwave at 200° C. for 1 hour. Thin layer chromatography (petroleum ether:ethyl acetate=5:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, followed by addition of water (100 mL), and was extracted with ethyl acetate (50 mL×3). The combined organic phase was washed with saturated brine (80 mL×3), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate=20:1), to afford compound TDI01106-2 (1.00 g, yellow solid, yield: 54.1%).

¹H NMR (400 MHz, CDCl₃) δ 8.22 (s, 1H), 7.90 (d, J=8.4 Hz, 1H), 7.72 (d, J=5.6 Hz, 1H), 7.60 (dd, J=8.4, 1.2 Hz, 1H), 7.42 (d, J=5.6 Hz, 1H).

Step 2:

Compound TDI01106-2 (800 mg, 5.09 mmol) and potassium hydroxide (2.85 g, 50.9 mmol) were dissolved in a mixture of methanol/water (2:1) (30 mL), and the reaction was performed in an oil bath at 120° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=1:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, and concentrated under reduced pressure to remove methanol before water (50 mL) was added. The pH was adjusted to 2 with 4N HCl, a large amount of solid precipitated, and was filtered after stir at room temperature for 30 minutes. The solid was dissolved in methanol, and the solution was concentrated under reduced pressure to afford compound TDI01106-3 (900 mg, yellow solid, yield: 99.2%).

¹H NMR (400 MHz, CDCl₃) δ 8.70 (s, 1H), 8.10 (dd, J=8.4, 1.2 Hz, 1H), 7.90 (d, J=8.4 Hz, 1H), 7.70 (d, J=5.4 Hz, 1H), 7.42 (d, J=5.4 Hz, 1H). MS m/z (ESI): 179.1 [M+H].

Step 3:

Compound TDI01106-3 (900 mg, 5.06 mmol) and isopropylamine (358 mg, 6.07 mmol) were dissolved in N,N-dimethylformamide (40 mL), HATU (2.31 g, 6.07 mmol) and diisopropylethylamine (2.61 g, 20.2 mmol) were added, and the reaction was performed at room temperature overnight. Thin layer chromatography (petroleum ether:ethyl acetate=1:1) indicated the reaction was complete. The reaction solution was added with water (50 mL), and extracted with ethyl acetate (80 mL×2). The organic phase was combined, successively washed with a saturated aqueous solution of ammonium chloride (100 mL×2) and saturated brine (80 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford compound TDI01106-4 (1.06 g, yellow solid, yield: 95.5%).

¹H NMR (400 MHz, CDCl₃) δ 8.33 (s, 1H), 7.84 (d, J=8.4 Hz, 1H), 7.71 (dd, J=8.4, 1.2 Hz, 1H), 7.58 (d, J=5.4 Hz, 1H), 7.37 (d, J=5.4 Hz, 1H), 6.03 (s, 1H), 4.37-4.29 (m, 1H), 1.29 (d, J=6.4 Hz, 6H). MS m/z (ESI): 220.1 [M+H].

Step 4:

Compound TDI01106-4 (1.06 g, 4.84 mmol) was dissolved in N,N-dimethylformamide (40 mL), N-bromosuccinimide (1.89 g, 10.7 mmol) was added, and the reaction solution was slowly warmed to 80° C., and was allowed to proceed at this temperature for 1 hour. Thin layer chromatography (petroleum ether:ethyl acetate=1:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, and slowly added to water (100 mL), and a large amount of solid precipitated. The solid was filtered after stir at room temperature for 30 minutes, and purified by column chromatography (petroleum ether:ethyl acetate=1:1) to afford compound TDI01106-5 (1.10 g, yellow solid, yield: 75.8%).

¹H NMR (400 MHz, CDCl₃) δ 8.32 (s, 1H), 7.86 (d, J=8.4 Hz, 1H), 7.81-7.76 (m, 1H), 7.58 (s, 1H), 5.99 (s, 1H), 4.38-4.29 (m, 1H), 1.30 (d, J=6.4 Hz, 6H). MS m/z (ESI): 298.0/300.0 [M+H].

Step 5:

Compound TDI01106-5 (1.00 g, 3.34 mmol) and bis(pinacolato)diboron (1.02 g, 4.01 mmol) were dissolved in 1,4-dioxane (40 mL), potassium acetate (980 mg, 10.0 mmol) and Pd(dppf)Cl₂ (242 mg, 0.33 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed in an oil bath at 80° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=1:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was separated and purified by column chromatography (petroleum ether:ethyl acetate=10:1 to 2:1) to afford compound TDI01106-6 (450 mg, yellow solid, yield: 39.1%). MS m/z (ESI): 346.1 [M+H].

Step 6:

Compound Reg-1-1 (200 mg, 0.58 mmol) and TDI01106-6 (240 mg, 0.69 mmol) were dissolved in a mixture of ethanol/water (10:1) (22 mL), sodium carbonate (123 mg, 1.16 mmol) and Pd(PPh₃)₂Cl₂ (42.0 mg, 0.06 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed in an oil bath at 110° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography to afford compound TDI01106 (87.1 mg, yellow solid, yield: 35.1%).

¹H NMR (400 MHz, CD₃OD) δ 8.81 (s, 1H), 8.70-8.65 (m, 1H), 8.46 (s, 1H), 8.27 (d, J=7.2 Hz, 1H), 8.11 (s, 1H), 8.06 (s, 1H), 7.69 (d, J=8.8 Hz, 2H), 7.58 (d, J=8.4 Hz, 1H), 6.89 (d, J=7.2 Hz, 1H), 4.27-4.20 (m, 1H), 1.27 (d, J=6.4 Hz, 6H). MS m/z (ESI): 429.2 [M+H].

Example 6: Preparation of 6-(4-((1H-indazol-5-yl)amino)pyridin-2-yl)-N-isopropylbenzo[b]thiophene-2-carboxamide (TDI01117)

Step 1:

Compound TDI01117-1 (500 mg, 2.15 mmol) and 2-chloro-4-iodopyridine (615 mg, 2.58 mmol) were dissolved in toluene (20 mL), palladium acetate (24.1 mg, 0.11 mmol), BINAP (137 mg, 0.22 mmol) and cesium carbonate (1.40 g, 4.30 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed in an oil bath at 90° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=1:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, and filtered. The filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography (petroleum ether:ethyl acetate=10:1 to 1:1) to afford compound TDI01117-2 (350 mg, yellow solid, yield: 47.3%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.09 (s, 1H), 9.00 (s, 1H), 8.05 (s, 1H), 7.93 (d, J=6.0 Hz, 1H), 7.59-7.58 (m, 2H), 7.23-7.18 (m, 1H), 6.75 (dd, J=6.0, 2.0 Hz, 1H), 6.70 (d, J=1.6 Hz, 1H).

Step 2:

Compound TDI01117-2 (200 mg, 0.82 mmol) and N-isopropyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophene-2-carboxamide (339 mg, 0.98 mmol, for preparation thereof, please refer to the synthesis of the corresponding intermediate in the preparation of TDI01104 in Table 2) were dissolved in a mixture of ethanol/water (10:1) (33 mL), sodium carbonate (174 mg, 1.64 mmol) and Pd(PPh₃)₂Cl₂ (56.2 mg, 0.08 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed in an oil bath at 110° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by preparative liquid chromatography to afford compound TDI01117 (85.0 mg, yellow solid, yield: 24.3%).

¹H NMR (400 MHz, CD₃OD) δ 8.38 (s, 1H), 8.17 (d, J=7.2 Hz, 1H), 8.14-8.07 (m, 2H), 8.05 (s, 1H), 7.84 (s, 1H), 7.76-7.71 (m, 2H), 7.40 (d, J=8.8 Hz, 1H), 7.29 (s, 1H), 7.06 (s, 1H), 4.25-4.18 (m, 1H), 1.29 (d, J=6.4 Hz, 6H). MS m/z (ESI): 428.2 [M+H].

Example 7: Preparation of 6-(5-((1H-indazol-5-yl)amino)-1,3,4-thiadiazol-2-yl)-N-isopropylbenzo[b]thiophene-2-carboxamide (TDI01139)

Step 1:

Compound TDI01139-1 (600 mg, 2.34 mmol) and isopropylamine (166 mg, 2.81 mmol) were dissolved in N,N-dimethylformamide (20 mL.), HATU (1.07 g, 2.81 mmol) and diisopropylethylamine (1.21 g, 9.36 mmol) were added, and the reaction was performed at room temperature overnight. Thin layer chromatography (petroleum ether:ethyl acetate=2:1) indicated the reaction was complete. The reaction solution was diluted with ethyl acetate (80 mL), and successively washed with water (50 mL×2), a saturated aqueous solution of ammonium chloride (80 mL×2) and saturated brine (80 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford compound TDI01139-2 (700 mg, yellow solid, yield: 99.5%).

¹H NMR (400 MHz, CDCl₃) δ 8.00 (s, 1H), 7.68-7.66 (m, 2H), 7.49 (dd, J=8.8, 1.6 Hz, 1H), 5.89 (s, 1H), 4.33-4.25 (m, 1H), 1.29 (d, J=6.4 Hz, 6H).

Step 2:

Compound TDI01139-2 (600 mg, 2.01 mmol) and CuCN (271 mg, 3.01 mmol) were dissolved in N-methylpyrrolidone (15 mL), and the reaction was performed under microwave at 200° C. for 2 hours. Thin layer chromatography (petroleum ether:ethyl acetate=2:1) indicated the reaction was complete. The reaction solution was diluted with ethyl acetate (80 mL), and successively washed with water (80 mL×2) and saturated brine (100 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1 to 2:1) to afford compound TDI01139-3 (350 mg, yellow solid, yield: 71.4%).

¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (d, J=7.2 Hz, 1H), 8.66 (s, 1H), 8.21 (s, 1H), 8.12 (d, J=8.4 Hz, 1H), 7.80 (d, J=8.4 Hz, 1H), 4.11-4.06 (m, 1H), 1.20 (d, J=6.4 Hz, 6H).

Step 3:

Compound TDI01139-3 (350 mg, 1.43 mmol) was dissolved in hydrochloric acid-methanol solution (20 mL), and the reaction was performed at 100° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=2:1) showed that some starting materials remained. The reaction solution was directly concentrated under reduced pressure, and the crude product was purified by column chromatography (petroleum ether:ethyl acetate=10:1 to 6:1) to afford compound TDI01139-4 (100 mg, white solid, yield: 25.2%).

¹H NMR (400 MHz, CDCl₃) δ 8.58 (s, 1H), 8.04 (dd, J=8.4, 1.2 Hz, 1H), 7.86 (d, J=8.4 Hz, 1H), 7.76 (s, 1H), 5.92 (d, J=6.0 Hz, 1H), 4.33-4.28 (m, 1H), 3.97 (s, 3H), 1.30 (d, J=6.4 Hz, 6H). MS m/z (ESI): 278.1 [M+H].

Step 4:

Compound TDI01139-4 (100 mg, 0.36 mmol) was dissolved in ethanol (5 mL), hydrazine hydrate (181 mg, 3.60 mmol) was added, and the reaction solution was slowly warmed to 80° C., and allowed to proceed at this temperature overnight. Thin layer chromatography (petroleum ether:ethyl acetate=2:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, and concentrated under reduced pressure to afford compound TDI01139-5 (70 mg, yellow solid, yield: 70.0%).

¹H NMR (400 MHz, DMSO-d₆) δ 9.88 (s, 1H), 8.60 (d, J=7.6 Hz, 1H), 8.44 (s, 1H), 8.15 (s, 1H), 7.98 (d, J=8.4 Hz, 1H), 7.86 (d, J=8.4 Hz, 1H), 4.54 (s, 2H), 4.11-4.04 (m, 1H), 1.19 (d, J=6.4 Hz, 6H).

Step 5:

Compound TDI01139-5 (70.0 mg, 0.25 mmol) and tert-butyl 5-isothiocyanato-1H-indazole-1-carboxylate (69.5 mg, 0.25 mmol) were dissolved in dichloromethane (5 mL), and the reaction solution was stirred at room temperature. Concentrated sulfuric acid (0.5 mL) was then slowly added to the reaction solution, and the reaction was performed at room temperature for 5 hours. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the pH was adjusted to 9 with saturated aqueous sodium carbonate. The precipitated solid was filtered, and purified by high-performance liquid chromatography to afford compound TDI01139 (4.2 mg, yellow solid, yield: 3.7%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.03 (s, 1H), 10.56 (s, 1H), 8.60 (d, J=7.6 Hz, 1H), 8.50 (s, 1H), 8.27 (s, 1H), 8.16 (s, 1H), 8.08-8.01 (m, 2H), 7.98 (d, J=8.4 Hz, 1H), 7.56 (d, J=8.8 Hz, 1H), 7.43 (d, J=8.8 Hz, 1H), 4.12-4.07 (m, 1H), 1.20 (d, J=6.4 Hz, 6H). MS m/z (ESI): 435.1 [M+H].

Example 8: Preparation of N-(2-(2-((isopropylamino)methyl)-1H-indol-6-yl)pyrimidin-4-yl)-1H-indazol-5-amine (TDI01155)

Step 1:

Compound TDI01155-1 (600 mg, 2.36 mmol) was dissolved in tetrahydrofuran (20 mL), LiAlH₄ (269.3 mg, 7.09 mmol) was slowly added at 0° C., the reaction was slowly warmed to room temperature after being stirred for 30 minutes, and was further stirred at room temperature for 5 h. LC-MS assay indicated the reaction was complete. Water (0.27 mL), NaOH (15% aq., 0.27 mL) and water (0.81 mL) were successively added to the above reaction mixture, which was stirred at room temperature for 30 min, then dried over anhydrous Mg₂SO₄, and filtered. The filter cake was washed, and the filtrate was collected and concentrated under reduced pressure to afford compound TDI01155-2 (600 mg, crude product).

¹H NMR (400 MHz, CDCl₃) δ 8.43 (s, 1H), 7.49 (s, 1H), 7.42 (d, J=8.4 Hz, 1H), 7.20 (m, 1H), 6.36 (s, 1H), 4.93-4.74 (m, 2H), 3.86-3.68 (m, 1H). MS m/z (ESI): 228.0 [M+H].

Step 2:

Compound TDI01155-2 (600 mg, 2.65 mmol) was dissolved in acetonitrile (20 mL), MnO₂ (692 mg, 7.96 mmol) was added, and the reaction was stirred at room temperature overnight. Thin layer chromatography (petroleum ether:ethyl acetate=5:1) and LC-MS assay indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1 to 1:1) to afford compound TDI01155-3 (520 mg, yellow solid, yield: 87.6%).

¹H NMR (400 MHz, CDCl₃) δ 9.86 (s, 1H), 9.22 (s, 1H), 7.65 (s, 1H), 7.61 (d, J=8.4 Hz, 1H), 7.30-7.28 (m, 1H), 7.25 (br, 1H). MS m/z (ESI): 224.0/226.0 [M+H].

Step 3:

Compound TDI01155-3 (200 mg, 0.89 mmol) and bis(pinacolato)diboron (272 mg, 1.07 mmol) were dissolved in 1,4-dioxane (20 mL), potassium acetate (262.5 mg, 2.68 mmol) and Pd(dppf)Cl₂ (33 mg, 0.045 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed in an oil bath at 90° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=5:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1 to 1:1) to afford compound TDI01155-4 (200 mg, yellow solid, yield: 82.6%).

¹H NMR (400 MHz, CDCl₃) δ 9.87 (s, 1H), 9.04 (s, 1H), 7.94 (s, 1H), 7.75 (d, J=8.0 Hz, 1H), 7.59 (d, J=8.0 Hz, 1H), 7.27 (br, 1H), 1.38 (s, 12H). MS m/z (ESI): 272.1 [M+H].

Step 4:

Compound TDI01155-4 (200 mg, 0.74 mmol) and isopropylamine (53 mg, 0.89 mmol) were dissolved in 1,2-dichloroethane (10 mL), and glacial acetic acid (10 drops) was added. After the reaction was stirred at room temperature for 1 h, sodium triacetoxyborohydride (471 mg, 2.22 mmol) was added. The reaction was stirred at room temperature overnight. Thin layer chromatography (dichloromethane/methanol=10:1) indicated the reaction was complete. The solvent was removed by concentration under reduced pressure, and the residue was purified by column chromatography (dichloromethane:methanol=10:1 to 1:1) to afford compound TDI01155-5 (185 mg, yellow solid, yield: 58.9%).

¹H NMR (400 MHz, CDCl₃) δ 10.53 (s, 1H), 8.00 (s, 1H), 7.55-7.50 (m, 2H), 6.54 (s, 1H), 4.29 (s, 2H), 3.11-3.05 (m, 1H), 1.38 (d, J=6.4 Hz, 6H), 1.35 (s, 12H). MS m/z (ESI): 315.2 [M+H].

Step 5:

Compound Reg-1-21 (170 mg, 0.49 mmol) and compound TDI01155-5 (185 mg, 0.59 mmol) were dissolved in a mixture of ethanol/water (10:1) (20 mL), sodium carbonate (104 mg, 0.98 mmol) and Pd(PPh₃)₂Cl₂ (35 mg, 0.049 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed in an oil bath at 110° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by liquid chromatography to afford compound TDI01155 (85 mg, yellow solid, yield: 21.4%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.05 (s, 1H), 11.03 (s, 1H), 9.15 (s, 2H), 8.38-8.34 (m, 2H), 8.19 (s, 2H), 7.94 (d, J=8.4 Hz, 1H), 7.80 (d, J=8.4 Hz, 1H), 7.68 (d, J=8.8 Hz, 1H), 7.62 (br, 1H), 6.88 (d, J=5.6 Hz, 1H), 6.76 (s, 1H), 4.42-4.41 (m, 2H), 3.41-3.33 (m, 1H), 1.32 (s, 3H), 1.30 (s, 3H). MS m/z (ESI): 398.1 [M+H].

Example 9: Preparation of 6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-N-(pyrazin-2-yl)-1H-indole-2-carboxamide (TDI01160)

Step 1:

Compound TDI01160-1 (1000 mg, 4.17 mmol) and pyrazin-2-amine (476 mg, 5.01 mmol) were dissolved in tetrahydrofuran (20 mL), pyridine (501 mg, 6.255 mmol) and phosphorus oxychloride (770 mg, 5.01 mmol) were added, and the reaction was performed at room temperature overnight. LC-MS indicated the reaction was complete. The reaction solution was slowly added to water (15 mL) under stirring, filtered, and the residue was rinsed with warmed methanol (50 mL) to afford crude product TDI01160-2 (260 mg, yellow solid, yield: 19.670).

¹H NMR (400 MHz, DMSO-d₆) δ 12.02 (s, 1H), 11.24 (s, 1H), 9.47 (s, 1H), 8.52-8.40 (m, 2H), 7.67 (dd, J=8.7, 4.1 Hz, 3H), 7.22 (dd, J=8.6, 1.2 Hz, 1H). MS m/z (ESI): 317.0 [M+H].

Step 2:

Compound TDI01160-2 (260 mg, 0.82 mmol) and bis(pinacolato)diboron (417 mg, 1.64 mmol) were dissolved in 1,4-dioxane (8 mL), potassium acetate (242 mg, 2.49 mmol) and palladium acetate (10 mg, 0.04 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed under microwave radiation at 110° C. for 1 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered followed by addition of water (5 mL), successively washed with dichloromethane (10 mL×3) and saturated brine (5 mL×2), dried over anhydrous sodium sulfate, concentrated before separated and purified by column chromatography (dichloromethane:methanol=100:0 to 20:1), to afford compound TDI01160-3 (80 mg, yellow solid, yield: 26.8%). MS m/z (ESI): 365.2 [M+H].

Step 3:

Compound TDI01160-3 (66 mg, 0.147 mmol) and Reg-1-27 (80 mg, 0.22 mmol) were dissolved in 1,4-dioxane:water=5:1 (2.4 mL in total), sodium carbonate (32 mg, 0.249 mmol) and Pd(PPh₃)₂Cl₂ (11 mg, 0.015 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed under microwave radiation at 110° C. for 1 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered followed by addition of water (5 mL), washed with dichloromethane (10 mL×3) and saturated brine (5 mL×2), dried over anhydrous sodium sulfate, and concentrated before purified by thin layer chromatography (dichloromethane:methanol=10:1), to afford compound TDI01160-4 (30 mg, yellow solid, yield: 37.3%). MS m/z (ESI): 548.3 [M+H].

Step 4:

Trifluoroacetic acid (1 mL) was added to a solution of TDI01160-4 (30 mg, 0.055 mmol) in dichloromethane (3 mL), and the reaction was performed at room temperature for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography to afford compound TDI01160 (5.4 mg, yellow solid, yield: 22.0%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.14 (s, 1H), 12.37 (s, 1H), 11.31 (s, 1H), 10.36 (s, 1H), 9.51 (s, 1H), 8.48 (dd, J=21.9, 6.7 Hz, 3H), 8.35 (d, J=6.4 Hz, 1H), 8.20 (d, J=18.1 Hz, 2H), 8.05 (d, J=8.4 Hz, 1H), 7.86 (d, J=8.6 Hz, 1H), 7.77 (s, 1H), 7.64 (d, J=8.4 Hz, 2H), 6.78 (d, J=6.4 Hz, 1H). MS m/z (ESI): 448.2 [M+H].

The compound in following table 3 was prepared according to a method similar to that described in Example 9.

TABLE 3 Starting material or Compound regent different from No. Compound Structure Name that in Example 9 Characterization Data TDI01236

7-(4-((1H)- indazol-5- yl)amino)- pyrimidin- 2-yl)-N- (pyridazin- 4-yl)quin- oline-2- carboxamide

in step 1 of Example 9 was replaced with

and

in step 4 was replaced with

¹H NMR (400 MHz, DMSO- d₆) δ 11.53 (s, 1H), 9.84 (d, J = 18.4 Hz, 2H), 9.32 (s, 1H), 9.21 (s, 1H), 8.72 (t, J = 10 Hz, 2H), 8.47 (d, J = 5.9 Hz, 1H), 8.39 (s, 1H), 8.33- 8.22 (m, 3H), 8.19 (s, 1H), 7.64 (s, 1H), 6.80 (d, J = 5.8 Hz, 1H). MS m/z (ESI): 460.3 [M + H].

Example 10: Preparation of 6-(3-((1H-indazol-5-yl)amino)pyrrolidin-1-yl)-N-(pyridazin-4-yl)-1H-indole-2-carboxamide (TDI01209)

Step 1:

Compound TDI01209-1 (1.0 g, 4.3 mmol), tertbutyl 3-oxopyrrolidine-1-carboxylate (800 mg, 4.3 mmol), 1,2-dichloroethane (30 mL) and glacial acetic acid (8 drops) were added to a 50 mL single neck flask, and the reaction was performed at room temperature (15˜25° C.) for 1.5 h. Sodium triacetoxyborohyride (2.73 g, 12.9 mmol) was then added, and the reaction was performed at 50° C. for 2 h. The reaction solution was added with 40 mL water, and extracted with dichloromethane (15 mL×2). The organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, and purified by column chromatography (petroleum ether:ethyl acetate=10:1-7:1) to afford TDI01209-2 (1.44 g, light yellow solid, yield: 83.7%).

¹H NMR (400 MHz, CDCl₃) δ 8.04-7.94 (m, 2H), 6.88 (dd, J=8.9, 2.1 Hz, 1H), 6.78 (d, J=1.9 Hz, 1H), 3.47 (s, 4H), 2.22 (s, 1H), 1.95 (d, J=9.0 Hz, 1H), 1.71 (s, 9H), 1.46 (s, 10H), 1.26 (t, J=7.1 Hz, 1H). MS m/z (ESI): 403.2 [M+H].

Step 2:

Compound TDI01209-2 (1.44 g, 3.58 mmol) and 30 mL hydrochloride methanol solution (3 mol/L) were added to a 50 mL single neck flask, and the reaction was warmed to 50° C., and allowed to proceed for 1 h. The reaction solution was concentrated under reduced pressure to remove methanol, followed by addition of methanol (20 mL), and sodium methoxide solid was added until the pH is basic. The reaction solution was filtered to collect filtrate, which was then evaporated to dryness to afford compound TDI01209-3 (1.14 g, grey solid, crude product).

¹H NMR (400 MHz, DMSO-d₆) δ 9.70 (s, 1H), 9.48 (s, 1H), 8.15 (s, 1H), 7.76 (s, 1H), 7.65 (d, J=8.9 Hz, 1H), 7.43 (d, J=8.5 Hz, 1H), 3.48 (ddd, J=19.5, 11.2, 5.2 Hz, 3H), 3.24 (dd, J=12.1, 6.2 Hz, 1H), 3.08-3.02 (m, 1H), 2.25-2.14 (m, 2H), 1.20 (t, J=7.3 Hz, 2H). MS m/z (ESI): 203.2 [M+H].

Step 3:

Compound TDI01209-4 (1 g, 4.167 mmol) and 4-aminopyridazine (475 mg, 4.999 mmol) were dissolved in N,N-dimethylformamide (40 mL), HATU (1.586 g, 4.167 mmol) and diisopropylethylamine (1.612 g, 12.501 mmol) were added, and the reaction was performed at room temperature for 16 h. After completion of the reaction, water (50 mL) was added, and a large amount of solid precipitated, and was filtered after being stirred for 30 min to afford compound TDI01209-5 (1.17 g, yellow solid, yield: 88.9%). MS m/z (ESI): 316.9 [M+H].

Step 4:

Compound TDI01209-5 (250 mg, 0.788 mmol), TDI01209-3 (175 mg, 0.867 mmol), Pd₂(dba)₃ (75 mg, 0.0788 mmol), t-BuXPhos (67 mg, 0.1576 mmol), cesium carbonate (770 mg, 2.364 mmol) and tert-butanol (10 mL) were added to a microwave tube, and the reaction was performed under microwave radiation at 110° C. for 2.5 h. The reaction solution was dissolved in methanol (20 mL), and concentrated to dryness after insoluble materials were filtered off. The residue was purified by high-performance liquid chromatography to afford TDI01209 (12.66 mg, yellow solid, yield: 3.7%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.07 (s, 1H), 11.00 (s, 1H), 9.60 (d, J=2.1 Hz, 1H), 9.15 (d, J=6.0 Hz, 1H), 8.93 (s, 2H), 8.22 (dd, J=6.0, 2.7 Hz, 1H), 8.13 (s, 1H), 7.92 (d, J=8.6 Hz, 1H), 7.77 (s, 1H), 7.70 (d, J=9.0 Hz, 1H), 7.64 (d, J=1.3 Hz, 1H), 7.53 (dd, J=8.6, 1.8 Hz, 1H), 6.98 (dd, J=9.0, 2.0 Hz, 1H), 6.86 (d, J=1.8 Hz, 1H), 4.15 (m, 1H), 3.48 (m, 1H), 3.33 (m, 2H), 3.12 (m, 1H), 2.26 (dd, J=14.0, 7.7 Hz, 1H), 1.95 (m, 1H). MS m/z (ESI): 439.1 [M+H].

Compound TDI01219 (6-(3-((1H-indazol-5-yl)amino)pyrrolidin-1-yl)-N-isopropyl-1H-indole-2-carboxamide) was prepared according to a method similar to that described in Example 10:

¹H NMR (400 MHz, DMSO-d₆) δ 11.66 (s, 1H), 8.86 (s, 2H), 8.30 (d, J=7.92 Hz, 1H), 8.10 (s, 1H), 7.77 (d, J=8.6 Hz, 1H), 7.70 (s, 1H), 7.65 (d, J=9.0 Hz, 1H), 7.42 (dd, J=8.6, 1.9 Hz, 1H), 7.23 (d, J=1.4 Hz, 1H), 6.95 (dd, J=9.0, 2.0 Hz, 1H), 6.83 (d, J=1.8 Hz, 1H), 5.87 (s, 1H), 4.14 (d, J=6.6 Hz, 2H), 3.35 (s, 2H), 3.12 (d, J=4.52 Hz, 1H), 2.36-2.21 (m, 2H), 1.95 (d, J=4.8 Hz, 1H), 1.21 (d, J=6.6 Hz, 6H). MS m/z (ESI): 403.2 [M+H].

Example 11: Preparation of 1-(6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-1H-indol-1-yl)ethan-1-one (TDI01229)

Step 1:

Compound TDI01229-1 (3 g, 15.3 mmol) was dissolved in anhydrous acetonitrile (100 mL), acetyl chloride (9.69 g, 61.2 mmol) and cesium carbonate (19.95 g, 61.2 mmol) were added, and the reaction was performed at 50° C. for 5 hours. LC-MS assay indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate=20:1) to afford compound TDI01229-2 (1 g, brow solid, crude product).

¹H NMR (400 MHz, CDCl₃) δ 8.66 (s, 1H), 7.40 (d, J=3.0 Hz, 1H), 7.39-7.37 (m, 1H), 6.60 (d, J=3.7 Hz, 1H), 2.62 (s, 3H). MS m/z (ESI): 240.0 [M+H].

Step 2:

Compound TDI01229-2 (1 g, 4.2 mmol) and bis(pinacolato)diboron (1.60 g, 6.3 mmol) were dissolved in 1,4-dioxane (40 mL), potassium acetate (1.23 g, 12.6 mmol) and Pd(dppf)Cl₂ (462 mg, 0.63 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed in an oil bath at 90° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=4:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1) to afford compound TDI01229-3 (372 mg, white solid, yield: 20.8%). MS m/z (ESI): 286.1 [M+H].

Step 3:

To a mixed solution of compound TDI01229-3 (300 mg, 0.87 mmol) and Reg-1-1 (372 mg, 1.3 mmol) in ethanol/water (10:1) (11 mL), potassium acetate (170 mg, 1.738 mmol) and Pd(dppf)Cl₂ (63.0 mg, 0.087 mmol) were added, purge with argon was performed, and the reaction was performed under microwave radiation at 110° C. for 1 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and the residue was purified by liquid chromatography to afford compound TDI01229 (3.99 mg, yellow solid, yield: 1.2%).

¹H NMR (400 MHz, CD₃OD) δ 8.42 (dd, J=30.4, 13.8 Hz, 4H), 8.27-8.14 (m, 3H), 7.99 (s, 1H), 7.69 (s, 2H), 6.90 (s, 1H), 2.57 (s, 3H). MS m/z (ESI): 369.3 [M+H].

Example 12: Preparation of 6-((4-(1H-pyrazol-4-yl)phenyl)amino)-N-(pyridazin-4-yl)-1H-indole-2-carboxamide (TDI01243)

Step 1:

TDI01243-1 (1.0 g, 4.17 mmol) and N,N-dimethylformamide (10 mL) were successively added to a 50 mL single neck flask, HATU (2.38 g, 5.0 mmol) and DIEA (1.72 mL, 10.43 mmol) were cautiously added under stirring, and the reaction was performed in an oil bath at 50° C. for 1 h. After the reaction was complete, the reaction solution was slowly poured into water (20 mL) under stirring. A large amount of solid precipitated, and was filtered after being stirred for 30 min. The solid was washed with water as well as a mixed solvent of petroleum ether and ethyl acetate (v/v=20/1) for several times, to afford TDI01243-2 (1.26 g, grey-yellow solid, yield: 95.5%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.08 (s, 1H), 10.83 (s, 1H), 9.56 (s, 1H), 9.10 (d, J=5.9 Hz, 1H), 8.12 (dd, J=5.5, 2.2 Hz, 1H), 7.73 (d, J=8.5 Hz, 1H), 7.66 (s, 1H), 7.54 (s, 1H), 7.25 (d, J=8.5 Hz, 1H). MS m/z (ESI): 317.0 [M+H].

Step 2:

Compound TDI01243-2 (190.3 mg, 0.6 mmol), Reg-1-16-e (130 mg, 0.5 mmol), Pd₂(dba)₃ (50 mg, 0.05 mmol), t-BuXPhos (106 mg, 0.25 mmol), cesium carbonate (325.8 mg, 1 mmol) and 10 mL tert-butanol were added to a 25 mL microwave tube, purge with argon was performed for 4 times, and the reaction was performed under microwave radiation at 115° C. for 2.5 h. LC-MS assay indicated the reaction was complete. The reaction solution was filtered, and concentrated under reduced pressure. The obtained solid was rinsed with 30 mL water and 30 mL dichloromethane to give 0.3 g solid, which was purified by preparative chromatography to afford TDI01243 (6.90 mg, dark brown solid, yield: 1.7%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.51 (s, 1H), 10.64 (s, 1H), 9.56 (s, 1H), 9.06 (d, J=5.9 Hz, 1H), 8.28 (s, 1H), 8.12 (d, J=3.3 Hz, 1H), 7.96 (s, 2H), 7.57 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.3 Hz, 2H), 7.45 (s, 1H), 7.17 (s, 1H), 7.13 (d, J=8.4 Hz, 2H), 6.89 (d, J=8.9 Hz, 1H), 6.57 (s, 1H). MS m/z (ESI): 396.1 [M+H].

Example 13: Preparation of 6-(2-((1H-indazol-6-yl)amino)pyrimidin-4-yl)-N-(pyridazin-4-yl)-1H-indole-2-carboxamide (TDI01249)

Preparation of TDI0124921.

TDI01249-1-a (2 g, 8.33 mmol) and methanol (20 mL) were added to a 100 mL flask, thionyl chloride (1.98 g, 16.66 mmol) was added, and then the reaction was performed at 60° C. for 3 hours. Thin layer chromatography (petroleum ether:ethyl acetate=10:1) indicated the reaction was complete. The reaction solution was concentrated to give a crude product, and the crude product was dissolved in dichloromethane (100 mL). The dicheoromethane phase was washed with a saturated aqueous solution of sodium hydrogen carbonate twice (50 mL. for each time). The dichloromethane phase was then washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain TDI01249-1-b (2.149 g, brown solid, yield: 10043%).

¹H NMR (400 MHz, CDCl₃) δ 7.59 (s, 1H), 7.54 (d, J=8.5 Hz, 1H), 7.25 (d, J=8.6 Hz, 1H), 7.18 (s, 1H), 3.96 (s, 3H).

TDI01249-1-b (2 g, 7.87 mmol) and bis(pinacolato)diboron (3.0 g, 11.81 mmol) were dissolved in 1,4-dioxane (20 mL), potassium acetate (2.32 g, 23.61 mmol) and Pd(dppf)Cl₂ (130 mg, 0.157 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 80° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=20:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was separated and purified by column chromatography (petroleum ether:ethyl acetate=100:1 to 5:1) to afford TDI01249-1 (2.0 g, white solid, yield: 84.37%).

¹H NMR (400 MHz, CDCl₃) δ 9.08-8.93 (m, 1H), 7.97-7.86 (m, 1H), 7.69 (d, J=8.1 Hz, 1H), 7.61-7.52 (m, 1H), 7.21 (dd, J=2.1, 1.0 Hz, 1H), 3.95 (s, 3H), 1.37 (s, 12H). MS m/z (ESI): 302.2 [M+H].

Step 1:

Compound TDI01249-1 (2 g, 6.64 mmol), 2,4-dichloropyrimidine (1.08 g, 7.30 mmol), Pd(PPh₃)₂Cl₂ (47 mg, 0.07 mmol), sodium carbonate (1.40 g, 13.28 mmol), 60 mL dioxane and 15 mL water were added to a 250 mL single neck flask, purge with argon was performed for 4 times, and the reaction was warmed to 105° C., and allowed to proceed for 3 h. LC-MS indicated the reaction was complete. The reaction solution was cooled followed by concentration under reduced pressure to remove dioxane, 100 mL water was added, and the solution was stirred at room temperature for 1 h. The reaction mixture was filtered to give a yellow solid (2.3 g), which was rinsed with dichloromethane (80 mL×4) to afford TDI01249-2 (0.62 g, yellow solid, yield: 32.6%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.33 (s, 1H), 8.78 (d, J=5.2 Hz, 1H), 8.34 (s, 1H), 8.13 (d, J=5.3 Hz, 1H), 7.89 (d, J=8.4 Hz, 1H), 7.83 (d, J=8.5 Hz, 1H), 7.24 (s, 1H), 3.91 (s, 3H). MS m/z (ESI): 288.0 [M+H].

Step 2:

Compound TDI01249-2 (400 mg, 1.39 mmol), tert-butyl 5-amino-1H-indazole-1-carboxylate (200 mg, 0.86 mmol), Pd₂(dba)₃ (85.6 mg, 0.09 mmol), 2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-biphenyl (182.4 mg, 0.43 mmol), potassium tert-butoxide (193 mg, 1.72 mmol) and 80 mL dioxane were added to a 250 mL single neck flask, purge with argon was performed for 4 times, and the reaction was warmed to 110° C., and allowed to proceed for 3 h. 20 mg Pd₂(dba)₃, 40 mg 2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-biphenyl and 50 mg potassium tert-butoxide were supplemented, and the reaction was continued for 1 h. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure to remove dioxane, 80 mL ethyl acetate was added, and filtered to obtain the filtrate, which was purified to afford TDI01249-3 (100 mg, yellow solid, yield: 24%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.31 (s, 1H), 9.92 (s, 1H), 8.58 (d, J=5.2 Hz, 1H), 8.55 (d, J=1.5 Hz, 1H), 8.46 (s, 1H), 8.35 (s, 1H), 8.03 (s, 1H), 7.94 (dd, J=9.2, 1.8 Hz, 1H), 7.91-7.88 (m, 1H), 7.84 (s, 1H), 7.45 (d, J=5.3 Hz, 1H), 7.25 (d, J=1.2 Hz, 1H), 3.92 (s, 3H), 1.67 (s, 9H). MS m/z (ESI): 485.1 [M+H].

Step 3:

Compound TDI01249-3 (100 mg, 0.135 mmol) and 2 mol/L hydrochloric acid/methanol (5 mL) were added to a 100 mL single neck flask. The reaction was warmed to 60° C., and allowed to proceed for 1.5 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, 10 mL 2 mol/L aqueous solution of sodium hydroxide was added, and the reaction was warmed to 60° C., and allowed to proceed for 0.5 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and the pH was adjusted to above 12 with concentrated hydrochloric acid. Methanol was removed through concentration under reduced pressure, 20 mL water was then added, and the reaction was filtered after stirring, the solid obtained after filtration was dried to afford compound TDI01249-4 (50 mg, yellow solid, yield: 23.8%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.22 (s, 1H), 9.82 (s, 1H), 8.57 (d, J=5.4 Hz, 1H), 8.39 (s, 2H), 8.15 (s, 1H), 7.92 (d, J=1.1 Hz, 1H), 7.87 (s, 1H), 7.72 (dd, J=10.6, 9.0 Hz, 1H), 7.60 (s, 1H), 7.46 (d, J=5.4 Hz, 1H), 7.22 (s, 1H). MS m/z (ESI): 371.0 [M+H].

Step 4:

Compound TDI01249-4 (50 mg, 0.135 mmol), pyridazin-4-amine (15.4 mg, 0.162 mmol), HATU (61.7 mg, 0.162 mmol), DIEA (70 mg, 0.54 mmol) and 4 mL N,N-dimethylformamide were added to a 25 mL single neck flask, and the reaction was performed at room temperature for 0.5 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and added to 20 mL water to give a solid, which was dried and purified by preparative chromatography to afford TDI01249 (14.38 mg, yellow solid, yield: 23.8%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.89 (s, 1H), 12.33 (s, 1H), 10.94 (s, 1H), 9.62 (d, J=17.6 Hz, 2H), 9.14 (d, J=5.8 Hz, 1H), 8.54 (d, J=5.2 Hz, 1H), 8.36 (d, J=5.8 Hz, 2H), 8.18 (d, J=3.2 Hz, 1H), 8.08 (s, 1H), 7.90 (s, 2H), 7.69 (s, 1H), 7.61 (s, 1H), 7.51 (d, J=8.8 Hz, 1H), 7.38 (d, J=5.2 Hz, 1H). MS m/z (ESI): 448.0 [M+H].

Example 14: Preparation of 6-(2-((1H-indazol-5-yl)amino)-6-methylpyrimidin-4-yl)-N-(pyridazin-4-yl)-1H-indole-2-carboxamide (TDI01261)

Step 1:

Compound TDI01261-1 (2.0 g, 8.58 mmol) and tert-butyl 5-amino-1H-indazole-1-carboxylate (1.68 g, 10.296 mmol) were dissolved in N,N-dimethylformamide (150 mL.), diisopropylethylamine (4.427 g, 34.32 mmol) was added, and the reaction was slowly warmed to 100° C., and allowed to proceed at this temperature for 16 hours. Thin layer chromatography (petroleum ether:ethyl acetate=2:1) indicated the reaction was complete. The reaction solution was slowly poured into water (900 ml.), stirred for 30 minutes followed by filtration. The residue was separated and purified by column chromatography (petroleum ether:ethyl acetate=1:0 to 1:1), to afford compound TDI01261-2 (300 mg, light yellow solid).

¹H NMR (400 MHz, DMSO-d₆) δ 10.18 (s, 1H), 8.40 (s, 1H), 8.37 (s, 1H), 7.98 (d, J=9.2 Hz, 1H), 7.77 (dd, J=9.2, 1.6 Hz, 1H), 6.92 (s, 1H), 2.40 (s, 3H), 1.65 (s, 8H). MS m/z (ESI): 360.0 [M+H].

Step 2:

Compound TDI01261-2 (300 mg, 0.836 mmol) and TDI01249-1 (299 mg, 1.672 mmol) were dissolved in a mixed solution of ethanol:water (10:1) (30 mL), sodium carbonate (177 mg, 1.672 mmol) and Pd(PPh₃)₂Cl₂ (59 mg, 0.0836 mmol) were added, purge with argon was performed for 3 times, and the reaction was perform in an oil bath at 110° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was dissolved in dichloromethane (500 mL), washed with water (500 mL×3), the pH of the aqueous phase was adjusted to 2 with concentrated hydrochloric acid (3 mL), and compound TDI01261-3 (110 mg, yellow solid, yield: 32.7%) was obtained by filtration.

¹H NMR (400 MHz, DMSO-d₆) δ 12.20 (s, 1H), 9.90 (s, 1H), 8.33 (d, J=5.6 Hz, 2H), 8.12 (s, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.81 (d, J=8.4 Hz, 1H), 7.71-7.66 (m, 1H), 7.56 (d, J=8.8 Hz, 1H), 7.42 (s, 1H), 7.17 (s, 1H), 2.09 (s, 3H). MS m/z (ESI): 385.1 [M+H].

Step 3:

Compound TDI01261-3 (100 mg, 0.26 mmol) and pyridazin-4-amine (30 mg, 0.313 mmol) were dissolved in N,N-dimethylformamide (10 mL), HATU (120 mg, 0.313 mmol) and diisopropylethylamine (130 mg, 1.04 mmol) were added, and the reaction was performed at room temperature overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and the residue was purified by liquid chromatography to afford compound TDI01261 (11.02 mg, yellow solid, yield: 10.2%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.07-12.76 (m, 1H), 12.35 (s, 1H), 11.07 (s, 1H), 9.61 (s, 2H), 9.18 (d, J=5.6 Hz, 1H), 8.39 (d, J=20.0 Hz, 2H), 8.26 (d, J=3.6 Hz, 1H), 8.09 (s, 1H), 7.90 (s, 2H), 7.72 (d, J=8.8 Hz, 1H), 7.63 (s, 1H), 7.51 (d, J=8.8 Hz, 1H), 7.32 (s, 1H), 2.46 (s, 3H). MS m/z (ESI): 462.1 [M+H].

Example 15: Preparation of 6-(5-((1H-indazol-5-yl)amino)-1,3,4-thiadiazol-2-yl)-N-isopropyl-1H-indole-2-carboxamide (TDI01147)

Step 1:

Compound TDI01147-1 (2.00 g, 8.33 mmol) was dissolved in anhydrous toluene (30 mL), 1,1-di-tert-butoxy-N,N-dimethylmethanamine (4.56 g, 22.5 mmol) was slowly added under reflux, and the reaction was performed in an oil bath at 120° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=4:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the crude product was separated and purified by column chromatography (petroleum ether:ethyl acetate=15:1) to afford compound TDI01147-2 (1.85 g, white solid, yield: 75.2%).

¹H NMR (400 MHz, CDCl₃) δ 8.95 (s, 1H), 7.59 (s, 1H), 7.53 (d, J=8.4 Hz, 1H), 7.24 (dd, J=8.4, 1.6 Hz, 1H), 7.10 (d, J=1.2 Hz, 1H), 1.62 (s, 9H).

Step 2:

Compound TDI01147-2 (1.85 g, 6.27 mmol) was dissolved in methanol (150 mL), triethylamine (1.90 g, 18.8 mmol) and Pd(dppf)Cl₂ (461 mg, 0.63 mmol) were added, purge with CO were performed for 3 times, and the reaction was placed in an oil bath at 80° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=4:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, and concentrated under reduced pressure. The residue was diluted with dichloromethane (150 mL), successively washed with water (150 mL) and saturated brine (150 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was separated and purified by column chromatography (ethyl acetate/petroleum ether=6.2%˜-8.5%) to afford compound TDI01147-3 (620 mg, yellow solid, yield: 36.0%).

¹H NMR (400 MHz, CDCl₃) δ 9.10 (s, 1H), 8.18 (s, 1H), 7.82 (dd, J=8.4, 1.2 Hz, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.16 (d, J=1.2 Hz, 1H), 3.95 (s, 3H), 1.63 (s, 9H).

Step 3:

Compound TDI01147-3 (570 mg, 2.07 mmol) was dissolved in ethanol (12 mL), hydrazine hydrate (3 mL) was added, and the reaction was performed under microwave radiation at 90° C. for 1 hour. LC-MS indicated half of the starting material was converted as the product. The reaction solution was diluted with ethyl acetate (80 mL), successively washed with water (100 mL) and saturated brine (100 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was rinsed with ethyl acetate to afford compound TDI01147-4 (300 mg, yellow solid, yield: 52.6%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.98 (s, 1H), 9.76 (s, 1H), 7.95 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.52 (dd, J=8.4, 1.2 Hz, 1H), 7.08 (s, 1H), 4.49 (s, 2H), 1.58 (s, 9H).

Step 4:

Compound TDI01147-4 (250 mg, 0.91 mmol) was dissolved in a mixed solution of anhydrous dichloromethane/1,2-dichloroethane (2:1) (15 mL), compound tert-butyl 5-isothiocyanato-1H-indazole-1-carboxylate (250 mg, 0.91 mmol) was added, and the reaction solution was slowly warmed to 50° C., and allowed to proceed at this temperature for 16 hours. The reaction solution was cooled to room temperature, concentrated sulfuric acid was slowly added thereto under stirring, and the reaction was performed at room temperature for 6 hours. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, the crude product was diluted with water (30 mL), and the pH was adjusted to 9 with saturated aqueous sodium carbonate. A large amount of solid precipitated, and was filtered after being stirred at room temperature for 1 hour. The solid was dissolved in toluene and then concentrated to afford compound TDI01147-5 (250 mg, yellow solid, yield: 73.3%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.02 (s, 2H), 12.00 (s, 1H), 10.46 (s, 1H), 8.27 (s, 1H), 8.07 (s, 1H), 7.91 (s, 1H), 7.77 (d, J=8.4 Hz, 1H), 7.60-7.54 (m, 2H), 7.43 (d, J=8.6 Hz, 1H), 7.15 (s, 1H). MS m/z (ESI): 377.1 [M+H].

Step 5:

Compound TDI01147-5 (100 mg, 0.27 mmol) was dissolved in N,N-dimethylformamide (6 mL), and HATU (122 mg, 0.32 mmol) and diisopropylethylamine (139 mg, 1.08 mmol) were added. After reaction at room temperature for 30 minutes, isopropylamine (18.8 mg, 0.32 mmol) was added, and the reaction was continued at room temperature overnight. LC-MS indicated the reaction was complete. The reaction solution was slowly added to water (20 mL), a large amount of solid precipitated, and was filtered after being stirred for 30 min. The solid was purified by high-performance liquid chromatography to afford compound TDI01147 (6.03 mg, yellow solid, yield: 5.4%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.01 (s, 1H), 11.79 (s, 1H), 10.44 (s, 1H), 8.34 (d, J=7.6 Hz, 1H), 8.27 (s, 1H), 8.07 (s, 1H), 7.90 (s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.56 (d, J=8.4 Hz, 2H), 7.43 (d, J=8.8 Hz, 1H), 7.22 (s, 1H), 4.17-4.12 (m, 1H), 1.21 (d, J=6.4 Hz, 6H). MS m/z (ESI): 418.1 [M+H].

Example 16: Preparation of 6-(3-((1H-indazol-5-yl)amino)piperidin-1-yl)-N-(pyridazin-4-yl)-1H-indole-2-carboxamide (TDI01234)

Step 1:

Compound TDI01234-1 (2.0 g, 8.86 mmol) was dissolved in 1,2-dichloroethane (150 mL), triethylamine (746 mg, 7.38 mmol) was added, and the reaction solution was warmed to 30° C. and stirred for 1.5 hours. Tert-butyl 5-amino-1H-indazole-1-carboxylate (1.72 g, 7.38 mmol) and acetic acid (443 mg, 7.38 mmol) were then added, after stir of 0.5 hour, sodium triacetoxyborohydride (4.69 g, 22.14 mmol) was added, and the reaction was maintained at 30° C. overnight. Thin layer chromatography (dichloromethane:methanol=60:1) assay indicated the reaction was complete. The reaction solution was dissolved in dichloromethane (1500 mL), successively washed with water (150 mL×2) and saturated brine (150 mL), and the organic phase was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (dichloromethane:methanol=1:0 to 60:1), to afford compound TDI01234-2 (1.0 g, brown yellow solid).

¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1H), 7.93 (d, J=8.8 Hz, 1H), 7.30 (dd, J=13.6, 5.2 Hz, 4H), 7.24 (dd, J=5.2, 3.2 Hz, 1H), 6.88 (dd, J=8.8, 2.1 Hz, 1H), 6.75 (d, J=1.6 Hz, 1H), 4.16 (s, 1H), 3.66-3.44 (m, 3H), 2.57 (d, J=120.0 Hz, 4H), 1.70 (s, 11H), 1.59 (s, 2H). MS m/z (ESI): 407.3 [M+H].

Step 2:

Compound TDI01234-2 (0.6 g, 1.478 mmol) was dissolved in methanol (50 mL), palladium/carbon (100 mg) was added, purge with hydrogen was performed for 3 times, and the reaction was placed in an oil bath at 35° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and purified by column chromatography (dichloromethane:methanol=1:0 to 10:1), to afford compound TDI01234-3 (200 mg, off-white solid).

¹H NMR (400 MHz, CDCl₃) δ 7.98 (s, 1H), 7.93 (d, J=8.8 Hz, 1H), 6.94-6.88 (m, 1H), 6.83-6.78 (m, 1H), 4.09 (s, 1H), 3.56 (s, 1H), 3.33-3.19 (m, 1H), 2.99-2.90 (m, 1H), 2.81 (d, J=8.0 Hz, 1H), 2.68 (dd, J=11.2, 7.1 Hz, 1H), 1.84 (dd, J=13.6, 6.7 Hz, 2H), 1.71 (s, 9H), 1.59 (dd, J=19.2, 13.9 Hz, 3H). MS m/z (ESI): 317.3 [M+H].

Step 3:

6-bromo-N-(pyridazin-4-yl)-1H-indole-2-carboxamide was prepared according to step 3 of Example 2, with

being replaced with

being replaced with

Compound TDI01234-3 (400 mg, 1.27 mmol) and 6-bromo-N-(pyridazin-4-yl)-1H-indole-2-carboxamide (400 mg, 1.27 mmol) were dissolved in dimethyl sulfoxide (10 mL). Pd₂(dba)₃ (120 mg, 0.127 mmol), t-BuXPhos (823 mg, 2.53 mmol) and cesium carbonate (268.4 mg, 0.63 mmol) were then added, and the reaction was performed under microwave radiation and the protection of argon for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, slowly added to water (80 mL), and filtered. The filter cake was rinsed with dichloromethane:ethyl acetate=1:1 (20 mL×2), and the residue was purified by liquid chromatography to afford compound TDI01234 (2.58 mg, yellow solid).

¹H NMR (400 MHz, DMSO-d₆) δ 12.06 (s, 1H), 11.05 (s, 1H), 10.20 (s, 1H), 9.61 (s, 1H), 9.10 (s, 2H), 8.95 (s, 1H), 8.18 (s, 1H), 8.07 (s, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.76 (s, 1H), 7.66 (d, J=9.6 Hz, 1H), 7.51 (d, J=8.8 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 6.89 (s, 1H), 3.24 (s, 1H), 2.87 (s, 1H), 1.95 (d, J=46.4 Hz, 3H), 1.74 (s, 2H), 1.52 (s, 2H). MS m/z (ESI): 451.3 [M−H].

Example 17: Preparation of 6-((3-(1H-pyrazol-4-yl)phenyl)amino)-N-(pyridazin-4-yl)-1H-indole-2-carboxamide (TDI01245)

Step 1:

Compound TDI01245-1 (5.0 g, 25.77 mmol) was dissolved in dichloromethane (100 mL), diisopropylethylamine (13.30 g, 100.08 mmol) and 4-dimethylaminopyridine (1.57 g, 12.88 mmol) were added, and di-tert-butyl dicarbonate (11.24 g, 51.55 mmol) was added after the reaction was stirred at room temperature for 10 minutes. Thin layer chromatography (petroleum ether:ethyl acetate=3:1) indicated the reaction was complete. The reaction solution was dissolved in dichloromethane (400 mL), and successively washed with water (500 mL×2) and saturated brine (500 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (petroleum ether:ethyl acetate=1:0 to 10:1), to afford compound TDI01245-2 (4.58 g, white solid).

¹H NMR (400 MHz, CDCl₃) δ 8.42-8.34 (m, 1H), 7.93 (s, 1H), 1.65 (s, 9H), 1.34 (s, 12H).

Step 2:

Compound TDI01245-2 (5.0 g, 17.01 mmol) and 1-bromo-3-nitrobenzene (2.863 g, 14.17 mmol) were dissolved in a mixed solution of 1,4-dioxane/water (8:1) (500 mL), potassium carbonate (3.91 g, 28.34 mmol) and Pd(dppf)Cl₂ (497 mg, 0.708 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 110° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was dissolved in dichloromethane (500 mL), and successively washed with water (500 mL×2) and saturated brine (500 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (dichloromethane:methanol=1:0 to 50:1) to afford compound TDI01245-3 (850 mg, yellow solid).

¹H NMR (400 MHz, DMSO-d₆) δ 13.14 (s, 1H), 8.44 (d, J=11.2 Hz, 2H), 8.20-8.06 (m, 2H), 8.03 (dd, J=8.0, 1.6 Hz, 1H), 7.65 (t, J=8.0 Hz, 1H). MS m/z (ESI): 190.3 [M+H].

Step 3:

Compound TDI01245-3 (850 mg, 4.497 mmol) was dissolved in dichloromethane (100 mL), diisopropylethylamine (2.32 g, 17.989 mmol) and 4-dimethylaminopyridine (274 mg, 2.249 mmol) were added, and di-tert-butyl dicarbonate (1.96 g, 8.995 mmol) was added after the reaction was stirred at room temperature for 10 minutes. Thin layer chromatography (dichloromethane) indicated the reaction was complete. The reaction solution was dissolved in dichloromethane (400 mL), and successively washed with water (250 mL×2) and saturated brine (250 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (petroleum ether:dichloromethane=10:1 to 1:1), to afford compound TDI01245-4 (820 mg, white solid).

¹H NMR (400 MHz, CDCl₃) δ 8.43 (s, 1H), 8.38 (t, J=1.6 Hz, 1H), 8.16 (dd, J=8.0, 1.2 Hz, 1H), 7.85 (d, J=7.6 Hz, 1H), 7.59 (t, J=8.0 Hz, 1H), 7.26 (s, 1H), 1.70 (s, 9H).

Step 4:

Compound TDI01245-4 (820 mg, 2.837 mmol) was dissolved in methanol (100 mL), palladium/carbon (100 mg) was added, purge with hydrogen was performed for 3 times, and the reaction was placed in an oil bath at 35° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and purified by column chromatography (dichloromethane:methanol=1:0 to 100:1) to afford compound TDI01245-5 (650 mg, off-white solid).

¹H NMR (400 MHz, CDCl₃) δ 8.25 (s, 1H), 7.95 (s, 1H), 7.18 (t, J=7.6 Hz, 1H), 6.92 (d, J=7.6 Hz, 1H), 6.84 (s, 1H), 6.63 (d, J=8.0 Hz, 1H), 3.71 (s, 2H), 1.67 (s, 9H). MS m/z (ESI): 249.0 [M−H].

Step 5:

Compound TDI01245-5 (300 mg, 1.158 mmol) and 6-bromo-N-(pyridazin-4-yl)-1H-indole-2-carboxamide (the preparation method thereof is as described in Example 12) (366 mg, 1.158 mmol) were dissolved in tert-butanol (8 mL). Pd₂(dba)₃ (110 mg, 0.116 mmol), t-BuXPhos (753 mg, 2.316 mmol) and cesium carbonate (245.5 mg, 0.579 mmol) were added, and the reaction was performed under microwave radiation at 115° C. and the protection of argon for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was rotary evaporated to dryness, slurried in dichloromethane (20 mL), and filtered. The residue was purified by liquid chromatography to afford compound TDI01245 (53.25 mg, brownish red solid).

¹H NMR (400 MHz, DMSO-d₆) δ 11.55 (s, 1H), 10.81 (s, 1H), 9.56 (s, 1H), 9.13 (s, 1H), 8.23 (s, 2H), 7.98 (s, 2H), 7.58 (d, J=8.8 Hz, 1H), 7.47 (s, 1H), 7.37 (s, 1H), 7.25 (s, 2H), 7.09 (d, J=7.6 Hz, 1H), 6.93 (dd, J=21.2, 7.9 Hz, 2H). MS m/z (ESI): 396.2 [M−H].

Example 18: Preparation of 6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-N-(1,3,4-thiadiazol-2-yl)-1H-indole-2-carboxamide (TDI01247)

Step 1:

Compound TDI01247-1 (the preparation thereof is as described in Example 13) (3.00 g, 9.97 mmol) was dissolved in tetrahydrofuran (50 mL), diisopropylethylamine (5.15 g, 39.9 mmol) and dimethylaminopyridine (182 mg, 1.50 mmol) were added, di-tert-butyl dicarbonate (3.25 g, 14.9 mmol) was added with stirring at room temperature, and the reaction was performed at room temperature overnight. Thin layer chromatography (petroleum ether:ethyl acetate=5:1) indicated the reaction was complete. The reaction solution was diluted with water (80 mL), and extracted with ethyl acetate (100 mL×2). The organic phase was combined, successively washed with 0.5M HCl (80 mL×2) and saturated brine (100 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound TDI01247-2 (2.8 g, yellow solid, yield: 70%).

¹H NMR (400 MHz, CDCl₃) δ 8.58 (s, 1H), 7.69 (d, J=8.0 Hz, 1H), 7.59 (d, J=8.0 Hz, 1H), 7.07 (s, 1H), 3.93 (s, 3H), 1.63 (s, 9H), 1.36 (s, 12H).

Step 2:

Compound TDI01247-2 (2.8 g, 6.98 mmol) was dissolved in a mixed solution of tetrahydrofuran/methanol/water (2:2:1) (25 mL), lithium hydroxide (2.93 g, 69.8 mmol) was added, and the reaction was performed at room temperature overnight. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was purified by column chromatography (dichloromethane/methanol=12:1) to afford compound TDI01247-3 (1.3 g, yellow solid, yield: 48.3%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.89 (s, 1H), 8.37 (s, 1H), 7.70 (d, J=8.0 Hz, 1H), 7.58 (d, J=8.0 Hz, 1H), 7.20 (s, 1H), 1.57 (s, 9H), 1.32 (s, 12H). MS m/z (ESI): 388.2 [M+H].

Step 3:

Compound TDI01247-3 (800 mg, 2.07 mmol) was dissolved in N,N-dimethylformamide (10 mL), and HATU (945 mg, 2.48 mmol) and diisopropylethylamine (1.07 g, 8.28 mmol) were added. After stirring at room temperature for 30 min, 1,3,4-thiadiazol-2-amine (250 mg, 2.48 mmol) was added, and the reaction was continued at room temperature overnight. LC-MS and thin layer chromatography (petroleum ether:ethyl acetate=1:1) indicated the reaction was complete. The reaction solution was washed with ethyl acetate (80 mL), and successively washed with water (60 mL×2) and saturated brine (80 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was separated and purified by column chromatography (ethyl acetate/petroleum ether=10%˜50%) to afford compound TDI01247-4 (100 mg, yellow solid, yield: 10.3%).

¹H NMR (400 MHz, CDCl₃) δ 11.45 (s, 1H), 8.86 (s, 1H), 8.65 (s, 1H), 7.74 (d, J=8.0 Hz, 1H), 7.66 (d, J=8.0 Hz, 1H), 7.39 (s, 1H), 1.60 (s, 9H), 1.37 (s, 12H). MS m/z (ESI): 471.2 [M+H].

Step 4:

Compound TDI01247-5 (6.00 g, 17.4 mmol) was dissolved in tetrahydrofuran (150 mL), diisopropylethylamine (8.98 g, 69.6 mmol) and dimethylaminopyridine (212 mg, 1.74 mmol) were added. Di-tert-butyl dicarbonate (4.55 g, 20.9 mmol) was slowly added under stirring at room temperature, and the reaction was performed at room temperature overnight. Thin layer chromatography (petroleum ether:ethyl acetate=1:1) indicated the reaction was complete. The reaction solution was diluted with water (80 mL), and extracted with ethyl acetate (100 mL×2) The organic phase was combined, successively washed with 0.5M HCl (150 mL×2) and saturated brine (200 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound TDI01247-6 (Reg-1-27, 7.0 g, yellow solid, yield: 90.9%).

¹H NMR (400 MHz, DMSO-d₆) δ 8.63 (d, J=6.0 Hz, 1H), 8.45 (s, 1H), 8.13 (d, J=8.8 Hz, 1H), 8.02 (d, J=6.0 Hz, 1H), 7.82 (d, J=2.0 Hz, 1H), 7.50 (dd, J=8.8, 2.0 Hz, 1H), 1.67 (s, 9H), 1.36 (s, 9H).

Step 5:

Compound TDI01247-4 (100 mg, 0.21 mmol) and TDI01247-6 (78.9 mg, 0.18 mmol) were dissolved in a mixed solution of ethanol/water (8:1) (9 mL), sodium carbonate (38.2 mg, 0.36 mmol) and Pd(PPh₃)₂Cl₂ (14.0 mg, 0.02 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 110° C., and allowed to proceed overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and the residue was purified by preparative thin layer chromatography (ethyl acetate) to afford compound TDI01247-7 (50 mg, yellow oil, yield: 51.0%). MS m/z (ESI): 554.2 [M+H].

Step 6:

Compound TDI01247-7 (50 mg, 0.09 mmol) was dissolved in dichloromethane (2 mL), trifluoroacetic acid (1 mL) was added at room temperature, and the reaction was performed in an oil bath at 40° C. for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was separated and purified by high-performance liquid chromatography (trifluoroacetic acid) to afford compound TDI01247 (8.23 mg, yellow solid, yield: 20.1%).

¹H NMR (400 MHz, CD₃OD, DMSO-d₆) δ 9.12 (s, 1H), 8.42 (s, 1H), 8.23 (d, J=7.2 Hz, 1H), 8.18 (s, 2H), 7.95 (d, J=8.4 Hz, 2H), 7.90 (d, J=8.8 Hz, 1H), 7.71 (d, J=8.8 Hz, 2H), 7.63 (s, 2H), 6.90 (d, J=6.8 Hz, 1H). MS m/z (ESI): 454.1 [M+H].

Example 19: Preparation of 1-(6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-1H-indol-1-yl)-2-(4-methylpiperazin-1-yl)ethan-1-one (TDI01230)

Step 1:

Compound 2-(4-methylpiperazin-1-yl)acetic acid (2.4 g, 15.3 mmol) was dissolved in N,N-dimethylformamide (10 mL), PyBOP (7.9 g, 15.3 mmol) was added, and the reaction solution was stirred at ambient temperature for 1 hour. TDI01230-1 (2 g, 10.2 mmol) and DIPEA (3.9 g, 30.6 mmol) were then added, and the reaction was continued at ambient temperature for 2 h. LC-MS indicated the reaction was complete. The reaction solution was added with water (25 mL), and extracted with dichloromethane (50 mL×3). The organic phase was washed with saturated brine (10 mL×2), dried over anhydrous sodium sulfate, and concentrated, followed by purification by column chromatography (dichloromethane:methanol=100:0 to 20:1), to afford compound TDI01230-2 (600 g, yellow solid, crude product, yield: 11.6%).

¹H NMR (400 MHz, DMSO-d₆) δ 8.51 (s, 1H), 7.95 (d, J=3.8 Hz, 1H), 7.60 (d, J=8.3 Hz, 1H), 7.46 (d, J=1.7 Hz, 1H), 6.76 (d, J=3.7 Hz, 1H), 3.89 (s, 2H), 2.70 (d, J=5.7 Hz, 8H), 2.38 (s, 3H). MS m/z (ESI): 336.1 [M+H].

Step 2:

Compound TDI01230-2 (600 mg, 1.79 mmol) and bis(pinacolato)diboron (908 mg, 6.3 mmol) were dissolved in 1,4-dioxane (10 mL), potassium acetate (527 mg, 5.37 mmol) and Pd(dppf)Cl₂ (132 mg, 0.18 mmol) were added, purge with argon was performed for 3 times, the reaction was placed in an oil bath at 110° C., and allowed to proceed overnight. Thin layer chromatography (petroleum ether:ethyl acetate=20:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane/methanol=100:0 to 20:1), to afford compound TDI01230-3 (300 mg, brown solid, yield: 43.8%). MS m/z (ESI): 384.3 [M+H].

Step 3:

Compound TDI01230-3 (100 mg, 0.225 mmol) and tert-butyl 5-((tert-butoxycarbonyl)(2-chloropyrimidin-4-yl)amino)-1H-indazole-1-carboxylate (for preparation process thereof, please refer to Example 18) (129 mg, 0.337 mmol) were dissolved in a mixed solution of tetrahydrofuran/water (1:2) (3 mL), potassium phosphate (96 mg, 0.45 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium (II) (4 mg, 0.005 mmol) were added, purge with argon was performed, and the reaction was placed in an oil bath at 60° C., and allowed to proceed for 2 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature followed by addition of water (5 mL), and then extracted with dichloromethane (5 mL×3). The organic phase was extracted with saturated brine (5 mL×2), dried over anhydrous sodium sulfate, and concentrated followed by purification by thin layer chromatography (dichloromethane:methanol=15:1) to afford compound TDI01230-4 (30 mg, yellow solid, yield: 20.0%). MS m/z (ESI): 369.3 [M+H].

Step 4:

Trifluoroacetic acid (1.5 mL) was added to a solution of TDI01230-4 (30 mg, 0.045 mmol) in dichloromethane (3 mL), and the reaction was performed at room temperature for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by liquid chromatography to afford compound TDI01230 (7.13 mg, yellow solid, yield: 34.0%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.47 (s, 1H), 9.77 (s, 1H), 9.55 (s, 1H), 8.64 (s, 1H), 8.44-8.31 (m, 2H), 8.26 (d, J=7.8 Hz, 1H), 8.09 (s, 1H), 7.81 (d, J=7.9 Hz, 1H), 7.63 (d, J=8.5 Hz, 1H), 7.52 (d, J=8.0 Hz, 1H), 6.95-6.78 (m, 2H), 4.14 (s, 2H), 3.47 (s, 2H), 3.20 (s, 4H), 2.85 (s, 3H), 2.73 (s, 2H). MS m/z (ESI): 467.3 [M+H].

Example 20: Preparation of 2-(5-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)isoindolin-2-yl)-N-(pyridazin-4-yl)acetamide (TDI01238)

Step 1:

Compound TDI01238-1 (1 g, 10.526 mmol), chloroacetyl chloride (1.3 g, 11.504 mmol) and triethylamine (1.17 g, 11.584 mmol) were dissolved in dichloromethane (10 mL), and the reaction was performed at room temperature for 3 hours. LC-MS indicated the reaction was complete. Water (25 mL) and dichloromethane (30 mL) were added to the reaction solution, and precipitation occurred. The filter cake was obtained after filtration, washed with water and n-hexane, and dried to afford compound TDI01238-2 (950 mg, brown solid, yield: 52.78%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.97 (s, 1H), 9.30 (dd, 1H), 9.07 (dd, 1H), 7.92 (dd, 1H), 4.37 (s, 2H). MS m/z (ESI): 172.1 [M+H].

Step 2:

Compound TDI01238-3 (500 mg, 2.132 mmol), 4-tosyl chloride (447 mg, 2.345 mmol), 4-dimethylaminopyridine (78 mg, 0.6396 mmol), diisopropylethylamine (825 mg, 6.396 mmol) and tetrahydrofuran/acetonitrile (20/8 mL) were mixed, and reacted at room temperature for 16 h. After the reaction was complete, the reaction solution was concentrated to dryness, and the residue was added with water, followed by extraction with ethyl acetate (20 mL×2). The organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated to dryness. The residue was rinsed with petroleum ether to afford compound TDI01238-4 (700 mg, white solid, yield: 93.58%).

¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, 2H), 7.33 (dd, 4H), 7.03 (d, 1H), 4.57 (d, 4H), 2.41 (s, 3H). MS m/z (ESI): 352.1 [M+H].

Step 3:

Compound TDI01238-4 (700 mg, 1.988 mmol) and bis(pinacolato)diboron (757 mg, 2.983 mmol) were dissolved in 1,4-dioxane (20 mL), potassium acetate (584 mg, 5.964 mmol) and Pd(dppf)Cl₂ (146 mg, 0.199 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 105° C., and allowed to proceed for 4 h. After the reaction was complete, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure to dryness. The residue was added with water, and extracted with dichloromethane (20 mL×2). The organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated to dryness. The residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1) to afford compound TDI01238-5 (740 mg, white solid, yield: 93.3%).

¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, 2H), 7.67 (d, 1H), 7.61 (s, 1H), 7.30 (d, 2H), 7.17 (d, 1H), 4.62 (d, 4H), 2.39 (s, 3H), 1.32 (s, 12H). MS m/z (ESI): 400.2 [M+H].

Step 4:

Compound TDI01238-5 (0.5 g, 1.253 mmol) and Reg-1-1 (288 mg, 0.835 mmol) were dissolved in a mixed solution of ethanol/water (8/1 mL), sodium carbonate (266 mg, 2.505 mmol) and Pd(PPh₃)₂Cl₂ (59 mg, 0.0835 mmol) were added, purge with argon was performed for 3 times, the reaction was placed in an oil bath at 100° C., and allowed to proceed for 2 h. After the reaction was complete, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure to dryness. The residue was added with water, and extracted with ethyl acetate (20 mL×3). The organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated to dryness. The residue was purified by column chromatography (dichloromethane:methanol=30:1-20:1) to afford compound TDI01238-6 (260 mg, yellow oil, yield: 64.68%).

¹H NMR (400 MHz, CDCl₃) δ 8.30 (dd, 1H), 8.20 (s, 0.5H), 8.09 (d, 1H), 7.77 (dd, 2.5H), 7.68 (m, 1H), 7.55 (dd, 1H), 7.47 (d, 0.5H), 7.32 (m, 5H), 7.17 (d, 0.3H), 7.02 (s, 0.4H), 6.49 (dd, 0.7H), 4.65 (dd, 4H), 2.40 (d, 3H). MS m/z (ESI): 483.3 [M+H].

Step 5:

Compound TDI01238-6 (245 mg, 0.508 mmol) and hydrobromic acid (5 mL) were placed in an oil bath at 95° C., and reacted for 6 h. After the reaction was complete, the reaction solution was concentrated under reduced pressure to dryness, toluene (10 mL) was added to dissolve the residue, and the resulted solution was then concentrated under reduced pressure to dryness, to afford compound TDI01238-7 (150 mg, yellow solid, yield: 90.36%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.47 (s, 1H), 9.69 (s, 2H), 9.48 (s, 1H), 8.40 (d, 1H), 8.19 (s, 2H), 7.70 (m, 2H), 7.49 (d, 1H), 7.13 (d, 1H), 4.67 (s, 3H), 4.53 (t, 2H). MS m/z (ESI): 329.2 [M+H].

Step 6:

Compound TDI01238-7 (100 mg, 0.244 mmol), TDI01238-2 (37 mg, 0.219 mmol) and N,N-diisopropylethylamine (94 mg, 0.732 mmol) were dissolved in acetonitrile (4 mL), and the reaction was performed in an oil bath at 70° C. for 3 h. After the reaction was complete, insoluble was removed by filtration, the filtrate was evaporated to dryness, and the residue was purified by preparative thin layer chromatography (dichloromethane:methanol=10:1), to give a crude product (50 mg), which was further purified by high-performance liquid chromatography to afford compound TDI01238 (13.17 mg, yellow solid, yield: 11.65%).

¹H NMR (400 MHz, DMSO-d₆) (13.07 (s, 1H), 11.30 (s, 1H), 9.92 (s, 1H), 9.36 (s, 1H), 9.14 (d, 1H), 8.36 (m, 2H), 8.19 (s, 1H), 8.11 (s, 1H), 7.97 (m, 1H), 7.57 (dd, 2H), 6.75 (d, 1H), 4.84 (s, 3H), 4.60 (s, 1H). MS m/z (ESI): 464.3 [M+H].

Example 21: Preparation of 5-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-N-(pyridazin-4-yl)isoindoline-2-carboxamide (TDI01237)

Step 1:

Under ice bath cooling, phenyl chloroformate (1.24 g, 7.89 mmol) was added to a solution of TDI01237-1 (500 mg, 5.27 mmol) and triethylamine (1.06 g, 10.54 mmol) in dichloromethane (10 mL), and the reaction was performed at room temperature for 2 h. LC-MS indicated the reaction was complete. The reaction was quenched by adding water (15 mL), extracted with dichloromethane (30 mL), washed with saturated brine (15 mL), dried, and concentrated to afford TDI01237-2 (600 mg, crude product). MS m/z (ESI): 216.1 [M+H].

Step 2:

Compound TDI01237-2 (410 mg, 1.91 mmol) and 5-bromoisoindoline hydrochloride (895 mg, 3.82 mmol) were dissolved in N,N-dimethylformamide (5 mL), triethylamine (2 mL) was added, and the reaction was performed in an oil bath at 100° C. for 1 h. LC-MS indicated the reaction was complete. Water (15 mL) was slowly added to the reaction solution, and a large amount of solid precipitated. The mixture was stirred for 30 min, filtered, and the solid thus obtained was TDI01237-3 (380 mg, wine red solid, yield: 62.56%). MS m/z (ESI): 319.2 [M+H].

Step 3:

Compound TDI01237-3 (350 mg, 1.09 mmol) and bis(pinacolato)diboron (558 mg, 2.19 mmol) were dissolved in dioxane (12 mL), potassium acetate (323 mg, 3.29 mmol) and Pd(dppf)Cl₂ (81 mg, 0.11 mmol) were added, purge with argon was performed for 3 times, the reaction was placed in an oil bath, and allowed to proceed overnight. Thin layer chromatography (dichloromethane/methanol=10:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was separated by column chromatography (dichloromethane/methanol=20:1), to afford compound TDI01237-4 (120 mg, yellow solid, yield: 30.08%). MS m/z (ESI): 367.2 [M+H].

Step 4:

Compound TDI01237-4 (100 mg, 0.273 mmol) and intermediate Reg-1-27 (80 mg, 0.182 mmol) were dissolved in ethanol/water=5/2 (7 mL), sodium carbonate (58 mg, 0.546 mmol) and Pd(PPh₃)₂ (13 mg, 0.018 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed under microwave radiation at 110° C. for 1.5 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, and concentrated followed by addition of water (5 mL). The solution was extracted with dichloromethane (15 mL), washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, and concentrated followed by purification by thin layer chromatography (dichloromethane:methanol=10:1) to afford compound TDI01237-5 (30 mg, yellow solid, yield: 30.03%). MS m/z (ESI): 550.3 [M+H].

Step 5: Trifluoroacetic acid (1 mL) was added to a solution of TDI01237-5 (30 mg, 0.055 mmol) in dichloromethane (3 mL), and the reaction was performed at room temperature for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by liquid chromatography to afford compound TDI01237 (2.13 mg, yellow solid, yield: 8.53%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.09 (s, 1H), 9.79 (s, 1H), 9.46 (d, J=2.3 Hz, 1H), 9.11 (d, J=6.4 Hz, 1H), 8.36 (d, J=6.2 Hz, 1H), 8.29 (d, J=8.1 Hz, 2H), 8.19 (dd, J=7.4, 4.8 Hz, 2H), 8.12 (s, 1H), 7.62-7.53 (m, 3H), 6.76 (d, J=6.2 Hz, 1H), 4.95 (s, 4H). MS m/z (ESI): 450.2 [M+H].

The compounds in following table 4 were prepared according to methods similar to that described in Example 21.

TABLE 4 Compound Starting material or regent No. Compound Structure Name different from that in Example 21 Characterization Data TDI01374

5-4((1H- indazol-5-yl)- amino)pyr- imidin-2-yl)- N-(3-chloro- pyridin-4- yl)isoin- doline-2- carboxamide

in synthesis step 1 of Example 21 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 13.11 (s, 1H), 10.10 (s, 1H), 8.62 (s, 1H), 8.42 (d, J = 5.3 Hz, 1H), 8.36 (d, J = 6.2 Hz, 1H), 8.27 (d, J = 7.9 Hz, 2H), 8.12 (dd, J = 21.4, 17.9 Hz, 4H), 7.59 (dd, J = 17.4, 8.2 Hz, 3H), 6.76 (d, J = 6.2 Hz, 1H), 4.98 (s, 4H). MS m/z (ESI): 483.1 [M + H]. TDI01376

6-(4-((1H- indazol-5-yl)- amino)pyr- imidin-2-yl)- N-(3-chloro- pyridin-4-yl)- indoline-1- carboxamide

in synthsis step 1 of Example 21 was replaced with

in step 4 was replaced with

¹H NMR (400 MHz, DMSO-d₆) δ 11.06 (s, 1H), 8.89 (s, 1H), 8.74 (s, 1H), 8.55 (d, J = 5.2 Hz, 1H), 8.42 (s, 1H), 8.31 (d, J = 6.8 Hz, 1H), 8.18-8.12 (m, 2H), 7.87 (d, J = 7.7 Hz, 1H), 7.62 (d, J = 8.7 Hz, 1H), 7.55 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 7.8 Hz, 1H), 6.91 (d, J = 6.4 Hz, 1H), 4.31 (t, J = 8.3 Hz, 2H), 3.30 (d, J = 8.2 Hz, 2H). MS m/z (ESI): 483.1 [M + H]. TDI01403

phenyl 5-(4- ((1H-indazol- 5-yl)amino)- pyrimidin- 2-yl)isoin- doline-2- carboxamide

was directly reacted with

¹H NMR (400 MHz, CD₃OD) δ 8.23 (d, J = 7.2 Hz, 1H), 8.14 (d, J = 7.2 Hz, 3H), 8.08 (s, 1H), 7.68 (d, J = 6.0 Hz, 1H), 7.64 (t, J = 6.0 Hz, 2H), 7.41 (t, J = 8.0 Hz, 2H), 7.26 (t, J = 7.2 Hz, in synthesis step 1 of 1H), 7.20 (d, J = 8.0 Hz, Example 21. 2H), 6.91 (d, J = 7.02 Hz, 1H), 5.08 (s, 2H), 4.90 (s, 2H). MS m/z (ESI): 449.1 [M + H]. TDI01534

phenyl 5-(4- ((4-(1H-pyrazol-4- yl)phenyl)- amino)pyr- imidin-2- yl)isoin- doline-2- carboxamide

was directly reacted with

in synthesis step 1 of Example 21;

(Reg-1-27) in step 4 was replaced with

(Reg-1-16). ¹H NMR (400 MHz, DMSO-d₆) δ 10.23 (s, 1H), 8.40 (d, J = 6.4 Hz, 1H), 8.29 (d, J = 8.0 Hz, 2H), 8.08 (s, 2H), 7.77 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 8.0 Hz, 1H), 7.44 (t, J = 7.6 Hz, 2H), 7.29- 7.22 (m, 3H), 6.83 (d, J = 6.0 Hz, 1H), 5.03 (d, J = 10.4 Hz, 2H), 4.84 (d, J = 12.0 Hz, 2H). MS m/z (ESI): 475.2 [M + H].

Example 22: Preparation of 2-(6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-1-oxoisoindolin-2-yl)-N-(pyridazin-4-yl)acetamide (TDI01239)

Step 1:

TDI01239-1 (500 mg, 2.358 mmol) was dissolved in tetrahydrofuran (24 mL), and cooled to 0° C. Under the protection of nitrogen, 60% NaH (236 mg, 5.895 mmol) was added to the above reaction solution, and the reaction was performed at room temperature for 1 h after the addition. Bromoethyl acetate was then added at 0° C., and the reaction was continued at room temperature for 2 h. LC-MS indicated the reaction was complete. After completion of the reaction, ice water and 1N HCl solution was added to quench the reaction, and the aqueous phase was extracted with ethyl acetate (15 mL). The combined organic phase was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated to dryness to afford TDI01239-2 (700 mg, yellow solid, yield: 99.57%). MS m/z (ESI): 298.1 [M+H].

Step 2:

TDI01239-2 (700 mg, 2.357 mmol), lithium hydroxide monohydrate (297 mg, 7.071 mmol) were added to a mixed solution of tetrahydrofuran (10 mL) and water (10 mL), and the reaction was stirred at room temperature for 2 h. LC-MS indicated the reaction was complete. After pH was adjusted to 3 with dilute hydrochloric acid, the solution was extracted with ethyl acetate (2 mL). The organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to afford TDI01239-3 (600 mg, yellow solid, yield: 94.64%). MS m/z (ESI): 270.1 [M+H].

Step 3:

TDI01239-3 (0.3 g, 1.115 mmol) and bis(pinacolato)diboron (425 mg, 1.673 mmol) were dissolved in 1,4-dioxane (10 mL), potassium acetate (328 mg, 3.345 mmol) and Pd(dppf)Cl₂ (82 mg, 0.1115 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 100° C., and allowed to proceed for 3 h. LC-MS indicated the reaction was complete. After the reaction was complete, the solution was filtered, and the filtrate was concentrated to afford TDI01239-4 (350 mg, black oil, crude product).

¹H NMR (400 MHz, DMSO-d₆) δ 7.96 (s, 1H), 7.90 (d, 1H), 7.64 (d, 1H), 4.55 (s, 2H), 4.27 (s, 2H), 1.32 (s, 12H). MS m/z (ESI): 318.2 [M+H].

Step 4:

TDI01239-4 (350 mg, 1.104 mmol) and Reg-1-1 (254 mg, 0.736 mmol) were dissolved in a mixed solution of ethanol (10 mL) and water (1.25 mL), sodium carbonate (234 mg, 2.208 mmol) and Pd(PPh₃)₂Cl₂ (52 mg, 0.0736 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 100° C., and allowed to proceed for 16 h. LC-MS indicated the reaction was complete. The reaction solution was filtered, the filtrate was evaporated to dryness, and the residue was purified by column chromatography (dichloromethane:methanol=20:1-1:1) to afford TDI01239-5 (130 mg, light yellow solid, yield: 29.48%).

¹H NMR (400 MHz, CDCl₃) δ 9.88 (s, 1H), 8.63 (s, 1H), 8.55 (d, 1H), 8.36 (d, J=5.9 Hz, 1H), 8.20 (s, 1H), 8.04 (s, 1H), 7.69 (d, 1H), 7.57 (s, 2H), 6.75 (d, 1H), 4.62 (s, 2H), 3.87 (s, 2H). MS m/z (ESI): 401.2 [M+H].

Step 5:

TDI01239-5 (70 mg, 0.175 mmol) and 4-aminopyridazine (20 mg, 0.21 mmol) were dissolved in N,N-dimethylformamide (2 mL), HATU (66 mg, 0.175 mmol) and diisopropylethylamine (68 mg, 0.525 mmol) were added, and the reaction was performed at room temperature for 16 h. LC-MS indicated the reaction was complete. The solvent was evaporated to dryness, and the residue was purified by preparative chromatograph (dichloromethane:methanol:aqueous ammonia=8:1:10 drops) to give a crude product, which was purified by high-performance liquid chromatography to afford compound TDI01239 (5.29 mg, yellow solid, yield: 6.37%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.10 (s, 1H), 10.32 (s, 1H), 9.33 (d, 1H), 9.11 (d, 1H), 8.65 (s, 1H), 8.55 (dd, 1H), 8.39 (d, 1H), 8.15 (s, 1H), 8.10 (s, 1H), 8.00 (dd, 1H), 7.84 (d, 1H), 7.62 (d, 1H), 7.55 (d, 1H), 6.81 (d, 1H), 4.70 (s, 2H), 4.56 (s, 2H). MS m/z (ESI): 478.2 [M+H].

The compound in following table 5 was prepared according to a method similar to that described in Example 22.

TABLE 5 Starting material or Compound regent different from No. Compound Structure Name that in Example 22 Characterization Data TDI01446

2-5-(4-((1H- indazol-5-yl)- amino)pyr- imidin-2-yl)- oxoisoin-

¹H NMR (400 MHz, DMSO- d₆) δ 13.09 (s, 1H), 10.02 (s, 1H), 8.51 (s, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.39 (d, J = 6.0 Hz, 1H), 8.19 (s, 1H), dolin-2-yl)- in synthesis step 5 8.13 (s, 1H), 8.02 (d, J = 7.2 N-isopropyl- of Example 22 Hz, 1H), 7.85 (d, J = 8.0 Hz, acetamide was replaced with 1H), 7.62-7.55 (m, 2H), 6.78 isopropylamine. (d, J = 6.0 Hz, 1H), 4.63 (s, 2H), 4.16 (s, 2H), 3.90-3.85 (m, 1H), 1.08 (d, J = 6.4 Hz, 6H). MS m/z (ESI): 442.1 [M + H].

Example 23: Preparation of N-(1H-indazol-5-yl)-2-(1-(1-methylpyrrolidin-3-yl)-1H-indol-6-yl)quinazolin-4-amine (TDI01272)

Step 1:

TDI01272-1 (10.0 g, 45.7 mmol) was dissolved in anhydrous methanol (100 mL), sodium borohydride (3.38 g, 91.4 mmol) was added in portions under cooling of an ice bath, and the reaction was performed at room temperature for 2 h. Thin layer chromatography (ethyl acetate) indicated the reaction was complete. The reaction solution was quenched by water (80 mL), and extracted with dichloromethane (300 mL). The combined organic phase was washed with saturated brine (300 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the crude product was separated and purified by column chromatography (petroleum ether:ethyl acetate=1:1 to 0:1) to afford TDI01272-2 (5.20 g, yellow oil, yield: 51.9%).

¹H NMR (400 MHz, CDCl₃) δ 7.34-7.21 (m, 5H), 4.32-4.28 (m, 1H), 3.60 (s, 2H), 2.86-2.79 (m, 1H), 2.66-2.63 (m, 1H), 2.54-2.51 (m, 1H), 2.31-2.26 (m, 1H), 2.22-2.12 (m, 1H), 1.75-1.65 (m, 1H).

Step 2:

TDI01272-2 (5.20 g, 23.6 mmol) was dissolved in dichloromethane (150 mL), triethylamine (7.15 g, 70.8 mmol) was added, and methylsulfonyl chloride (4.04 g, 35.5 mmol) was added under ice bath cooling. The reaction was performed at room temperature for 3 h. Thin layer chromatography indicated the reaction was complete. The reaction solution was quenched by water (100 mL), and extracted with dichloromethane (300 mL). The combined organic phase was washed with saturated brine (400 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford TDI01272-3 (7.50 g, yellow oil, crude product).

¹H NMR (400 MHz, CDCl₃) δ 7.33-7.29 (m, 4H), 7.28-7.24 (m, 1H), 5.21-5.15 (m, 1H), 3.68 (d, J=12.8 Hz, 1H), 3.62 (d, J=12.8 Hz, 1H), 2.98 (s, 3H), 2.86-2.78 (m, 3H), 2.53-2.47 (m, 1H), 2.35-2.28 (m, 1H), 2.11-2.04 (m, 1H).

Step 3:

6-bromo-1H-indole (2.50 g, 12.8 mmol) was dissolved in N,N-dimethylformamide (40 mL), sodium hydride (1.03 g, 25.6 mmol) was added under ice bath cooling, and the reaction was performed at 0° C. for 30 minutes. TDI01272-3 (7.20 g, 24.1 mmol) was slowly added to the reaction solution, and the reaction was performed at 50° C. overnight. Thin layer chromatography (petroleum ether:ethyl acetate=5:1) indicated the reaction was complete. The reaction solution was quenched by water (100 mL), and extracted with ethyl acetate (200 mL). The combined organic phase was sequentially washed with a saturated aqueous solution of ammonium chloride (300 mL) and saturated brine (300 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated and purified by column chromatography (petroleum ether:ethyl acetate=20:1 to 8:1) to afford TDI01272-4 (4.10 g, yellow oil, yield: 80.4%).

¹H NMR (400 MHz, CDCl₃) δ 7.76 (s, 1H), 7.45 (d, J=8.4 Hz, 1H), 7.39 (d, J=7.2 Hz, 2H), 7.34 (dd, J=9.2, 6.0 Hz, 3H), 7.27 (s, 1H), 7.17 (dd, J=8.4, 1.6 Hz, 1H), 6.45 (d, J=3.2 Hz, 1H), 4.94-4.88 (m, 1H), 3.74 (d, J=12.8 Hz, 1H), 3.65 (d, J=12.8 Hz, 1H), 3.10-3.07 (m, 1H), 3.00-2.96 (m, 1H), 2.80-2.76 (m, 1H), 2.50-2.43 (m, 2H), 2.12-2.05 (m, 1H).

Step 4:

TDI01272-4 (2.00 g, 5.01 mmol) and bis(pinacolato)diboron (2.54 g, 10.0 mmol) were dissolved in 1,4-dioxane (40 mL), potassium acetate (4.90 g, 20.0 mmol) and Pd(dppf)Cl₂ (366 mg, 0.50 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed in an oil bath (90° C.) overnight. Thin layer chromatography (petroleum ether:ethyl acetate=5:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was separated and purified by column chromatography (petroleum ether:ethyl acetate=20:1 to 8:1) to afford TDI01272-5 (2.10 g, yellow oil, yield: 93.9%).

¹H NMR (400 MHz, CDCl₃) δ 7.92 (s, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.54-7.50 (m, 2H), 7.38 (d, J=7.2 Hz, 2H), 7.32 (t, J=7.2 Hz, 2H), 7.26-7.24 (m, 1H), 6.51 (d, J=3.2 Hz, 1H), 5.17-5.10 (m, 1H), 3.71 (d, J=12.8 Hz, 1H), 3.66 (d, J=12.8 Hz, 1H), 3.06-3.02 (m, 1H), 2.95-2.92 (m, 1H), 2.83-2.79 (m, 1H), 2.54-2.45 (m, 2H), 2.08-2.02 (m, 1H), 1.37 (s, 12H).

Step 5:

TDI01272-5 (2.10 g, 4.71 mmol) was dissolved in methanol (50 mL), Pd/C (210 mg) was added, and the reaction solution was purged with argon (3 times) and then hydrogen (3 times). The reaction was performed under an atmosphere of hydrogen at room temperature for 6 hours. Thin layer chromatography (petroleum ether:ethyl acetate=5:1) and LC-MS indicated the reaction was complete. The reaction solution was filtered, the filtrate was concentrated under reduced pressure, and the crude product was separated and purified by column chromatography (dichloromethane/methanol=20:1 to 10:1) to afford TDI01272-6 (550 mg, yellow oil, yield: 37.6%).

¹H NMR (400 MHz, CDCl₃) δ 7.91 (s, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.56 (d, J=8.0 Hz, 1H), 7.30 (d, J=3.2 Hz, 1H), 6.53 (d, J=3.2 Hz, 1H), 5.14-5.08 (m, 1H), 3.41-3.36 (m, 1H), 3.31-3.25 (m, 1H), 3.17-3.10 (m, 2H), 2.43-2.34 (m, 1H), 2.16-2.09 (m, 1H), 1.38 (s, 12H). MS m/z (ESI): 313.3 [M+H].

Step 6:

TDI01272-6 (300 mg, 0.96 mmol) and paraformaldehyde (144 mg, 4.81 mmol) were dissolved in 1,2-dichloroethane (10 mL), acetic acid (5 drops) was added, and the reaction was stirred at room temperature for 1 hour followed by addition of NaBH(OAc)₃ (611 mg, 2.88 mmol). The reaction was performed at room temperature overnight. Thin layer chromatography (dichloromethane/methanol=10:1) and LC-MS indicated the reaction was complete. The reaction solution was quenched by water (40 mL), and extracted with dichloromethane (100 mL). The combined organic phase was sequentially washed with saturated aqueous sodium carbonate (100 mL) and saturated brine (160 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated and purified by preparative thin layer chromatography (dichloromethane/methanol=10:1) to afford TDI01272-7 (100 mg, yellow oil, yield: 31.9%).

¹H NMR (400 MHz, CDCl₃) δ 7.87 (s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.54 (d, J=8.0 Hz, 1H), 7.50 (d, J=3.2 Hz, 1H), 6.54 (d, J=3.2 Hz, 1H), 5.25-5.20 (m, 1H), 3.12-3.06 (m, 1H), 2.99-2.98 (m, 2H), 2.66-2.61 (m, 1H), 2.58-2.54 (m, 1H), 2.50 (s, 3H), 2.19-2.14 (m, 1H), 1.37 (s, 12H). MS m/z (ESI): 327.3 [M+H].

Step 7:

TDI01272-7 (98.8 mg, 0.303 mmol) and Reg-1-2 (100 mg, 0.253 mmol) were dissolved in a mixed solution of ethanol:water (8:1) (9 mL), sodium carbonate (53.6 mg, 0.506 mmol) and Pd(PPh₃)Cl₂ (17.6 mg, 0.025 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed under microwave radiation (110° C.) for 1 hour. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the crude product was added with methanol and filtered. The resulted solid was purified by high-performance liquid chromatography to afford compound TDI01272 (86.9 mg, yellow solid, yield: 74.9%).

¹H NMR (400 MHz, CD₃OD) δ 8.60 (d, J=8.4 Hz, 1H), 8.44 (s, 1H), 8.23 (d, J=3.2 Hz, 2H), 8.13-8.06 (m, 2H), 7.99 (dd, J=8.4, 1.6 Hz, 1H), 7.84 (t, J=6.8 Hz, 1H), 7.79-7.74 (m, 4H), 6.73 (d, J=3.2 Hz, 1H), 5.50-5.43 (m, 1H), 3.99-3.58 (m, 4H), 3.03 (s, 3H), 2.73-2.68 (m, 1H), 2.52-2.47 (m, 1H). MS m/z (ESI): 460.2 [M+H].

Example 24: Preparation of N-(2-(1-(2-(dimethylamino)ethyl)-1H-indol-6-yl)pyrimidin-4-yl)-1H-indazol-5-amine (TDI01287)

Step 1:

Under ice bath cooling, NaH (612 mg, 15.3 mmol) was added to a solution of TDI01287-1 (1.0 g, 7.6 mmol) in N,N-dimethylformamide (10 mL). The reaction was warmed to room temperature and stirred for 1 h, and then dimethylaminoethyl chloride hydrochloride (1.1 g, 7.6 mmol) was added The reaction was performed for 2 h. LC-MS indicated the reaction was complete. The reaction solution was added with water (25 mL), extracted with dichloromethane (150 mL), washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (dichloromethane:methanol=100:0 to 15:1) to afford TDI01287-2 (500 mg, yellow solid, yield: 12.23%). MS m/z (ESI): 267.1 [M+H].

Step 2:

TDI01287-2 (500 mg, 1.873 mmol) and bis(pinacolato)diboron (952 mg, 3.75 mmol) were dissolved in dioxane (8 mL), potassium acetate (368 mg, 3.75 mmol) and Pd(dppf)Cl₂ (138 mg, 0.187 mmol) were added, purge with argon was performed for 3 times, the reaction was placed in an oil bath at 90° C., and allowed to proceed overnight. Thin layer chromatography (dichloromethane:methanol=15:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was separated and purified by column chromatography (petroleum ether:ethyl acetate=4:1) to afford TDI01287-3 (360 mg, yellow solid, yield: 61.21%). MS m/z (ESI): 315.3 [M+H].

Step 3:

Compound Reg-1-27 (200 mg, 0.637 mmol) and TDI01287-3 (189 mg, 0.425 mmol) were dissolved in 1,4-dioxane/water=4/1 (5 mL), sodium carbonate (91 mg, 0.85 mmol) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (40 mg, 0.085 mmol) and tris(dibenzylideneacetone)dipalladium (39 mg, 0.043 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed under microwave radiation at 110° C. for 1 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, added with water (5 mL), extracted with dichloromethane (30 mL), washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by thin layer chromatography (dichloromethane:methanol=10:1) to afford TDI01287-4 (50 mg, yellow solid, yield: 15.79%). MS m/z (ESI): 498.4 [M+H].

Step 4: Trifluoroacetic acid (1 mL) was added to a solution of TDI01287-4 (50 mg, 0.1 mmol) in dichloromethane (3 mL), and the reaction was performed at room temperature for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by liquid chromatography to afford compound TDI01287 (2.41 mg, yellow solid, yield: 6.07%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.77 (s, 1H), 9.86 (s, 1H), 8.48 (s, 1H), 8.38 (d, J=6.6 Hz, 1H), 8.21 (s, 1H), 8.16 (s, 1H), 7.99 (d, J=8.2 Hz, 1H), 7.79 (d, J=8.4 Hz, 1H), 7.71 (s, 1H), 7.66 (d, J=8.8 Hz, 1H), 7.60 (d, J=8.8 Hz, 1H), 6.84 (d, J=3.8 Hz, 1H), 6.66 (d, J=3.0 Hz, 1H), 4.67 (t, J=6.7 Hz, 2H), 3.60 (t, J=6.3 Hz, 2H), 2.81 (s, 6H). MS m/z (ESI): 398.2 [M+H].

Example 25: Preparation of N-(2-(2-methylisoindolin-5-yl)pyrimidin-4-yl)-1H-indazol-5-amine (TDI01288)

Step 1:

TDI01288-1 (450 mg, 1.919 mmol), 40% formaldehyde solution (576 mg, 7.676 mmol), DCE (20 mL) and glacial acetic acid (5 drops) were added to a 50 mL single neck flask, and the reaction was performed at room temperature for 1 h. Sodium triacetoxyborohyride (1.6 g, 7.676 mmol) was then added, and the reaction was continued at room temperature for 2 h. The reaction solution was filtered, and the filtrate was evaporated to dryness to afford TDI01288-2 (405 mg, black oil). MS m/z (ESI): 212.1 [M+H].

Step 2:

TDI01288-2 (400 mg, 1.896 mmol) and bis(pinacolato)diboron (963 mg, 3.791 mmol) were dissolved in dioxane (18 mL), potassium acetate (557 mg, 5.688 mmol) and Pd(dppf)Cl₂ (138 mg, 0.189 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 100° C., and allowed to proceed for 3.5 h. After the reaction was complete, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane:methanol=50:1-20:1) to afford TDI01288-3 (520 mg, black oil). MS m/z (ESI): 260.2 [M+H].

Step 3:

TDI01288-3 (300 mg, 1.159 mmol) and Reg-1-1 (200 mg, 0.579 mmol) were dissolved in a mixed solution of ethanol (8 mL) and water (1 mL), sodium carbonate (184 mg, 1.737 mmol) and Pd(PPh₃)₂Cl₂ (41 mg, 0.0579 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed under microwave radiation (115° C.) for 3 h. The reaction solution was filtered, the filtrate was concentrated, and then purified by preparative thin layer chromatography (dichloromethane:methanol=5:1) to give a crude product (60 mg), which was then purified by high-performance liquid chromatography to afford compound TDI01288 (8.09 mg, yellow solid, yield: 4.04%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.87 (s, 1H), 9.95 (s, 1H), 8.35 (m, 3H), 8.20 (s, 1H), 8.11 (s, 1H), 7.57 (m, 3H), 6.75 (d, 1H), 4.91 (m, 2H), 4.57 (s, 2H), 3.07 (s, 3H). MS m/z (ESI): 343.2 [M+H].

Example 26: Preparation of methyl 2-(8-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-4-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-1-yl)acetate (TDI01298)

Step 1:

TDI01298-1 (6 g, 27.27 mmol), methyl 3-aminopropanoate (3.8 g, 27.27 mmol), potassium carbonate (11.29 g, 81.81 mmol) and tetrahydrofuran 60 mL were added to a 100 mL sealed tube. The reaction was warmed to 100° C., and allowed to proceed for 5 h. LC-MS indicated the reaction was complete. The reaction solution was filtered, and the filtrate was collected, and concentrated under reduced pressure to afford TDI01298-2 (8.5 g, yellow solid, yield: 100%). MS m/z (ESI): 305.1 [M+H].

Step 2:

TDI01298-2 (8.5 g, 28 mmol), zinc powder (18.2 g, 280 mmol), ammonium chloride (15 g, 280 mmol) and 260 mL methanol were added to a 500 mL flask. The reaction was warmed to 50° C., and allowed to proceed for 2 h. LC-MS indicated the reaction was complete. The reaction solution was filtered, and the filtrate was collected, and concentrated to dryness to give an oil, which was purified by column chromatography (petroleum ether:ethyl acetate=10:1˜3:1), to afford TDI01298-3 (5.4 g, brown solid, yield: 70.7%).

¹H NMR (400 MHz, CDCl₃) δ 6.80-6.72 (m, 2H), 6.56 (d, J=8.1 Hz, 1H), 3.71 (s, 3H), 3.39 (t, J=6.3 Hz, 4H), 2.66 (t, J=6.3 Hz, 2H). MS m/z (ESI): 275.1 [M+H].

Step 3:

TDI01298-3 (5.0 g, 18.3 mmol), sodium hydroxide (2.2 g, 54.9 mmol), 100 mL methanol and 10 mL water were added to a 250 mL flask. The reaction was warmed to 50° C., and allowed to proceed for 1 h. LC-MS indicated the reaction was complete. The reaction solution was adjusted to pH 4-5 with concentrated hydrochloric acid, concentrated under reduced pressure to remove most of methanol, and filtered to collect the solid, so as to afford TDI01298-4 (4.4 g, brown solid, yield: 92.8%).

¹H NMR (400 MHz, DMSO-d₆) δ 6.55 (dd, J=8.1, 2.1 Hz, 1H), 6.47 (t, J=5.7 Hz, 2H), 3.23 (t, J=6.7 Hz, 2H), 2.53-2.49 (m, 2H). MS m/z (ESI): 259.1 [M+H].

Step 4:

TDI01298-4 (4 g, 15.44 mmol), HATU (7.06 g, 18.53 mmol), diisopropylethylamine (8.0 g, 61.8 mmol) and 150 mL N,N-dimethylformamide were added to a 250 mL flask, and the reaction was performed at room temperature for 0.5 h. LC-MS indicated the reaction was complete. The reaction solution was combined, added to 600 mL water, and extracted with ethyl acetate (600 mL). The organic phase was dried, concentrated under reduced pressure to give a brown red solid, which was rinsed with 10 mL ethyl acetate and 60 mL petroleum ether, to afford TDI01298-5 (3.8 g, brown solid, yield: 100%).

¹H NMR (400 MHz, DMSO-d₆) δ 9.49 (s, 1H), 6.91 (s, 1H), 6.80 (d, J=8.4 Hz, 1H), 6.73 (s, 1H), 6.01 (s, 1H), 2.71 (d, J=17.3 Hz, 1H), 2.52 (d, J=5.2 Hz, 3H). MS m/z (ESI): 241.1 [M+H].

Step 5:

Compound TDI01298-5 (800 mg, 3.32 mmol) and 40 mL tetrahydrofuran was added to a 100 mL flask. The reaction was cooled to 0˜10° C., sodium hydride (146 mg, 3.65 mmol) was added, and the reaction was performed for 20 minutes. methyl 2-bromoacetate (813 mg, 5.31 mmol) was added, and the reaction was warmed to room temperature, and allowed to proceed for 0.5 h. TLC indicated the reaction was complete. The reaction solution was filtered, and the filtrate was collected, concentrated under reduced pressure to give a brown red oil, which was purified by column chromatography (petroleum ether:ethyl acetate=8:1˜1:1) to afford TDI01298-6 (900 mg, brown red oil, yield: 86.5%).

¹H NMR (400 MHz, DMSO-d₆) δ 7.11 (d, J=2.1 Hz, 1H), 6.99 (dt, J=8.6, 5.3 Hz, 2H), 5.66 (s, 1H), 4.37 (s, 2H), 3.67 (s, 3H), 3.60-3.54 (m, 2H), 2.48-2.43 (m, 2H). MS m/z (ESI): 315.21 [M+H].

Step 6:

Compound TDI01298-6 (850 mg, 2.71 mmol), bis(pinacolato)diboron (826 mg, 3.25 mmol), Pd(PPh₃)₂Cl₂ (95 mg, 0.14 mmol), sodium carbonate (575 mg, 5.42 mmol) and 15 mL methanol were added to a 30 mL microwave tube. Purge with argon was performed for 4 times, the reaction was warmed to 95° C., and allowed to proceed for 1.5 h. LC-MS indicated the reaction was complete. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to give a dark brown oil, which was purified by column chromatography (petroleum ether:ethyl acetate=4:1˜1:1) to obtain TDI01298-7 (650 mg, yellow solid, yield: 66.6%).

¹H NMR (400 MHz, DMSO-d₆) δ 7.34 (s, 1H), 7.18 (d, J=7.8 Hz, 1H), 7.07 (d, J=7.9 Hz, 1H), 5.34 (s, 1H), 4.38 (s, 2H), 3.68 (s, 3H), 3.57 (t, J=6.1 Hz, 2H), 2.41 (t, J=6.2 Hz, 2H), 1.28 (s, 12H). MS m/z (ESI): 361.3 [M+H].

Step 7:

Compound TDI01298-7 (240 mg, 0.67 mmol), Reg-1-1 (150 mg, 0.43 mmol), Pd(PPh₃)₂Cl₂ (28 mg, 0.04 mmol), sodium carbonate (92 mg, 0.86 mmol) and 12 mL methanol were added to a 30 mL microwave tube. The reaction solution was purged with argon for 1 minute, warmed to 100° C., and allowed to react under microwave radiation for 3 h. LC-MS indicated the reaction was complete. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to dryness to give a solid, which was washed with 5 mL ethyl acetate and 20 mL petroleum ether, to obtain 0.48 g solid. The solid was further purified by high-performance liquid chromatography to afford TDI01298 (62.97 mg, yellow solid, yield: 33%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.48 (s, 1H), 8.32 (d, J=6.5 Hz, 1H), 8.15 (d, J=4.1 Hz, 2H), 7.85 (s, 1H), 7.76-7.72 (m, 1H), 7.61 (q, J=8.9 Hz, 2H), 7.28 (d, J=8.5 Hz, 1H), 6.80 (d, J=6.5 Hz, 1H), 4.46 (s, 2H), 3.70 (s, 3H), 3.68-3.62 (m, 4H). MS m/z (ESI): 444.3 [M+H].

Example 27: Preparation of 6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-N-(pyridin-2-yl)-1H-indole-2-carboxamide (TDI01311)

Step 1:

TDI01311-1 (2.4 g, 10 mmol) and thionyl chloride (10 mL) were sequentially added to a 25 mL flask, N,N-dimethylformamide (1 drop) was cautiously added under stirring, the reaction was warmed to 70° C. in an oil bath, and allowed to proceed for 1 h. After the reaction solution became clear, thionyl chloride was removed under reduced pressure. The residue was dissolved in dichloromethane (10 mL), and directly used in the next reaction.

Step 2:

2-aminopyridine (1.13 g, 12 mmol), diisopropylethylamine (3.88 g, 30 mmol) and dichloromethane (10 mL) were sequentially added to a 50 mL tree-neck flask, and purge with nitrogen was performed for 3 times. In an ice bath and under the protection of nitrogen, a solution of the product prepared in the last step in dichloromethane (10 mL) was cautiously added dropwise. After the dropwise addition, the reaction was stirred at 0° C. for 15 minutes, and then performed at room temperature for 2 hours after the ice bath was removed. LC-MS indicated the reaction was complete. At this point, a large amount of yellow solid precipitated, which was filtered, washed with a mixed solvent of water (20 mL) and petroleum ether:ethyl acetate (20 mL), and then washed with acetonitrile (20 mL), to afford the first batch of the product (yellow solid, 2.1 g). The filtrate was extracted with dichloromethane (60 mL), and the organic phase was successively washed with water (30 mL) and saturated brine (30 mL), dried over anhydrous sodium sulfate for half an hour, filtered, and concentrated to dryness to afford the second batch of the product (yellow product, 0.9 g). The two batches were both TDI01311-3 (3.0 g, yield: 94.9%, yellow solid). MS m/z (ESI): 316.1 [M+H].

Step 3:

TDI01311-3 (800 mg, 2.53 mmol), bis(pinacolato)diboron (964 mg, 3.80 mmol), potassium acetate (496 mg, 5.06 mmol), and dioxane (20 mL) were sequentially added to a 100 mL flask, and purge with nitrogen was performed for 3 times. Under the protection of nitrogen, Pd(dppf)Cl₂ (185 mg, 0.253 mmol) was cautiously added. After the addition was complete, the reaction was performed in an oil bath at 120° C. for 2 hours. After the reaction was complete, the reaction solution was cooled to room temperature, filtered to remove insoluble, and washed with ethyl acetate (10 mL×2). The filtrate was evaporated under reduced pressure to remove the solvent, and purified to afford TDI01311-4 (458 mg, yield: 50.0%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.94 (s, 1H), 10.88 (s, 1H), 8.42 (d, J=3.6 Hz, 1H), 8.24 (d, J=8.4 Hz, 1H), 7.89-7.85 (m, 2H), 7.68-7.63 (m, 2H), 7.36 (d, J=8.1 Hz, 1H), 7.21-7.15 (m, 1H), 1.16 (s, 12H). MS m/z (ESI): 364.3 [M+H].

Step 4:

TDI01311-4 (200 mg, 0.449 mmol), Reg-1-27 (196 mg, 0.539 mmol), potassium phosphate (190 mg, 0.898 mmol), tetrahydrofuran (3 mL) and water (0.5 mL) were sequentially added to a 10 mL flask, purge with nitrogen was performed for 3 minutes, chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium (II) (7 mg, 0.009 mmol) was cautiously added, and the reaction was performed in an oil bath at 70° C. for 2 hours. LC-MS indicated about 18% of the target product was formed. The reaction solution was cooled to room temperature, and then poured into 10 mL water. The solution was extracted with ethyl acetate (60 mL), and the organic phase was combined, washed with water (20 mL) and saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product (85 mg), which was then separated by preparative thin layer chromatography to afford TDI01311-5 (25 mg, yellow solid, yield: 8.6%). MS m/z (ESI): 647.5 [M+H].

Step 5:

TDI01311-5 (20 mg, 0.03 mmol) and dichloromethane (1 mL) were sequentially added to a 10 mL flask, and trifluoroacetic acid (1 mL) was cautiously added dropwise under stirring. After the dropwise addition, the reaction was stirred at room temperature for 1 hour. LC-MS indicated the reaction was complete. The solvent was removed by evaporation under reduced pressure to afford compound TDI01311 (7.24 mg, yellow solid, yield: 41.9%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.37 (s, 1H), 11.00 (s, 1H), 8.45 (s, 1H), 8.43 (d, J=3.8 Hz, 1H), 8.34 (d, J=6.7 Hz, 1H), 8.25 (d, J=8.3 Hz, 1H), 8.19 (s, 1H), 7.99 (d, J=8.7 Hz, 1H), 7.92-7.85 (m, 2H), 7.75 (d, J=1.2 Hz, 1H), 7.65 (t, J=9.5 Hz, 2H), 7.24 (s, 1H), 7.21 (dd, J 7.3, 5.5 Hz, 1H), 7.11 (s, 1H), 6.98 (s, 1H), 6.83 (d, J=6.4 Hz, 1H). MS m/z (ESI): 447.2 [M+H].

Example 28: Preparation of 5-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-N-isopropylisoindoline-2-carboxamide (TDI01312)

Step 1:

TDI01312-1 (150 mg, 1.765 mmol), 5-bromoisoindoline (620 mg, 2.647 mmol), diisopropylethylamine (341 mg, 2.647 mmol) and dichloromethane (9 mL) were added to a 50 mL single neck flask, and the reaction was performed at room temperature for 2 h. The reaction solution was added with 10 mL water, and extracted with dichloromethane (10 mL×2). The organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to afford TDI01312-2 (575 mg, brown solid, crude product).

¹H NMR (400 MHz, CDCl₃) δ 7.41 (m, 2H), 7.13 (m, 1H), 4.65 (d, 4H), 4.04 (m, 1H), 1.22 (t, 6H). MS m/z (ESI): 283.1 [M+H].

Step 2:

TDI01312-2 (300 mg, 1.064 mmol) and bis(pinacolato)diboron (405 mg, 1.596 mmol) were dissolved in dioxane (10 mL), potassium acetate (312 mg, 3.192 mmol) and Pd(dppf)Cl₂ (79 mg, 0.1064 mmol) were added, purge with argon was performed for 3 times, the reaction was placed in an oil bath at 100° C., and allowed to proceed for 2 h. After the reaction was complete, the reaction solution was filtered, and the filtrate was concentrated under reduced pressure to afford TDI01312-3 (400 mg, black solid, crude product). MS m/z (ESI): 331.3 [M+H].

Step 3:

Compound TDI01312-3 (400 mg, 1.212 mmol) and Reg-1-1 (279 mg, 0.808 mmol) were dissolved in a mixed solution of ethanol (8 mL) and water (1 mL), sodium carbonate (257 mg, 2.424 mmol) and Pd(PPh₃)₂Cl₂ (57 mg, 0.08 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed at 100° C. for 16 h. The reaction solution was filtered, and the filtrate was concentrated. Then the residue was purified by thin layer chromatography (dichloromethane:methanol=8:1, containing 1% aqueous ammonia), to afford a crude product (100 mg), which was then purified by high-performance liquid chromatography to afford compound TDI01312 (34.73 mg, yellow solid, yield: 10.43%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.15 (s, 1H), 10.47 (s, 1H), 8.35 (d, 1H), 8.17 (dd, 4H), 7.62 (d, 1H), 7.54 (t, 2H), 6.81 (d, 1H), 6.05 (d, 1H), 4.67 (s, 4H), 3.83 (d, 1H), 1.12 (d, 6H). MS m/z (ESI): 414.2 [M+H].

The compounds in following table 6 were prepared according to methods similar to that described in Example 28.

TABLE 6 Starting material or Compound regent different from Characterization No. Compound Structure Name that in Example 28 Data TDI01366

5-(4-((4- (1H-pyra- zol-4-yl) phenyl)ami- no)pyrimi- din-2-yl)- N,N-di- methyliso- indoline-2- carbox- amide

¹H NMR (400 MHz, CD₃OD) δ 8.24 (d, J = 7.2 Hz, 1H), 8.12-8.10 (m, 2H), 8.02 (s, 2H), 7.74-7.71 (m, 4H), 7.57 (d, J = 8.0 Hz, 1H), 6.94 (d, J = 7.2 Hz, 1H), 4.90 (s, 4H), 2.97 (s, 6H). MS m/z (ESI): 426.1 [M + H]. TDI01375

(6-(4-((1H- indazol-5- yl)ami- no)pyri- midin-2-yl) indolin-1- yl)(4-meth- yl-pipera- zin-1-yl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.53 (s, 1H), 10.07 (s, 1H) 8.34 (d, J = 6.4 Hz, 2H), 8.20 (d, J = 9.6 Hz, 2H), 7.88 (d, J = 7.2 Hz, 1H), 7.61 (d, J = 8.8 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 7.2 Hz, 1H), 6.82 (d, J = 6.4 Hz, 1H), 4.04 (t, J = 8.8 Hz, 2H), 3.93 (d, J = 12.0 Hz, 2H), 3.46 (s, 2H), 3.18 (dd, J = 18.2, 9.6 Hz, 4H), 3.07 (s, 2H), 2.84 (s, 3H). MS m/z (ESI): 455.2 [M + H]. TDI01383

8-(4-((1H- indazol-5- yl)ami- no)pyrimi- din-2-yl)- N-isopro- pyl-4-oxo- 2,3,4,5- tetrahydro- 1H-benzo [b][1,4] diazepine- 1-carbox- amide

¹H NMR (400 MHz, DMSO-d₆) δ 10.39 (s, 1H), 10.04 (s, 1H), 8.33 (d, J = 6.4 Hz, 1H), 8.28- 8.19 (m, 2H), 8.15 (d, J = 8.4 Hz, 1H), 8.08 (s, 1H), 7.59 (d, J = 8.8 Hz, 1H), 7.52 (d, J = 9.3 Hz, 1H), 7.25 (d, J = 8.5 Hz, 1H), 6.78 (d, J = 6.4 Hz, 1H), 5.98 (d, J = 7.9 Hz, 1H), 3.94 (t, J = 6.5 Hz, 2H), 3.80 (s, 1H), 2.47 (d, J = 6.7 Hz, 2H), 0.97 (d, J = 6.6 Hz, 6H). MS m/z (ESI): 457.2 [M + H]. TDI01411

5-(4-((4- (1H-pyra- zol- 4-yl)phe- nyl)amino) pyrimidin- 2-yl)-N- ethyliso- indoline-2- carbox- amide

¹H NMR (400 MHz, DMSO-d₆) δ 9.99 (s, 1H), 9.59 (s, 1H), 8.37 (d, J = 6.4 Hz, 1H), 8.33- 8.22 (m, 2H), 8.04 (s, 2H), 7.75 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 7.2 Hz, 1H), 6.77 (d, J = 6.4 Hz, 1H), 6.39 (s, 1H), 4.67 (d, J = 8.8 Hz, 4H), 2.77 (d, J = 4.8 Hz, 2H), 1.07 (t, J = 7.2 Hz, 3H). MS m/z (ESI): 426.5 [M + H].

Example 29: Preparation of 2-(5-(4-((1H-indazol-5-yl)amino)thieno[3,2-d]pyrimidin-2-yl)isoindolin-2-yl)-N-isopropylacetamide (TDI01271)

Step 1:

TDI01271-1 (1.0 g, 16.95 mmol) was dissolved in anhydrous dichloromethane (20 mL), and triethylamine (1.88 g, 18.64 mmol) and chloroacetyl chloride (2.1 g, 18.64 mmol) were slowly added dropwise. The reaction was performed at room temperature for 5 hours. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was extracted with saturated dichloromethane (150 mL), and washed with saturated brine (100 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford TDI01271-2 (440 mg, crude product).

¹H NMR (400 MHz, DMSO-d₆) δ 8.13 (s, 1H), 3.99 (s, 2H), 3.87-3.79 (m, 1H), 1.07 (d, J=6.4 Hz, 6H). MS m/z (ESI): 136.2 [M+H].

Step 2:

TDI01271-2 (400 mg, 2.96 mmol) and 5-bromoisoindoline hydrochloride (696.3 mg, 2.96 mmol) were dissolved in anhydrous acetonitrile (20 mL), potassium carbonate (1.7 g, 11.85 mmol) was added, and the reaction was performed at 90° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was extracted with saturated dichloromethane (150 mL), and washed with saturated brine (150 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford TDI01271-3 (400 mg, crude product).

¹H NMR (400 MHz, CDCl₃) δ 7.36 (d, J=4.0 Hz, 2H), 7.13-7.05 (m, 1H), 6.90 (s, 1H), 4.19-4.12 (m, 1H), 4.01 (s, 2H), 3.97 (s, 2H), 3.38 (s, 2H), 1.17 (d, J=6.8 Hz, 6H). MS m/z (ESI): 297.1 [M+H].

Step 3:

TDI01271-3 (400 mg, 1.347 mmol) and bis(pinacolato)diboron (648 mg, 2.694 mmol) were dissolved in 1,4-dioxane (20 mL), potassium acetate (528 mg, 5.388 mmol) and Pd(dppf)Cl₂ (98 mg, 0.1347 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 80° C., and allowed to proceed overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was separated and purified by column chromatography to afford TDI01271-4 (300 mg, white solid, yield: 64.7%). MS m/z (ESI): 345.3 [M+H].

Step 4:

TDI01271-4 (274.3 mg, 0.797 mmol) and Reg-1-28 (200 mg, 0.665 mmol) were dissolved in a mixed solvent of ethanol/water (10:1) (22 mL), sodium carbonate (141 mg, 1.329 mmol) and Pd(PPh₃)₂Cl₂ (47 mg, 0.0665 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 110° C., and allowed to proceed overnight. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was purified by high-performance liquid chromatography to afford compound TDI01271 (40.0 mg, yellow solid, yield: 10.4%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.13 (s, 1H), 11.03 (s, 1H), 9.92 (s, 1H), 8.45 (d, J=7.2 Hz, 1H), 8.39 (d, J=5.6 Hz, 2H), 8.22 (d, J=5.6 Hz, 1H), 8.14 (d, J=9.2 Hz, 2H), 7.69 (d, J=8.8 Hz, 1H), 7.62 (d, J=8.8 Hz, 1H), 7.53 (d, J=8.4 Hz, 1H), 7.50 (d, J=5.6 Hz, 1H), 4.92 (s, 2H), 4.63 (s, 2H), 4.23 (s, 2H), 3.99-3.90 (m, 1H), 1.13 (d, J=6.8 Hz, 6H). MS m/z (ESI): 484.2 [M+H].

Example 30: Preparation of 2-(6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-1H-indol-1-yl)-N-isopropylacetamide (TDI01286)

Step 1:

TDI01286-1 (1.0 g, 16.95 mmol) was dissolved in anhydrous dichloromethane (20 mL), and triethylamine (1.88 g, 18.64 mmol) and chloroacetyl chloride (2.1 g, 18.64 mmol) were slowly added dropwise. The reaction was performed at room temperature for 5 hours. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was extracted with saturated dichloromethane (150 mL), and washed with saturated brine (100 mL) successively. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford TDI01286-2 (800 mg, crude product). MS m/z (ESI): 136.2 [M+H].

Step 2:

5-bromo-1H-indole (700 mg, 3.57 mmol) was dissolved in anhydrous DMF (10 mL), NaH (60%, 429 mg, 10.71 mmol) was added at 0° C., the reaction solution was slowly warmed to room temperature, and allowed to proceed overnight. Then TDI01286-2 (579 mg, 4.29 mmol) was added at room temperature, and the reaction was further stirred for 3 hours at room temperature. LC-MS indicated the reaction was complete. The reaction solution was slowly added to 100 mL water, and stirred at room temperature for 30 min. A large amount of solid precipitated, and was filtered by suction. The filter cake was washed, collected and dried to afford TDI01286-3 (800 mg, crude product).

¹H NMR (400 MHz, DMSO-d₆) δ 8.17 (d, J=7.2 Hz, 1H), 7.61 (s, 1H), 7.50 (d, J=8.4 Hz, 1H), 7.33 (d, J=3.2 Hz, 1H), 7.15 (d, J=8.4 Hz, 1H), 6.46 (d, J=2.8 Hz, 1H), 4.77 (s, 2H), 3.88-3.80 (m, 1H), 1.09 (d, J=6.4 Hz, 6H). MS m/z (ESI): 297.2 [M+H].

Step 3:

TDI01286-3 (500 mg, 1.695 mmol) and bis(pinacolato)diboron (861 mg, 3.390 mmol) were dissolved in dioxane (20 mL), potassium acetate (664.4 mg, 6.780 mmol) and Pd(dppf)Cl₂ (124 mg, 0.1695 mmol) were added, purge with argon was performed for 3 times, the reaction was placed in an oil bath at 80° C., and allowed to proceed overnight. Thin layer chromatography indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was separated and purified by column chromatography to afford TDI01286-4 (400 mg, yellow solid, yield: 69%). MS m/z (ESI): 343.3 [M+H].

Step 4:

Reg-1-21 (300 mg, 0.87 mmol) and TDI01286-4 (357 mg, 1.04 mmol) were dissolved in a mixture of ethanol/water (10:1)(15 mL), sodium carbonate (184 mg, 1.74 mmol) and Pd(PPh₃)₂Cl₂ (61.0 mg, 0.087 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed under microwave radiation at 110° C. for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and the residue was purified by liquid chromatography to afford compound TDI01286 (30 mg, yellow solid, yield: 8.1%).

¹H NMR (400 MHz, CD₃OD) δ 8.46 (s, 1H), 8.30 (d, J=6.0 Hz, 2H), 8.16 (d, J=8.4 Hz, 1H), 8.10 (s, 1H), 7.67-7.58 (m, 3H), 7.39 (d, J=3.2 Hz, 1H), 6.63 (d, J=6.0 Hz, 1H), 6.54 (d, J=3.2 Hz, 1H), 4.89 (s, 2H), 3.97-3.90 (m, 1H), 1.10 (d, J=6.4 Hz, 6H). MS m/z (ESI): 426.4 [M+H].

The compound in following table 7 was prepared according to a method similar to that described in Example 30.

TABLE 7 Starting material or regent different Compound from that in No. Compound Structure Name Example 30 Characterization Data TDI01358

2-(8-(4-((1H- indazol-5-yl) amino)pyri- midin-2-yl)- 4-oxo- 2,3,4,5- tetrahydro- 1H- benzo[b][1,4] diazepin-1- yl)-N-iso- propyl- acetamide

¹H NMR (400 MHz, DMSO-d₆) δ 10.65 (s, 1H), 8.34 (d, J = 6.6 Hz, 1H), 8.15 (d, J = 8.0 Hz, 2H), 7.91 (dd, J = 10.8, 4,7 Hz, 2H), 7.83 (dd, J = 8.4, 1.8 Hz, 1H), 7.62 (dd, J = 19.5, 8.9 Hz, 2H), 7.44 (d, J = 8.4 Hz, 1H), 6.84 (d, J = 6.6 Hz, 1H), 4.28 (s, 2H), 3.82 (d, J = 7.0 Hz, 1H), 3.66 (t, J = 6.4 Hz, 2H), 2.47 (d, J = 6.5 Hz, 2H), 1.03 (d, J = 6.6 Hz, 6H). MS m/z (ESI): 471.3 [M + H].

Example 31: Preparation of 1-(6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)indolin-1-yl)-2-(4-methylpiperazin-1-yl)ethanone (TDI01326)

Step 1:

TDI01326-1 (5.0 g, 25.64 mmol) was dissolved in dichloromethane (400 mL), trifluoroacetic acid (27.5 mL) was added, and then triethylsilane (10.5 mL, 64.1 mmol) was added. The reaction was performed at room temperature for 16 hours. Thin layer chromatography indicated the reaction was complete. The reaction system was slowly added with aqueous ammonia to adjust the pH to about 9, followed by supplementary addition of dichloromethane (200 mL), and was successively washed with water (750 mL) and saturated brine (250 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was separated and purified by column chromatography to afford TDI01326-2 (3.6 g, light yellow oil).

¹H NMR (400 MHz, CDCl₃) δ 6.93 (d, J=7.6 Hz, 1H), 6.78 (dd, J=7.6, 1.6 Hz, 1H), 6.73 (d, J=1.6 Hz, 1H), 3.56 (t, J=8.4 Hz, 2H), 2.96 (t, J=8.4 Hz, 2H). MS m/z (ESI): 200.1 [M+H].

Step 2:

TDI01326-2 (2.6 g, 13.2 mmol) was dissolved in N,N-dimethylformamide (100 mL), HATU (5.03 g, 13.2 mmol) and diisopropylethylamine (5.68 g, 44 mmol) were added. After stir of 30 minutes, 2-(4-methylpiperazin-1-yl)acetic acid (1.74 g, 11 mmol) was added, and the reaction was performed at room temperature for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was dissolved in ethyl acetate (500 mL), and successively washed with water (500 mL) and saturated brine (250 mL). The organic phase was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford TDI01326-3 (3.1 g, light yellow oil).

¹H NMR (400 MHz, DMSO-d₆) δ 7.96 (s, 2H), 7.20-7.17 (m, 1H), 2.90 (s, 6H), 2.74 (s, 6H), 2.69 (s, 5H). MS m/z (ESI): 338.3 [M+H].

Step 3:

TDI01326-3 (3.0 g, 8.90 mmol) and bis(pinacolato)diboron (3.4 g, 13.35 mmol) were dissolved in dioxane (100 mL), potassium acetate (2.62 g, 26.7 mmol) and Pd(dppf)Cl₂ (312 mg, 0.45 mmol) were added, purge with argon was performed for 3 times, the reaction was placed in an oil bath at 80° C., and allowed to proceed overnight. Thin layer chromatography indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by column chromatography to afford TDI01326-4 (2.0 g, brown yellow oil).

¹H NMR (400 MHz, CDCl₃) δ 8.61 (s, 1H), 7.49 (d, J=7.2 Hz, 1H), 7.20 (d, J=7.2 Hz, 1H), 4.08 (t, J=8.0 Hz, 2H), 3.31 (s, 2H), 3.19 (t, J=8.0 Hz, 2H), 2.81 (br.s, 5H), 2.47 (br.s, 3H), 2.03 (s, 3H), 1.32 (s, 12H).

Step 4:

TDI01326-4 (134 mg, 0.35 mmol) and Reg-1-1 (100 mg, 0.29 mmol) were dissolved in a mixed solution of ethanol/water (8:1) (2.7 mL), sodium carbonate (61.5 mg, 0.58 mmol) and Pd(PPh₃)₂Cl₂ (21.1 mg, 0.03 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed under microwave radiation at 110° C. for 1 hour. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by high-performance liquid chromatography to afford compound TDI01326 (5.18 mg, yellow solid, yield: 3.8%).

¹H NMR (400 MHz, DMSO-d₆) δ 9.21 (s, 1H), 8.76 (s, 1H), 8.45 (s, 1H), 8.20 (d, J=7.2 Hz, 1H), 7.85 (d, J=7.6 Hz, 1H), 7.66 (d, J=8.8 Hz, 1H), 7.51 (d, J=8.0 Hz, 2H), 6.94 (s, 1H), 4.24 (t, J=8.4 Hz, 2H), 3.67 (s, 2H), 3.50-3.48 (m, 4H), 3.37 (t, J=8.4 Hz, 2H), 3.16-3.02 (m, 4H), 2.96 (s, 3H). MS m/z (ESI): 469.3 [M+H].

Example 32: Preparation of N-(2-(2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)pyrimidin-4-yl)-1H-indazol-5-amine (TDI01264)

Step 1:

TDI01264-1 (3.0 g, 1.38 mmol) and 1,3-dibromopropane (8.35 g, 4.14 mmol) were dissolved in acetonitrile (100 mL), potassium carbonate (6.09 g, 4.14 mmol) was added, the reaction was placed in an oil bath at 80° C., and allowed to proceed for 12 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and the residue was separated and purified by column chromatography to afford TDI01264-2 (3.2 g, brick red oil, 68.6%).

¹H NMR (400 MHz, CDCl₃) δ 7.98 (t, J=6.1 Hz, 1H), 7.64 (dd, J=8.9, 2.5 Hz, 1H), 7.01 (d, J=8.9 Hz, 1H), 4.25 (t, J=5.7 Hz, 2H), 3.65 (t, J=6.2 Hz, 2H), 2.48-2.27 (m, 2H).

Step 2:

TDI01264-2 (2.9 g, 8.56 mmol) was dissolved in methanol (100 mL), ammonium chloride (9.15 g, 171.10 mmol) was added, and then zinc powder (5.59 g, 85.6 mmol) was added in portions. The reaction was performed at ambient temperature for 12 h. LC-MS indicated the reaction was complete. The reaction solution was filtered, and concentrated under reduced pressure to give a crude product, which was separated by medium pressure preparative column chromatography to afford TDI01264-3 (0.9 g, brown solid, yield: 34.05%).

¹H NMR (400 MHz, CD₃OD) δ 7.54 (dd, J=8.9, 2.4 Hz, 1H), 7.50-7.46 (m, 1H), 7.04 (dt, J=11.0, 5.5 Hz, 1H), 4.10 (s, 2H), 3.46 (dd, J=13.7, 6.6 Hz, 2H), 2.23-2.12 (m, 2H). MS m/z (ESI): 307.9; 309.9 [M+H].

Step 3:

TDI01264-3 (0.7 g, 2.27 mmol) was dissolved in acetonitrile (100 mL), potassium carbonate (0.626 g, 4.53 mmol) was added, the reaction was placed in an oil bath at 80° C., and allowed to proceed for 12 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and the residue was purified by column chromatography to afford TDI01264-4 (0.3 g, brown solid, yield: 58.06%).

¹H NMR (400 MHz, CD₃OD) δ 7.10 (d, J=2.3 Hz, 1H), 6.96 (dd, J=8.5, 2.4 Hz, 1H), 6.85 (d, J=8.5 Hz, 1H), 4.07-4.00 (m, 2H), 3.25-3.16 (m, 2H), 2.05-1.99 (m, 2H). MS m/z (ESI): 228.0 [M+H].

Step 4:

TDI01264-4 (0.27 g, 1.18 mmol) and bis(pinacolato)diboron (0.599 g, 2.36 mmol) were dissolved in dioxane (30 mL), potassium acetate (0.347 g, 3.54 mmol) and Pd(dppf)Cl₂ (48 mg, 0.059 mmol) were added, purge with argon was performed for 3 times, the reaction was placed in an oil bath at 80° C., and allowed to proceed for 12 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was separated and purified by column chromatography to afford TDI01264-5 (0.2 g, brown solid, yield: 61.4%). MS m/z (ESI): 276.2 [M+H].

Step 5:

TDI01264-5 (160 mg, 0.581 mmol) and Reg-1-27 (0.20 g, 0.465 mmol) were dissolved in a mixed solution of ethanol/water (10:1) (11 mL), sodium carbonate (0.18 g, 11.74 mmol) and Pd(PPh₃)₂Cl₂ (20.39 mg, 0.029 mmol) were added, purge with argon was performed for 3 times, the reaction was performed under microwave radiation at 110° C. for 2 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, concentrated under reduced pressure, and the crude product was separated by preparative liquid chromatography to afford TDI01264 (13.69 mg; yellow solid, yield: 6.57%).

¹H NMR (400 MHz, CD₃OD) δ 8.14 (d, J=6.7 Hz, 2H), 7.68 (d, J=8.3 Hz, 2H), 7.59 (s, 1H), 7.50 (d, J=8.2 Hz, 1H), 7.06 (d, J=8.4 Hz, 1H), 6.84 (s, 1H), 4.28-4.12 (m, 2H), 3.28 (s, 2H), 2.09-1.96 (m, 2H). MS m/z (ESI): 359.2 [M+H].

Example 33: Preparation of 7-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one (TDI01265)

Step 1:

Compound TDI01265-1 (2 g, 9.1 mmol), methyl 3-aminopropanoate hydrochloride (1.27 g, 9.1 mmol), potassium carbonate (3.8 g, 27.3 mmol) and tetrahydrofuran (30 mL) were added to a 50 mL sealed tube. The reaction was warmed to 100° C. for 4.5 h. LC-MS indicated the reaction was complete. The reaction solution was filtered, and the filtrate was collected, and concentrated under reduced pressure to give a solid, which was purified by column chromatography (petroleum ether:ethyl acetate=20:1˜8:1) to afford TDI01265-2 (1.8 g, yellow solid, yield: 65.2%).

¹H NMR (400 MHz, CDCl₃) δ 8.21 (s, 1H), 8.04 (d, J=9.1 Hz, 1H), 7.04 (d, J=1.8 Hz, 1H), 6.79 (dd, J=9.1, 1.9 Hz, 1H), 3.75 (s, 3H), 3.62 (dd, J=12.4, 6.5 Hz, 2H), 2.73 (t, J=6.6 Hz, 2H). MS m/z (ESI): 305.1 [M+H].

Step 2:

Compound TDI01265-2 (1.3 g, 4.29 mmol), zinc powder (2.79 g, 42.9 mmol), ammonium chloride (2.30 g, 42.9 mmol) and 50 mL methanol were added to a 100 mL flask, and the reaction was warmed to 50° C., and allowed to proceed for 2 h. LC-MS indicated the reaction was complete. The reaction solution was filtered, and the filtrate was collected, concentrated to dryness to give an oil, which was purified by column chromatography (petroleum ether:ethyl acetate=10:1˜4:1) to afford TDI01265-3 (1 g, brown red oil, yield: 85.5%).

¹H NMR (400 MHz, CDCl3) δ 6.80-6.71 (m, 2H), 6.55 (d, J=8.1 Hz, 1H), 3.71 (s, 3H), 3.39 (t, J=6.3 Hz, 2H), 2.65 (t, J=6.3 Hz, 2H). MS m/z (ESI): 275.1 [M+H].

Step 3:

15 mL methanol was added to a 100 mL flask, and cooled to 0° C. Sodium metal (0.25 g, 10.99 mmol) was added in portions, and the solid completely dissolve. TDI01265-3 (1.0 g, 3.66 mmol) and 15 mL methanol were added to another 100 mL flask, cooled to 0° C., and the freshly prepared solution of sodium methoxide was added dropwise. After the addition, the reaction was performed at room temperature overnight, and then warmed to 60° C., and allowed to proceed for 2 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to 0˜10° C., the pH was adjusted to 6 with a hydrochloride methanol solution. The reaction solution was concentrated under reduced pressure followed by addition of 20 mL anhydrous ethanol, and the solution was filtered to collect the filtrate, which was concentrated under reduced pressure to afford TDI01265-4 (0.98 g, brown red solid, yield: 100%). MS m/z (ESI): 259.0[M+H].

Step 4:

Compound TDI01265-4 (500 mg, 1.92 mmol), HATU (880 mg, 2.30 mmol), diisopropylethylamine (990 mg, 7.68 mmol) and 100 mL N,N-dimethylformamide were added to a 250 mL flask, and the reaction was performed at room temperature for 10 minutes. LC-MS indicated the reaction was complete. The reaction solution was added to 500 mL water, extracted with ethyl acetate (200 mL×2), and the organic phase was dried, and concentrated under reduced pressure to give a brown yellow oil, which was purified by column chromatography (petroleum ether:ethyl acetate=5:1˜1:2) to afford TDI01265-5 (250 mg, brown red solid, yield: 53.9%).

¹H NMR (400 MHz, CDCl₃) δ 8.09 (s, 1H), 6.88 (d, J=6.9 Hz, 2H), 6.74 (d, J=8.3 Hz, 1H), 3.91 (s, 1H), 3.65 (d, J=1.5 Hz, 2H), 2.76-2.69 (m, 2H). MS m/z (ESI): 241.1 [M+H].

Step 5:

Compound TDI01265-5 (150 mg, 0.62 mmol), bis(pinacolato)diboron (190 mg, 0.75 mmol), Pd(PPh₃)₂Cl₂ (42 mg, 0.06 mmol), Na₂CO₃ (131 mg, 1.24 mmol), 10 mL ethanol and 2 mL water were added to a 25 mL flask, purge with argon was performed for 4 times, and the reaction was warmed to 100° C., and allowed to proceed for 2 h. LC-MS indicated the reaction was complete. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to give a solid, which was purified by column chromatography (petroleum ether:ethyl acetate=10:1˜1:2) to afford TDI01265-6 (100 mg, off-white solid, yield: 56%).

¹H NMR (400 MHz, DMSO-d₆) δ 9.54 (s, 1H), 7.16 (s, 1H), 6.93 (d, J=7.9 Hz, 1H), 6.87 (d, J=7.8 Hz, 1H), 5.71 (s, 1H), 3.40 (d, J=5.7 Hz, 2H), 2.49-2.47 (m, 2H), 1.26 (s, 12H). MS m/z (ESI): 289.2 [M+H].

Step 6:

Compound TDI01265-6 (70 mg, 0.24 mmol), Reg-1-1 (70 mg, 0.20 mmol), Pd(PPh₃)₂Cl₂ (14 mg, 0.02 mmol), sodium carbonate (42 mg, 0.40 mmol), 15 mL ethanol and 2 mL water were added to a 30 mL microwave tube, the system was purged with argon for 1 minute, the reaction was warmed to 95° C., and performed under microwave radiation for 1 h, LC-MS indicated the reaction was complete. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to give a solid, which was purified by high-performance liquid chromatography to afford TDI01265 (8.95 mg, yellow solid, yield: 12%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.99 (s, 1H), 9.57 (d, J=37.4 Hz, 2H), 8.28 (d, J=5.3 Hz, 1H), 8.13 (d, J=31.2 Hz, 2H), 7.82 (s, 1H), 7.64-7.54 (m, 3H), 6.99 (d, J=8.0 Hz, 1H), 6.62 (d, J=5.7 Hz, 1H), 5.94 (s, 1H), 3.47 (s, 2H), 2.57 (s, 2H). MS m/z (ESI): 372.3 [M+H].

Example 34: Preparation of (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone (TDI01470)

Step 1:

Compound TDI01470-1 (20 g, 83.31 mmol) and ethanol (200 mL) were added to a 500 mL flask, thionyl chloride (19.82 g, 166.63 mmol) was added, and then the reaction was performed at 60° C. for 3 hours. Thin layer chromatography (petroleum ether/ethyl acetate=10:1) assay indicated the reaction was complete. The reaction solution was concentrated to afford a crude product, which was dissolved in dichloromethane (500 mL), and the resulting solution was washed twice with a saturated aqueous solution of sodium bicarbonate (150 mL each). The organic phase was washed with saturated brine, then dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound TDI01470-2 (21 g, brown solid, yield: 94.01%). MS m/z (ESI): 266.1; 268.1 [M−H].

Step 2:

Compound TDI01470-2 (21 g, 78.33 mmol) and bis(pinacolato)diboron (26.85 g, 105.74 mmol) were dissolved in 1,4-dioxane (200 mL), potassium acetate (23.06 g, 234.98 mmol) and Pd(dppf)Cl₂ (3.24 g, 3.91 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 80° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under pressure, and the residue was purified by column chromatography (petroleum ether/ethyl acetate=100:1 to 5:1) to afford compound TDI01470-3 (17.5 g, white solid, yield: 70.89%).

¹H NMR (400 MHz, CDCl₃) δ 8.92 (s, 1H), 7.92 (s, 1H), 7.69 (d, J=8.1 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.22-7.18 (m, 1H), 4.42 (q, J=7.1 Hz, 2H), 1.42 (t, J=7.1 Hz, 3H), 1.37 (s, 12H). MS m/z (ESI): 316.2 [M+H].

Step 3:

Compound TDI01470-3 (10.0 g, 31.8 mmol) was dissolved in tetrahydrofran (250 mL), sodium hydride (1.91 g, 47.8 mmol) was added under ice bath cooling, and then the reaction was performed for 30 minutes. Iodomethane (13.5 g, 95.4 mmol) was slowly added to the reaction solution, and the reaction was performed at room temperature overnight. Thin layer chromatography (petroleum ether/ethyl acetate=5:1) indicated the reaction was complete. The reaction solution was quenched with water (100 mL), and extracted with ethyl acetate (150 mL×2). The combined organic phases were washed sequentially with a saturated aqueous solution of ammonium chloride (200 mL×2) and saturated brine (300 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated and purified by column chromatography (petroleum ether/ethyl acetate=15:1) to afford compound TDI01470-4 (6.5 g, yellow solid, yield: 62.5%).

¹H NMR (400 MHz, CDCl₃) δ 7.91 (s, 1H), 7.68-7.65 (m, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.27 (s, 1H), 4.12 (s, 3H), 3.91 (s, 3H), 1.38 (s, 12H).

Step 4:

Compound Reg-1-16 (1.00 g, 2.70 mmol) and TDI01470-4 (1.33 g, 4.04 mmol) were dissolved in a mixed solution of ethanol/water (8:1) (120 mL), sodium carbonate (572 mg, 5.40 mmol) and Pd(PPh₃)Cl₂ (189 mg, 0.27 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 110° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and concentrated under reduced pressure. The residue was diluted with water (30 mL), and the pH was adjusted to 1 with 6N HCl. A large amount of solid precipitated, and was filtered. The solid was washed with methanol to afford compound TDI01470-5 (900 mg, yellow solid, crude product).

¹H NMR (400 MHz, DMSO-d₆) δ 11.54 (s, 1H), 8.77 (s, 1H), 8.38 (d, J=7.2 Hz, 1H), 8.14 (s, 2H), 8.03 (d, J=8.8 Hz, 1H), 7.92 (d, J=8.4 Hz, 1H), 7.80-7.69 (m, 4H), 7.33 (s, 1H), 7.07 (d, J=8.0 Hz, 1H), 4.16 (s, 3H).

Step 5:

Compound TDI01470-5 (300 mg, 0.73 mmol) was dissolved in N,N-dimethylformamide (6 mL), HATU (335 mg, 0.88 mmol) and DIEA (377 mg, 2.92 mmol) were added, and the reaction was performed at room temperature for 30 mm. Then, compound TDI01470-a (114 mg, 0.88 mmol) was added, and the reaction was continued at room temperature for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was purified by high performance liquid chromatography to afford compound TDI01470 (185 mg, yellow solid, yield: 52.1%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.63 (s, 1H), 8.52 (s, 1H), 8.41 (d, J=6.4 Hz, 1H), 8.09 (s, 2H), 8.06 (dd, J=8.4, 1.2 Hz, 1H), 7.83 (d, J=8.4 Hz, 1H), 7.77 (d, J=8.0 Hz, 2H), 7.72 (d, J=8.4 Hz, 2H), 7.13 (s, 1H), 6.86 (d, J=6.4 Hz, 1H), 4.91 (s, 2H), 4.57 (s, 2H), 4.05 (s, 3H). MS m/z (ESI): 486.2 [M+H].

The compounds in following table 8 were prepared according to methods similar to that described in the synthetic route of TDI01470 in Example 34.

TABLE 8 Starting material or regent different from that in the synthetic route of No. Compound Structure Compound Name TDI01470 in Example 34 Characterization Data TDI01457

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-N- (1,1,1-trifluoropropan-2- yl)-1H-indole-2- carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 10.44 (s, 1H), 9.07 (d, J = 8.8 Hz, 1H), 8.54 (s, 1H), 8.41 (d, J = 6.2 Hz, 1H), 8.10 (d, J = 7.4 Hz, 3H), 7.96-7.64 (m, 5H), 7.33 (s, 1H), 6.84 (d, J = 6.1 Hz, 1H), 4.90-4.85 (m, 1H), 4.09 (s, 3H), 1.40 (d, J = 6.5 Hz, 3H). MS m/z (ESI): 506.2 [M + H]. TDI01504

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-N,1-dimethyl-N- (2- (trifluoromethyl)cyclopro- pyl)-1H-indole-2- carboxamide

¹H NMR (400 MHz, CD₃OD) δ 8.42 (s, 1H), 8.24 (d, J = 7.2 Hz, 1H), 8.02 (t, J = 5.2 Hz, 2H), 7.98 (dd, J = 8.4, 1.2 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.77- 7.71 (m, 4H), 6.95 (s, 1H), 6.89 (d, J = 7.2 Hz, 1H), 3.93 (s, 3H), 3.18 (s, 3H), 2.17-2.11 (m, 2H), 1.24-1.19 (m, 2H). MS m/z (ESI): 532.3 [M + H]. TDI01505

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(3-hydroxy-3- (trifluoromethyl)pyrroli- din-1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.73 (s, 1H), 8.50 (s, 1H), 8.40 (d, J = 6.7 Hz, 1H), 8.10 (s, 2H), 8.04 (d, J = 8.3 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.77 (s, 2H), 7.73 (d, J = 8.5 Hz, 2H), 7.04 (d, J = 5.3 Hz, 1H), 6.87 (d, J = 6.6 Hz, 1H), 3.95 (s, 3H), 3.81-3.71 (m, 4H), 2.25-2.23 (m, 1H), 2.10-2.08 (m, 1H). MS m/z (ESI): 548.2 [M + H]. TDI01506

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(3-(tri- fluoromethyl)pyrrolidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.72 (s, 1H), 8.50 (s, 1H), 8.41 (d, J = 6.5 Hz, 1H), 8.10 (s, 2H), 8.04 (d, J = 8.6 Hz, 1H), 7.87-7.71 (m, 6H), 7.01 (d, J = 17.7 Hz, 1H), 6.88 (d, J = 6.4 Hz, 1H), 3.93 (s, 3H), 3.41-3.37 (m, 3H), 2.51-2.33 (m, 2H), 2.24-2.09 (m, 2H). MS m/z (ESI): 532.2 [M + H]. TDI01507

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(3,3- difluoropyrrolidin-1- yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.42 (s, 1H), 8.24 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.96 (d, J = 8.5 Hz, 1H), 7.89 (d, J = 8.5 Hz, 1H), 7.75 (d, J = 7.0 Hz, 4H), 7.03 (s, 1H), 6.92 (d, J = 7.2 Hz, 1H), 4.10 (d, J = 33.4 Hz, 2H), 4.00 (s, 6H), 2.52 (s, 2H). MS m/z (ESI): 500.3 [M + H]. TDI01508

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)ami- no)thieno[3,2- d]pyrimidin-2-yl)-1- methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.71 (s, 1H), 8.56 (s, 1H), 8.40 (d, J = 5.3 Hz, 1H), 8.13 (d, J = 9.2 Hz, 3H), 7.92-7.70 (m, 6H), 7.60 (d, J = 5.4 Hz, 1H), 7.12 (s, 1H), 4.90 (s, 2H), 4.62-4.53 (m, 2H), 4.06 (s, 3H). MS m/z (ESI): 542.2 [M + H]. TDI01512

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amion)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(6,6-difluoro- 3- azabicyclo[3.1.0]hexan- 3-yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.47 (s, 1H), 8.29 (d, J = 6.0 Hz, 1H ), 8.15 (dd, J = 8.4, 1.2 Hz, 1H), 7.96 s, 2H), 7.77 (d, J = 8.4 Hz, 2H), 7.71 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 8.8 Hz, 2H), 6.84 (s, 1H), 6.66 (d, J = 6.0 Hz, 1H), 4.34- 4.31 (m, 1H), 4.10-4.02 (m, 2H), 3.90 (s, 3H), 3.86-3.80 (m, 1H), 2.54-2.46 (m, 2H). MS m/z (ESI): 512.2 [M + H]. TDI01513

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(1,1-difluoro- 5-azaspiro[2.4]heptan-5- yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.41 (s, 1H), 8.24 (d, J = 7.2 Hz, 1H), 8.06 (s, 2H), 7.96 (d, J = 7.6 Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.82-7.73 (m, 4H), 7.00 (d, J = 10.8 Hz, 1H), 6.92 (d, J = 7.2 Hz, 1H), 3.99 (s, 3H), 3.88-3.84 (m, 2H), 2.32-2.07 (m, 3H), 1.62- 1.50 (m, 3H). MS m/z (ESI): 526.2 [M + H]. TDI01514

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)((3S,4R)-3,4- difluoropyrrolidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.76 (s, 1H), 8.52 (s, 1H), 8.41 (d, J = 6.6 Hz, 1H), 8.12-8.03 (m, 3H), 7.86- 7.71 (m, 5H), 7.08 (s, 1H), 6.89 (d, J = 6.7 Hz, 1H), 5.60-5.20 (m, 2H), 4.15 (m, 2H), 3.95 (s, 3H), 3.74 (d, J = 4.4 Hz, 2H). MS m/z (ESI): 500.2 [M + H]. TDI01515

2-(1-(6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indole-2- carbonyl)azetidin-3- ylidene)acetontrile

¹H NMR (400 MHz, DMSO-d₆) δ 10.42 (s, 1H), 8.52 (s, 1H), 8.41 (d, J = 6.4 Hz, 1H), 8.08 (s, 3H), 7.83-7.76 (m, 3H), 7.70 (d, J = 8.4 Hz, 2H), 7.12 (s, 1H), 6.83 (d, J = 6.4 Hz, 1H), 5.96 (s, 1H), 5.26 (d, J = 43.3 Hz, 2H), 4.88 (d, J = 26.0 Hz, 2H), 4.05 (s, 3H). MS m/z (ESI): 487.2 [M + H]. TDI01516

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(3- ethynylazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 8.51 (s, 2H), 8.40 (d, J = 6.4 Hz, 1H), 8.10- 8.08 (m, 3H), 7.80-7.77 (m, 3H), 7.69 (d, J = 8.4 Hz, 2H), 7.01 (s, 1H), 6.80 (d, J = 6.4 Hz, 2H), 4.71-4.62 (m, 2H), 4.42-4.38 (m, 2H), 4.04 (s, 3H), 3.62-3.56 (m, 2H). MS m/z (ESI): 471.4 [M + H]. TDI01517

1-(1-(6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indole-2- carbonyl)azetidin-3- yl)ethan-1-one

¹H NMR (400 MHz, DMSO-d₆) δ 12.91 (s, 1H), 9.67 (s, 1H), 8.54 (s, 1H), 8.40 (d, J = 5.8 Hz, 1H), 8.18 (d, J = 8.3 Hz, 2H), 7.93 (s, 1H), 7.81 (d, J = 8.3 Hz, 2H), 7.74 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.5 Hz, 2H), 6.97 (s, 1H), 6.71 (d, J = 5.8 Hz, 1H), 4.58 (s, 1H), 4.50 (s, 1H), 4.23-4.13 (m, 2H), 4.03 (s, 3H), 3.71 (d, J = 8.9 Hz, 1H), 2.19 (s, 3H). MS m/z (ESI): 492.3 [M + H]. TDI01518

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)((3R,4R)-3- fluoro-4- hydroxypyrrolidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆, D₂O) δ 8.46 (s, 1H), 8.37 (dd, J = 7.2, 1.6 Hz, 1H), 8.12 (s, 2H), 7.98 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.84- 7.72 (m, 4H), 7.08 (d, J = 2.0 Hz, 1H), 6.94 (d, J = 7.2 Hz, 1H), 5.16-5.19 (m, 1H), 5.03-4.96 (m, 1H), 4.37- 4.28 (m, 1H), 4.14-4.01 (m, 1H), 3.95 (s, 3H), 3.91-3.83 (m, 1H), 3.77-3.74 (m, 1H). MS m/z (ESI): 498.2 [M + H]. TDI01519

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)((3R,4R)-3- bromo-4- fluoropyrrolidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 7.60 (s, 1H), 7.43 (d, J = 7.2 Hz, 1H), 7.23 (s, 2H), 7.15 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H), 6.98-6.92 (m, 4H), 6.25-6.18 (m, 1H), 6.11 (d, J = 7.2 Hz, 1H), 4.70-4.50 (m, 1H), 3.93- 3.82 (m, 1H), 3.67-3.60 (m, 1H), 3.54- 3.46 (m, 1H), 3.34-3.23 (m, 1H), 3.18 (s, 3H), 3.12-3.01 (m, 1H). MS m/z (ESI): 560.2 [M + H]. TDI01520

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)((3S,4R)-3- fluoro-4- hydroxypyrrolidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 7.59 (s, 1H), 7.42 (d, J = 7.2 Hz, 1H), 7.23 (s, 2H), 7.14 (d, J = 7.6 Hz, 1H), 7.10- 7.00 (m, 2H), 6.99-6.92 (m, 3H), 6.17 (d, J = 10.0 Hz, 1H), 6.10 (d, J = 6.8 Hz, 1H), 4.42-4.17 (m, 2H), 3.70- 3.53 (m, 1H), 3.27-3.19 (m, 1H), 3.16 (s, 3H), 3.07 (s, 1H), 2.88-2.72 (m, 1H). MS m/z (ESI): 498.2 [M + H]. TDI01523

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(3-hydroxy-3- (trifluoromethyl)azetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.56 (s, 1H), 8.52 (s, 1H), 8.41 (d, J = 6.4 Hz, 1H), 8.12-8.04 (m, 3H), 7.83 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.0 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 7.12 (s, 1H), 6.86 (d, J = 6.4 Hz, 1H), 4.76- 4.70 (m, 1H), 4.46-4.44 (m, 1H), 4.35- 4.33 (m, 1H), 4.14-4.10 (m, 1H), 4.05 (s, 3H). MS m/z (ESI): 534.3 [M + H]. TDI01524

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(3-fluoro-3- (fluoromethyl)azetidin-1- yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.45 (s, 1H), 8.26 (d, J = 6.5 Hz, 1H), 8.06 (d, J = 8.6 Hz, 1H), 7.98 (s, 2H), 7.74 (s, 3H), 7.66 (d, J = 8.5 Hz, 2H), 7.00 (s, 1H), 6.77 (d, J = 6.5 Hz, 1H), 4.72 (d, J = 21.5 Hz, 2H), 4.64 (s, 2H), 4.44- 4.25 (m, 2H), 4.07 (s, 3H). MS m/z (ESI): 500.3 [M + H]. TDI01531

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-N-ethyl-N,1- dimethyl-1H-indol-2- carboxamide

¹H NMR (400 MHz, CD₃OD) δ 8.40 (s, 1H), 8.23 (d, J = 7.2 Hz, 1H), 8.04 (s, 2H), 7.96 (d, J = 8.5 Hz, 1H), 7.86 (d, J = 8.5 Hz, 3H). 7.76 (s, 2H), 6.91 (d, J = 7.2 Hz, 1H), 6.81 (d, J = 6.9 Hz, 1H), 3.90 (d, J = 3.4 Hz, 3H), 3.60 (dd, J = 50.8, 6.8 Hz, 2H), 3.16 (s, 3H), 1.33-1.20 (m, 3H). MS m/z (ESI): 452.3 [M + H]. TDI01532

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-1,3,5- triazin-2-yl)-1-methyl- 1H-indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

MS m/z (ESI): 487.2 [M + H]. TDI01533

(6-(7-((4-(1H-pyrazol-4- yl)phenyl)amino)imidazo [1,2-c]pyrimidin-5-yl)-1- methyl-1H-indol-2- yl)(3,3-difluoroacetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.43 (s, 1H), 9.00 (s, 1H), 8.59 (s, 2H), 8.42 (s, 1H), 8.41 (d, J = 8.0 Hz, 1H), 7.94 (s, 1H), 7.78-7.82 (m, 3H), 7.09 (s, 1H), 7.01 (d, J = 8.0 Hz, 2H), 4.30- 4.57 (m, 4H), 4.13 (s, 3H). MS m/z (ESI): 525.3 [M + H]. TDI01538

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(3- (trifluoromethyl)azetidin- 1-yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.43 (s, 1H), 8.25 (d, J = 7.2 Hz, 1H), 8.04 (s, 2H), 7.97 (dd, J = 8.4, 1.2 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.87-7.71 (m, 4H), 7.06 (s, 1H), 6.94 (d, J = 7.2 Hz, 1H), 4.76-4.68 (m, 1H), 4.58- 4.51 (m, 1H), 4.48-4.41 (m, 1H), 4.28- 5.21 (m, 1H), 4.10 (s, 3H), 3.66-3.58 (m, 1H). MS m/z (ESI): 518.3 [M + H].

Compound TDI01434 was prepared according to a method similar to that described in Example 34, with step 3 omitted

¹H NMR (400 MHz, DMSO-d₆) δ 12.28 (s, 1H), 10.61 (s, 1H), 8.48 (s, 1H), 8.35 (d, J=6.4 Hz, 1H), 8.07 (s, 2H), 8.00 (d, J=8.4 Hz, 1H), 7.83 (d, J=8.4 Hz, 1H), 7.79 (d, J=7.6 Hz, 2H), 7.71 (d, J=8.4 Hz, 2H), 7.03 (s, 1H), 6.85 (d, J=6.4 Hz, 1H), 5.03 (s, 2H), 4.58 (s, 2H). MS m/z (ESI): 472.1 [M+H].

The compounds in following table 9 were prepared according to methods similar to that described in the synthetic route of TDI01434 in Example 34.

TABLE 9 Starting material or regent different from that in the synthetic route of No. Compound Structure Compound Name TDI01434 in Example 34 Characterization Data TDI01381

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N-methyl-N- (tetrahydro-2H-pyran-4- yl)-1H-indole-2- carboxamide

¹H NMR (400 MHz, CD3OD) δ 8.42 (s, 1H), 8.20 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.88 (s, 3H), 7.74 (d, J = 7.7 Hz, 3H), 6.98 (s, 1H), 6.91 (d, J = 7.2 Hz, 1H), 4.05 (d, J = 8.3 Hz, 2H), 3.51 (s, 3H), 3.20 (s, 3H), 2.01 (s, 2H), 1.74 (d, J = 11.7 Hz, 2H). MS m/z (ESI): 494.3 [M + H]. TDI01408

5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N,N-diethyl-1H- indole-2-carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 11.93 (s, 1H). 10.39 (s, 1H), 8.66 (s, 1H), 8.35 (d, J = 6.3 Hz, 1H), 8.17 (d, J = 8.7 Hz, 1H), 8.07 (s, 2H), 7.79 (d, J = 7.7 Hz, 2H), 7.71 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.7 Hz, 1H), 6.99 (s, 1H), 6.80 (d, J = 6.1 Hz, 1H), 3.62- 3.60 (m, 4H), 1.20-1.28 (m, 6H). MS m/z (ESI): 452.3 [M + H]. TDI01418

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N-(3- hydroxycyclobutyl)-N- methyl-1H-indole-2- carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 12.19 (s, 1H), 10.89 (s, 1H), 8.42 (s, 1H), 8.35 (d, J = 6.5 Hz, 1H), 8.09 (s, 2H), 7.93 (s, 1H), 7.86 (s, 1H), 7.76 (d, J = 11.7 Hz, 4H), 6.89 (d, J = 6.3 Hz, 2H), 4.43 (d, J = 8.3 Hz, 1H), 3.85 (s, 1H), 3.15 (s, 3H), 2.13 (s, 3H). MS m/z (ESI): 480.3 [M + H]. TDI01419

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N-methyl-N- (tetrahydrofuran-3-yl)- 1H-indole-2- carboxamide

¹H NMR (400 MHz, CD₃OD) δ 8.60 (s, 1H), 8.38 (d, J = 2.8 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 8.07 (s, 2H), 7.90 (d, J = 8.4 Hz, 2H), 7.79 (d, J = 8.4 Hz, 1H), 7.72 (d, J = 8.4 Hz, 2H), 6.98 (s, 1H), 6.73 (d, J = 6.0 Hz, 1H), 5.35 (d, J = 8.8 Hz, 1H), 4.33 (s, 3H), 4.16-4.12 (m, 1H), 4.00-3.96 (m, 1H), 3.90-3.86 (m, 1H), 3.77-3.71 (m, 1H), 2.45-2.40 (m, 1H), 2.15- 2.10 (m, 1H). MS m/z (ESI): 480.3 [M + H]. TDI01420

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N-cyclobutyl-N- methyl-1H-indole-2- carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 12.12 (s, 1H), 10.64 (s, 1H), 8.41 (d, J = 34.4 Hz, 2H), 8.09 (s, 2H), 7.98 (s, 1H), 7.88-7.67 (m, 4H), 6.89 (d, J = 25.6 Hz, 2H), 4.93 (s, 1H), 3.15 (s, 3H), 2.33 (s, 2H), 2.16 (s, 2H), 1.68 (s, 2H). MS m/z (ESI): 464.2 [M + H]. TDI01426

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2-yl)-N- methyl-N-(2,2,2- trifluoroethyl)-1H- indole- 2-carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 11.99 (s, 1H), 9.65 (s, 1H), 8.48 (s, 2H), 8.06 (d, J = 4.9 Hz, 3H), 7.94 (d, J = 8.6 Hz, 2H), 7.70 (dd, J = 18.3, 8.6 Hz, 3H), 7.08 (s, 1H), 4.50 (s, 2H), 3.46 (s, 3H). MS m/z (ESI): 510.2 [M + H]. TDI01429

5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-y1)-N-methyl-N- (2,2,2-trifluoroethyl)- 1H- indole-2-carboxamide

1H NMR (400 MHz, DMSO-d₆) δ 7.92 (s, 1H), 7.53 (s, 1H), 7.47-7.29 (m. 3H), 7.04-6.97 (m. 5H), 6.54 (s, 1H), 6.25-6.16 (m, 1H), 3.73 (s, 2H), 2.79 (s, 3H). MS m/z (ESI): 492.2 [M + H]. TDI01430

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N-(cyanomethyl)- N-methyl-1H-indole-2- carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 12.25 (s, 1H), 10.50 (s, 1H), 8.49 (s, 1H), 8.37 (d, J = 6.4 Hz, 1H), 8.08 (s, 2H), 8.03 (d, J = 8.3 Hz, 1H), 7.82 (dd, J = 15.7, 8.1 Hz, 3H), 7.71 (d, J = 8.2 Hz, 2H), 7.13 (s, 1H), 6.84 (d, J = 6.3 Hz, 1H), 4.69 (s, 2H), 3.40 (s, 3H). MS m/z (ESI): 449.2 [M + H]. TDI01431

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- methylmorpholino) methanone

¹H NMR (400 MHz, CD₃OD) δ 8.41 (s, 1H), 8.21 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.88 (s, 2H), 7.75 (d, J = 7.4 Hz, 3H), 6.96-6.87 (m, 2H), 4.61 (s, 1H), 4.21 (d, J = 9.1 Hz, 1H), 3.95 (d, J = 7.2 Hz, 1H), 3.71 (dd, J = 14.6, 11.8 Hz, 2H), 3.56 (d, J = 6.8 Hz, 2H), 1.46 (d, J = 6.9 Hz, 3H). MS m/z (ESI): 480.3 [M + H]. TDI01433

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- (trifluoromethyl) azetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.16 (s, 1H), 10.26 (s, 1H), 8.51 (s, 1H), 8.36 (d. J = 6.3 Hz, 1H), 8.05 (d, J = 9.5 Hz, 3H), 7.80 (t, J = 8.6 Hz, 3H), 7.69 (d. J = 8.3 Hz, 2H), 7.03 (s, 1H), 6.79 (d, J = 5.9 Hz, 1H), 4.81 (s, 1H), 4.62 (s, 1H), 4.38 (s, 1H), 4.10 (s, 1H), 3.79 (dd, J = 3.5, 1.3 Hz, 1H). MS m/z (ESI): 504.2 [M + H]. TDI01435

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- (difluoromethyl) azetidin- 1-yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.42 (s, 1H), 8.20 (d, J = 1.1 Hz, 1H), 8.03 (s, 2H), 7.88 (dd, J = 18.4, 8.5 Hz, 2H), 7.74 (s, 3H), 6.99 (s, 1H), 6.90 (d, J = 7.1 Hz, 1H), 6.21 (dd, J = 57.6, 54.6 Hz, 1H), 4.73 (s, 1H), 4.60 (s, 1H), 4.22 (dd, J = 74.1, 31.0 Hz, 4H). MS m/z (ESI): 486.2 [M + H]. TDI01436

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- (trifluoromethoxy) azetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 8.53 (s, 1H), 8.37 (d, J = 6.1 Hz, 1H), 8.08 (d, J = 9.0 Hz, 3H), 7.82 (d, J = 8.0 Hz, 2H), 7.77 (d, J = 8.4 Hz, 1H), 7.70 (s, 2H), 6.97 (s, 1H), 6.75 (d, J = 5.8 Hz, 1H), 5.35 (s, 1H), 4.95 (s, 1H), 4.72 (s, 1H), 4.56 (s, 1H), 4.20 (s, 1H). MS m/z (ESI): 520.2 [M + H]. TDI01437

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- hydroxyazetidin-1- yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.43 (s, 1H), 8.21 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.92-7.84 (m, 2H), 7.75 (s, 4H), 6.99 (s, 1H), 6.91 (d, J = 7.2 Hz, 1H), 4.72-4.71 (m, 1H), 4.67 (s, 1H), 4.46 (s, 1H), 4.39 (s, 1H), 4.02 (s, 1H). MS m/z (ESI): 452.2 [M + H]. TDI01438

(S)-(6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- hydroxypyrrolidin-1- yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.42 (s, 1H), 8.20 (d, J = 7.2 Hz, 1H), 8.06 (s, 2H), 7.74 (m, 6H), 7.12 (d, J = 24.7 Hz, 1H), 6.90 (d, J = 7.2 Hz, 1H), 4.54 (d, J = 24.2 Hz, 1H), 4.14- 3.67 (m, 4H), 2.22-1.97 (m, 2H). MS m/z (ESI): 466.1 [M + H]. TDI01441

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- fluoro-3-methylazetidin- 1-yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.43 (s, 1H), 8.21 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.90 (t, J = 8.1 Hz, 2H), 7.75 (s, 4H), 7.00 (s, 1H), 6.91 (d, J = 7.2 Hz, 1H), 4.65 (s, 2H), 4.29 (s, 2H), 1.70 (d, J = 21.6 Hz, 3H). MS m/z (ESI): 468.2 [M + H]. TDI01442

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-N-(2-cyanoethyl)- N-methyl-1H-indole-2- carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 12.16 (s, 1H), 10.57 (s, 1H), 8.49 (s, 1H), 8.37 (d, J = 6.5 Hz, 1H), 8.08 (s, 2H), 8.01 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 8.6 Hz, 3H), 7.71 (d, J = 8.5 Hz, 2H), 7.05 (s, 1H), 6.85 (d, J = 6.5 Hz, 1H), 3.39 (s, 4H), 2.93 (s, 3H). MS m/z (ESI): 463.3 [M + H]. TDI01444

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- (trifluoromethyl) pyrrolidin- 1-yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 1H), 8.21 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.96-7.82 (m, 3H), 7.75 (d, J = 8.0 Hz, 3H), 7.15 (s, 1H), 6.92 (d, J = 7.2 Hz, 1H), 4.26 (s, 1H), 4.09 (d, J = 28.2 Hz, 2H), 3.99-3.83 (m, 2H), 2.35 (d, J = 41.6 Hz, 2H). MS m/z (ESI): 518.3 [M + H]. TDI01445

1-(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indole-2- carbonyl)piperidine-4- carbonitrile

¹H NMR (400 MHz, CD₃OD) δ 8.38 (s, 1H), 8.19 (d, J = 7.1 Hz, 1H), 8.03 (s, 2H), 7.77 (dd, J = 42.4, 15.3 Hz, 6H), 6.99-6.84 (m, 2H), 4.10 (d, J = 12.3 Hz, 2H), 3.68 (s, 2H), 3.14 (s, 1H), 2.05 (s, 2H), 1.96-1.80 (m, 2H). MS m/z (ESI): 489.2 [M + H]. TDI01447

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- (4-methylpiperazin-1- yl)piperidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.12 (s, 1H), 10.51 (s, 1H), 8.47 (s, 1H), 8.37 (d, J = 6.4 Hz, 1H), 8.07 (s, 2H), 8.02 (d, J = 8.5 Hz, 1H), 7.80 (d, J = 4.3 Hz, 3H), 7.71 (d, J = 8.3 Hz, 2H), 6.92-6.77 (m, 2H), 4.39 (s, 2H), 4.25 (d, J = 10.7 Hz, 2H), 3.02 (d, J = 80.3 Hz, 7H), 2.77 (s, 3H), 2.63 (s, 2H), 1.96 (s, 1H), 1.82 (s, 1H), 1.64- 1.46 (m, 2H). MS m/z (ESI): 562.4 [M + H]. TDI01448

1-(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indole-2- carbonyl)pyrrolidine-3- carbonitrile

¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 1H), 8.21 (d, J = 7.1 Hz, 1H), 8.02 (s, 2H), 7.91 (s, 2H), 7.75 (s, 4H), 7.15 (d, J = 9.2 Hz, 1H), 6.90 (d, J = 7.2 Hz, 1H), 4.22-3.85 (m, 4H), 3.48 (d, J = 3.4 Hz, 1H), 2.41 (t, J = 26.9 Hz, 2H). MS m/z (ESI): 475.2 [M + H]. TDI01450

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) thieno[3,2- d]pyrimidin-2-yl)-1H- indol-2- yl)(morpholino) methanone

¹H NMR (400 MHz, CD₃OD) δ 11.93 (s, 1H), 9.94 (s, 1H), 8.57 (s, 1H), 8.26 (d, J = 8.0 Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H), 8.09 (s, 2H), 7.92 (d, J = 8.0 Hz, 2H), 7.71 (d, J = 8.0 Hz, 3H), 7.56 (s, 1H), 6.88 (s, 1H), 3.79-3.68 (m, 8H). MS m/z (ESI): 522.2 [M + H]. TDI01451

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) thieno[3,2- d]pyrimidin-2-yl)- N,N-diethyl-1H- indole-2- carboxamide

1H NMR (400 MHz, DMSO-d₆) δ 10.13 (s, 2H), 9.70 (s, 1H), 8.96 (s, 1H), 8.82 (s, 1H), 8.50 (s, 1H), 8.40- 8.23 (m, 3H), 8.10 (d, J = 12.0 Hz, 3H), 7.93 (dd, J = 34.6, 8.8 Hz, 3H), 3.02 (s, 3H), 2.75 (s, 3H). MS m/z (ESI): 508.3 [M + H]. TDI01455

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin-2-yl)- 1H-indol-2-yl)(3- fluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.21 (s, 1H), 10.53 (s, 1H), 8.49 (s, 1H), 8.37 (d, J = 6.4 Hz, 1H), 8.08 (s, 2H), 8.01 (d, J = 8.8 Hz, 1H), 7.81 (dd, J = 8.8, 4.0 Hz, 3H), 7.71 (d, J = 8.8 Hz, 2H), 6.97 (s, 1H), 6.84 (d, J = 6.4 Hz, 1H), 5.54 (d, J = 57.6 Hz, 1H), 4.86 (s, 1H), 4.65 (s, 1H), 4.48 (s, 1H), 4.12 (s, 1H). MS m/z (ESI): 454.2 [M + H]. TDI01458

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(4- hydroxypiperidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.04 (s, 1H), 10.32 (s, 1H), 8.47 (s, 1H), 8.36 (d, J = 6.3 Hz, 1H), 8.09- 8.01 (m, 3H), 7.81-7.76 (m, 3H), 7.70 (d, J = 8.5 Hz, 2H), 6.85 (s, 1H), 6.80 (d, J = 6.2 Hz, 1H), 4.11-4.08 (m, 4H), 3.81-3.79 (m, 1H), 1.87-1.80 (m, 2H), 1.47-1.40 (m, 2H). MS m/z (ESI): 480.2 [M +H]. TDI01461

1-(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indole-2- carbonyl)-3- methylazetidine-3- carbonitrile

¹H NMR (400 MHz, CD₃OD) δ 8.43 (s, 1H), 8.21 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.89 (dd, J = 16.6, 8.6 Hz, 2H), 7.75 (s, 4H), 6.99 (s, 1H), 6.91 (d, J = 7.2 Hz, 1H), 4.77 (s, 1H), 4.55 (s, 2H), 4.18 (s, 1H), 1.76 (s, 3H). MS m/z (ESI): 475.3 [M + H]. TDI01462

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2- yl)(pyrrolidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.14 (s, 1H), 10.66 (s, 1H), 8.48 (s, 1H), 8.35 (d, J = 6.6 Hz, 1H), 8.08 (s, 2H), 7.98 (d, J = 8.5 Hz, 1H), 7.83 (d, J = 8.7 Hz, 3H), 7.72 (d, J = 8.4 Hz, 2H), 7.09 (s, 1H), 6.85 (d, J = 5.9 Hz, 1H), 3.86 (t, J = 6.5 Hz, 2H), 3.59 (s, 2H), 1.99 (d, J = 6.6 Hz, 2H), 1.93- 1.86 (m, 2H). MS m/z (ESI): 466.3 [M + H]. TDI01463

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2- yl)(3,3- difluoropyrrolidin-1- yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.41 (s, 1H), 8.20 (d, J = 6.2 Hz, 1H), 8.03 (s, 2H), 7.97-7.56 (m, 6H), 7.13 (s, 1H), 6.90 (d, J = 6.4 Hz, 1H), 4.22- 4.20 (m, 2H), 3.98-3.96 (m, 2H), 2.57-2.55 (m, 2H). MS m/z (ESI): 486.1 [M + H]. TDI01464

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2- yl)(1,7- diazaspiro[3.5]nonan-7- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 8.42 (s, 1H), 8.22 (d, J = 6.0 Hz, 1H), 8.06 (s, 2H), 7.89 (s, 2H), 7.80-7.75 (m 4H), 6.97 (s, 1H), 6.92 (d, J = 5.6 Hz, 1H), 4.14-4.00 (m, 4H), 3.79- 3.64 (m, 2H), 2.57-2.53 (m, 2H), 2.23-2.16 (m, 4H). MS m/z (ESI): 505.3 [M + H]. TDI01465

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- (methylsulfonyl) azetidin- 1-yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.41 (s, 1H), 8.20 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.74 (s, 6H), 7.02 (s, 1H), 6.90 (d, J = 7.2 Hz, 1H), 4.45 (dd, J = 15.5, 11.5 Hz, 4H), 3.06 (s, 3H). MS m/z (ESI): 514.3 [M + H]. TD101468

7-(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indole-2- carbonyl)-1,7- diazaspiro[3.5]nonan- 2-one

¹H NMR (400 MHz, CD₃OD) δ 8.41 (s, 1H), 8.21 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.93-7.82 (m, 3H), 7.79- 7.74 (m, 3H), 6.95 (s, 1H), 6.91 (d, J = 7.2 Hz, 1H), 4.00-3.93 (m, 2H), 3.85-3.76 (m, 2H), 2.81 (s, 2H), 1.99- 1.87 (m, 4H). MS m/z (ESI): 519.3 [M + H]. TDI01472

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) thieno[3,2- d]pyrimidin-2-yl)-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.19 (s, 1H), 10.33 (s, 1H), 8.56 (s, 1H), 8.34 (d, J = 5.6 Hz, 1H), 8.19- 8.08 (m, 3H), 7.90 (d, J = 8.8 Hz, 2H), 7.77 (dd, J = 21.2, 8.4 Hz, 3H), 7.58 (d, J = 5.6 Hz, 1H), 7.01 (s, 1H), 5.03 (s, 2H), 4.61 (s, 2H). MS m/z (ESI): 528.1 [M + H]. TDI01473

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- fluoropyrrolidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.22 (s, 1H), 10.75 (s, 1H), 8.47 (s, 1H), 8.35 (d, J = 6.6 Hz, 1H), 8.09 (s, 2H), 7.97 (d, J = 8.4 Hz, 1H), 7.92- 7.67 (m, 4H), 7.14 (d, J = 22.2 Hz, 1H), 6.87 (d, J = 6.6 Hz, 1H), 4.19- 4.07 (m, 2H), 3.97-3.83 (m, 3H), 3.66 (s, 1H), 2.27 (d, J = 48.5 Hz, 2H). MS m/z (ESI): 468.2 [M + H]. TDI01477

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2- yl)((3S,4R)-3,4- difluoropyrrolidin-1- yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 1H), 8.22 (d, J = 7.2 Hz, 1H), 8.03 (s, 2H), 7.94 (d, J = 8.5 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.76 (s, 4H), 7.17 (s, 1H), 6.92 (d, J = 7.2 Hz, 1H), 5.42 (m, 1H), 5.25 (m, 1H), 4.38 (m, 2H), 4.09 (m, 2H). MS m/z (ESI): 486.3 [M + H]. TDI01478

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2- yl)((3S,4S)-3,4- difluoropyrrolidin-1- yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.52 (s, 1H), 8.29 (d, J = 6.0 Hz, 1H), 8.12 (dd, J = 8.5, 1.4 Hz, 1H), 7.96 (s, 2H), 7.79 (dd, J = 15.2, 8.5 Hz, 3H), 7.64 (d, J = 8.7 Hz, 2H), 7.12 (s, 1H), 6.67 (d, J = 6.0 Hz, 1H), 5.36 (s, 2H), 4.28 (s, 2H), 4.05 (d, J = 18.3 Hz, 2H). MS m/z (ESI): 486.2 [M + H]. TDI01485

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2- yl)(4,4- difluoropiperidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.05 (s, 1H), 10.15 (s, 1H), 8.51 (s, 1H), 8.37 (d, J = 6.1 Hz, 1H), 8.10- 8.04 (m, 3H), 7.82 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.5 Hz, 1H), 7.68 (d, J = 8.5 Hz, 2H), 6.94 (s, 1H), 6.78 (d, J = 6.1 Hz, 1H), 3.87 (br. s, 4H), 2.12 (br. s, 4H). MS m/z (ESI): 500.2 [M + H]. TDI01486

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2- yl)(1,1-difluoro-5- azaspiro[2.4]heptan-5- yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.36 (s, 1H), 8.17 (d, J = 6.8 Hz, 1H), 8.02 (s, 2H), 7.93-7.58 (m, 6H), 7.06 (d, J = 14.4 Hz, 1H), 6.86 (d, J = 6.9 Hz, 1H), 4.18-3.69 (m, 4H), 2.21 (t, J = 32.1 Hz, 2H), 1.57 (s, 2H). MS m/z (ESI): 512.2 [M + H]. TDI01487

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) thieno[3,2- d]pyrimidin-2-yl)-N- (3-fluorocyclobutyl)-1H- indole-2-carboxamide

1H NMR (400 MHz, DMSO-d₆) δ 11.95 (s, 1H), 9.99 (s, 1H), 8.81 (s, 1H), 8.57 (s, 1H), 8.28 (s, 1H), 8.16 (s, 1H), 8.09 (s, 2H), 7.94 (d, J = 6.4 Hz, 2H), 7.76-7.71 (m, 3H), 7.56 (s, 1H), 7.24 (s, 1H), 5.39-5.25 (m, 1H), 4.97-4.84 (m, 1H), 4.69-4.57 (m, 1H), 4.09-4.03 (m, 1H), 2.83-2.73 (m, 2H). MS m/z (ESI): 524.2 [M + H]. TDI01489

N-(1-(6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indole-2- carbonyl)azetidin-3- yl)methanesulfonamide

¹H NMR (400 MHz, CD₃OD) δ 8.43 (s, 1H), 8.22 (d, J = 6.9 Hz, 1H), 8.02 (s, 2H), 7.88 (q, J = 8.6 Hz, 2H), 7.73 (t, J = 8.2 Hz, 4H), 6.96 (s, 1H), 6.87 (d, J = 6.9 Hz, 1H), 4.52 (d, J = 31.4 Hz, 4H), 4.12 (s, 1H), 3.00 (s, 3H). MS m/z (ESI): 529.3 [M + H]. TDI01490

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)aimno) pyrimidin- 2-yl)-1H-indol-2- yl)(6,6-difluoro-3- azabicyclo[3.1.0]hexan- 3-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.08 (s, 1H), 10.30 (s, 1H), 8.50 (s, 1H), 8.35 (s, 1H), 8.06-8.03 (m, 3H), 7.81-7.80 (m, 3H), 7.70 (d, J = 8.0 Hz, 2H), 7.10 (s, 1H), 6.80 (d, J = 5.6 Hz, 1H), 4.25-4.20 (m, 2H), 4.156- 4.13 (m, 1H), 3.90-3.86 (m, 1H), 2.79-2.74 (m 1H), 2.69-2.65 (m, 1H). MS m/z (ESI): 498.2 [M + H]. TDI01495

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)anuno) pyrimidin- 2-yl)-1H-indol-2- yl)(2,5-dihydro-1H- pyrrol-1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 11.93 (s, 1H), 9.67 (s, 1H), 8.59 (s, 1H), 8.38 (d, J = 5.8 Hz, 2H), 8.15 (d, J = 8.5 Hz, 1H), 8.04 (s, 1H), 7.85 (d, J = 8.3 Hz, 2H), 7.74 (d, J = 8.5 Hz, 1H), 7.66 (d, J = 8.5 Hz, 2H), 7.10 (s, 1H), 6.69 (d, J = 5.8 Hz, 1H), 6.03 (s, 2H), 4.70 (br. s, 2H), 4.40 (br, 2H). MS m/z (ESI): 448.2 [M + H]. TDI01497

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2- yl)(1,1- dioxidothiomorpholino) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.13 (s, 1H), 10.41 (s, 1H), 8.48 (s, 1H), 8.36 (d, J = 6.4 Hz, 1H), 8.10- 8.01 (m, 3H), 7.80 (d, J = 8.5 Hz, 3H), 7.70 (d, J = 8.6 Hz, 2H), 6.99 (d, J = 1.6 Hz, 1H), 6.81 (d, J = 6.4 Hz, 1H), 4.16 (br. s, 4H), 3.35 (br, 4H). MS m/z (ESI): 514.2 [M + H]. TDI01498

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino) pyrimidin- 2-yl)-1H-indol-2-yl)(3- (hydroxyimino)azetidin- l-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 8.44 (s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 8.04 (s, 2H), 7.90-7.86 (m, 3H), 7.74- 7.72 (m, 3H), 7.03 (d, J = 12.0 Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 5.83- 5.81 (m, 4H), MS m/z (ESI): 465.2 [M + H].

Example 35: Preparation of 1-(5-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)isoindolin-2-yl)-2-(dimethylamino)ethan-1-one (TDI01364)

Step 1:

Compound TDI01364-1 (1.36 g, 5.82 mmol) and N,N-dimethylaminoacetic acid (500 mg, 4.85 mmol) were dissolved in N,N-dimethylformamide (50 mL), HATU (2.22 g, 5.82 mmol) and diisopropylethylamine (2.5 g, 19.4 mmol) were added, and the reaction was performed at room temperature overnight. LC-MS indicated the reaction was complete. The reaction solution was dissolved in ethyl acetate (250 mL), washed sequentially with water (250 mL×3) and saturated brine (250 mL×2), and the organic phase was dried over anhydrous sodium sulfate, and concentrated to afford compound TDI01364-2 (1.05 g, light yellow oil).

¹H NMR (400 MHz, DMSO-d₆) δ 7.59 (d, J=6.4 Hz, 1H), 7.48 (d, J=8.0 Hz, 1H), 7.34-7.30 (m, 1H), 4.87 (d, J=16.0 Hz, 2H), 4.62 (d, J=16.8 Hz, 2H), 3.15 (s, 2H), 2.25 (s, 6H). MS m/z (ESI): 283.1 [M+H].

Step 2:

Compound TDI01364-2 (1.0 g, 3.55 mmol) and bis(pinacolato)diboron (1.8 g, 7.09 mmol) were dissolved in 1,4-dioxane (100 mL), potassium acetate (1.04 g, 10.64 mmol) and Pd(dppf)Cl₂ (125 mg, 0.18 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 80° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane:methanol=1:0 to 10:1), to afford compound TDI01364-3 (400 mg, light yellow oil).

¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J=14.4 Hz, 2H), 7.30 (d, J=7.2 Hz, 1H), 4.89 (d, J 18.4 Hz, 2H), 4.82 (d, J=4.8 Hz, 2H), 3.25 (s, 2H), 2.42 (s, 6H), 1.35 (s, 12H). MS m/z (ESI): 331.4 [M+H].

Step 3:

Compound TDI01364-3 (115 mg, 0.35 mmol) and Intermediate Reg-1-1 (100 mg, 0.29 mmol) were dissolved in a mixed solution of ethanol/water (10:1) (5 mL), sodium carbonate (62 mg, 0.58 mmol) and Pd(PPh₃)₂Cl₂ (21 mg, 0.03 mmol) were added, purge with argon was performed for 3 times, and the reaction was performed under microwave at 110° C. for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and concentrated under reduced pressure. The residue was dissolved in dimethyl sulfoxide (5 mL), filtered, and the filtrate was purified by liquid chromatography, to afford compound TDI01364 (21.4 mg, white solid).

¹H NMR (400 MHz, DMSO-d₆) δ 13.02 (s, 1H), 9.62 (s, 1H), 8.36-8.30 (m, 2H), 8.28 (d, J 5.6 Hz, 1H), 8.18 (s, 1H), 8.09 (s, 1H), 7.57 (t, J=7.2 Hz, 2H), 7.48 (t, J=8.8 Hz, 1H), 6.68 (d, J=5.6 Hz, 1H), 4.97 (s, 2H), 4.73 (d, J=14.4 Hz, 2H), 3.18 (d, J=7.2 Hz, 2H), 2.27 (d, J=5.6 Hz, 6H). MS m/z (ESI): 414.2 [M+H].

Example 36: Preparation of 5-(4-((1H-indazol-5-yl)amino)pyridin-2-yl)-N-(pyridazin-4-yl)-1H-indole-2-carboxamide (TDI01384)

Step 1:

Compound TDI01384-1 (500 mg, 2.14 mmol), 2-chloro-4-iodopyridine (332 mg, 1.62 mmol), cesium carbonate (2.09 g, 6.42 mmol) and BINAP (68.49 mg, 0.11 mmol) were dissolved in toluene (20 mL), palladium acetate (24.70 mg, 0.11 mmol) was then added, and the reaction was placed in an oil bath at 100° C. for 4 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, and separated by column chromatography (dichloromethane:methanol=100:1˜10:1) to afford compound TDI01384-2 (170 mg, 23.0%, yellow solid). MS m/z (ESI): 345.1 [M+H].

Step 2:

Compound TDI01384-2 (170 mg, 0.493 mmol) and Intermediate TDI01247-1 (178.17 mg, 0.591 mmol) in Example 18 were dissolved in a mixed solution of ethanol/water (8:1) (45 mL), sodium carbonate (156.77 mg, 1.48 mmol) and Pd(PPh₃)₂Cl₂ (17.30 mg, 0.0247 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 110° C. overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure, the residue was diluted with water (40 mL), and the pH was adjusted with 6N HCl to 1. A large amount of solid precipitated, which was filtered, and slurried with methanol to afford compound TDI01384-3 (100 mg, yellow solid, yield 43.2%). MS m/z (ESI): 370.1 [M+H].

Step 3:

Compound TDI01384-3 (90.0 mg, 0.243 mmol) was dissolved in N,N-dimethylformamide (5 mL), HATU (110 mg, 0.29 mmol) and diisopropylethylamine (94.22 mg, 0.73 mmol) were added, and the reaction was performed at room temperature for 30 min. Compound 4-aminopyridazine (27.81 mg, 0.29 mmol) was then added, and the reaction was continued at room temperature overnight. MS indicated the reaction was complete. The reaction solution was concentrated, and the solid was purified by high performance liquid chromatography (trifluoroacetic acid) to afford compound TDI01384 (13.32 mg, yellow solid, yield 12.24%).

¹H NMR (400 MHz, CD₃OD) δ 9.59 (s, 1H), 9.18 (d, J=6.5 Hz, 1H), 8.55 (s, 1H), 8.13 (s, 2H), 7.96-7.91 (m, 1H), 7.84 (s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.58 (s, 1H), 7.47 (d, J=7.4 Hz, 2H), 7.41 (d, J=7.4 Hz, 1H), 7.35 (d, J=8.2 Hz, 1H), 7.08-7.01 (m, 1H). MS m/z (ESI): 447.1 [M+H].

Example 37: Preparation of 9-(6-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)-1H-indole-2-carbonyl)-3,9-diazaspiro[5.5]undecane-3-carboximidamide (TDI01400)

Compound TDI01360 (30.00 mg, 0.059 mmol) in Table 1 of Example 1, compound 1H-pyrazolecarboximidamide (10.42 mg, 0.071 mmol) and diisopropylethylamine (23 mg, 0.178 mmol) were dissolved in N,N-dimethylformamide (1 mL), and the reaction was stirred at ambient temperature overnight. The reaction solution was concentrated under reduced pressure, separated by preparative liquid chromatography, and lyophilized to afford target compound (8.04 mg, yield 24.25%).

¹H NMR (400 MHz, CD₃OD) δ 8.36 (s, 1H), 8.19 (d, J=7.2 Hz, 1H), 8.16 (s, 1H), 7.98 (s, 1H), 7.86 (s, 2H), 7.69 (s, 2H), 6.92 (s, 2H), 3.86 (s, 4H), 3.59-3.40 (m, 4H), 1.70 (s, 6H), 1.37 (s, 2H). MS m/z (ESI): 529.3 [M+H].

Example 38: Preparation of (3,3-difluoroazetidin-1-yl)(1-methyl-6-(4-((4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1H-indol-2-yl)methanone (TDI01698)

Compound TDI01698-1 was synthesized according to step 1 to step 3 of Example 46.

Step 1:

Compound TDI01698-1 (5 g, 13.3 mmol), 2-chloro-4-aminopyrimidine (1.7 g, 13 mmol) and potassium carbonate (5.38 g, 39 mmol) were mixed in a mixed solvent of 1,4-dioxane (100 mL) and water (10 mL), Pd(dppf)Cl₂ (952 mg, 1.3 mmol) was added, the flask was purged with N₂ 3 times, and the reaction solution was heated to reflux and reacted overnight. LC-MS indicated the product was a mixture of target product TDI01698-2 and byproduct TDI01699B. The reaction solution was cooled to room temperature, and filtered to remove salt impurities. The filtrate was concentrated under reduced pressure, and the crude product was separated by preparative flash chromatography (methanol/dichloromethane=0˜4%), to afford compound TDI01698-2 (0.36 g, light brown solid, gross yield: 8%) and TDI01699B (0.1 g, light yellow solid, gross yield: 1.8%).

TDI01698-2: ¹H NMR (400 MHz, DMSO-d₆) δ 8.45 (s, 1H), 8.19 (d, J=5.7 Hz, 1H), 8.14 (d, J=8.4 Hz, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.04 (s, 1H), 6.90 (s, 2H), 6.36 (d, J=5.8 Hz, 1H), 4.84 (s, 2H), 4.58 (s, 2H), 4.00 (s, 3H).

Step 2:

Compound TDI01698-3 (223 mg, 1 mmol) was dissolved in DMF (3 mL), and cooled to 0° C. in an ice-water bath under protection of N₂. NaH (60%, 60 mg, 1.5 mmol) was added, and the reaction was stirred for 0.5 hour before addition of iodomethane (213 mg, 1.5 mmol). The reaction was stirred at room temperature overnight. LC-MS indicated the reaction was complete. Water (20 mL) was added, the mixture was stirred for 10 minutes, and filtered. The filter cake was washed with water (10 mL), dried under reduced pressure to afford compound TDI01698-4 (0.2 g, brown solid, yield: 84%).

¹H NMR (400 MHz, DMSO-d₆) δ 8.17 (s, 1H), 7.88 (s, 1H), 7.52 (s, 4H), 3.85 (s, 3H).

Step 3:

Compound TDI01698-2 (70 mg, 0.2 mmol), compound TDI01698-4 (48 mg, 0.2 mmol) and cesium carbonate (196 mg, 0.6 mmol) were mixed in 1,4-dioxane (3 mL), Pd₂(dba)₃ (37 mg, 0.04 mmol) and Xantphos (69 mg, 0.12 mmol) were added, the flask was purged with N₂ 3 times, and the reaction solution was heated to reflux and reacted overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and filtered to remove salt impurities. The filtrate was concentrated under reduced pressure, and the crude product was separated by preparative HPLC (acetonitrile/water (0.5% TFA)=20˜60%, 30 minutes), to afford compound TDI01698 (10 mg, yellow solid, yield: 8%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.59 (s, 1H), 8.52 (s, 1H), 8.40 (d, J=8.4 Hz, 1H), 8.14 (s, 1H), 8.06 (d, J=8.4 Hz, 1H), 7.88 (s, 1H), 7.82 (d, J=8.3 Hz, 1H), 7.77 (d, J=7.4 Hz, 2H), 7.66 (d, J=8.3 Hz, 2H), 7.12 (s, 1H), 6.85 (d, J=6.7 Hz, 1H), 4.89 (s, 2H), 4.57 (s, 2H), 4.05 (s, 3H), 3.88 (s, 3H). MS m/z (ESI): 500.1 [M+H].

Example 39: Preparation of 1-(6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1H-indole-2-carbonyl)azetidine-3-carboxylic acid (TDI01466)

Step 1:

Compound TDI01466-2 was obtained by reacting Intermediate TDI01434-1, as a starting material, with Intermediate TDI01466-1, according to the synthetic method in step 5 of the synthetic process of TDI01434.

¹H NMR (400 MHz, DMSO-d₆) δ 12.10 (s, 1H), 8.54 (s, 1H), 8.36 (d, J=6.2 Hz, 1H), 8.14-8.02 (m, 3H), 7.92-7.64 (m, 5H), 6.91 (d, J=37.8 Hz, 2H), 4.74 (d, J=8.5 Hz, 1H), 4.61 (s, 1H), 4.31 (t, J=9.3 Hz, 1H), 4.15 (s, 1H), 3.61-3.59 (m, 1H), 3.38 (s, 3H). MS m/z (ESI): 494.2 [M+H].

Step 2:

Compound TDI01466-2 (50 mg, 0.1 mmol) was dissolved in (dichloromethane (10 mL)/water (5 mL)), LiOH (42 mg, 1.0 mmol) was then added, and the reaction was performed at 50° C. for 1 hour. LC-MS indicated the reaction was complete. The solvent was rotary evaporated to dryness, and 5 mL water was added. The mixture was filtered, and purified by preparative chromatography to afford compound TDI01466 (15 mg, yellow solid, 30.0%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.26 (s, 1H), 10.75 (s, 1H), 8.46 (s, 1H), 8.35 (s, 1H), 8.09 (s, 2H), 7.97 (d, J=7.5 Hz, 1H), 7.83-7.74 (m, 5H), 6.99 (s, 1H), 6.87 (s, 1H), 4.75 (s, 1H), 4.62 (s, 1H), 4.31 (s, 1H), 4.16 (s, 1H), 3.60-3.59 (m, 1H). MS m/z (ESI): 480.2 [M+H].

Example 40: Preparation of (5-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)isoindolin-2-yl)(3,3-difluoroazetidin-1-yl)methanone (TDI01467)

Step 1:

Compound 5-bromoisoindoline hydrochloride (5.0 g, 21.3 mmol) was dissolved in tetrahydrofuran (100 mL), di-tert-butyl dicarbonate (9.3 g, 42.6 mmol), diisopropylethylamine (11.0 g, 85.2 mmol) and 4-dimethylaminopyridine (123 mg, 1.06 mmol) were added, and the reaction was performed at room temperature overnight. Thin layer chromatography (petroleum ether/ethyl acetate=5:1) indicated the reaction was complete. The reaction solution was diluted with ethyl acetate (100 mL), and washed sequentially with saturated ammonium chloride (150 mL×2) and saturated sodium chloride (200 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (petroleum ether/ethyl acetate=10:1) to afford compound TDI01467-1 (2.7 g, white solid, yield 42.9%).

¹H NMR (400 MHz, CDCl₃) δ 7.42-7.36 (m, 2H), 7.15-7.08 (m, 1H), 4.63 (t, J=15.2 Hz, 4H), 1.51 (s, 9H).

Step 2:

Compound TDI01467-1 (2.70 g, 9.06 mmol) and bis(pinacolato)diboron (3.45 g, 13.6 mmol) were dissolved in 1,4-dioxane (100 mL), potassium acetate (2.67 g, 27.2 mmol) and Pd(dppf)Cl₂ (666 mg, 0.91 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 100° C. overnight. Thin layer chromatography (petroleum ether/ethyl acetate=5:1) indicated the reaction was complete. The reaction solution was cooled to room temperature, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether/ethyl acetate=10:1) to afford compound TDI01467-2 ((3.0 g, white solid, yield 96.1%)

¹H NMR (400 MHz, CDCl₃) δ 7.72 (s, 1H), 7.71-7.65 (m, 1H), 7.29-7.23 (m, 1H), 4.70-4.62 (m, 4H), 1.52 (s, 9H), 1.35 (s, 12H).

Step 3:

Compound TDI01467-2 (1.00 g, 2.89 mmol) was dissolved in methanol (10 mL), a 3M hydrochloric acid methanol solution (10 mL) was added, and the reaction solution was stirred at room temperature overnight. Thin layer chromatography (petroleum ether/ethyl acetate=5:1) indicated the reaction was complete. The reaction solution was concentrated under reduced pressure to afford compound TDI01467-3 (800 mg, yellow solid, crude product).

¹H NMR (400 MHz, DMSO-d₆) δ 9.95 (s, 1H), 7.71 (s, 1H), 7.65 (d, J=7.6 Hz, 1H), 7.42 (d, J=7.6 Hz, 1H), 4.54-4.47 (m, 4H), 1.17 (s, 12H).

Step 4:

Compound TDI01467-3 (800 mg, 2.84 mmol) was dissolved in tetrahydrofuran (20 mL), diisopropylethylamine (1.47 g, 11.4 mmol) was added, 4-nitrophenyl carbonochloridate (570 mg, 2.84 mmol) was added under ice bath cooling, and the reaction was continued at room temperature overnight. LC-MS indicated the reaction was complete. The reaction solution was diluted with ethyl acetate (50 mL), and successively washed with water (40 mL×2), saturated ammonium chloride (50 mL×2) and saturated sodium chloride (80 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated by column chromatography (petroleum ether/ethyl acetate=10:1) to afford compound TDI01467-4 (670 mg, yellow solid, yield 57.6%)

¹H NMR (400 MHz, CDCl₃) δ 8.32-8.25 (m, 2H), 8.19-8.14 (m, 1H), 7.42-7.37 (m, 2H), 7.36-7.29 (m, 1H), 6.91-6.86 (m, 1H), 4.95 (d, J=15.2 Hz, 2H), 4.85 (d, J=8.0 Hz, 2H), 1.37 (s, 12H). MS m/z (ESI): 411.2 [M+H].

Step 5:

Compound TDI01467-4 (400 mg, 0.98 mmol) and Intermediate TDI01470-a (151 mg, 1.17 mmol) were dissolved in N,N-dimethylformamide (10 mL), diisopropylethylamine (506 mg, 3.92 mmol) was added, and the reaction was performed in an oil bath at 100° C. for 24 hours. LC-MS indicated the reaction was complete. The reaction solution was diluted with ethyl acetate (40 mL), and successively washed with water (50 mL×2), saturated ammonium chloride (80 mL×2) and saturated sodium chloride (100 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated by column chromatography (petroleum ether/ethyl acetate=3:1) to afford compound TDI01467-5 (140 mg, yellow solid, yield 39.4%).

¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J=7.6 Hz, 1H), 7.71 (s, 1H), 7.28 (s, 1H), 4.74 (s, 2H), 4.72 (s, 2H), 4.39 (t, J=12.4 Hz, 4H), 1.35 (s, 12H). MS m/z (ESI): 365.1 [M+H].

Step 6:

Intermediate compound Reg-1-16 (90 mg, 0.174 mmol) and TDI01467-5 (95 mg, 0.262 mmol) were dissolved in a mixed solution of dioxane/water (10:1) (8.8 mL), potassium carbonate (48 mg, 0.348 mmol) and Pd(dppf)Cl₂ (12.7 mg, 0.017 mmol) were added, purge with argon was performed for 3 times, and the reaction was placed in an oil bath at 100° C. overnight. LC-MS indicated the starting material reacted completely. The reaction solution was concentrated under reduced pressure, the crude product was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the reaction was performed at room temperature for 2 hours. LC-MS indicated the reaction was complete. The reaction solution was concentrated under reduced pressure, and the crude product was purified by high performance liquid chromatography to afford compound TDI01467 (11.71 mg, yellow solid, yield 20.9%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.25 (s, 1H), 8.38 (d, J=6.0 Hz, 1H), 8.24 (d, J=7.2 Hz, 2H), 8.06 (d, J=6.0 Hz, 2H), 7.75 (d, J=6.4 Hz, 2H), 7.68 (d, J=7.2 Hz, 2H), 7.53 (d, J=7.6 Hz, 1H), 6.82 (d, J=6.4 Hz, 1H), 4.77 (d, J=6.4 Hz, 4H), 4.49-4.41 (m, 4H). MS m/z (ESI): 474.3 [M+H].

Example 41: Preparation of (5-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)isoindolin-2-yl)(pyridin-4-yl)methanone (TDI01544)

Step 1:

Intermediate compound Reg-1-1 (500 mg, 1.45 mmol) and TDI01544-1 (599 mg, 1.74 mmol) were dissolved in ethanol (30 mL) and water (3 mL), sodium carbonate (459.77 mg, 4.34 mmol) and Pd(PPh₃)₂Cl₂ (50.75 mg, 0.072 mmol) were added, and the reaction was refluxed at 110° C. under protection of nitrogen. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and filtered through Celite. The filtrate was concentrated, and separated by column chromatography (dichloromethane:methanol=100:1˜10:1) to afford compound TDI01544-2 (600 mg, yield 78.50%).

¹H NMR (400 MHz, CDCl₃) δ 8.35 (d, J=5.9 Hz, 1H), 8.33-8.19 (m, 2H), 8.08 (s, 1H), 7.76 (d, J=4.6 Hz, 1H), 7.48 (t, J=14.6 Hz, 2H), 7.39-7.32 (m, 1H), 7.28 (d, J=5.7 Hz, 1H), 4.70 (dd, J=18.6, 8.9 Hz, 4H), 1.54 (s, 9H). MS m/z ESI: 429.3 [M+H].

Step 2:

Compound TDI01544-2 (0.6 g, 1.41 mmol) was dissolved in dichloromethane (20 mL), trifluoroacetic acid (2 mL) was then added, and the reaction was stirred at 30° C. for 3 hours. LC-MS indicated the reaction was complete. The reaction solution was rotary evaporated to dryness to afford TDI01544-3 (0.35 g, brown oil, yield 76.12%).

¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (d, J=6.7 Hz, 1H), 8.22 (d, J=11.8 Hz, 2H), 8.18-8.09 (m, 2H), 7.65 (d, J=9.6 Hz, 2H), 7.56 (d, J=9.0 Hz, 1H), 6.89 (d, J=6.7 Hz, 1H), 4.72-4.57 (m, 4H). MS m/z ESI: 329.1 [M+H].

Step 3:

Compound TDI01544-3 (50 mg, 0.152 mmol) and 4-pyridinecarboxy acid (22.41 mg, 0.182 mmol) were dissolved in N,N-dimethylformamide (5 mL), HATU (69.16 mg, 0.182 mmol) and diisopropylethylamine (58.94 mg, 0.456 mmol) were added, and the reaction was performed at room temperature for 1 hour. LC-MS indicated the reaction was complete. The solvent was evaporated off under reduced pressure, and the crude product was separated by high performance liquid chromatography to afford compound TDI01544 (4.04 mg, yellow solid, yield 6.12%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.38 (s, 1H), 8.87 (s, 1H), 8.73 (s, 1H), 8.34 (dd, J=17.0, 10.2 Hz, 2H), 8.25-8.17 (m, 1H), 8.17-8.06 (m, 3H), 7.57 (ddd, J=42.5, 24.1, 8.5 Hz, 4H), 6.79 (t, J=6.6 Hz, 1H), 4.99 (d, J=9.7 Hz, 2H), 4.93 (d, J=11.8 Hz, 2H). MS m/z ESI: 434.2 [M+H].

The compound in following table 10 was prepared according to a method similar to that described in Example 41.

TABLE 10 Starting material or Compound regent different from Characterization No. Compound Structure Name that in Example 41 Data TD101545

(5-(4-((1H- indazol-5- yl)amino)pyri- midin-2- yl)isoindolin- 2-yl)(pyridin- 3- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.19 (d, J = 16.3 Hz, 1H), 8.79 (s, 3H), 8.35 (dd, J = 12.8, 5.5 Hz, 2H), 8.25 (dd, J = 12.0, 8.2 Hz, 1H), 8.16-8.09 (m, 2H), 7.83 (d, J = 5.3 Hz, 1H), 7.69-7.57 (m, 4H), 6.78 (t, J = 6.8 Hz,1H), 4.97 (d, J = 10.8 Hz, 2H), 4.86 (d, J = 12.1 Hz, 2H). MS: 434.2 [M + H].

Example 42: Preparation of pyridin-4-yl 5-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)isoindoline-2-carboxylate (TDI01535)

Step 1:

Compound TDI01535-1 (46 g, 0.15 mol) and bis(pinacolato)diboron (46 g, 0.18 mol) were dissolved in N,N-dimethylformamide (800 mL), potassium acetate (46 g, 0.47 mol) and Pd(dppf)Cl₂ (10 g, 14 mmol) were added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 110° C. for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (petroleum ether:ethyl acetate=20:1 to 5:1) to afford compound TDI01535-2 (37 g, white solid, yield 73%).

¹H NMR (400 MHz, CDCl₃) δ 7.67-7.72 (m, 2H), 7.22-7.29 (m, 1H), 4.62-4.69 (m, 4H), 1.52 (s, 9H), 1.35 (s, 12H), MS m/z (ESI): 367.9 [M+Na].

Step 2:

Compound TDI01535-2 (5.17 g, 13.9 mmol) and compound Reg-1-16 (4.8 g, 13.9 mmol) were dissolved in a mixed solution of dioxane (100 mL) and water (10 mL), potassium carbonate (5.76 g, 41.7 mmol) was added, and the flask was purged with nitrogen three times. Pd(dppf)Cl₂ (3.05 g, 4.17 mmol) was added, the flask was purged with nitrogen three times again, and the reaction solution was stirred at 110° C. for 16 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (petroleum ether:ethyl acetate=4:1 to pure ethyl acetate) to afford compound TDI01535-3 (2.5 g, off-white solid).

¹H NMR (400 MHz, DMSO-d₆) δ 9.87 (s, 1H), 8.38 (d, J=6.0 Hz, 1H), 8.29-8.24 (m, 2H), 8.05 (s, 2H), 7.76 (d, J=8.4 Hz, 2H), 7.66 (d, J=8.5 Hz, 2H), 7.49 (d, J=4.5 Hz, 1H), 6.76 (d, J=6.0 Hz, 1H), 4.68 (t, J=9.9 Hz, 4H), 1.48 (s, 9H). MS m/z (ESI): 455.0 [M+H].

Step 3:

Compound TDI01535-3 (2.5 g, 5.5 mmol) was dissolved in dichloromethane (20 mL), a hydrochloric acid/dioxane solution (8 mL) was dropwise added, and a large amount of solid precipitated. The reaction was continually stirred at room temperature for 16 h. LC-MS indicated the reaction was complete. The reaction solvent was removed through rotary evaporation under vacuum to afford TDI01535-4 (2.2 g, yellow solid, crude product).

¹H NMR (400 MHz, DMSO-d₆) δ 10.01 (s, 1H), 9.58 (s, 2H), 8.39 (d, J=6.0 Hz, 1H), 8.34 (d, J=8.2 Hz, 2H), 8.04 (s, 2H), 7.76 (d, J=8.4 Hz, 2H), 7.66 (d, J=8.6 Hz, 2H), 7.59 (d, J=7.9 Hz, 1H), 6.80 (d, J=6.0 Hz, 1H), 4.61 (dd, J=10.7, 5.2 Hz, 4H). MS m/z (ESI): 354.7 [M+H].

Step 4:

Compound 4-hydroxypyridine (25 mg, 0.26 mmol) and DNPC (79 mg, 0.26 mmol) were dissolved in N,N-dimethylformamide (4 mL), diisopropylethylamine (134 mg, 1.04 mmol) was added, and the reaction was stirred at room temperature for 1 h. TDI01535-4 (92 mg, 0.26 mmol) was added, and the reaction was stirred at room temperature for 16 h. LC-MS indicated the reaction was complete, the reaction solvent was removed through rotary evaporation under vacuum, and the residue was purified by preparative liquid chromatography to afford compound TDI01535 (18.8 mg, yield 15.2%)

¹H NMR (300 MHz, DMSO-d₆) δ 10.45 (s, 1H), 8.35 (d, J=6.4 Hz, 1H), 8.19 (dd, J=23.5, 7.2 Hz, 4H), 8.04 (s, 2H), 7.69 (dd, J=20.8, 8.4 Hz, 4H), 7.56 (d, J=7.3 Hz, 1H), 6.85 (s, 1H), 6.42-6.33 (m, 2H), 4.99 (d, J=7.3 Hz, 4H). MS m/z (ESI): 475.6 [M+H].

The compounds in following table 11 were prepared according to methods similar to that described in Example 42.

TABLE 11 Starting material or regent No. Compound Structure Compound Name different from that in Example 42 Characterization Data TDI01543

pyridin-4-yl 5-(4- ((1H-indazol-5- yl)amino)pyrimidin- 2-yl)isoindoline-2- carboxylate

¹H NMR (300 MHz, DMSO-d₆) δ 13.04 (s, 1H), 10.16 (s, 1H), 8.34-8.18 (m, 3H), 8.15-7.99 (m, 4H), 7.57 (t, J = 7.5 Hz, 3H), 6.73 (d, J = 6.0 Hz, 1H), 6.23 (d, J = 7.3 Hz, 2H), 4.97 (d, J = 7.0 Hz, 4H). MS m/z (ESI): 449.6 [M + H]. TDI01551

pyrrolidin-3-yl 5-(4- ((4-(1H-pyrazol-4- yl)phenyl)amino)py- rimidin-2- yl)isoindoline-2- carboxylate

¹H NMR (300 MHz, DMSO-d₆) δ 11.88 (s, 1H), 8.96 (s, 3H), 8.41-8.15 (m, 6H), 7.78 (d, J = 15.8 Hz, 4H), 7.62 (t, J = 9.2 Hz, 1H), 7.20 (s, 1H), 6.98 (d, J = 6.7 Hz, 1H), 4.80 (d, J = 23.1 Hz, 4H), 3.72-3.51 (m, 2H), 3.44-3.28 (m, 1H), 3.18 (s, 2H), 2.95 (d, J = 31.8 Hz, 4H), 2.05 (dd, J = 21.5, 12.2 Hz, 4H), 1.75 (d, J = 48.5 Hz, 4H). MS m/z (ESI): 467.8 [M + H]. TDI01552

1-methylpyrrolidin- 3-yl5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)py- rimidin-2- yl)isoindoline-2- carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 10.07 (s, 1H), 9.95 (s, 1H), 8.38 (d, J = 6.0 Hz, 1H), 8.31 (s, 1H), 8.04 (s, 2H), 7.75 (d, J = 6.1 Hz, 2H), 7.68-7.63 (m, 2H), 7.54-7.49 (m, 1H), 6.77 (d, J = 6.0 Hz, 1H), 5.31 (s, 1H), 4.83-4.72 (m, 4H), 3.75 (d, J = 7.5 Hz, 3H), 3.35-3.26 (m, 2H), 2.95 (d, J = 4.2 Hz, 2H), 2.88 (d, J = 4.1 Hz, 2H). MS m/z (ESI): 482.0 [M + H]. TDI01555

(5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)py- rimidin-2- yl)isoindolin-2- yl)(4-(oxetan-3- yl)piperazin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.82 (s, 1H), 9.68 (s, 1H), 8.38 (d, J = 5.9 Hz, 1H), 8.29 (d, J = 7.7 Hz, 2H), 8.04 (s, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.3 Hz, 1H), 6.72 (d, J = 5.9 Hz, 1H), 4.80 (d, J = 10.0 Hz, 4H), 4.53 (d, J = 34.5 Hz, 4H), 3.47 (s, 1H), 3.33 (s, 4H), 2.33 (s, 4H). MS m/z (ESI): 522.8 [M + H]. TDI01557

N-(4-(1H-pyrazol-4- yl)phenyl)-2- (isoindolin-5- yl)pyrimidin-4- amine Intermediate TDI01535-4 ¹H NMR (400 MHz, DMSO-d₆) δ 10.01 (s, 1H), 9.58 (s, 2H), 8.39 (d, J = 6.0 Hz, 1H), 8.34 (d, J = 8.2 Hz, 2H), 8.04 (s, 2H), 7.76 (d, J = 8.4 Hz, 2H), 7.66 (d, J = 8.6 Hz, 2H), 7.59 (d, J = 7.9 Hz, 1H), 6.80 (d, J = 6.0 Hz, 1H), 4.61 (dd, J = 10.7, 5.2 Hz, 4H). MS m/z (ESI): 354.7 [M + H]. TDI01557B

tert-butyl 5-(4-((4- (1H-pyrazol-4- yl)phenyl)amino)py- rimidin-2- yl)isoindoline-2- carboxylate Intermediate TDI01535-3 ¹H NMR (400 MHz, DMSO-d₆) δ 9.87 (s, 1H), 8.38 (d, J = 6.0 Hz, 1H), 8.29-8.24 (m, 2H), 8.05 (s, 2H), 7.76 (d, J = 8.4 Hz, 2H), 7.66 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 4.5 Hz, 1H), 6.76 (d, J = 6.0 Hz, 1H), 4.68 (t, J = 9.9 Hz, 4H), 1.48 (s, 9H). MS m/z (ESI): 455.0 [M + H]. TDI01571B

tert-butyl 6-(4-((4- (1H-pyrazol-4- yl)phenyl)amino)py- rimidin-2-yl)-1,1- dimethylisoindoline- 2-carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 8.39 (d, J = 6.2 Hz, 1H), 8.18 (s, 3H), 8.06 (s, 2H), 7.74 (s, 2H), 7.67 (s, 2H), 7.50 (s, 1H), 6.80 (s, 1H), 4.67 (d, J = 8.5 Hz, 2H), 1.67 (d, J = 5.9 Hz, 6H), 1.49 (d, J = 12.9 Hz, 9H). MS m/z (ESI): 482.8 [M + H]. TDI01562

3,3- difluorocyclobutyl 5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)py- rimidin-2- yl)isoindoline-2- carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 9.73 (s, 1H), 8.37 (d, J = 5.7 Hz, 1H), 8.33-8.27 (m, 2H), 8.03 (s, 2H), 7.76 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 8.3 Hz, 2H), 7.60-7.36 (m, 2H), 6.73 (d, J = 5.8 Hz, 1H), 4.75 (dd, J = 23.4, 12.7 Hz, 4H), 3.12-3.05 (m, 2H), 2.76 (td, J = 13.6, 6.6 Hz, 2H). MS m/z (ESI): 489.0 [M + H]. TDI01580

3,3- difluorocyclobutyl 5-(4-((1H-indazol-5- yl)amino)pyrimidin- 2-yl)isoindoline-2- carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 13.15 (s, 1H), 10.43 (s, 1H), 8.34 (d, J = 6.3 Hz, 1H), 8.21 (d, J = 10.8 Hz, 2H), 8.13 (s, 2H), 7.62 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 4.1 Hz, 2H), 6.80 (d, J = 6.1 Hz, 1H), 4.92 (s, 1H), 4.76 (dd, J = 22.3, 7.3 Hz, 4H), 3.12-3.05 (m, 2H), 2.79-2.71 (m, 2H). MS m/z (ESI): 462.6 [M + H]. TDI01609

3,3- difluorocyclobutyl 5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2- yl)isoindoline-2- carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 9.68 (s, 1H), 8.47 (s, 1H), 8.22 (d, J = 8.9 Hz, 2H), 8.07 (s, 2H), 7.88 (d, J = 7.8 Hz, 2H), 7.63 (dd, J = 26.8, 8.6 Hz, 2H), 7.47 (d, J = 7.7 Hz, 1H), 4.92 (s, 1H), 4.73 (dd, J = 23.6, 12.3 Hz, 4H), 3.09 (d, J = 6.9 Hz, 2H), 2.81-2.69 (m, 2H). MS m/z (ESI): 506.5 [M + H]. TDI01613

3,3- difluorocyclobutyl 5-(4-((1H-indazol-5- yl)amino)-5- fluoropyrimidin-2- yl)isoindoline-2- carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 13.04 (s, 1H), 9.72 (s, 1H), 8.44 (s, 1H), 8.19 (t, J = 8.9 Hz, 3H), 8.12 (s, 1H), 7.73 (d, J = 7.7 Hz, 1H), 7.59 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 5.9 Hz, 1H), 4.91 (s, 1H), 4.71 (dd, J = 22.7, 9.6 Hz, 4H), 3.07 (d, J = 5.1 Hz, 2H), 2.75 (dd, J = 13.2, 6.9 Hz, 2H). MS m/z (ESI): 480.7 [M + H]. TDI01620

(1s,4s)-quinuclidin- 3-yl6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)py- rimidin-2-yl)-3,4- dihydroisoquinoline- 2(1H)-carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 10.34 (s, 1H), 9.68 (s, 1H), 8.37 (d, J = 6.3 Hz, 1H), 8.11 (d, J = 7.7 Hz, 3H), 8.06 (s, 2H), 7.74 (d, J = 8.3 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.42 (s, 1H), 6.82 (d, J = 6.2 Hz, 1H), 4.94 (s, 1H), 4.77-4.62 (m, 2H), 3.78- 3.59 (m, 4H), 3.35-3.23 (m, 3H), 3.19 (s, 2H), 2.95 (s, 2H), 2.29 (s, 1H), 2.07 (s, 1H), 1.96-1.72 (m, 3H). MS m/z (ESI): 521.8 [M + H]. TDI01621

3,3- difluorocyclobutyl 6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)py- rimidin-2-yl)-3,4- dihydroisoquinoline- 2(1H)-carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 10.55 (s, 1H), 8.37 (d, J = 6.5 Hz, 1H), 8.08 (s, 4H), 7.70 (t, J = 7.7 Hz, 4H), 7.43 (d, J = 7.5 Hz, 1H), 6.85 (d, J = 6.6 Hz, 1H), 4.87 (s, 1H), 4.67 (d, J = 24.4 Hz, 2H), 3.68 (s, 2H), 3.04 (dt, J = 14.7, 7.5 Hz, 2H), 2.94 (s, 2H), 2.73 (dt, J = 19.4, 12.3 Hz, 2H). MS m/z (ESI): 503.1 [M + H]. TDI01634

2- azaspiro[3.3]heptan- 6-yl 5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)py- rimidin-2- yl)isoindoline-2- carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 9.91 (s, 1H), 8.57 (s, 2H), 8.38 (d, J = 5.7 Hz, 1H), 8.32-8.25 (m, 2H), 8.05 (s, 2H), 7.76 (d, J = 7.8 Hz, 2H), 7.66 (d, J = 8.0 Hz, 2H), 7.50 (s, 1H), 6.77 (s, 1H), 4.88-4.84 (m, 1H), 4.72 (t, J = 12.9 Hz, 4H), 4.00 (d, J = 19.8 Hz, 4H), 2.68 (s, 2H), 2.33 (s, 2H). MS m/z (ESI): 493.9 [M + H] TDI01656

4,4- difluorocyclohexyl 6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)py- rimidin-2-yl)-3,4- dihydroisoquinoline- 2(1H)-carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 10.62 (s, 1H), 8.37 (d, J = 6.5 Hz, 1H), 8.08 (s, 4H), 7.70 (t, J = 6.7 Hz, 4H), 7.45 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 6.6 Hz, 1H), 4.84 (s, 1H), 4.66 (s, 2H), 3.68 (s, 2H), 2.94 (s, 2H), 2.10-1.91 (m, 4H), 1.91-1.70 (m, 4H). MS m/z (ESI): 531.1 [M + H]. TDI01667

3,3- difluorocyclobutyl 7-(5-fluoro-4-((6- methoxy-1-indazol- 5- yl)amino)pyrimidin- 2-yl)-3,4- dihydroisoquinoline- 2(1H)-carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 12.95 (s, 1H), 8.82 (s, 1H), 8.40 (d, J = 3.4 Hz, 1H), 8.16 (d, J = 9.3 Hz, 1H), 8.01 (s, 1H), 7.95 (s, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.23 (d, J = 7.9 Hz, 1H), 7.10 (s, 1H), 4.84 (d, J = 5.1 Hz, 1H), 4.58 (d, J = 34.7 Hz, 2H), 3.87 (s, 3H), 3.60 (s, 2H), 3.11-2.95 (m, 2H), 2.82 (s, 2H), 2.73 (d, J = 11.8 Hz, 2H). MS m/z (ESI): 524.7 [M + H].

TDI01672

3,3- difluorocyclobutyl 5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2- yl)indoline-1- carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 9.56 (s, 1H), 8.85 (s, 1H), 8.41 (s, 1H), 8.36 (d, J = 3.5 Hz, 1H), 8.01-7.89 (m, 4H), 7.81 (d, J = 8.4 Hz, 2H), 6.52 (d, J = 8.2 Hz, 1H), 6.01 (s, 1H), 5.25-5.19 (m, 1H), 3.51 (t, J = 8.3 Hz, 2H), 3.23-3.18 (m, 2H), 3.07- 2.96 (m, 4H). MS m/z (ESI): 506.5 [M + H].

TDI01951

5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)py- rimidin-2-yl)-N-(3,3- difluorocyclobutyl) isoindoline-2- carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 10.46 (s, 1H), 8.39 (d, J = 6.4 Hz, 1H), 8.25-8.17 (m, 2H), 8.08 (s, 2H), 7.72 (dd, J = 21.9, 8.6 Hz, 4H), 7.56 (d, J = 8.0 Hz, 1H), 6.84 (t, J = 6.2 Hz, 2H), 4.71 (d, J = 4.7 Hz, 4H), 4.12-4.03 (m, 1H), 2.87 (ddd, J = 14.2, 9.8, 3.7 Hz, 2H), 2.70 (dt, J = 19.0, 6.6 Hz, 2H). MS m/z (ESI): 487.8 [M + H]. TDI01957

(7-(4-((4-(1H- pyrazol-4- yl)phenylamino)py- rimidin-2-yl)-3,4- dihydroisoquinolin- 2(1H)-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.54 (s, 0H), 8.37 (d, J = 8.0 Hz, 1H), 8.08-8.05 (m, 4H), 7.74-7.67 (m, 4H), 7.41 (d, J = 8.0 Hz, 1H), 6.85 (d, J = 8.0 Hz, 1H), 4.57 (s, 2H), 4.41 (t, J = 13.0 Hz, 4H), 3.55 (t, J = 6.0 Hz, 2H), 2.91 (t, J = 6.0 Hz, 2H). MS m/z (ESI): 487.6 [M + H]. TDI01959

(6-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)py- rimidin-2-yl)-3,4- dihydroisoquinolin- 2(1H)-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (300 MHz, DMSO-d₆) δ 12.89 (s, 1H), 9.68 (s, 1H), 8.34 (d, J = 5.8 Hz, 1H), 8.14 (d, J = 5.1 Hz, 2H), 8.01 (s, 2H), 7.75 (d, J = 8.2 Hz, 2H), 7.62 (d, J = 8.2 Hz, 2H), 7.32 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 5.9 Hz, 1H), 4.53 (s, 2H), 4.40 (t, J = 12.9 Hz, 4H), 3.55 (s, 2H), 2.92 (s, 2H). MS m/z (ESI): 488.1 [M + H]. TDI01974

5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)furo [3,2-d]pyrimidin-2- yl)-N,N- dimethylisoindoline- 2-carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 10.01 (s, 1H), 8.39 (d, J = 2.2 Hz, 1H), 8.31 (d, J = 5.7 Hz, 2H) 8.06 (s, 2H), 7.95 (d, J = 8.6 Hz, 2H), 7.67 (d, J = 8.6 Hz, 2H), 7.43 (d, J = 8.4 Hz, 1H), 7.13 (d, J = 2.2 Hz, 1H), 4.78 (d, J = 13.9 Hz, 4H), 2.87 (s, 6H). MS m/z (ESI): 466.0 [M + H]. TDI01861

5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)furo [3,2-d]pyrimidin-2- yl)-N- isopropylisoindoline- 2-carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 10.09 (s, 1H), 8.41 (s, 1H), 8.33-8.27 (m, 2H), 8.07 (s, 2H), 7.93 (d, J = 8.2 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 7.9 Hz, 1H), 7.15 (s, 1H), 6.04 (d, J = 6.7 Hz, 2H), 4.66 (d, J = 11.8 Hz, 4H), 3.83 (s, 1H), 1.12 (d, J = 6.5 Hz, 6H). MS m/z (ESI): 479.9 [M + H].

Example 43: Preparation of N-(4-(1H-pyrazol-4-yl)phenyl)-2-(2-(ethylsulfonyl)isoindolin-5-yl)pyrimidin-4-amine (TDI01558)

Step 1:

Compound TDI01557 (80 mg, 0.224 mmol) was dissolved in N,N-dimethylformamide (5 mL), diisopropylethylamine (144 mg, 1.12 mmol) and ethanesulfonyl chloride (28 mg, 0.224 mmol) were added, and the reaction was stirred at room temperature for 16 h. LC-MS indicated the reaction was complete. The reaction solvent was removed through rotary evaporation under vacuum, and the residue was purified by preparative liquid chromatography to afford compound TDI01558 (65 mg, yield 65%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.38 (d, J=6.3 Hz, 1H), 8.25 (d, J=9.6 Hz, 2H), 8.06 (s, 2H), 7.71 (dd, J=28.0, 8.4 Hz, 4H), 7.54 (d, J=7.9 Hz, 1H), 6.83 (d, J=5.4 Hz, 1H), 4.78 (d, J=10.1 Hz, 4H), 3.23 (q, J=7.4 Hz, 2H), 1.25 (t, J=7.4 Hz, 3H). MS m/z (ESI): 447.1 [M+H].

The compound in following table 12 was prepared according to a method similar to that described in Example 43.

TABLE 12 TDI01559

benzyl 5-(4- ((4-(1H- pyrazol- 4-yl) phenyl) amino) pyrimi- din-2- yl)isoin- dolin-2- car- boxylate

¹H NMR (400 MHz, DMSO-d₆) δ 10.30 (s, 2H), 8.38 (d, J = 6.3 Hz, 1H), 8.24 (d, J = 9.2 Hz, 2H), 8.06 (s, 2H), 7.72 (dd, J = 27.9, 7.6 Hz, 4H), 7.55 (t, J = 9.1 Hz, 1H), 7.39 (ddd, J = 23.8, 13.8, 7.0 Hz, 5H), 6.83 (d, J = 6.0 Hz, 1H), 5.18 (s, 2H), 4.80 (dd, J = 21.6, 10.7 Hz, 4H). MS m/z (ESI): 489.0 [M + H].

Example 44: Preparation of (5-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)isoindolin-2-yl)(7-azaspiro[3.5]nonan-2-yl)methanone (TDI01546)

The synthesis of Step 1 to Step 3 of Example 44 was performed according to Step 1 to Step 2 of Example 42.

Step 4:

Compound TDI01546-4 (30 mg, 0.085 mmol) and HATU (39 mg, 0.102 mmol) were dissolved in N,N-dimethylformamide (3 mL), 7-(tert-butoxycarbonyl)-7-azaspiro[3,5]nonane-2-carboxylic acid (23 mg, 0.085 mmol) and diisopropylethylamine (32 mg, 0.255 mmol) were added, and the reaction was stirred at room temperature for 2 h. The reaction solution was diluted with water (10 mL), extracted with dichloromethane (20 mL, x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (dichloromethane:methanol=20:1) to afford compound TDI01546-5 (43 mg, yellow oil, crude product).

MS m/z (ESI): 605.8 [M+H]

Step 5:

Compound TDI01546-5 (43 mg, 0.071 mmol) was dissolved in dichloromethane (5 mL), a hydrochloric acid/dioxane solution (3 mL) was added, and the reaction was performed at room temperature for 16 h. The reaction solution was concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography to afford compound TDI01546 (17 mg, yellow solid, yield 48%).

¹H NMR (301 MH-z, DMSO-d₆) δ 10.22 (s, 1H), 8.38 (d, J=5.6 Hz, 2H), 8.30-8.16 (m, 2H), 8.06 (s, 2H), 7.71 (dd, J=24.1, 7.0 Hz, 4H), 7.59-7.46 (m, 1H), 6.81 (d, J=5.9 Hz, 1H), 4.82 (s, 2H), 4.73 (d, J=8.6 Hz, 2H), 3.45-3.27 (m, 1H), 2.99 (d, J=28.4 Hz, 4H), 2.21-1.95 (m, 4H), 1.80 (s, 2H), 1.65 (s, 2H). MS m/z (ESI): 505.8 [M+H].

The compounds in following table 13 were prepared according to methods similar to that described in Example 44.

TABLE 13 Starting material or regent different from No. Compound Structure Compound Name that in Example 44 Characterization Data TDI01553

5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)-2-prolylisoindoline

¹H NMR (400 MHz, DMSO-d₆) δ 10.07 (s, 1H), 9.41 (s, 1H), 8.67 (s, 1H), 8.52-8.22 (m, 3H), 8.05 (s, 2H), 7.86-7.52 (m, 4H), 6.80 (d, J = 6.1 Hz, 1H), 5.11-4.76 (m, 4H), 4.56 (s, 1H), 3.28 (dd, J = 31.9, 5.1 Hz, 2H), 2.54 (s, 2H), 1.97 (s, 2H). MS m/z (ESI): 451.7 [M + H]. TDI01554

1-(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2-yl)-2,6- diaminohexan-1-one

¹HNMR(400 MHz, DMSO-d₆) δ 9.72 (s, 1H), 8.39-8.31 (m, 5H), 8.28 (s, 2H), 8.04 (s, 1H), 7.77 (d, J = 7.1 Hz, 2H), 7.65 (d, J = 8.5 Hz, 2H), 7.58-7.47 (m, 1H), 6.74 (d, J = 5.9 Hz, 1H), 5.11 (s, 1H), 4.94 (s, 1H), 4.82-4.71 (m, 3H), 3.64 (s, 1H), 3.51 (s, 7H), 2.78 (s, 2H), 1.56 (t, J = 37.2 Hz, 8H). MS m/z (ESI): 482.8 [M + H]. TDI01560

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2- yl)(tetrahydro-2H-pyran-4- yl)methanone

¹H NMR (301 MHz, DMSO-d₆) δ 10.50 (s, 1H), 8.38 (d, J = 4.8 Hz, 1H), 8.29-8.15 (m, 2H), 8.08 (s, 2H), 7.84-7.64 (m, 4H), 7.56 (t, J = 6.7 Hz, 1H), 6.85 (d, J = 6.3 Hz, 1H), 5.04 (s, 2H), 4.74 (d, J = 7.7 Hz, 2H), 3.90 (d, J = 10.7 Hz, 2H), 3.41 (s, 2H), 2.83 (d, J = 4.7 Hz, 1H), 1.66 (s, 4H). MS m/z (ESI): 466.8 [M + H]. TDI01561

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2-yl)(3- hydroxycyclobutyl) methanone

¹HNMR(400 MHz, DMSO-d₆) δ 8.38 (d, J = 6.2 Hz, 1H), 8.27 (s, 3H), 8.07 (s, 1H), 7.75 (s, 2H), 7.68 (s, 2H), 7.53 (s, 2H), 6.80 (s, 2H), 4.87 (d, J = 8.2 Hz, 2H), 4.73 (d, J = 12.8 Hz, 2H), 4.02 (s, 2H), 2.79 (s, 1H), 2.45 (d, J = 6.6 Hz, 1H), 2.02 (dd, J = 19.8, 9.6 Hz, 4H). MS m/z (ESI): 452.8 [M + H]. TDI01563

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2-yl)(1- (oxetan-3-yl)piperidin-4- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.31 (s, 1H), 10.03 (s, 1H), 8.39 (dd, J = 6.1, 1.7 Hz, 1H), 8.34-8.24 (m, 2H), 8.05 (d, J = 3.5 Hz, 2H), 7.76 (d, J = 5.7 Hz, 2H), 7.71- 7.62 (m, 2H), 7.57-7.50 (m, 1H), 6.79 (d, J = 5.3 Hz, 1H), 5.05 (d, J = 4.7 Hz, 2H), 4.83- 4.68 (m, 6H), 4.40 (s, 1H), 3.48 (d, J = 11.3 Hz, 2H), 2.90 (s, 3H), 2.06 (d, J = 14.0 Hz, 2H), 1.89 (dd, J = 25.6, 12.8 Hz, 2H). MS m/z (ESI): 521.8 [M + H]. TDI01570

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2-yl)(3,3- difluoro-1- methylcyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.20 (s, 1H), 8.38 (d, J = 6.1 Hz, 1H), 8.25 (dd, J = 14.0, 5.5 Hz, 2H), 8.06 (s, 2H), 7.81-7.63 (m, 4H), 7.54 (dd, J = 20.3, 7.9 Hz, 1H), 6.81 (d, J = 5.7 Hz, 1H), 4.91-4.77 (m, 4H), 3.16 (d, J = 16.0 Hz, 2H), 2.56 (s, 2H), 1.49 (s, 3H). MS m/z (ESI): 486.6 [M + H]. TD101575

(7-(4-((1H-indazol-5- yl)amino)pyrimidin-2-yl)- 3,4-dihydroisoquinolin- 2(1H)-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.85 (s, 1H), 8.34 (d, J = 8.0 Hz, 1H), 8.19-8.02 (m, 4H), 7.66-7.63 (m, 1H), 7.55 (d, J = 8.0 1H), 7.42 (t, J = 8.0 Hz, 1H), 6.85 (t, J = 8.0 Hz, 1H), 4.73 (d, J = 8.0 Hz, 2H), 3.77- 3.66 (m, 2H), 3.46-3.35 (m, 1H), 3.00- 2.69 (m, 6H). MS m/z (ESI): 460.7 [M + H].

TDI01588

3-(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2-yl)-3- oxopropanenitrile

¹H NMR (400 MHz, DMSO-d₆) δ 10.03 (s, 1H), 8.38 (d, J = 6.0 Hz, 1H), 8.31-8.23 (m, 2H), 8.05 (s, 2H), 7.74 (s, 2H), 7.67 (d, J = 5.0 Hz, 2H), 7.57-7.52 (m, 1H), 6.78 (d, J = 5.8 Hz, 1H), 4.90 (d, J = 7.1 Hz, 2H), 4.77 (d, J = 14.1 Hz, 2H), 4.11 (s, 2H). MS m/z (ESI): 422.1 [M + H]. TDI01594

1-(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2- yl)isoindolin-2-yl)-2- methoxypropan-1-one

¹H NMR (400 MHz, DMSO-d₆) δ 9.69 (s, 1H), 8.48 (s, 1H), 8.27-8.21 (m, 2H), 8.07 (s, 2H), 7.92-7.85 (m, 2H), 7.67 (d, J = 5.9 Hz, 2H), 7.48 (t, J = 8.2 Hz, 1H), 5.03 (d, J = 10.7 Hz, 1H), 4.93 (d, J = 8.7 Hz, 1H), 4.79-4.72 (m, 2H), 4.21-4.17 (m, 1H), 3.25 (s, 3H), 1.28 (d, J = 6.4 Hz, 3H). MS m/z (ESI): 458.7 [M + H].

TD101594B

1-(4-(4-((5-fluoro-2-(2-(2- methoxypropanoyl) isoindolin- 5-yl)pyrimidin-4- yl)amino)phenyl)-1H- pyrazol-1-yl)-2- methoxypropan-1-one

¹H NMR (400 MHz, DMSO-d₆) δ 9.74 (d, J = 41.4 Hz, 1H), 8.91-8.50 (d, J = 9.6 Hz, 2H) 8.27-8.20 (m, 2H), 8.07 (s, 1H), 7.99- 7.94 (m, 1H), 7.87 (d, J = 6.7 Hz, 2H), 7.67 (d, J = 6.0 Hz, 1H), 7.48 (t, J = 8.4 Hz, 1H), 5.07 (d, J = 16.9 Hz, 1H), 4.93 (d, J = 9.7 Hz, 1H), 4.81-4.72 (m, 2H), 4.22-4.17 (m, 2H), 3.29 (d, J = 31.0 Hz, 6H), 1.48-1.22 (m, 6H). MS m/z (ESI): 544.5 [M + H].

TDI01597B

1-(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2-yl)-2- (tetrahydrofuran-3-yl)ethan- 1-one

¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (d, J = 6.4 Hz, 1H), 8.28-8.23 (m, 2H), 8.06 (s, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 6.4 Hz, 2H), 7.54 (t, J = 8.4 Hz, 1H), 6.80 (d, J = 6.2 Hz, 1H), 4.93 (d, J = 6.7 Hz, 2H), 4.74 (d, J = 12.7 Hz, 3H), 3.88 (t, J = 6.7 Hz, 2H), 3.75 (dd, J = 13.5, 8.3 Hz, 2H), 3.65 (dd, J = 15.2, 7.5 Hz, 2H), 3.31 (d, J = 7.3 Hz, 1H), 2.08 (s, 1H), 1.56 (s, 1H). MS m/z (ESI): 466.8 [M + H]. TDI01618A

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2- yl)indolin-1-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.68 (s, 1H), 8.44 (d, J = 3.6 Hz, 1H), 8.21-8.10 (m, 3H), 8.07 (s, 2H), 7.87 (d, J = 8.4 Hz, 2H), 7.66 (d, J = 8.4 Hz, 2H), 4.12 (t, J = 8.0 Hz, 2H), 3.38-3.32 (m, 1H), 3.23 (t, J = 8.5 Hz, 2H), 2.92-2.84 (m, 4H). MS m/z (ESI): 491.1 [M + H].

TDI01628

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2- yl)isoindolin-2-yl)(3,3- difluoro-1- methylcyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.68 (s, 1H), 8.48 (s, 1H), 8.28-8.19 (m, 2H), 8.07 (s, 2H), 7.93-7.83 (m, 2H), 7.73-7.63 (m, 2H), 7.46 (dd, J = 20.5, 7.8 Hz, 1H), 4.81 (dd, J = 31.0, 11.6 Hz, 4H), 3.20-3.09 (m, 2H), 2.54 (s, 2H), 1.49 (s, 3H). MS m/z 505.0 [M + H].

TDI01655

(7-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2-yl)-3,4- dihydroisoquinolin-2(1H)- yl)(3,3-difluoro-1- methylcyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.67 (s, 1H), 8.96 (s, 1H), 8.46 (s, 1H), 8.12 (d, J = 45.0 Hz, 4H), 7.88 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 7.6 Hz, 2H), 7.31 (d, J = 7.8 Hz, 1H), 4.71 (s, 1H), 4.57 (s, 1H), 3.72 (s, 1H), 3.57 (s, 1H), 3.12-3.06 (m, 2H), 2.89 (d, J = 24.0 Hz, 2H), 2.65 (d, J = 15.8 Hz, 2H), 1.43 (d, J = 28.2 Hz, 3H). MS m/z (ESI): 518.6 [M + H].

TDI01657

(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2-yl)-3,4- dihydroisoquinolin-2(1H)- yl)(4,4- difluorocyclohexyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.68 (s, 1H), 8.46 (d, J = 3.3 Hz, 1H), 8.09 (d, J = 8.0 Hz, 2H), 8.06 (s, 1H), 7.87 (d, J = 8.5 Hz, 2H), 7.84-7.78 (m, 1H), 7.65 (d, J = 8.1 Hz, 1H), 7.58-7.49 (m (m, 1H), 7.32 (d, J = 8.2 Hz, 1H), 4.67 (s, 2H), 3.80-3.72 (m, 2H), 2.97-2.93 (m, 2H), 2.04-1.86 (m, 5H), 1.81-1.71 (m, 2H), 1.67-1.56 (m, 2H). MS m/z (ESI): 533.1 [M + H].

TDI01658

(7-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-5- fluoropydin-2-yl)-3,4- dihydroisoquinolin-2(1H)- yl)(4,4- difluorocyclohexyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.66 (s, 1H), 8.96 (s, 1H), 8.46 (s, 1H), 8.09 (t, J = 22.0 Hz, 4H), 7.88 (d, J = 6.7 Hz, 2H), 7.65 (d, J = 8.1 Hz, 2H), 7.31 (d, J = 6.2 Hz, 1H), 4.85 (s, 1H), 4.70 (s, 1H), 3.80 (s, 1H), 3.71 (s, 1H), 3.10 (d, J = 6.1 Hz, 2H), 2.83 (s, 1H), 2.10-1.86 (m, 4H), 1.77 (s, 2H), 1.62 (d, J = 12.6 Hz, 2H). MS m/z (ESI): 532.6 [M + H].

TDI01665

(8-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2-yl)-2,3- dihydrobenzo[f](1,4] oxazepin- 4(5H)-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.72 (s, 1H), 8.48 (s, 1H), 8.09 (s, 2H), 7.94-7.89 (m, 1H), 7.85 (d, J = 8.5 Hz, 2H), 7.79 (s, 1H), 7.66 (d, J = 8.3 Hz, 2H), 7.48 (dd, J = 72.6, 7.7 Hz, 1H), 4.67 (d, J = 12.0 Hz, 2H), 4.18 (s, 2H), 3.90 (s, 2H), 3.28 (dd, J = 19.2, 7.3 Hz, 1H), 2.76 (dd, J = 27.6, 14.9 Hz, 4H). MS m/z (ESI): 520.6 [M + H].

TDI01674

1-(6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)-3,4 dihydroisoquinolin-2(1H)- yl)-2-hydroxypropan-1-one

¹H NMR (400 MHz, DMSO-d₆) δ 10.65 (s, 1H), 8.37 (d, J = 6.6 Hz, 1H), 8.14-8.02 (s, 4H), 7.77-7.65 (m, 4H), 7.50-7.39 (m, 1H), 6.87 (d, J = 6.5 Hz, 1H), 4.95-4.74 (m, 2H), 4.73 (d, J = 9.6 Hz, 1H), 4.58- 4.50 (m, 2H), 3.89-3.76 (m, 2H), 3.04- 2.85 (m, 2H), 1.28-1.16 (m, 3H). MS m/z (ESI): 440.8 [M + H].

TDI01676

(7-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)-3,4- dihydroisoquinolin-2(1H)- yl)(3,3-difluoro-1- methylcyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.79- 10.08 (s, 1H), 8.38 (d, J = 6.4 Hz, 1H), 8.08 (s, 4H), 7.77-7.66 (m, 4H), 7.40 (s, 1H), 6.83 (s, 1H), 4.75 (s, 1H), 4.60 (s, 1H), 3.75 (s, 1H), 3.60 (s, 1H), 3.09-2.92 (m, 4H), (s, 2H), 1.45 (d, J = 26.7 Hz, 3H). MS m/z (ESI): 500.8 [M + H]. TDI01965

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2- yl)(pyridin-3-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.88 (s, 1H), 9.84 (d, J = 8.9 Hz, 1H), 8.86 (s, 1H), 8.74-8.69 (m, 1H), 8.41-8.28 (m, 3H), 8.12-7.98 (m, 3H), 7.79 (t, J = 8.9 Hz, 2H), 7.64 (dd, J = 12.9, 8.6 Hz, 2H), 7.57-7.41 (m, 2H), 6.77 (t, J = 6.2 Hz, 1H), 4.95 (dd, J = 23.6, 15.8 Hz, 4H). MS m/z (ESI): 459.6 [M + H]. TDI01966

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2- yl)(pyridin-4-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 13.13 (s, 1H), 9.76 (d, J = 10.1 Hz, 1H), 8.79-8.73 (m, 3H), 8.41-8.28 (m, 3H), 8.03 (d, J = 9.0 Hz, 2H), 7.83-7.75 (m, 4H), 7.63 (dd, J = 7.1, 2.8 Hz, 4H), 6.77-6.73 (m, 1H), 4.97 (d, J = 14.0 Hz, 2H), 4.85 (d, J = 17.9 Hz, 2H). MS m/z (ESI): 459.6 [M + H]. TDI01967

(5-(4-((1H-indazol-5- yl)amino)pyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 13.19 (s, 1H), 10.60 (s, 1H), 8.35 (d, J = 6.1 Hz, 1H), 8.23-8.11 (m, 4H), 7.60 (dd, J = 32.2, 8.4 Hz, 3H), 6.82 (d, J = 5.0 Hz, 1H), 4.92 (s, 2H), 4.77 (d, J = 9.8 Hz, 2H), 3.32-3.27 (m, 1H), 2.86 (dd, J = 16.4, 8.4 Hz, 4H). MS m/z (ESI): 447.0 [M + H].

TDI01968A

5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)-2-(methyl-L- prolyl)isoindoline

¹H NMR (400 MHz, DMSO-d₆) δ 10.06 (s, 1H), 9.71 (s, 1H), 8.41-8.37 (m, 1H), 8.33 (d, J = 4.4 Hz, 1H), 8.05 (d, J = 3.3 Hz, 2H), 7.75 (d, J = 4.2 Hz, 2H), 7.69-7.63 (m, 2H), 7.57 (t, J = 8.5 Hz, 1H), 6.79 (d, J = 6.1 Hz, 1H), 5.07 (d, J = 14.2 Hz, 2H), 4.91 (dd, J = 14.7, 7.6 Hz, 2H), 3.64 (s, 1H), 2.85 (d, J = 4.4 Hz, 3H), 2.67 (s, 2H), 2.07 (dd, J = 62.3, 20.0 Hz, 4H). MS m/z (ESI): 466.1 [M + H]. TDI01968B

5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)-2-(methyl-D- prolyl)isoindoline

¹H NMR (400 MHz, DMSO-d₆) δ 10.22 (s, 1H), 9.72 (s, 1H), 8.41-8.38 (m, 1H), 8.30 (dd, J = 16.6, 8.3 Hz, 2H), 8.06 (d, J = 3.2 Hz, 2H), 7.75 (s, 2H), 7.70-7.65 (m, 2H), 7.59 (t, J = 8.6 Hz, 1H), 6.83 (d, J = 6.2 Hz, 1H), 5.05 (t, J = 23.5 Hz, 2H), 4.91 (dd, J = 14.7, 6.7 Hz, 2H), 3.21-3.14 (m, 1H), 2.86 (d, J = 2.6 Hz, 3H), 2.68 (s, 2H), 2.23-1.84 (m, 4H). MS m/z (ESI): 465.7 [M + H]. TDI01969

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2-yl)(1- methylazetidin-2- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.97 (d, J = 32.8 Hz, 3H), 8.40-8.28 (m, 4H), 8.04 (d, J = 2.8 Hz, 2H), 7.77-7.73 (m, 2H), 7.67- 7.63 (m, 2H), 7.55 (d, J = 7.6 Hz, 1H), 6.77 (d, J = 5.9 Hz, 1H), 5.36 (d, J = 7.5 Hz, 1H), 4.91-4.81 (m, 4H), 4.01 (d, J = 5.8 Hz, 2H), 2.85 (d, J = 3.7 Hz, 5H). MS m/z (ESI): 452.0 [M + H]. TDI01973

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2-yl)(5- methyl-4,5,6,7- tetrahydrothiazolo[5,4- c]pyridin-2-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 10.00 (s, 1H), 8.37 (dd, J = 20.8, 14.4 Hz, 3H), 8.06 (s, 2H), 7.77 (d, J = 5.6 Hz, 2H), 7.64 (dd, J = 25.3, 7.4 Hz, 3H), 6.80 (d, J = 5.4 Hz, 1H), 5.46 (d, J = 6.9 Hz, 2H), 5.03 (d, J = 12.6 Hz, 2H), 4.81 (s, 1H), 4.53 (s, 1H), 3.81 (s, 1H), 3.57 (s, 1H), 3.25 (s, 2H), 3.01 (s, 3H). MS m/z (ESI): 535.1 [M + H]. TDI01976

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)furo[3,2- d]pyrimidin-2-yl)isoindolin- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.30 (s, 1H), 8.45 (s, 1H), 8.30 (dd, J = 15.2, 6.9 Hz, 2H), 8.09 (d, J = 2.3 Hz, 2H), 7.92 (dd, J = 8.2, 3.0 Hz, 2H), 7.68 (dd, J = 8.4, 3.1 Hz, 2H), 7.53-7.47 (m, 1H), 7.16 (s, 1H), 4.90 (d, J = 11.0 Hz, 2H), 4.76 (d, J = 17.2 Hz, 2H), 3.32-3.27 (m, 1H), 2.90-2.83 (m, 4H). MS m/z (ESI): 512.6 [M + H].

TDI01978

(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.68 (s, 1H), 8.47 (d, J = 2.6 Hz, 1H), 8.23 (dd, J = 16.6, 8.4 Hz, 2H), 8.07 (s, 2H), 7.94-7.81 (m, 2H), 7.66 (dd, J = 8.4, 3.8 Hz, 2H), 7.47 (dd, J = 15.2, 8.0 Hz, 1H), 4.89 (d, J = 9.6 Hz, 2H), 4.74 (d, J = 15.1 Hz, 2H), 3.31- 3.26 (m, 1H), 2.86 (dd, J = 16.4, 8.4 Hz, 4H). MS m/z (ESI): 490.9 [M + H].

TDI01989

1-(5-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin- 2-yl)isoindolin-2-yl)-2- hydroxypropan-1-one

¹H NMR (400 MHz, DMSO-d₆) δ 10.07 (s, 1H), 8.39 (d, J = 6.0 Hz, 1H), 8.28 (dd, J = 13.6, 5.1 Hz, 2H), 8.06 (s, 2H), 7.79-7.65 (m, 3H), 7.58-7.50 (m, 1H), 6.79 (d, J = 5.6 Hz, 1H), 5.10 (dd, J = 15.4, 6.0 Hz, 1H), 4.98 (dd, J = 14.9, 6.7 Hz, 1H), 4.82-4.71 (m, 2H), 4.45-4.40 (m, 1H), 3.15 (dd, J = 7.3, 4.2 Hz, 1H), 1.30-1.26 (m, 3H). MS m/z (ESI): 426.9 [M + H].

Example 45: Preparation of (5-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)isoindolin-2-yl)(3,3-difluorocyclobutyl)methanone (TDI01944)

Step 1:

Compound TDI01944-1 (20 g, 67 mmol) was dissolved in dichloromethane (20 mL), trifluoroacetic acid (50 mL) was added, and the reaction solution was stirred at room temperature for 16 hours. The reaction solvent and trifluoroacetic acid were removed through rotary evaporation under vacuum, and the residue was added with 20 mL water and 40 mL concentrated hydrochloric acid. A solid precipitated, and was filtered and dried to afford compound TDI01944-2 (15.3 g, grey solid).

¹H NMR (400 MHz, CDCl₃) δ 7.39 (s, 1H), 7.34 (d, J=8.2 Hz, 1H), 7.12 (d, J=8.0 Hz, 1H), 4.22 (d, J=14.1 Hz, 4H). MS m/z (ESI): 197.9, 199.8 [M−Cl]⁺.

Step 2:

Compound 3,3-difluorocyclobutanecarboxylic acid (3.1 g, 23 mmol) was dissolved in N,N-dimethylformamide (100 mL), HATU (9.5 g, 25 mmol), diisopropylethylamine (8.7 g, 67 mmol) and TDI01944-2 (4.5 g, 19 mmol) were successively added, and the reaction was continually stirred at room temperature for 16 hours. The reaction solvent was removed through rotary evaporation under vacuum, the residue was dissolved in 20 mL dichloromethane, washed with water (20 mL×3), and then the organic phase was concentrated until a solid precipitated. After the solid precipitated completely, it was filtered and dried to afford TDI01944-3 (4.2 g, grey solid, crude product, 70% yield).

MS m/z (ESI): 315.7, 317.8 [M+H].

Step 3:

Compound TDI01944-3 (4.1 g, 13 mmol) and bis(pinacolato)diboron (4.1 g, 16 mmol) were dissolved in N,N-dimethylformamide (100 mL), potassium acetate (4.1 g, 16 mmol) and Pd(dppf)Cl₂ (0.95 g, 1.3 mmol) were added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 110° C. for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (petroleum ether:ethyl acetate=5:1), to afford compound TDI01944-4 (3.8 g, white solid, 81% yield).

¹H NMR (400 MHz, CDCl₃) δ 7.73-7.79 (m, 2H), 728-7.35 (m, 1H), 4.78-4.85 (m, 4H), 3.09-3.17 (m, 1H), 2.94-3.05 (m, 2H), 2.80-2.85 (m, 2H), 1.38 (s, 12H). MS m/z (ESI): 363.9 [M+H].

Step 4:

Compound TDI01944-4 (3.72 g, 10.0 mmol) and compound Reg-1-16 (3.63 g, 10.0 mmol) were dissolved in a mixed solution of dioxane (80 mL) and water (8 mL), potassium carbonate (4.15 g, 30.0 mmol) was added, and the flask was purged with nitrogen three times. Pd(dppf)Cl₂ (1.46 g, 2.0 mmol) was added, the flask was purged with nitrogen three times again, and the reaction solution was stirred at 110° C. for 16 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (petroleum ether:ethyl acetate=4:1 to pure ethyl acetate) to afford compound TDI01944 (1.35 g, off-white solid, 28.7% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 12.90 (s, 1H), 9.68 (s, 1H), 8.38 (dd, J=5.8, 1.2 Hz, 1H), 8.36-8.28 (m, 2H), 8.16 (s, 1H), 7.92 (s, 1H), 7.77 (d, J=6.7 Hz, 2H), 7.64 (dd, J=8.6, 3.5 Hz, 2H), 7.49 (dd, J=15.4, 8.0 Hz, 1H), 6.73 (d, J=5.9 Hz, 1H), 4.91 (d, J=11.0 Hz, 2H), 4.76 (d, J=14.9 Hz, 2H), 3.29 (d, J=8.3 Hz, 1H), 2.87 (dd, J=16.5, 8.6 Hz, 4H). MS m/z (ESI): 472.5 [M+H].

The compounds in following table 14 were prepared according to methods similar to that described in Example 45.

TABLE 14 Starting material or regent No. Compound Structure Compound Name different from that in Example 45 Characterization Data TDI01958

(7-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino)pyrimi- din-2-yl)-3,4- dihydroisoquinolin- 2(1H)-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.89 (s, 1H), 9.66 (s, 1H), 8.36 (d, J = 6.0 Hz, 1H), 8.26-8.11 (m, 3H), 7.91 (s, 1H), 7.81-7.71 (m, 2H), 7.63 (d, J = 8.0 Hz, 2H), 7.32 (dd, J = 8.0, 4 Hz, 1H), 6.71 (d, J = 6.0 Hz, 1H), 4.73 (d, J = 8.0 Hz, 2H), 3.71 (dt, J = 27.8, 5.8 Hz, 2H), 3.45-3.35 (m, 1H), 2.95-2.74 (m, 6H). MS m/z (ESI): 486.6 [M + H]. TDI01962

(5-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-6- methyl-6,7-dihydro-5H- pyrrolo[3,4- d]pyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.73 (s, 1H), 9.46 (s, 1H), 8.34-8.24 (m, 2H), 8.07 (s, 2H), 7.76 (s, 2H), 7.70 (s, 2H), 7.48 (s, 1H), 4.89 (s, 2H), 4.76 (d, J = 13.4 Hz, 4H), 4.46 (s, 2H), 3.29 (s, 1H), 3.12 (s, 3H), 2.92-2.76 (m, 4H). MS m/z (ESI): 527.6 [M + H]. TDI01979

(5-(4-((5-(1H-pyrazol- 4-yl)pyridin-2- yl)amino)pyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.85 (s, 1H), 8.68 (s, 1H), 8.53 (d, J = 6.0 Hz, 1H), 8.31 (s, 1H), 8.27 (d, J = 2.0 Hz, 1H), 8.14- 8.10 (m, 3H), 7.94-7.85 (m, 1H), 7.73-7.65 (m, 2H), 7.58-7.51 (m, 1H), 4.91 (s, 2H), 4.79 (s, 2H), 3.34-3.24 (m, 1H), 2.90-2.81 (m, 4H). MS m/z (ESI): 474.0 [M + H]. TDI01990

(5-(6-((4-(1H-pyrazol- 4- yl)phenyl)amino)pyridin- 2-yl)isoindolin-2- yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.16 (s, 1H), 8.04-7.98 (m, 4H), 7.77 (d, J = 8.0 Hz, 2H), 7.66 (t, J = 8.0 Hz, 1H), 7.56 (dd, J = 8.0, 4.0 Hz, 2H), 7.47 (dd, J = 16.0, 8.0 Hz, 1H), 7.31 (dd, J = 8.0, 4.0 Hz, 1H), 6.81 (d, J = 8.0 Hz, 1H), 4.89 (d, J = 12.0 Hz, 1H), 4.75 (d, J = 12.0 Hz, 1H), 3.36-3.23 (m, 1H), 2.96- 2.74 (m, 4H). MS m/z (ESI): 472.0 [M + H]. TDI01991

(5-(6-((4-(1H-pyrazol- 4- yl)phenyl)amino)pyrazin- 2-yl)isoindolin-2- yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.61 (s, 1H), 8.52 (d, J = 4.0 Hz, 1H), 8.18 (s, 1H), 8.13-7.98 (m, 4H), 7.79 (d, J = 8.0 Hz, 2H), 7.60 (dd, J = 8.0, 4.0 Hz, 2H), 7.51 (q, J = 8.0 Hz, 1H), 4.90 (d, J = 16.0 Hz, 2H), 4.76 (d, J = 16.0 Hz, 2H), 3.32-3.26 (m, 1H), 2.90- 2.83 (m, 4H). MS m/z (ESI): 472.6 [M + H]. TDI01999

(5-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-6,7- dihydro-5H- pyrrolo[3,4- d]pyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (300 MHz, DMSO-d₆) δ 9.48 (s, 2H), 9.37 (s, 1H), 8.30-8.22 (m, 2H), 8.05 (s, 2H), 7.75 (d, J = 3.4 Hz, 2H), 7.67 (d, J = 6.2 Hz, 2H), 7.54-7.41 (m, 1H), 4.88 (s, 2H), 4.75 (d, J = 10.2 Hz, 2H), 4.51 (d, J = 14.3 Hz, 4H), 3.27 (d, J = 9.6 Hz, 1H), 2.86 (dd, J = 16.3, 8.4 Hz, 4H). MS m/z (ESI): 513.6 [M + H]. TDI01536

(5-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)- 1,3,5-triazin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.35 (s, 1H), 8.84 (s, 1H), 8.43-8.31 (m, 2H), 8.05 (s, 1H), 7.79 (s, 2H), 7.65 (s, 2H), 7.56 (d, J = 8.1 Hz, 1H), 4.92 (s, 2H), 4.78 (d, J = 9.8 Hz, 2H), 3.31 (s, 1H), 2.87 (dd, J = 16.3, 8.6 Hz, 4H). MS m/z (ESI): 473.8 [M + H]. TDI01550

(3,3- difluorocyclobutyl)(5- (4-((2-methoxy-4-(1H- pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)isoindolin-2- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.91 (dd, J = 34.5, 20.4 Hz, 2H), 8.33 (d, J = 6.2 Hz, 1H), 8.26-8.02 (m, 4H), 7.85 (s, 1H), 7.55 (dd, J = 14.8, 8.1 Hz, 1H), 7.38 (s, 1H), 7.33-7.27 (m, 1H), 6.86 (s, 1H), 4.90 (s, 2H), 4.76 (d, J = 7.8 Hz, 2H), 3.93 (s, 3H), 3.29 (dd, J = 10.0, 6.3 Hz, 1H), 2.86 (dd, J = 16.3, 8.4 Hz, 4H). MS m/z (ESI): 502.6 [M + H]. TDI01564

(5-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5H- pyrrolo[3,2- d]pyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 11.85 (s, 1H), 8.22 (dd, J = 16.1, 8.3 Hz, 2H), 8.10 (s, 2H), 7.93-7.86 (m, 2H), 7.78-7.70 (m, 2H), 7.61 (dd, J = 15.1, 7.8 Hz, 2H), 6.66 (s, 1H), 4.94 (d, J = 7.0 Hz, 2H), 4.80 (d, J = 15.9 Hz, 2H), 3.32 (d, J = 8.2 Hz, 1H), 2.88 (dd, J = 16.3, 8.2 Hz, 4H). MS m/z (ESI): 511.6 [M + H]. TDI01565

(5-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-7H- pyrrolo[2,3- d]pyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 11.81 (s, 1H), 9.43 (s, 1H), 8.33 (d, J = 18.2 Hz, 3H), 8.06 (s, 2H), 7.97 (d, J = 5.5 Hz, 2H), 7.66 (d, J = 4.3 Hz, 2H), 7.49-7.44 (m, 1H), 7.28 (s, 1H), 6.82 (s, 1H), 4.90 (d, J = 16.4 Hz, 2H), 4.76 (d, J = 21.9 Hz, 2H), 3.30 (s, 1H), 2.87 (dd, J = 16.3, 8.4 Hz, 4H). MS m/z (ESI): 512.1 [M + H]. TDI01566

1-(5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)-6,7- dihydro-5H- pyrrolo[3,4- d]pyrimidin-2- yl)isoindolin-2-yl)-2- hydroxypropan-1-one

¹H NMR (400 MHz, DMSO-d₆) δ 9.50 (s, 2H), 9.39 (s, 1H), 8.35-8.22 (m, 2H), 8.07 (s, 2H), 7.78 (s, 2H), 7.69 (s, 2H), 7.49 (d, J = 8.8 Hz, 1H), 5.05 (s, 1H), 4.96 (s, 1H), 4.74 (d, J = 13.6 Hz, 2H), 4.52 (d, J = 19.2 Hz, 4H), 4.41 (s, 1H), 1.27 (d, J = 6.4 Hz, 3H). MS m/z (ESI): 467.7 [M + H].

TDI01567B

ethyl 4-((4-(1H- pyrazol-4- yl)phenyl)amino)-2-(2- (3,3- difluorocyclobutane-1- carbonyl)isoindolin-5- yl)pyrimidine-5- carboxylate

¹H NMR (400 MHz, DMSO-d₆) δ 10.26 (s, 1H), 9.05 (s, 1H), 8.34 (dd, J = 16.4, 8.1 Hz, 3H), 8.10 (s, 2H), 7.80 (s, 3H), 7.73-7.70 (m, 2H), 7.53 (dd, J = 15.5, 7.8 Hz, 1H), 4.92 (d, J = 5.9 Hz, 3H), 4.77 (d, J = 13.9 Hz, 3H), 4.42 (d, J = 7.2 Hz, 3H), 3.29 (s, 2H), 2.90-2.83 (m, 6H), 1.40 (t, J = 7.1 Hz, 4H). MS m/z (ESI): 545.0 [M + H]. TDI01569

(5-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-6- (2- (dimethylamino)ethoxy) pyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.83 (s, 1H), 9.65 (s, 1H), 8.02 (s, 2H), 7.96 (d, J = 6.6 Hz, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 8.3 Hz, 2H), 7.54-7.48 (m, 1H), 6.97 (s, 1H), 4.89 (s, 2H), 4.78-4.69 (m, 4H), 3.59 (s, 2H), 3.28 (d, J = 8.0 Hz, 1H), 2.94-2.77 (m, 10H). MS m/z (ESI): 559.5 [M + H]. TDI01578

(5-(4-((1H-indazol-5- yl)amino)thieno[3,2- d]pyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 13.14 (d, J = 14.1 Hz, 1H), 10.07 (s, 1H), 8.36-8.30 (m, 2H), 8.22 (d, J = 4.9 Hz, 1H), 8.14 (s, 2H), 7.67 (s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 7.48 (dd, J = 15.1, 6.7 Hz, 2H), 4.89 (d, J = 8.7 Hz, 2H), 4.75 (d, J = 13.4 Hz, 2H), 3.32-3.27 (m, 1H), 2.90-2.81 (m, 4H). MS m/z (ESI): 502.5 [M + H]. TDI01584

(5-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino)thieno [3,2-d]pyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.06 (s, 1H), 8.46-8.21 (m, 4H), 8.10 (s, 2H), 7.85 (d, J = 5.7 Hz, 2H), 7.70 (dd, J = 8.3, 2.5 Hz, 2H), 7.55-7.48 (m, 2H), 4.91 (d, J = 9.8 Hz, 2H), 4.77 (d, J = 17.4 Hz, 2H), 3.32-3.26 (m, 1H), 2.87 (dd, J = 16.5, 8.5 Hz, 4H). MS m/z (ESI): 528.5 [M + H]. TDI01585

(3,3- difluorocyclobutyl)(5- (5-fluoro-4-((4-(5- methyl-1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)isoindolin-2- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.73 (s, 1H), 8.48 (d, J = 3.2 Hz, 1H), 8.26-8.17 (m, 2H), 7.95-7.83 (m, 3H), 7.55-7.42 (m, 3H), 4.88 (d, J = 7.7 Hz, 2H), 4.74 (d, J = 14.1 Hz, 2H), 3.32-3.24 (m, 1H), 2.85 (dd, J = 16.4, 8.4 Hz, 4H), 2.41 (s, 3H). MS m/z (ESI): 504.5 [M + H]. TD01586

(5-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5- fluoropyrimidin-2- yl)isoindolin-2- yl)(tetrahydro-2H- pyran-4-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.68 (s, 1H), 8.47 (s, 1H), 8.27-8.17 (m, 2H), 8.06 (s, 2H), 7.87 (s, 2H), 7.67 (s, 2H), 7.47 (s, 1H), 5.01 (d, J = 7.4 Hz, 2H), 4.71 (d, J = 14.2 Hz, 2H), 3.90 (d, J = 10.9 Hz, 2H), 3.40 (s, 2H), 2.87-2.79 (m, 1H), 1.66 (s, 4H). MS m/z (ESI): 484.6 [M + H].

TDI01587

1-(4-(((4-(1H-pyrazol-4- yl)phenyl)amino)-2-(2- (3,3- difluorocyclobutane-1- carbonyl)isoindolin-5- yl)-5,7-dihydro-6H- pyrrolo[3,4- d]pyrimidin-6-yl)ethan- 1-one

¹H NMR (400 MHz, DMSO-d₆) δ 9.23 (d, J = 6.8 Hz, 1H), 8.36-8.24 (m, 2H), 8.06 (s, 2H), 7.85 (d, J = 4.0 Hz, 2H), 7.66 (s, 2H), 7.48 (dd, J = 14.9, 7.9 Hz, 1H), 4.96-4.69 (m, 6H), 4.59 (d, J = 27.2 Hz, 2H), 3.29 (s, 1H), 2.86 (dd, J = 16.3, 8.3 Hz, 4H), 2.12 (d, J = 7.4 Hz, 3H). MS m/z (ESI): 556.2 [M + H]. TDI01589

(5-(4-((1H-indazol-5- yl)amino)-5- fluoropyrimidin-2- yl)isoindolin-2-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 13.15- 12.97 (m, 0H), 9.71 (s, 0H), 8.45 (d, J = 2.4 Hz, 0H), 8.34-8.07 (m, 1H), 7.73 (d, J = 8.9 Hz, 0H), 7.59 (d, J = 8.9 Hz, 0H), 7.45 (dd, J = 16.7, 8.0 Hz, 0H), 4.87 (d, J = 8.8 Hz, 1H), 4.72 (d, J = 11.9 Hz, 0H), 3.28 (d, J = 3.9 Hz, 1H), 2.85 (dd, J = 16.4, 8.4 Hz, 4H). MS m/z (ESI): 464.7 [M + H]. TDI01596

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5- fluoropyrimidin-2-yl)- 3,4-dihydroisoquinolin- 2(1H)-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.68 (s, 1H), 8.46 (d, J = 2.6 Hz, 1H), 8.07 (d, J = 7.0 Hz, 5H), 7.87 (d, J = 7.9 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 7.2 Hz, 1H), 4.68 (d, J = 12.5 Hz, 2H), 3.70 (d, J = 31.3 Hz, 3H), 2.94 (s, 2H), 2.84 (dd, J = 15.9, 8.5 Hz, 4H). MS m/z (ESI): 504.7 [M + H].

TDI01596B

(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino)pyrimi- din-2-yl)-3,4- dihydroisoquinolin- 2(1H)-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.32 (s, 1H), 8.36 (d, J = 6.3 Hz, 1H), 8.08 (d, J = 12.4 Hz, 4H), 7.69 (t, J = 11.5 Hz, 4H), 7.42 (t, J = 8.1 Hz, 2H), 6.82 (d, J = 6.2 Hz, 1H), 4.72 (d, J = 12.8 Hz, 2H), 3.70 (dd, J = 21.5, 16.0 Hz, 3H), 3.41-3.36 (m, 1H), 2.91-2.80 (m, 4H). MS m/z (ESI): 486.6 [M + H]. TDI01598

(3,3- difluorocyclobutyl)(5- (5-fluoro-4-((2-fluoro- 4-(1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)isoindolin-2- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.52 (s, 1H), 8.46 (s, 1H), 8.15 (d, J = 14.0 Hz, 3H), 8.09-8.02 (m, 2H), 7.65 (d, J = 12.1 Hz, 1H), 7.58 (d, J = 7.0 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.41-7.35 (m, 1H), 4.83 (s, 2H), 4.68 (d, J = 7.6 Hz, 2H), 3.26 (s, 1H), 2.83 (dd, J = 14.9, 7.5 Hz, 4H). MS m/z (ESI): 509.1 [M + H]. TDI01611

N-(5-(4-((4-(1H- pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2-yl)- 2,3-dihydro-1H-inden- 2-yl)-3,3- difluorocyclobutane-1- carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ 9.67 (s, 1H), 8.45 (d, J = 2.8 Hz, 1H), 8.38 (d, J = 6.6 Hz, 1H), 8.22-8.02 (m, 4H), 7.87 (d, J = 8.2 Hz, 2H), 7.65 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 7.8 Hz, 1H), 4.52 (d, J = 6.0 Hz, 1H), 3.25 (td, J = 16.5, 7.2 Hz, 2H), 2.83 (d, J = 7.2 Hz, 3H), 2.67 (s, 4H). MS m/z (ESI): 504.6 [M + H].

TDI01662

(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)(methyl) amino)- 5-fluoropyrimidin-2- yl)-3,4- dihydroisoquinolin- 2(1H)-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 8.31 (d, J = 8.0 Hz, 1H), 8.18-8.14 (m, 2H), 8.09 (s, 2H), 7.64 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 8.2 Hz, 3H), 4.68 (s, 2H), 3.75-3.68 (m, 2H), 3.58 (s, 3H), 3.41-3.35 (m, 1H), 2.97-2.76 (m, 6H). MS m/z (ESI): 519.1 [M + H].

TDI01682

(7-(4-((1H-indazol-5- yl)amino)pyrimidin-2- yl)-3,4- dihydroisoquinolin- 2(1H)-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 13.17 (s, 1H), 10.76 (s, 1H), 8.35 (d, J = 6.8 Hz, 1H), 8.13 (t, J = 6.5 Hz, 2H), 8.09-7.99 (m, 2H), 7.67-7.61 (m, 1H), 7.59-7.51 (m, 1H), 7.42 (t, J = 8.1 Hz, 1H), 6.88-6.78 (m, 1H), 4.77- 4.70 (m, 2H), 3.78-3.72 (m, 1H), 3.70-3.65 (t, J = 5.6 Hz, 2H), 3.46-3.33 (s, 1H), 2.98- 2.91 (m, 1H), 2.91-2.74 (m, 5H). MS m/z (ESI): 460.7 [M + H].

TDI01683

(6-(4-((1H-indazol-5- yl)amino)pyrimidin-2- yl)-3,4- dihydroisoquinolin- 2(1H)-yl)(3,3- difluorocyclobutyl) methanone

¹H NMR (400 MHz, DMSO-d₆) δ 13.15 (s, 1H), 10.65 (s, 1H), 8.35 (d, J = 6.6 Hz, 1H), 8.14 (s, 2H), 8.06 (d, J = 8.6 Hz, 2H), 7.64 (d, J = 8.6 Hz, 1H), 7.56 (s, 1H), 7.44 (t, J = 8.2 Hz, 1H), 6.82 (d, J = 5.7 Hz, 1H), 4.73 (d, J = 12.2 Hz, 2H), 3.76 (s, 1H), 3.69 (s, 1H), 3.41- 3.36 (m, 1H), 2.96 (s, 1H), 2.91-2.78 (m, 5H). MS m/z (ESI): 460.7 [M + H].

Example 46: Preparation of (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)furo[3,2-d]pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone (TDI01916)

Step 1:

TDI1916-1 (31.3 g, 130 mmol), 3,3-difluoroazetidine hydrochloride (20 g, 140 mmol), HATU (60 g, 160 mmol) and DMF (330 mL) were added to a 1 L flask, DIEA (50 g, 390 mmol) was added, and the reaction was stirred at room temperature overnight. LC-MS indicated the reaction was complete. The reaction solution was concentrated to afford a crude product, which was added with water (200 mL), methanol (20 mL) and acetonitrile (20 mL), and the mixture was stirred at room temperature for 1 hour. The mixture was filtered, and the solid thus obtained was once again subjected to the above slurry process, and dried to afford TDI1916-2 (41 g, brown solid, yield: 100%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.88 (s, 1H), 7.61 (s, 1H), 7.60 (d, J=8.6 Hz, 1H), 7.20 (d, J=8.6 Hz, 1H), 6.94 (s, 1H), 4.98 (s, 2H), 4.56 (s, 2H). MS m/z (ESI): 314.9, 316.9 [M+H, Br].

Step 2:

TDI1916-2 (30 g, 96 mmol) was dissolved in DMF (300 mL), and was cooled to 0° C. in an ice-water bath under protection of N₂. NaH (60%, 7.62 g, 191 mmol) was added portionwise, and the reaction was stirred for 1 hour before iodomethane (41 g, 288 mmol) was added. The reaction was stirred at 30° C. for 3 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to 0° C., and water (300 mL) was added. A large amount of solid precipitated, which was filtered, and the filter cake was washed with water (1 L) to neutral, and dried to afford TDI1916-3 (30.5 g, brown solid, yield: 96.5%).

¹H NMR (400 MHz, DMSO-d₆) δ 7.85 (s, 1H), 7.58 (d, J=8.4 Hz, 1H), 7.25 (d, J=8.4 Hz, 1H), 7.03 (s, 1H), 4.83 (s, 2H), 4.53 (s, 2H), 3.92 (s, 3H). MS m/z (ESI): 328.9, 330.9 [M+H, Br].

Step 3:

TDI1916-3 (30.5 g, 93 mmol), bis(pinacolato)diboron (26 g, 100 mmol) and potassium acetate (27.3 g, 280 mmol) were dissolved in 1,4-dioxane (500 mL), the flask was purged with N₂ 3 times, followed by addition o Pd(dppf)Cl₂ (10 g, 14 mmol). The flask was purged with N₂ 3 times again, and then the reaction was placed in an oil bath at 108° C. for 4 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure to afford a crude product, which was separated through column chromatography on silica gel (petroleum ether:ethyl acetate=1:1) to afford TDI1916-4 (27.5 g, brown solid, yield: 78.6%).

¹H NMR (400 MHz, DMSO-d₆) δ 7.82 (s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.41 (d, J=8.0 Hz, 1H), 7.02 (s, 1H), 4.85 (s, 2H), 4.54 (s, 2H), 3.97 (s, 3H), 1.32 (s, 12H). MS m/z (ESI): 377.0 [M+H].

Step 4:

Compound TDI01916-4 (3.0 g, 7.28 mmol) and compound Reg-1-44 (2.74 g, 7.28 mmol) were dissolved in a mixed solution of dioxane (80 mL) and water (8 mL), potassium carbonate (3 g, 21.8 mmol) was added, and the flask was purged with nitrogen three times. Pd(dppf)Cl₂ (1.6 g, 2.18 mmol) was added, the flask was purged with nitrogen three times again, and the reaction solution was stirred at 110° C. for 16 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (dichloromethane:methanol=60:1-40:1), to afford a crude product of compound TDI01916 (2 g), which was stirred in 10 mL dichloromethane for 0.5 h, filtered, and the filter cake was washed with dichloromethane (2 mL×3), and dried in vacuum to afford an off-white solid, TDI01916 (1.7 g, 44.4% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 12.92 (s, 1H), 10.02 (s, 1H), 8.56 (s, 1H), 8.39 (s, 1H), 8.25-8.17 (m, 2H), 8.02-7.93 (m, 3H), 7.70 (dd, J=18.9, 8.4 Hz, 3H), 7.17 (s, 1H), 7.07 (s, 1H), 4.85 (s, 2H), 4.59 (s, 2H), 4.05 (s, 3H). MS m/z (ESI): 525.6 [M+H].

The compounds in following Table 15 were prepared according to methods similar to that described in Example 46.

TABLE 15 No. Compound Structure Compound Name Starting material or regent different from that in Example 46 Characterization Data TDI01851

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-6,7- dihydro- [1,4]dioxino[2,3- d]pyrimidin-2-yl)-1- methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 8.93 (s, 1H), 8.36 (s, 1H), 8.05 (d, J = 5.6 Hz, 3H), 7.93 (d, J = 8.6 Hz, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 8.5 Hz, 2H), 7.05 (s, 1H), 4.90 (s, 4H), 4.56 (s, 2H), 4.43 (s, 2H), 4.02 (s, 3H). MS m/z (ESI): 543.9 [M + H]. TDI01898B

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-6- benzylpyrimidin-2-yl)- 1-methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.48 (s, 1H), 8.01 (d, J = 9.9 Hz, 3H), 7.90 (d, J = 8.5 Hz, 1H), 7.69 (d, J = 7.8 Hz, 4H), 7.50-7.38 (m, 5H), 7.08 (s, 1H), 6.40 (s, 1H), 4.63 (s, 4H), 4.28 (s, 2H), 4.12 (s, 3H). MS m/z (ESI): 575.8 [M + H]. TDI01903

(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino)pyrimi- din-2-yl)-1-ethyl-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 8.54 (s, 1H), 8.41 (s, 1H), 8.08 (s, 3H), 7.90-7.73 (m, 3H), 7.69 (d, J = 8.1 Hz, 2H), 7.11 (s, 1H), 6.83 (s, 1H), 4.92 (s, 2H), 4.58 (d, J = 6.9 Hz, 4H), 1.41 (t, J = 6.9 Hz, 3H). MS m/z (ESI): 499.2 [M + H]. TDI01905

(3,3-difluoroazetidin-1- yl)(6-(4-((3-fluoro-4- (1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 13.09 (s, 1H), 9.95 (s, 1H), 8.56 (s, 1H), 8.45 (d, J = 5.7 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.15-7.96 (m, 3H), 7.75 (t, J = 8.6 Hz, 2H), 7.48 (d, J = 8.4 Hz, 1H), 7.08 (s, 1H), 6.76 (d, J = 5.7 Hz, 1H), 4.89 (s, 2H), 4.56 (s, 2H), 4.08-4.01 (m, 3H). MS m/z (ESI): 503.5 [M + H]. TDI01906

(6-(4-((1H-indazol-5- yl)amino)pyrimidin-2- yl)-1-methyl-1H-indol- 2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.71 (s, 1H), 8.52 (s, 1H), 8.37 (s, 1H), 8.19 (d, J = 32.9 Hz, 2H), 8.03 (s, 1H), 7.84 (s, 1H), 7.63 (d, J = 32.1 Hz, 2H), 7.12 (s, 1H), 6.84 (s, 1H), 5.76 (s, 1H), 4.55 (s, 4H), 4.04 (s, 3H). MS m/z (ESI): 460.0 [M + H]. TDI01910

(3,3-difluoroazetidin-1- yl)(6-(4-((3-methoxy-4- (1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)methanone

¹H NMR (400 MHz, CD₃OD) δ 8.43 (s, 1H), 8.28 (d, J = 7.2 Hz, 1H), 8.13 (s, 2H), 8.01 (d, J = 8.6 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.75 (d, J = 8.3 Hz, 2H), 7.36 (s, 1H), 7.10 (s, 1H), 6.97 (d, J = 7.2 Hz, 1H), 4.63 (s, 4H), 4.11 (s, 3H), 4.01 (s, 3H). MS m/z (ESI): 515.7 [M + H]. TDI01915

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5- methoxypyrimidin-2- yl)-1-methyl-1H-indol- 2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.02 (s, 1H), 8.44 (s, 1H), 8.19 (s, 1H), 8.10 (d, J = 8.6 Hz, 2H), 7.99 (d, J = 8.5 Hz, 3H), 7.71 (s, 1H), 7.64 (d, J = 8.5 Hz, 2H), 7.05 (s, 1H), 4.72 (d, J = 105.4 Hz, 4H), 4.03 (s, 6H). MS m/z (ESI): 516.0 [M + H]. TDI01918

(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino)quinaz- olin-2-yl)-1-methyl-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (d, J = 7.8 Hz, 1H), 8.60 (s, 1H), 8.15 (s, 3H), 8.05 (s, 2H), 7.92 (d, J = 7.8 Hz, 2H), 7.83 (dd, J = 15.2, 8.6 Hz, 4H), 7.13 (s, 1H), 4.92 (s, 2H), 4.54 (d, J = 7.0 Hz, 2H), 4.05 (s, 3H). MS m/z (ESI): 535.9 [M + H]. TDI01920

(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino)pyrimi- din-2-yl)-1- (methoxymethyl)-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.43 (s, 1H), 8.62 (s, 1H), 8.40 (d, J = 6.4 Hz, 1H), 8.12 (s, 1H), 8.07 (s, 2H), 7.91-7.74 (m, 3H), 7.69 (d, J = 8.2 Hz, 2H), 7.22 (s, 1H), 6.83 (d, J = 6.0 Hz, 1H), 5.93 (s, 2H), 4.90 (s, 2H), 4.60 (s, 2H), 3.23 (s, 3H). MS m/z (ESI): 515.6 [M + H]. TDI01921

(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino)pyrimi- din-2-yl)-2-(2- methoxyethyl)-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.50 (s, 1H), 8.57 (s, 1H), 8.40 (d, J = 6.4 Hz, 1H), 8.07 (s, 2H), 7.80 (s, 2H), 7.69 (d, J = 7.9 Hz, 2H), 7.21 (s, 1H), 7.09 (s, 1H), 6.96 (s, 1H), 6.83 (s, 1H), 4.79 (s, 2H), 4.72 (s, 2H), 4.56 (d, J = 12.9 Hz, 2H), 3.68-3.63 (m, 2H), 3.18 (s, 3H). MS m/z (ESI): 529.6 [M + H]. TDI01932

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5- fluoropyrimidin-2-yl)- 1-methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.76 (s, 1H), 8.51 (d, J = 3.6 Hz, 1H), 8.46 (s, 1H), 8.12-8.07 (m, 3H), 7.93 (d, J = 8.5 Hz, 2H), 7.71 (dd, J = 17.3, 8.5 Hz, 3H), 7.07 (s, 1H), 4.89 (s, 2H), 4.58 (s, 2H), 4.03 (s, 3H). MS m/z (ESI): 504.0 [M + H]. TDI01936

(6-(4-((6-(1H-pyrazol- 4-yl)pyridin-3- yl)amino)pyrimidin-2- yl)-1-methyl-1H-indol- 2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (301 MHz, DMSO-d₆) δ 10.67 (s, 1H), 9.03 (s, 1H), 8.61- 8.49 (m, 3H), 8.42-8.26 (m, 3H), 8.08 (d, J = 8.0 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.11 (s, 1H), 6.89 (d, J = 6.2 Hz, 1H), 4.88 (s, 2H), 4.58 (s, 2H), 4.04 (s, 3H). MS m/z (ESI): 486.6 [M + H]. TDI01937B

(6-(4-((5-(1H-pyrazol- 4-yl)pyridin-2- yl)amino)pyrimidin-2- yl)-1-methyl-1H-indol- 2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (301 MHz, DMSO-d₆) δ 11.07 (s, 1H), 8.85 (s, 1H), 8.51- 8.29 (m, 3H), 8.19 (s, 1H), 7.95 (s, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.0 Hz, 2H), 7.06 (s, 1H), 4.82-4.45 (m, 4H), 4.03 (s, 3H). MS m/z (ESI): 486.6 [M + H]. TDI01943

(3,3-difluoroazetidin-1- yl)(6-(4-((2-hydroxy-4- (1H-pyrazol-4- yl)phenyl)amino)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.15 (s, 1H), 8.48 (s, 1H), 8.36 (s, 1H), 8.01 (s, 4H), 7.88-7.77 (m, 2H), 7.20 (d, J = 4.6 Hz, 3H), 7.12 (s, 1H), 4.91 (s, 2H), 4.55 (s, 2H), 4.03 (s, 3H). MS m/z (ESI): 501.6 [M + H]. TDI01945

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5- methyl-5H-pyrrolo[3,2- d]pyrimidin-2-yl)-1- methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 8.40 (s, 2H), 8.14 (s, 2H), 7.97- 7.67 (m, 7H), 7.09 (s, 2H), 6.63 (s, 1H), 4.87 (s, 3H), 4.55 (d, J = 11.6 Hz, 3H), 4.28 (s, 3H), 3.98 (s, 3H). MS m/z (ESI): 538.5 [M + H]. TDI01947

(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino)thieno [2,3-d]pyrimidin-2-yl)- 1-methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.93 (s, 1H), 9.78 (s, 1H), 8.59 (s, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.96 (dd, J = 24.2, 7.1 Hz, 4H), 7.72 (dd, J = 13.3, 5.9 Hz, 4H), 7.56 (s, 1H), 7.08 (s, 1H), 4.89 (s, 2H), 4.56 (s, 2H), 4.06 (s, 3H). MS m/z (ESI): 541.9 [M + H]. TDI01948

(6-(4-((4-(1H-pyrazol- 4- yl)phenyl)amino)pyrrolo [2,1-f][1,2,4]triazin-2- yl)-1-methyl-1H-indol- 2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.91 (s, 1H), 9.97 (s, 1H), 8.43 (s, 1H), 8.06 (dd, J = 17.6, 8.4 Hz, 3H), 7.86 (s, 1H), 7.73 (dd, J = 8.2, 4.3 Hz, 2H), 7.50 (s, 1H), 7.22 (s, 1H), 7.08 (s, 1H), 6.78 (d, J = 3.0 Hz, 1H), 4.88 (s, 2H), 4.59 (s, 2H), 4.05 (s, 3H). MS m/z (ESI): 524.9 [M + H]. TDI01949

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5- chloropyrimidin-2-yl)- 1-methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.24 (s, 1H), 8.57 (s, 1H), 8.47 (s, 1H), 8.10 (s, 2H), 8.07 (dd, J = 8.5, 1.3 Hz, 1H), 7.82 (d, J = 8.7 Hz, 2H), 7.71 (dd, J = 8.4, 5.1 Hz, 3H), 7.07 (s, 1H), 4.88 (s, 2H), 4.57 (s, 2H), 4.01 (s, 3H). MS m/z (ESI): 519.9 [M + H]. TDI01950

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5- methylpyrimidin-2-yl)- 1-methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.63 (s, 1H), 8.45 (s, 1H), 8.36 (s, 1H), 8.11 (s, 2H), 7.95 (d, J = 8.4 Hz, 1H), 7.76 (dt, J = 16.5, 6.7 Hz, 6H), 7.10 (s, 1H), 4.88 (s, 2H), 4.56 (s, 2H), 4.01 (s, 3H), 2.33 (s, 3H). MS m/z (ESI): 499.2 [M + H]. TDI01952

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5,7- dihydrofuro[3,4- d]pyrimidin-2-yl)-1- methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.29 (s, 1H), 8.52 (s, 1H), 8.28- 8.01 (m, 3H), 7.85 (s, 2H), 7.78- 7.65 (m, 2H), 7.07 (s, 1H), 5.03 (d, J = 40.1 Hz, 4H), 4.03 (s, 3H). MS m/z (ESI): 527.6 [M + H]. TDI01953

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-6,7- dihydro-5H- pyrrolo[3,4- d]pyrimidin-2-yl)-1- methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.50 (s, 2H), 9.40 (s, 1H), 8.52 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 8.08 (s, 2H), 7.83 (d, J = 8.3 Hz, 2H), 7.72 (dd, J = 16.5, 8.4 Hz, 3H), 7.08 (s, 1H), 4.92-4.77 (m, 4H), 4.53 (d, J = 5.1 Hz, 4H), 4.03 (s, 3H). MS m/z (ESI): 526.6 [M + H]. TDI01954

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-6- methyl-6,7-dihydro-5H- pyrrolo[3,4- d]pyrimidin-2-yl)-1- methyl-1H-indol-2- yl)(3,3-difluoroazetidin- 1-yl)methanone

¹H NMR (300 MHz, DMSO-d₆) δ 10.76 (s, 1H), 9.45 (s, 1H), 8.50 (s, 1H), 8.18-8.02 (m, 3H), 7.73 (dt, J = 12.8, 8.4 Hz, 5H), 7.06 (s, 1H), 4.79 (s, 2H), 4.47 (s, 2H), 4.02 (s, 4H), 3.13 (s, 3H), 2.45-2.44 (m, 3H). MS m/z (ESI): 540.5 [M + H]. TDI01955

(3,3-difluoroazetidin-1- yl)(1-methyl-6-(4-((4- (5-methyl-1H-pyrazol- 4- yl)phenyl)amino)pyrimi- din-2-yl)-1H-indol-2- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.57 (s, 1H), 8.53 (s, 1H), 8.41 (d, J = 6.5 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.82 (dd, J = 9.9, 7.0 Hz, 4H), 7.57 (d, J = 8.6 Hz, 2H), 7.13 (s, 1H), 6.86 (d, J = 6.6 Hz, 1H), 4.91 (s, 2H), 4.56 (s, 2H), 4.05 (s, 3H). MS m/z (ESI): 500.0 [M + H]. TDI01960

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-6,7- dihydro-5H- cyclopenta[d]pyrimidin- 2-yl)-1-methyl-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.90 (s, 1H), 8.80 (s, 1H), 8.51 (s, 1H), 8.17 (d, J = 8.1 Hz, 2H), 8.02- 7.86 (m, 3H), 7.67 (dd, J = 21.6, 8.4 Hz, 3H), 7.05 (s, 1H), 4.87 (d, J = 10.1 Hz, 2H), 4.58 (s, 2H), 4.03 (s, 3H), 2.99-2.85 (m, 4H), 2.10 (dd, J = 14.9, 7.7 Hz, 2H). MS m/z (ESI): 526.0 [M + H]. TDI01537

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5,6- dimethylpyrimidin-2- yl)-1-methyl-1H-indol- 2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.14 (s, 0H), 8.64 (s, 0H), 8.35 (d, J = 10.9 Hz, 1H), 7.75 (t, J = 9.0 Hz, 1H), 7.09 (s, 0H), 7.03 (d, J = 7.6 Hz, 1H), 4.87 (s, 1H), 4.63 (s, 1H), 4.08 (s, 1H), 2.69 (s, 3H), 2.58 (s, 3H). MS m/z (ESI): 514.0 [M + H]. TDI01617

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5- fluoropyrimidin-2-yl)- 1-(methoxymethyl)-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.70 (s, 1H), 8.57 (s, 1H), 8.49 (d, J = 2.9 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8.06 (s, 2H), 7.91 (d, J = 8.2 Hz, 2H), 7.75 (d, J = 8.3 Hz, 1H), 7.68 (s, 2H), 7.17 (s, 1H), 5.92 (s, 2H), 4.86 (d, J = 11.6 Hz, 2H), 4.63 (d, J = 25.1 Hz, 2H), 3.21 (s, 3H). MS m/z (ESI): 533.6 [M + H]. TDI01633

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-6,7- dihydro-5H- pyrrolo[3,4- d]pyrimidin-2-yl)-1- (methoxymethyl)-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.52 (s, 2H), 9.41 (s, 1H), 8.62 (s, 1H), 8.20 (d, J = 8.4 Hz, 1H), 8.06 (s, 2H), 7.92-7.76 (m, 3H), 7.69 (d, J = 8.1 Hz, 2H), 7.18 (s, 1H), 5.92 (s, 2H), 4.89 (dd, J = 28.9, 11.9 Hz, 2H), 4.55 (s, 4H), 4.12 (d, J = 14.8 Hz, 2H), 3.21 (s, 3H). MS m/z (ESI): 556.5 [M + H]. TDI01668

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5- (methoxymethyl)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 12.94 (s, 1H), 8.58 (s, 1H), 8.53 (s, 1H), 8.40 (s, 1H), 8.15 (d, J = 8.5 Hz, 2H), 7.96 (s, 2H), 7.84 (d, J = 8.1 Hz, 2H), 7.70 (dd, J = 13.9, 8.5 Hz, 2H), 7.07 (s, 1H), 4.85 (dd, J = 43.7, 16.3 Hz, 4H), 4.59 (s, 2H), 4.03 (s, 3H), 3.40 (s, 3H). MS m/z (ESI): 530.1 [M + H]. TDI01681

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)-5- (trifluoromethyl)pyrimi- din-2-yl)-1-methyl-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 9.13 (s, 1H), 8.76 (s, 1H), 8.46 (s, 1H), 8.12 (s, 2H), 8.04 (d, J = 8.4 Hz, 1H), 7.70 (t, J = 8.7 Hz, 3H), 7.63 (d, J = 8.3 Hz, 2H), 7.05 (s, 1H), 4.87 (s, 2H), 4.55 (s, 2H), 3.95 (s, 3H). MS m/z (ESI): 553.7 [M + H]. TDI01690

(6-(4-((4-(1H-pyrazol- 4-yl)phenyl)amino)- 1,3,5-triazin-2-yl)-1- (methoxymethyl)-1H- indol-2-yl)(3,3- difluoroazetidin-1- yl)methanone

¹H NMR (400 MHz, DMSO-d₆) δ 10.33 (s, 1H), 8.84 (s, 1H), 8.73 (s, 1H), 8.26 (d, J = 7.8 Hz, 1H), 8.04 (s, 2H), 7.82 (d, J = 8.4 Hz, 3H), 7.64 (s, 2H), 7.21 (s, 1H), 5.94 (s, 2H), 4.90 (s, 2H), 4.60 (s, 2H), 3.22 (s, 3H). MS m/z (ESI): 516.6 [M + H].

Example 47: Preparation of N-(4-(1H-pyrazol-4-yl)phenyl)-2-(2-(thiazol-2-yl)-1H-indol-6-yl)pyrimidin-4-amine (TDI01826)

Step 1:

Compound TDI01826-1 (10.0 g, 41.6 mmol), NH₄Cl (2.67 g, 49.9 mmol), HATU (18.96 g, 49.9 mmol) and DIPEA (22 mL, 124.8 mmol) were dissolved in DMF (60 mL). The reaction solution was stirred at room temperature for 16 hours. LC-MS assay indicated the reaction was complete, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (petroleum ether:ethyl acetate=1:1) to afford compound TDI01826-2 (9.3 g, off-white solid, 93.5% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 11.70 (s, 1H), 8.04 (s, 1H), 7.59 (d, J=8.0 Hz, 2H), 7.45 (s, 1H), 7.18-7.13 (m, 2H). MS m/z (ESI): 238.9 [M+H].

Step 2:

Compound TDI01826-2 (9.3 g, 38.9 mmol) and Lawesson reagent (18.9 g, 46.7 mmol) were dissolved in tetrahydrofuran (200 mL), and the reaction solution was stirred at 90° C. for 2 hours. LC-MS indicated the reaction was complete, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was added with a saturated aqueous solution of sodium bicarbonate (150 mL) and ethyl acetate (150 mL), extracted and separated. The organic phase was dried and then rotary evaporated to remove the solvent, to afford compound TDI01826-3 (16 g, crude product). MS m/z (ESI): 254.9 [M+H].

Step 3:

Compound TDI01826-3 (16 g, crude product, 62.7 mmol) and bromoacetaldehyde diethylacetal (13.6 g, 69 mmol) were dissolved in ethanol (125 mL), concentrated hydrochloric acid (2.5 mL) was added, and the reaction solution was stirred at 90° C. for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, the reaction solvent was removed through rotary evaporation under vacuum, and the residue was purified by column chromatography (ethyl acetate; dichloromethane:methanol=10:1), to afford compound TDI01826-4 (4.9 g, 45% yield).

¹H NMR (300 MHz, DMSO-d₆) δ 12.04 (s, 1H), 7.92 (d, J=3.1 Hz, 1H), 7.79 (d, J=1.6 Hz, 1H), 7.54 (d, J=12.4 Hz, 2H), 7.15 (d, J=8.4 Hz, 1H), 7.06 (s, 1H). MS m/z (ESI): 278.7 [M+H].

Step 4:

Compound TDI01826-4 (4.9 g, 17.55 mmol) and bis(pinacolato)diboron (5.35 g, 21.06 mmol) were dissolved in 1,4-dioxane (60 mL), potassium acetate (5.16 g, 52.65 mmol) was added, and the flask was purged with nitrogen three times. Pd(dppf)Cl₂ (1.28 g, 1.755 mmol) was added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 100° C. for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (petroleum ether:ethyl acetate=1:1), to afford compound TDI01826-5 (1.27 g, white solid, 22% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 12.06 (s, 1H), 7.96 (d, J=3.2 Hz, 1H), 7.83-7.80 (m, 2H), 7.58 (d, J=8.0 Hz, 1H), 7.34 (dd, J=8.0, 0.8 Hz, 1H), 7.08 (d, J=1.4 Hz, 1H), 1.32 (s, 12H). MS m/z (ESI): 326.9 [M+H].

Step 5:

Compound TDI01826-5 (180 m g, 0.55 mmol) and Reg-1-16 (150 mg, 0.55 mmol) were dissolved in 1,4-dioxane:water (15:2 mL), potassium carbonate (229 mg, 1.66 mmol) was added, and the flask was purged with nitrogen three times. Pd(dppf)Cl₂ (80 mg, 0.11 mmol) was added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 110° C. for 16 hours. LC-MS indicated the reaction was complete, the reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (dichloromethane:methanol=10:1), to afford compound TDI01826 (39 mg, 16% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 12.20 (s, 1H), 9.63 (s, 1H), 8.54 (s, 1H), 8.37 (d, J=4.0 Hz, 1H), 8.13 (d, J=8.0 Hz, 2H), 8.04 (s, 2H), 7.96 (s, 1H), 7.85-7.81 (m, 3H), 7.67 (t, J=8.0 Hz, 3H), 7.11 (s, 1H), 6.68 (d, J=4.0 Hz, 1H). MS m/z (ESI): 436.2 [M+H].

The compounds in following table 16 were prepared according to methods similar to that described in Example 47.

TABLE 16 Compound Starting material or regent No. Compound Structure Name different from that in Example 47 Characterization Data TDI01871

N-(4-(1H- pyrazol-4- yl)phenyl)-5- methoxy-2-(2- (thiazol-2-yl)- 1H-indol-6- yl)pyrimidin-4- aine

¹H NMR (400 MHz, DMSO-d₆) δ 12.36 (s, 1H), 8.37 (s, 1H), 8.11 (d, J = 10.9 Hz, 3H), 7.97 (dd, J = 15.2, 5.3 Hz, 4H), 7.85 (d, J = 2.8 Hz, 1H), 7.72 (t, J = 9.9 Hz, 3H), 7.15 (s, 1H), 4.07 (s, 3H). MS m/z (ESI): 466.0 [M + H]. TDI01908

N-(3-fluoro-1- (1H-pyrazol-4- yl)phenyl)-2-(2- (thiazol-2-yl)- 1H-indol-6- yl)pyrimidin-4- amine

¹H NMR (400 MHz, DMSO-d₆) δ 12.44 (s, 1H), 8.47 (s, 1H), 8.41 (d, J = 6.3 Hz, 1H), 8.07 (s, 2H), 8.05-7.98 (m, 2H), 7.88 (d, J = 13.1 Hz, 2H), 7.80 (dd, J = 22.0, 8.4 Hz, 2H), 7.60 (d, J = 7.9 Hz, 1H), 7.17 (s, 1H), 6.83 (s, 1H). MS m/z (ESI): 453.9 [M + H]. TDI01912

N-(3-methoxy-4- (1H-pyrazol-4- yl)phenyl)-2-(2- (thiazol-2-yl)- 1H-indol-6- yl)pyrimidin-4- amine

¹H NMR (400 MHz, DMSO-d₆) δ 12.72 (s, 1H), 11.84 (s, 1H), 8.48 (s, 1H), 8.34 (d, J = 6.9 Hz, 1H), 8.23 (d, J = 5.0 Hz, 2H), 8.06 (d, J = 8.2 Hz, 1H), 8.01 (d, J = 2.8 Hz, 1H), 7.89 (d, J = 2.9 Hz, 1H), 7.81 (dd, J = 22.7, 8.4 Hz, 3H), 7.46 (s, 1H), 7.22 (s, 1H), 7.17 (s, 1H), 3.95 (s, 3H). MS m/z (ESI): 465.6 [M + H]. TDI01940

N-(6-(1H- pyrazol-4- yl)pyridin-3-yl)- 2-(2-(thiazol-2- yl)-1H-indol-6- yl)pyrimidin-4- amine

¹H NMR (400 MHz, DMSO-d₆) δ 12.41 (s, 1H), 10.63 (s, 1H), 8.97 (s, 1H), 8.50-8.40 (m, 2H), 8.36 (d, J = 8.0 Hz, 1H), 8.27 (s, 2H), 8.02-7.99 (m, 2H), 7.92 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 4.0 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.17 (d, J = 2.0 Hz, 1H), 6.87 (d, J = 8.0 Hz, 1H). MS m/z (ESI): 437.0 [M + H]. TDI01941

N-(4-(1H- pyrazol-4- yl)phenyl)-2-(2- (thiazol-2-yl)- 1H-indol-6- yl)furo[3,2- d]pyrimidin-4- amine

¹H NMR (400 MHz, DMSO-d₆) δ 12.92 (s, 1H), 12.18 (s, 1H), 9.98 (s, 1H), 8.55 (s, 1H), 8.38 (d, J = 1.9 Hz, 1H), 8.17 (d, J = 8.3 Hz, 2H), 8.03 (d, J = 8.5 Hz, 2H), 7.96 (d, J = 3.1 Hz, 2H), 7.81 (d, J = 3.1 Hz, 1H), 7.68 (m, J = 9.1 Hz, 3H), 7.18-7.09 (m, 2H). MS m/z (ESI): 475.6 [M + H]. TDI01975

5-fluoro-N-(3- fluoro-4-(1H- pyrazol-4- yl)phenyl)-2-(2- (thiazol-2-yl)- 1H-indol-6- yl)pyrimidin-4- amine

¹H NMR (400 MHz, DMSO-d₆) δ 12.23 (s, 1H), 9.82 (s, 1H), 8.52 (d, J = 3.3 Hz, 1H), 8.45 (s, 1H), 8.05 (d, J = 13.7 Hz, 3H), 7.99-7.92 (m, 2H), 7.85- 7.80 (m, 2H), 7.69 (d, J = 8.4 Hz, 1H), 7.63-7.55 (m, 1H), 7.11 (s, 1H). MS m/z (ESI): 472.0 [M + H].

Example 48: Preparation of N-(4-(1H-pyrazol-4-yl)phenyl)-2-(1-methyl-(2-(thiazol-2-yl)-1H-indol-6-yl)pyrimidin-4-amine (TDI01919)

Step 1:

Compound TDI01826-5 (489 mg, 1.5 mmol) was dissolved in N,N-dimethylformamide (30 mL), sodium hydride (72 mg, 3 mmol) was added at 0° C., the reaction was stirred for 30 min before addition of iodomethane (638 mg, 4.5 mmol), and the reaction solution was stirred at room temperature for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was rotary evaporated under vacuum to remove the reaction solvent, and the residue was purified by column chromatography (petroleum ether ethyl acetate=4:1) to afford compound TDI01919-1 (420 mg, white solid, 82.3% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 8.02 (d, J=3.3 Hz, 1H), 7.88-7.83 (m, 2H), 7.63 (d, J=8.0 Hz, 1H), 7.42 (d, J=7.9 Hz, 1H), 7.11 (s, 1H), 4.18 (s, 3H), 1.33 (s, 12H). MS m/z (ESI): 341.0 [M+H].

Step 2:

Compound TDI01919-1 (150 mg, 0.44 mmol) and Reg-1-16 (164 mg, 0.44 mmol) were dissolved in 1,4-dioxane:water (8:0.8 mL), potassium carbonate (182 mg, 1.32 mmol) was added, and the flask was purged with nitrogen three times. Pd(dppf)Cl₂ (129 mg, 0.176 mmol) was added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 110° C. for 16 hours. LC-MS indicated the reaction was complete, the reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by preparative liquid chromatography to afford compound TDI01919 (40 mg, 20% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.78 (s, 1H), 8.53 (s, 1H), 8.40 (d, J=6.6 Hz, 1H), 8.07 (dd, J 15.3, 12.2 Hz, 4H), 7.93 (d, J=3.0 Hz, 1H), 7.88-7.70 (m, 5H), 7.23 (s, 1H), 6.87 (s, 1H), 4.26 (s, 3H). MS m/z (ESI): 449.9 [M+H].

Example 49: Preparation of 1-(5-(4-((1H-indazol-5-yl)amino)pyrimidin-2-yl)isoindolin-2-yl)-2-morpholinoethan-1-one (TDI01806)

Compound TDI01806-1 was synthesized according to a method similar to that described in step 1 to step 3 of Example 35.

Under protection of nitrogen, TDI01806-1 (100 mg, 0.305 mmol) was added to dichloromethane (10 mL), the reaction was cooled to 0° C., 2-bromoacetyl bromide (38 mg, 0.336 mmol) and trifluoroacetic acid (31 mg, 0.305 mmol) were slowly dropwise added, and the reaction was stirred at room temperature for 2 hours. morpholine (200 mg, 2.30 mmol) was added in one portion, and the reaction was allowed to warmed to room temperature, and stirred for 2 hours. LC-MS indicated the reaction was complete. The solvent was evaporated to afford a crude product, which was separated to afford compound TDI01806 (12 mg, yellow solid, yield: 90).

¹H NMR (400 MHz, DMSO-d₆) δ 8.32 (d, J=5.1 Hz, 1H), 8.19 (dd, J=24.1, 14.6 Hz, 4H), 7.59 (dt, J=14.1, 7.8 Hz, 3H), 6.82 (d, J=6.4 Hz, 1H), 4.91 (s, 2H), 4.83 (d, J=8.5 Hz, 2H), 4.34 (s, 2H), 3.75 (s, 4H), 3.08 (s, 4H). MS m/z (ESI): 456.0 [M+H].

Example 50: Preparation of N-(2-(2-(benzo[d]oxazol-2-yl)-1H-indol-6-yl]pyrimidin-4-yl)-1H-indazol-5-amine (TDI01816)

Step 1:

Compound TDI01816-1 (5 g, 20.8 mmol) and thionyl chloride (25 mL) were mixed, and stirred at room temperature until TLC indicated no starting materials remained. The reaction mixture was concentrated to remove thionyl chloride, and dissolved in dry dichloromethane (50 mL), a solution of 2-aminophenol (2.15 g, 19.7 mmol) in dichloromethane (50 mL) was added dropwise at 0° C., and the reaction was stirred at room temperature for 16 hours. The reaction solution was filtered to remove the insolubles, and the filtrate was concentrated to afford compound TDI01816-2 (1.95 g, brown solid, crude product, 28% yield).

MS m/z (ESI): 330.9 [M+H].

Step 2:

Compound TDI01816-2 (500 mg, 1.51 mmol) was dissolved in toluene (50 mL), p-toluenesulfonic acid (321 mg, 1.86 mmol) was added, and the reaction solution was stirred at 120° C. for 48 hours. LC-MS assay indicated that the reaction was substantially complete. The reaction solution was cooled to room temperature, 100 mL ethyl acetate and 50 mL saturated aqueous solution of sodium bicarbonate were added, and the aqueous phase was extracted with ethyl acetate (50 mL) after phase separation. The organic phases were combined and evaporated to dryness, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1 to 5:1) to afford compound TDI01816-3 (249 mg, white solid, 53% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 12.48 (s, 1H), 7.83-7.80 (m, 2H), 7.68 (d, J=8.8 Hz, 1H), 7.66 (s, 1H), 7.49-7.42 (m, 2H), 7.38 (s, 1H), 7.25 (d, J=8.4 Hz, 1H). MS m/z (ESI): 312.9, 314.8 [M+H].

Step 3:

Compound TDI01816-3 (210 mg, 0.67 mmol) and bis(pinacolato)diboron (170 mg, 0.67 mol) were dissolved in 1,4-dioxane (20 mL), potassium acetate (197 mg, 2.01 mmol) and Pd (dppf)Cl₂ (49 mg, 0.067 mmol) were added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 100° C. for 8 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered, the reaction solvent was removed through rotary evaporation under vacuum, and the residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1 to 5:1) to afford compound TDI01816-4 (153 mg, 63% yield).

MS m/z (ESI): 361.0 [M+H].

Step 4:

Compound TDI01816-4 (100 mg, 0.28 mmol) and Reg-1-1 (96 mg, 0.28 mmol) were dissolved in tetrahydrofuran (20 mL) and water (2 mL), tripotassium phosphate (176 mg, 0.83 mmol) and Pd(PPh₃)₄ (32 mg, 0.028 mmol) were added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 80° C. for 16 hours. LC-MS assay indicated the reaction was incomplete. The reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by preparative high pressure liquid chromatography to afford compound TDI01816 (1.8 mg, 1.5% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 12.78 (s, 1H), 10.22 (s, 1H), 8.55 (s, 2H), 8.38 (s, 2H), 8.24 (d, J=29.3 Hz, 2H), 8.13 (s, 1H), 7.87 (s, 3H), 7.65 (s, 2H), 7.46 (t, J=14.8 Hz, 2H), 6.74 (s, 1H). MS m/z (ESI): 443.7 [M+H].

The compound in following table 18 was prepared according to a method similar to that described in Example 50.

TABLE 18 Starting material or regent Com- different from that in No. Compound Structure pound Name Example 50 Characterization Data TDI01816B

N-(4-(1H- pyrazol-4- yl)phenyl)- 2-(2- (benzo[d] oxazol-2- yl)-1H- indol-6- yl)pyrimidin- 4- amine

¹H NMR (400 MHz, DMSO-d₆) δ 12.81 (s, 1H), 8.55 (s, 1H), 8.38 (d, J = 6.4 Hz, 1H), 8.09 (s, 3H), 7.93- 7.77 (m, 6H), 7.72 (d, J = 8.3 Hz, 2H), 7.47 (dd, J = 8.2, 4.4 Hz, 3H), 6.81 (s, 1H). MS m/z (ESI): 470.2 [M + H].

Example 51: Preparation of 4-((4-(1H-pyrazol-4-yl)phenyl)amino)-2-(2-(3,3-difluorocyclobutane-1-carbonyl)isoindolin-5-yl)pyrimidin-5-carboxylic acid (TDI01567C) and 4-((4-(1H-pyrazol-4-yl)phenyl)amino)-2-(2-(3,3-difluorocyclobutane-1-carbonyl)isoindolin-5-yl)pyrimidin-5-carboxamide (TDI01567)

Step 1:

Compound TDI01567B (195 mg, 0.358 mmol) was dissolved in THF (6 mL) and MeOH (6 mL), and 1 M aqueous solution of sodium hydroxide (6 mL) was added. The reaction was performed at room temperature for 3 h. LC-MS indicated the reaction was complete. The reaction solvent was removed through rotary evaporation under vacuum, and the residue was purified by preparative high pressure liquid chromatography to afford compound TDI01567C (117 mg, yellow solid, yield 64%).

¹H NMR (400 MHz, DMSO-d₆) δ 10.56 (s, 1H), 9.02 (s, 1H), 8.35 (dd, J=16.6, 8.7 Hz, 2H), 8.10 (s, 2H), 7.83-7.78 (m, 2H), 7.71 (dd, J=8.4, 4.0 Hz, 2H), 7.53 (dd, J=15.5, 8.0 Hz, 2H), 4.92 (d, J=6.7 Hz, 2H), 4.77 (d, J=12.7 Hz, 2H), 3.28 (d, J=5.8 Hz, 1H), 2.87 (dd, J=16.4, 8.6 Hz, 4H). MS m/z (ESI): 516.7 [M+H].

Step 2:

Compound TDI01567C (100 mg, 0.194 mmol) and HATU (81 mg, 0.213 mmol) were dissolved in N,N-dimethylformamide, and diisopropylethylamine (125 mg, 0.968 mmol) was added. Ammonia gas was bubbled through the reaction solution, and the reaction solution was stirred at room temperature for 2 h. LC-MS indicated the reaction was complete, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by preparative high pressure liquid chromatography to afford compound TDI01567 (20.59 mg, yellow solid, yield 20%).

¹H NMR (400 MHz, DMSO-d₆) δ 11.49-11.46 (m, 1H), 9.01 (s, 1H), 8.44 (s, 1H), 8.32 (d, J=9.7 Hz, 2H), 8.08 (s, 2H), 7.89-7.83 (m, 1H), 7.80-7.77 (m, 2H), 7.70-7.67 (m, 2H), 7.56-7.49 (m, 1H), 4.91 (s, 2H), 4.76 (s, 2H), 2.87 (d, J=8.6 Hz, 4H). MS m/z (ESI): 515.8 [M+H].

Example 52: Preparation of 6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-N-(3-cyanopyridin-4-yl)-1H-indole-2-carboxamide (TDI01829B)

Compound TDI01829C (30 mg, 0.05 mmol) and Zn(CN)₂ (17 mg, 0.15 mmol) were dissolved in N,N-dimethylformamide (3 mL), Pd(PPh₃)₄ (11 mg, 0.01 mmol) was added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 110° C. for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, added with water (5 mL), extracted with ethyl acetate (10 mL×3), and the organic phase was rotary evaporated under vacumm to remove the solvent. The residue was purified by preparative high pressure liquid chromatography, to afford compound TDI01829B (2.37 mg, yellow solid, 10% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 12.52 (s, 1H), 11.08 (s, 1H), 9.03 (s, 1H), 8.85 (s, 1H), 8.54 (s, 1H), 8.38 (d, J=5.6 Hz, 1H), 8.09 (s, 4H), 7.96 (s, 1H), 7.76 (dd, J=27.9, 10.9 Hz, 6H), 7.59 (s, 1H), 6.85 (s, 1H). MS m/z (ESI): 498.0 [M+H].

Example 53: Preparation of (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1H-indol-2-yl)dimethylphosphine oxide (TDI01846)

Step 1:

Compound TDI01846-1 (1.0 g, 5.1 mmol) and bis(pinacolato)diboron (1.3 g, 5.1 mmol) were dissolved in 1,4-dioxane (20 mL), potassium acetate (1.5 g, 15.3 mmol) and Pd(dppf)Cl₂ (373 mg, 0.51 mmol) were added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 100° C. for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered to remove the insolubles, and the filtrate was rotary evaporated under vacuum to remove solvents. The residue was purified by column chromatography (petroleum ether:ethyl acetate=4:1), to afford compound TDI01846-2 (670 mg, yellow solid, 54% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 11.17 (s, 1H), 7.76 (s, 1H), 7.52 (d, J=7.9 Hz, 1H), 7.44 (t, J=2.7 Hz, 1H), 7.28 (d, J=7.9 Hz, 1H), 6.43 (s, 1H), 1.30 (s, 12H). MS m/z (ESI): 244.0 [M+H].

Step 2:

Compound TDI01846-2 (150 mg, 0.6 mmol) and compound Reg-1-16 (290 mg, 0.78 mmol) were dissolved in a mixed solution of dioxane (15 mL) and water (1.5 mL), tripotassium phosphate (382 mg, 1.8 mmol) and Pd(dppf)Cl₂ (42 mg, 0.06 mmol) were added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 100° C. for 16 h. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered to remove the insolubles, and the filtrate was rotary evaporated under vacuum to remove the reaction solvent. The residue was purified by column chromatography (dichloromethane:methanol=30:1) to afford compound TDI01846-3 (344 mg, crude product).

MS m/z (ESI): 453.0 [M+H].

Step 3:

Compound TDI01846-3 (344 mg, 0.76 mmol) was dissolved in dichloromethane (10 mL), triethylamine (232 mg, 23 mmol) and 4,4-dimethylaminopyridine 9 mg, 0.076 mmol) were added, Boc₂O (479 mg, 2.3 mmol) was then added, and the reaction was performed at room temperature overnight. The reaction solution was concentrated to afford a crude product, The residue was purified by column chromatography (petroleum ether:ethyl acetate=4:1) to afford compound TDI01846-4 (120 mg, off-white solid, 24% yield).

MS m/z (ESI): 652.8 [M+H].

Step 4: A mixture of compound TDI01846-4 (70 mg, 0.11 mmol), Ag₂CO₃ (41 mg, 0.15 mmol) and Mg(NO₃)₂ (22 mg, 0.15 mmol) was added to acetonitrile (5 mL), HPOMe₂ (12 mg, 0.15 mmol) was then added in one portion, the flask was purged with nitrogen three times, and the reaction solution was stirred at 80° C. for 24 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, the reaction solvent was removed through rotary evaporation under vacuum, and the residue was purified by preparative thin layer chromatography (developing agent:dichloromethane:methanol=15:1), to afford compound TDI01846-5 (100 mg, crude product).

MS m/z (ESI): 628.9 [M+H].

Step 5:

Compound TDI01846-5 (100 mg, crude product, theoretically 0.11 mmol) was dissolved in tetrahydrofuran (2 mL), 4M HCl/dioxane (1 mL) was added, and the reaction solution was stirred at room temperature for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, the reaction solvent was removed through rotary evaporation under vacuum, and the residue was purified by preparative liquid chromatography to afford compound TDI01846 (6.1 mg, yellow solid, yield 13%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.20 (s, 1H), 8.46 (s, 1H), 8.36 (s, 1H), 8.08 (s, 1H), 8.03 (s, 1H), 7.92-7.76 (m, 3H), 7.71 (d, J=8.2 Hz, 2H), 7.66 (s, 1H), 7.02 (s, 1H), 6.89-6.75 (m, 2H), 1.77 (t, J=26.9 Hz, 6H). MS m/z (ESI): 428.9 [M+H].

Example 54: Preparation of N-(2-(2-(benzo[d]thiazol-2-yl)-1H-indol-6-yl)pyrimidin-4-yl)-1H-indazol-5-amine (TDI01881)

Step 1:

Compound TDI01881-1 (200 mg, 0.59 mmol), 2-iodobenzo[d]thiazole (170 mg, 0.65 mmol), sodium carbonate (191 mg, 1.77 mmol) and Pd(PPh₃)Cl₂ (42 mg, 0.059 mmol) were mixed in mixed solvents of acetonitrile (20 mL) and water (2 mL), the flask was purged with N₂ 3 times, and then the reaction solution was heated to reflux and reacted for 1 hour. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered to remove salt impurities, the filtrate was concentrated under reduced pressure, and the crude product was separated through column chromatography on silica gel (petroleum ether:ethyl acetate=5:1) to afford compound TDI01881-2 (160 mg, brown viscous oil, yield: 63.5%).

¹H NMR (400 MHz, DMSO-d₆) δ 8.23 (d, J=12.7 Hz, 2H), 8.12 (d, J=8.0 Hz, 1H), 8.02 (d, J=8.3 Hz, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.62 (d, J=7.5 Hz, 1H), 7.52 (m, 2H), 1.25 (s, 9H). MS m/z (ESI): 428.5, 430.5 [M+H, Br].

Step 2:

Compound TDI01881-2 (160 mg, 0.37 mmol), bis(pinacolato)diboron (150 mg, 0.49 mmol), potassium acetate (109 mg, 1.11 mmol) and Pd(dppf)Cl₂ (27 mg, 0.037 mmol) were dissolved in 1,4-dioxane (8 mL), the flask was purged with N₂ 3 times, and the reaction was refluxed in an oil bath at 108° C. for 10 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure to afford a crude product, which was separated through column chromatography on silica gel (petroleum ether:ethyl acetate=4:1) to afford compound TDI01881-3 (158 mg, orange solid, yield: 88.8%).

¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (s, 1H), 8.23 (d, J=7.8 Hz, 1H), 8.11 (d, J=8.2 Hz, 1H), 7.75 (d, J=7.8 Hz, 1H), 7.61 (m, 2H), 7.53 (m, 1H), 7.36 (s, 1H), 1.34 (s, 12H), 1.24 (s, 9H).

Step 3:

Compound TDI01881-3 (50 mg, 0.24 mmol), compound Reg-1-1 (98 g, 0.28 mmol), potassium carbonate (116 mg, 0.84 mmol) and Pd(dppf)Cl₂ (82 mg, 0.112 mmol) were mixed in mixed solvents of 1,4-dioxane (5 mL) and water (0.5 mL), the flask was purged with N₂ 3 times, and then the reaction solution was heated to reflux overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered to remove salt impurities, and the filtrate was concentrated under reduced pressure to afford a crude product, which was separated to afford compound TDI01881-4 (16 mg, yellow solid, yield: 27.3%).

MS m/z (ESI): 559.5 [M+H].

Step 4:

Compound TDI01881-4 (16 mg, 0.029 mmol) was dissolved in trifluoroacetic acid (2 mL) and tetrahydrofuran (3 mL), and heated to reflux overnight. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure to afford a crude product, which was separated to afford compound TDI01881 (1.45 mg, yellow solid, yield: 11.2%).

¹H NMR (400 MHz, DMSO-d₆) δ 13.12 (s, 1H), 12.68 (s, 1H), 8.52 (s, 1H), 8.35 (d, J=6.1 Hz, 1H), 8.28-8.16 (m, 3H), 8.09 (d, J=7.9 Hz, 1H), 7.81 (s, 1H), 7.68-7.56 (m, 3H), 7.52-7.48 (m, 1H), 7.36 (s, 1H), 7.20 (s, 1H), 6.74 (s, 1H), 6.66 (s, 1H). MS m/z (ESI): 460.0 [M+H].

The compound in following table 19 was prepared according to a method similar to that described in Example 54.

TABLE 19 Starting material or regent different No. Compound Structure Compound Name from that in Example 54 Characterization Data TDI01870

N-(4-(1H-pyrazol-4-yl)phenyl)-2-(2- (pyrimidin-2-yl)-1H-indol-6-yl)pyrimidin- 4-amine

¹H NMR (400 MHz, DMSO-d₆) δ 12.48 (s, 1H), 10.77 (s, 1H), 8.95 (d, J = 4.8 Hz, 2H), 8.52 (s, 1H), 8.36 (d, J = 6.7 Hz, 1H), 8.11 (s, 2H), 7.96 (d, J = 8.2 Hz, 1H), 7.91-7.79 (m, 3H), 7.75 (d, J = 8.4 Hz, 2H), 7.49 (m, J = 4.9 Hz, 1H), 7.43 (s, 1H), 6.88 (d, J = 6.0 Hz, 1H). MS m/z (ESI): 430.7 [M + H].

Example 55: Preparation of 2-(2-(1H-imidazol-1-yl)-1-methyl-1H-indol-6-yl)-N-(4-(1H-pyrazol-4-yl)phenyl)pyrimidin-4-amine (TDI01876B)

Step 1:

Compound TDI01876B-1 (200 mg, 1.05 mmol) was dissolved in tetrahydrofuran (5 mL), and cooled to 0° C. under protection of nitrogen. Sodium hydride (63 mg, 60%, 1.53 mmol) was added portionwise, and the reaction was performed at 0° C. for 0.5 hour. Iodomethane (435 mg, 3.06 mmol) was added in one portion, and the reaction was stirred at room temperature overnight after the addition. LC-MS indicated the reaction was complete. 0.1 mL water was added dropwise, and the solvent was rotary evaporated to afford the crude product, which was separated through column chromatography on silica gel (petroleum ether:ethyl acetate=10:1) to afford compound TDI01876B-2 (180 mg, brown solid, yield: 84.5%).

¹H NMR (400 MHz, DMSO-d₆) δ 7.69 (s, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.34 (d, J=3.0 Hz, 1H), 7.13 (m, 1H), 6.44 (d, J=3.0 Hz, 1H), 3.78 (s, 3H).

Step 2:

Compound TDI01876B-2 (180 mg, 0.86 mmol) and imidazole (146 mg, 2.15 mmol) were dissolved in mixed solvents of 1,4-dioxane (1 mL) and a saturated aqueous solution of ammonium formate, solid iodine (539 mg, 2.125 mmol) was added in one portion, and the reaction was stirred at room temperature overnight. LC-MS indicated the reaction was complete. Iodine was removed by washing with a saturated solution of sodium thiosulfate, the mixture was extracted with ethyl acetate (15 mL for three times), and the organic phases were combined and rotary evaporated to afford the crude product, which was purified by flash column chromatography to afford compound TDI01876B-3 (110 mg, brown solid, yield: 46.4%).

¹H NMR (400 MHz, DMSO-d₆) δ 8.03 (s, 1H), 7.86 (s, 1H), 7.58 (m, 2H), 7.26 (d, J=8.4 Hz, 1H), 7.19 (s, 1H), 6.66 (s, 1H), 3.56 (s, 3H). MS m/z (ESI): 275.9, 278.0 [M+H, Br].

Step 3:

Compound TDI01876B-3 (110 mg, 0.4 mmol), bis(pinacolato)diboron (112 mg, 0.44 mmol) and potassium acetate (118 g, 1.2 mmol) were dissolved in 1,4-dioxane (10 mL), the flask was purged with N₂ 3 times, followed by addition of Pd(dppf)Cl₂ (30 mg, 0.04 mmol), the flask was purged with N₂ 3 times again, and then the reaction was placed in an oil bath at 108° C. for 4 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated under reduced pressure to afford the crude product, which was separated through column chromatography on silica gel (petroleum ether:ethyl acetate=8:1) to afford compound TDI01876B-4 (80 mg, yellow solid, yield: 62%).

¹H NMR (400 MHz, DMSO-d₆) δ 8.03 (s, 1H), 7.82 (s, 1H), 7.60 (d, J=7.4 Hz, 2H), 7.44 (d, J=7.9 Hz, 1H), 7.19 (s, 1H), 6.64 (s, 1H), 3.60 (s, 3H), 1.32 (s, 9H). MS m/z (ESI): 324.2 [M+H].

Step 4:

Compound TDI01876B-4 (80 mg, 0.25 mmol), Reg-1-16 (92 mg, 0.25 mmol) and potassium carbonate (104 mg, 0.75 mmol) were mixed in mixed solvents of 1,4-dioxane (5 mL) and water (0.5 mL), Pd(dppf)Cl₂ (37 mg, 0.05 mmol) was added, the flask was purged with N₂ 3 times, and then the reaction solution was heated to reflux and reacted for 20 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered to remove salt impurities, and the filtrate was concentrated under reduced pressure to afford the crude product, which was separated to afford TDI01876B (10 mg, yellow solid, yield: 9.3%).

¹H NMR (400 MHz, DMSO-d₆) δ 12.90 (s, 1H), 9.66 (s, 1H), 8.54 (s, 1H), 8.40 (d, J=5.4 Hz, 1H), 8.22 (d, J=8.3 Hz, 1H), 8.16 (s, 1H), 8.07 (s, 1H), 7.92 (s, 1H), 7.82 (d, J=7.6 Hz, 2H), 7.76-7.60 (m, 4H), 7.21 (s, 1H), 6.69 (s, 2H), 3.66 (s, 3H). MS m/z (ESI): 433.1 [M+H].

The compound in following table 20 was prepared according to a method similar to that described in Example 55.

TABLE 20 Starting material or Compound regent different from that No. Compound Structure Name in Example 55 Characterization Data TDI01684

2-(2-(1H- imidazol-1- yl)-1- methyl-1H- indol-6-yl)- N-(3-fluoro- 4-(1H- pyrazol-4- yl)phenyl)py- rimidin-4- amine

¹H NMR (400 MHz, DMSO-d₆) δ 10.31 (s, 1H), 9.06 (s, 1H), 8.58 (s, 1H), 8.46 (d, J = 6.0 Hz, 1H), 8.18 (d, J = 8.2 Hz, 1H), 8.14-8.00 (m, 4H), 7.88-7.66 (m, 4H), 7.47 (d, J = 8.5 Hz, 1H), 6.91 (s, 1H), 6.82 (d, J = 5.8 Hz, 1H), 3.74 (s, 3H). MS m/z (ESI): 451.1 [M + H].

Example 56: Preparation of (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-vinyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone (TDI01923)

Starting compound TDI01923-1 was synthesized according to the method in step 1 of Example 46.

Step 1:

Compound TDI01923-1 (500 mg, 1.59 mmol) was dissolved in DMF (15 mL), and cooled to 0° C. in an ice-water bath under protection of N₂. NaH (60%, 96 mg, 2.39 mmol) was was added portionwise, and 1-bromo-2-chloroethane (339 mg, 2.39 mmol) was added after the reaction was stirred for 15 minutes. The reaction was stirred at 30° C. for 16 hours. LC-MS indicated half completion of the reaction. The reaction solution was cooled to 0° C., added with water (45 mL), and then extracted with ethyl acetate (15 mL×3). The residue obtained after evaporation of the organic phase was purified by column chromatography (petroleum ether:ethyl acetate=5:1) to afford compound TDI01923-2 (280 mg, white solid, 47% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 7.98 (s, 1H), 7.60 (d, J=8.5 Hz, 1H), 7.27 (dd, J=8.5, 1.1 Hz, 1H), 7.09 (s, 1H), 4.84 (t, J=6.0 Hz, 2H), 4.82 (s, 2H), 4.53 (s, 2H), 3.95 (t, J=6.0 Hz, 2H). MS m/z (ESI): 398.6, 400.4 [M+Na].

Step 2:

Compound TDI01923-2 (280 mg, 0.74 mmol), potassium hydroxide (376 mg, 6.7 mmol) and hydroquinone (2 mg, 0.0074 mmol) were dissolved in toluene (10 mL), the reaction was purged with nitrogen three times, and placed in an oil bath at 115° C. for 16 hours. LC-MS assay indicated the reaction was complete. The reaction solution was cooled to room temperature, concentrated, and the residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1) to afford compound TDI01923-3 (70 mg, white solid, 28% yield).

MS m/z (ESI): 340.9, 342.9 [M+H].

Step 3:

Compound TDI01923-3 (70 mg, 0.21 mmol) and bis(pinacolato)diboron (63 mg, 0.25 mmol) were dissolved in 1,4-dioxane (10 mL), potassium acetate (62 mg, 0.63 mmol) and Pd(dppf)Cl₂ (31 mg, 0.042 mmol) were added, and the reaction was purged with nitrogen three times, and placed in an oil bath at 110° C. for 16 hours. LC-MS assay indicated the reaction was complete. The reaction solution was cooled to room temperature, filtered to remove the insolubles, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1 to 5:1), to afford compound TDI01923-4 (55 mg, white solid, 67% yield).

MS m/z (ESI): 389.0 [M+H].

Step 4:

Compound TDI01923-4 (55 mg, 0.14 mmol) and Reg-1-16 (58 mg, 0.16 mmol) were dissolved in 1,4-dioxane:water (5:0.5 mL), potassium carbonate (58 mg, 0.42 mmol) and Pd(dppf)Cl₂ (20 mg, 0.028 mmol) were added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 110° C. for 16 hours. LC-MS indicated the reaction was complete, the reaction solution was cooled to room temperature, filtered to remove the insolubles, and the filtrate was rotary evaporated under vacuum to remove solvents. The residue was purified by preparative high pressure liquid chromatography to afford compound TDI01923 (5.7 mg, yellow solid, 8% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 10.45 (s, 1H), 8.81 (s, 1H), 8.40 (d, J=6.4 Hz, 1H), 8.15 (d, J=8.4 Hz, 1H), 8.10 (s, 2H), 7.86 (d, J=8.4 Hz, 1H), 7.78 (d, J=7.8 Hz, 2H), 7.68 (d, J=8.4 Hz, 2H), 7.56 (d, J=7.0 Hz, 1H), 7.26 (s, 1H), 6.84 (d, J=6.4 Hz, 1H), 5.60 (d, J=16.0 Hz, 2H), 5.41 (d, J=8.8 Hz, 1H), 4.90 (s, 2H), 4.55 (s, 2H). MS m/z (ESI): 498.0 [M+H].

Example 57: Preparation of (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-(2,2-difluoroethyl)-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone (TDI01678)

Compound TDI01678-1 in Example 57 was synthesized according to step 3 to step 4 of Example 2.

Step 1:

Compound TDI01678-1 (200 mg, 0.55 mmol) was dissolved in N,N-dimethylformamide (5 mL), sodium hydride (33 mg, 0.83 mmol) was added at 0° C., after being stirred for 30 min, 1,1-difluoro-2-iodoethane (159 mg, 0.83 mmol) was added, and the reaction solution was stirred at room temperature for 16 hours. LC-MS indicated there was product formation. The reaction solution was rotary evaporated under vacuum to remove the reaction solvent, and the residue was purified by column chromatography (petroleum ether:ethyl acetate=4:1) to afford compound TDI01678-2 (105 mg, 44.8% yield).

MS m/z (ESI): 426.9 [M+H].

Step 2:

Compound TDI01678-2 (105 mg, 0.246 mmol) and Reg-1-16 (92 mg, 0.246 mmol) were dissolved in 1,4-dioxane:water (10:1 mL), potassium carbonate (102 mg, 0.738 mmol) was added, and the flask was purged with nitrogen three times. Pd(dppf)Cl₂ (54 mg, 0.074 mmol) was added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 110° C. for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by preparative liquid chromatography to afford compound TDI01678 (7 mg).

¹H NMR (400 MHz, DMSO-d₆) δ 10.37 (s, 1H), 8.64 (s, 1H), 8.41 (d, J=6.2 Hz, 1H), 8.13 (d, J=8.3 Hz, 1H), 8.04 (s, 2H), 7.89-7.79 (m, 3H), 7.68 (d, J=8.1 Hz, 2H), 7.25 (s, 1H), 6.83 (d, J=5.9 Hz, 1H), 6.66-6.38 (m, 1H), 5.01 (dd, J=36.5, 21.2 Hz, 4H), 4.57 (s, 2H). MS m/z (ESI): 535.5 [M+H].

Example 58: Preparation of 5-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)-5-fluoropyrimidin-2-yl)-2-((3,3-difluorocyclobutyl)methyl)isoindolin-1-one (TDI01593)

Step 1:

Compound TDI01593-1 (5 g, 40.95 mmol) and 4-toluene sulfonyl chloride (9.37 g, 49.14 mmol) were dissolved in dichloromethane (150 mL), 4-dimethylaminopyridine (500 mg, 4.095 mmol) and triethylamine (12.4 g, 123.0 mmol) were added, and the reaction solution was stirred at room temperature for 16 hours. LC-MS indicated the reaction was complete, the reaction solution was rotary evaporated under vacuum to remove the reaction solvent, and the residue was purified by column chromatography (petroleum ether ethyl acetate=4:1) to afford compound TDI01593-2 (11.2 g, 99% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 7.81 (d, J=7.9 Hz, 2H), 7.50 (d, J=7.9 Hz, 2H), 4.10 (d, J=6.6 Hz, 2H), 2.67-2.56 (m, 2H), 2.43 (s, 4H), 2.30 (dd, J=14.0, 6.3 Hz, 2H). MS m/z (ESI): 299.0 [M+Na].

Step 2:

Compound TDI01593-2 (6.5 g, 23.6 mmol) and 5-bromoisoindolin-1-one (2.0 g, 9.43 mmol) were dissolved in acetonitrile (100 mL), cesium carbonate (7.7 mg, 23.6 mmol) and sodium iodide (3.54 g, 23.6 mmol) were added, and the reaction solution was stirred at 100° C. for 16 hours. LC-MS assay indicated there was product formation. The reaction solution was subjected to vacuum filtration, the filtrate was rotary evaporated under vacuum to remove solvents, and the residue was purified by column chromatography (petroleum ether:ethyl acetate=4:1 to 1:1) to afford compound TDI01593-3 (800 mg, 26.8% yield).

¹H NMR (400 MHz, DMSO-d₆) δ 7.87 (s, 1H), 7.69 (d, J=8.1 Hz, 1H), 7.62 (d, J=8.1 Hz, 1H), 4.50 (s, 2H), 3.65 (d, J=7.3 Hz, 2H), 2.74-2.64 (m, 2H), 2.48-2.30 (m, 3H). MS m/z (ESI): 315.7 [M+H].

Step 3:

Compound TDI01593-3 (600 mg, 1.9 mmol) and bis(pinacolato)diboron (579 mg, 2.28 mmol) were dissolved in 1,4-dioxane (20 mL), potassium acetate (559 mg, 5.7 mmol) was added, and the flask was purged with nitrogen three times. Pd(dppf)Cl₂ (278 mg, 0.38 mmol) was added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 100° C. for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography (petroleum ether:ethyl acetate=4:1) to afford compound TDI01593-4 (620 mg, 89.8% yield).

MS m/z (ESI): 364.1 [M+H].

Step 4:

Compound TDI01593-4 (200 mg, 0.55 mmol) and Reg-1-40 (215 mg, 0.55 mmol) were dissolved in 1,4-dioxane:water (10:1 mL), potassium carbonate (228 mg, 1.65 mmol) was added, and the flask was purged with nitrogen three times. Pd(dppf)Cl₂ (121 mg, 0.165 mmol) was added, the flask was purged with nitrogen three times, and the reaction solution was stirred at 110° C. for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was cooled to room temperature, and the reaction solvent was removed through rotary evaporation under vacuum. The residue was purified by column chromatography and preparative liquid chromatography, to afford compound TDI01593 (52 mg).

¹H NMR (400 MHz, DMSO-d₆) δ 9.75 (s, 1H), 8.53 (d, J=3.1 Hz, 1H), 8.44 (s, 1H), 8.40 (d, J=7.7 Hz, 1H), 8.07 (s, 2H), 7.87 (d, J=8.2 Hz, 2H), 7.79 (d, J=8.0 Hz, 1H), 7.67 (d, J=8.2 Hz, 2H), 4.60 (s, 2H), 3.69 (d, J=6.9 Hz, 3H), 2.68 (s, 4H). MS m/z (ESI): 491.1 [M+H].

The compound in following table 21 was prepared according to a method similar to that described in Example 58.

TABLE 21 Starting material or regent different from that in Example No. Compound Structure Compound Name 58 Characterization Data TDI01590

6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)-5- fluoropyrimidin-2-yl)-2-((3,3- difluorocyclobutyl)methyl)isoin- dolin-1-one

¹H NMR (400 Mhz, DMSO-d₆) δ 9.73 (s, 1H), 8.56-8.46 (m, 3H), 8.08 (s, 2H), 7.86 (d, J = 8.3 Hz, 2H), 7.72 (d, J = 7.8 Hz, 1H), 7.67 (d, J = 8.5 Hz, 2H), 4.58 (s, 2H), 3.69 (d, J = 6.8 Hz, 2H), 2.70 (d, J = 14.4 Hz, 3H), 2.42 (s, 2H). MS m/z (ESI): 491.1 [M + H].

Biological Assay

The kinase IC₅₀ was determined by a commercialized CISBIO kinase detection kit, HTRF KinEASE-STK S2 kit (62ST2PEC). ROCK2 (01-119) employed in the reaction was purchased from Carna Biosciences.

Before the assay, the following working solutions as needed were formulated with corresponding reagents according to the instruction of the kinase detection kit: 1×kinase buffer, 5×STK-S2 substrate working solution (1.5 μM) and 5×ATP working solution (1.5 μM), 5×ROCK2 kinase working solution, 4×Streptavidin-XL665 working solution, and 4×xSTK-Ab-Cryptate 2 detection solution. Then the assay was performed according to the following procedure.

A solution of a compound at a concentration of 10000 nM was prepared with the 1×kinase buffer containing 2.5% DMSO. Gradient dilution of the solution of the compound was performed with the kinase buffer containing DMSO, so as to obtain solutions of a test compound at 9 different concentrations. In addition to wells of test compounds, a positive well (containing all the reagents except the compound) and a negative well (containing all the reagents except the test compound and kinase) were set. Except for the control wells (positive and negative wells), a solution of a test compound (4 μL) was added to each of the reaction wells, and a solution of 2.5% DMSO was added to the control wells. Then the substrate (2 μM, i.e., 2 μL 5×STK-S2 substrate working solution) was added to each of the reaction wells. The 5×ROCK2 kinase working solution (2 μL, containing 1.4 ng ROCK2 kinase) was added to each of the reaction wells except for the negative well, the volume of which was made up with the 1×kinase buffer (2 μL). The 5×ATP working solution (2 μL) was added to each of the reaction wells, and the mixtures were incubated at room temperature for 2 hours. After the kinase reaction was complete, the 4×xStreptavidin-XL665 working solution was added to each of the reaction wells, the solutions were mixed, followed by immediate addition of the 4×STK-Ab-Cryptate 2 detection solution (5 μL), and the mixtures were incubated at room temperature for 1 hour. The fluorescence signal was read on ENVISION (Perkinelmer) (excitation wavelength: 320 nm, and emission wavelength: 665 nm and 615 nm). The inhibitory rate in each well was calculated based on the fluorescence intensity value: ER (Emission Ratio)=(fluorescence intensity at 665 nm/fluorescence intensity at 615 nm); inhibitory rate=(ER_(positive)−ER_(test compound))/(ER_(positive)−ER_(negative))*100%. Curves were plotted and fitted to obtain the median inhibitory concentration (IC₅₀) of each teat compound with the PRISM 5.0 software. IC₅₀ value of each compound is as shown in the following table.

Compound No. ROCK2 IC₅₀ (nM) TDI01102 110 TDI01103 167 TDI01104 71 TDI01106 112 TDI01108 22 TDI01109 447 TDI01110 422 TDI01111 100 TDI01112 185 TDI01113 42 TDI01114 157 TDI01116 236 TDI01121 470 TDI01122 219 TDI01127 100 TDI01128 145 TDI01130 33 TDI01131 101 TDI01134 62 TDI01135 123 TDI01136 66 TDI01140 109 TDI01141 73 TDI01142 225 TDI01143 72 TDI01149 100 TDI01151 45 TDI01152 88 TDI01153 16 TDI01156 25 TDI01160 54 TDI01161 210 TDI01164 438 TDI01167 223 TDI01171 63 TDI01175 197 TDI01176 28 TDI01177 71 TDI01178 168 TDI01180 37 TDI01181 92 TDI01182 46 TDI01188 123 TDI01191 225 TDI01199 30 TDI01200 23 TDI01201 48 TDI01213 255 TDI01215 382 TDI01221 91 TDI01230 109 TDI01232 295 TDI01236 135 TDI01237 171 TDI01247 134 TDI01248 500 TDI01250 208 TDI01251 101 TDI01258 62 TDI01276 113 TDI01280 94 TDI01285 116 TDI01289 72 TDI01290 46 TDI01291 32 TDI01292 242 TDI01294 352 TDI01296 211 TDI01299 463 TDI01311 465 TDI01312 73 TDI01315 126 TDI01316 87 TDI01317 112 TDI01318 18 TDI01319 258 TDI01320 410 TDI01324 101 TDI01327 472 TDI01330 474 TDI01331 260 TDI01332 257 TDI01337 121 TDI01338 115 TDI01339 147 TDI01343 436 TDI01344 97 TDI01344-2A 107 TDI01345 333 TDI01347 356 TDI01353 307 TDI01354 254 TDI01355 54 TDI01360 26 TDI01363 104 TDI01366 260 TDI01368 412 TDI01369 266 TDI01370 109 TDI01372 123 TDI01374 64 TDI01379 411 TDI01381 341 TDI01385 107 TDI01390 18 TDI01392 172 TDI01393 258 TDI01394 28 TDI01397 120 TDI01398 16 TDI01400 240 TDI01403 110 TDI01404 35 TDI01405 160 TDI01406 285 TDI01408 400 TDI01411 258 TDI01415 262 TDI01418 272 TDI01419 385 TDI01420 477 TDI01421 289 TDI01423 264 TDI01424 138 TDI01425 119 TDI01426 365 TDI01428 69 TDI01429 99 TDI01430 116 TDI01431 203 TDI01433 13 TDI01434 34 TDI01435 28 TDI01437 247 TDI01438 402 TDI01439 203 TDI01441 181 TDI01442 305 TDI01444 32 TDI01445 64 TDI01448 13 TDI01450 453 TDI01455 29 TDI01456 15 TDI01457 395 TDI01461 140 TDI01462 240 TDI01463 11 TDI01464 175 TDI01465 398 TDI01467 75 TDI01470 33 TDI01472 174 TDI01473 18 TDI01477 47 TDI01485 276 TDI01486 185 TDI01487 193 TDI01490 81 TDI01497 319 TDI01498 415 TDI01500 13 TDI01505 209 TDI01506 295 TDI01507 113 TDI01508 159 TDI01512 22 TDI01513 269 TDI01514 49 TDI01515 110 TDI01516 322 TDI01517 92 TDI01518 78 TDI01519 102 TDI01520 15 TDI01523 86 TDI01524 30 TDI01525 335 TDI01532 49 TDI01534 114 TDI01536 105 TDI01538 198 TDI01546 26 TDI01550 21 TDI01551 31 TDI01552 51 TDI01555 140 TDI01557B 49 TDI01559 170 TDI01560 83 TDI01561 205 TDI01562 23 TDI01564 29 TDI01565 57 TDI01567 65 TDI01567C 29 TDI01570 22 TDI01575 169 TDI01578 129 TDI01580 19 TDI01581 28 TDI01582 24 TDI01584 60 TDI01585 93 TDI01586 162 TDI01587 25 TDI01589 39 TDI01590 266 TDI01596 275 TDI01596B 130 TDI01597B 123 TDI01598 216 TDI01609 69 TDI01613 27 TDI01617 255 TDI01618A 129 TDI01621 219 TDI01628 28 TDI01633 27 TDI01634 16 TDI01655 331 TDI01656 442 TDI01658 477 TDI01668 42 TDI01675 84 TDI01676 242 TDI01678 159 TDI01681 238 TDI01682 360 TDI01683 360 TDI01684 171 TDI01690 427 TDI01691 6 TDI01801 68 TDI01813 90 TDI01814 18 TDI01816 111 TDI01823 336 TDI01826 75 TDI01829B 82 TDI01829C 97 TDI01832 167 TDI01840 5 TDI01841 11 TDI01842 120 TDI01842B 61 TDI01844 370 TDI01847 14 TDI01847B 26 TDI01848 90 TDI01849 132 TDI01849B 210 TDI01851 15 TDI01852 482 TDI01853 275 TDI01855 147 TDI01856 141 TDI01861 41 TDI01862 382 TDI01864 30 TDI01865 400 TDI01868 32 TDI01870 46 TDI01876B 240 TDI01878 9 TDI01881 161 TDI01882 8 TDI01884 26 TDI01898 350 TDI01901 387 TDI01903 118 TDI01905 9 TDI01906 49 TDI01908 27 TDI01910 6 TDI01912 44 TDI01914 23 TDI01915 18 TDI01916 80 TDI01918 165 TDI01919 62 TDI01920 200 TDI01921 355 TDI01923 50 TDI01932 12 TDI01936 27 TDI01937B 39 TDI01940 147 TDI01943 34 TDI01944 44 TDI01945 76 TDI01947 88 TDI01948 103 TDI01949 59 TDI01950 19 TDI01951 27 TDI01952 10 TDI01953 4 TDI01954 14 TDI01955 33 TDI01957 214 TDI01958 214 TDI01959 131 TDI01960 50 TDI01962 40 TDI01965 393 TDI01966 313 TDI01967 45 TDI01968A 296 TDI01973 52 TDI01974 186 TDI01976 18 TDI01978 45 TDI01979 137 TDI01989 385 TDI01991 39 TDI01999 10

According to a biological test method similar to the above, the IC₅₀ values of the compounds on ROCK1 were tested. The results are shown in the following table.

Compound No. ROCK1 IC₅₀ (nM) TDI01103 2055 TDI01104 870 TDI01109 >10000 TDI01110 >10000 TDI01111 1407 TDI01113 554 TDI01116 >10000 TDI01122 3267 TDI01134 1372 TDI01135 3000 TDI01136 827 TDI01141 839 TDI01143 1484 TDI01149 1323 TDI01151 892 TDI01152 >10000 TDI01153 2720 TDI01156 1994 TDI01160 2236 TDI01161 >10000 TDI01164 >10000 TDI01167 >10000 TDI01175 5189 TDI01176 521 TDI01177 894 TDI01180 2776 TDI01181 947 TDI01182 712 TDI01188 1279 TDI01191 2526 TDI01199 1098 TDI01200 559 TDI01201 6916 TDI01213 >10000 TDI01230 1503 TDI01232 >10000 TDI01236 >10000 TDI01237 >10000 TDI01247 >10000 TDI01250 >10000 TDI01251 >10000 TDI01276 >10000 TDI01280 1023 TDI01289 980 TDI01290 >10000 TDI01291 573 TDI01292 4839 TDI01294 >10000 TDI01296 2868 TDI01311 >10000 TDI01312 1843 TDI01315 2150 TDI01316 999 TDI01318 274 TDI01319 >10000 TDI01324 1741 TDI01330 7934 TDI01331 >10000 TDI01332 6272 TDI01337 2760 TDI01338 1802 TDI01343 7107 TDI01344-2A 4208 TDI01345 3909 TDI01347 5584 TDI01354 >10000 TDI01355 >10000 TDI01360 1470 TDI01363 >10000 TDI01366 >10000 TDI01368 >10000 TDI01369 6792 TDI01370 1491 TDI01372 >10000 TDI01374 >10000 TDI01379 >10000 TDI01381 4114 TDI01390 456 TDI01392 >10000 TDI01393 >10000 TDI01394 >10000 TDI01397 5999 TDI01398 >10000 TDI01403 3000 TDI01404 1522 TDI01405 4062 TDI01408 5629 TDI01411 >10000 TDI01415 3715 TDI01418 5384 TDI01419 >10000 TDI01420 9294 TDI01421 5942 TDI01423 >10000 TDI01424 4975 TDI01425 2945 TDI01426 >10000 TDI01428 >10000 TDI01429 >10000 TDI01430 >10000 TDI01431 4343 TDI01433 1969 TDI01434 >10000 TDI01435 1225 TDI01437 >10000 TDI01438 >10000 TDI01439 >10000 TDI01441 6068 TDI01442 >10000 TDI01444 8258 TDI01445 3000 TDI01448 3000 TDI01450 >10000 TDI01455 >10000 TDI01456 >10000 TDI01457 4892 TDI01461 4526 TDI01462 3589 TDI01463 >10000 TDI01464 2283 TDI01465 >10000 TDI01467 >10000 TDI01470 >10000 TDI01472 >10000 TDI01473 592 TDI01477 1132 TDI01485 3993 TDI01486 2997 TDI01487 5044 TDI01490 2254 TDI01497 >10000 TDI01498 >10000 TDI01500 >10000 TDI01505 5672 TDI01506 7296 TDI01507 6837 TDI01508 >10000 TDI01512 3629 TDI01513 7418 TDI01514 2734 TDI01515 6855 TDI01517 >10000 TDI01518 3033 TDI01519 5239 TDI01520 >10000 TDI01523 1889 TDI01524 1416 TDI01525 >10000 TDI01532 >10000 TDI01534 >10000 TDI01536 >10000 TDI01538 4926 TDI01546 1550 TDI01550 >10000 TDI01551 1728 TDI01552 2946 TDI01555 >10000 TDI01557B >10000 TDI01559 >10000 TDI01560 >10000 TDI01561 >10000 TDI01562 >10000 TDI01564 >10000 TDI01565 >10000 TDI01567 >10000 TDI01567C >10000 TDI01570 >10000 TDI01575 >10000 TDI01578 >10000 TDI01580 3292 TDI01581 >10000 TDI01582 >10000 TDI01584 >10000 TDI01585 >10000 TDI01586 >10000 TDI01587 >10000 TDI01589 >10000 TDI01590 >10000 TDI01596 >10000 TDI01596B >10000 TDI01597B >10000 TDI01598 >10000 TDI01609 >10000 TDI01613 >10000 TDI01617 >10000 TDI01618A >10000 TDI01621 >10000 TDI01628 >10000 TDI01633 >10000 TDI01634 2038 TDI01655 >10000 TDI01656 >10000 TDI01658 >10000 TDI01668 >10000 TDI01675 >10000 TDI01676 >10000 TDI01678 >10000 TDI01681 >10000 TDI01683 >10000 TDI01690 >10000 TDI01691 159 TDI01813 >10000 TDI01816 6011 TDI01823 >10000 TDI01826 >10000 TDI01829B >10000 TDI01829C >10000 TDI01832 >10000 TDI01840 89 TDI01841 1000 TDI01842 3000 TDI01842B 2771 TDI01844 >10000 TDI01847B 3380 TDI01851 >10000 TDI01852 >10000 TDI01853 2826 TDI01855 5424 TDI01856 2036 TDI01861 >10000 TDI01862 >10000 TDI01864 3000 TDI01868 >10000 TDI01870 >10000 TDI01876B >10000 TDI01881 >10000 TDI01882 139 TDI01884 >10000 TDI01898 >10000 TDI01903 5578 TDI01905 2300 TDI01906 >10000 TDI01908 >10000 TDI01910 >10000 TDI01912 >10000 TDI01915 >10000 TDI01916 >10000 TDI01918 >10000 TDI01919 4065 TDI01920 >10000 TDI01921 >10000 TDI01923 >10000 TDI01932 >10000 TDI01936 >10000 TDI01937B >10000 TDI01940 >10000 TDI01943 >10000 TDI01944 >10000 TDI01945 >10000 TDI01947 >10000 TDI01948 >10000 TDI01949 >10000 TDI01950 >10000 TDI01951 >10000 TDI01952 >10000 TDI01953 >10000 TDI01954 >10000 TDI01955 >10000 TDI01957 >10000 TDI01958 >10000 TDI01959 >10000 TDI01960 >10000 TDI01962 >10000 TDI01965 >10000 TDI01966 >10000 TDI01967 >10000 TDI01968A >10000 TDI01973 >10000 TDI01974 >10000 TDI01976 >10000 TDI01978 >10000 TDI01979 >10000 TDI01989 >10000 TDI01991 >10000 TDI01999 >10000

According to the above data, the IC₅₀ values of the tested compounds on ROCK2 are significantly lower than those on ROCK1, indicating the compound of the present invention has good selectivity towards ROCK2.

Various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. Each reference, including all patents, applications, journal articles, books and any other disclosure, referred to herein is hereby incorporated by reference in its entirety. 

1-18. (canceled)
 19. A compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein the compound has the structure of Formula (I):

wherein: X and Y are each independently selected from the group consisting of a direct bond, C(═O), O, S(═O)_(i) and NR, provided that at least one of X and Y is not a direct bond; R is selected from the group consisting of H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, saturated or partially unsaturated C₃₋₁₀ cyclic hydrocarbyl, saturated or partially unsaturated 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl, and at most 2 ring members in the cyclic hydrocarbyl and heterocyclyl are C(═O); ring A and ring B are each independently selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O); provided that when ring B is a heterocycle containing a nitrogen atom, ring B is not attached to X via the nitrogen atom; ring C is selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O); ring D is absent, or is selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O); ring E is selected from the group consisting of

ring F is selected from the group consisting of saturated or partially unsaturated C₃₋₁₀ hydrocarbon ring, saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aromatic ring and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the hydrocarbon ring and heterocycle are C(═O); R¹ is selected from the group consisting of H, —NH₂, C₁₋₆ alkyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, N-methylpyrrolidinyl, N-methylpiperidinyl,

—C(═O)—(C₁₋₆ alkylene)_(n)-CF₃, —C(═O)—(C₁₋₆ alkylene)_(n)-CN, —C(═O)-(saturated or partially unsaturated C₃₋₁₀ cyclic hydrocarbyl), —NHC(═O)-(saturated or partially unsaturated C₃₋₁₀ cyclic hydrocarbyl), —C(═O)-(saturated or partially unsaturated 3- to 10-membered heterocyclyl), —C(═O)—C₁₋₆ alkylene-(saturated or partially unsaturated 3- to 10-membered heterocyclyl), —C(═O)-(5- to 14-membered heteroaryl), —C(═O)—C₁₋₆ alkylene-NH(C₁₋₆ alkyl), —C(═O)—C₁₋₆ alkylene-N(C₁₋₆ alkyl)₂, N-methylpiperazine substituted acetyl, —S(═O)₂R^(1a), —P(═O)R^(1a)R^(1b),

provided that when one of R¹ and R¹⁰ is C₁₋₆ alkyl, and the other is FI or C₃₋₁₀ cyclic hydrocarbyl, then at least one of X and Y is a direct bond, and ring C is not a 5-membered heteroaromatic ring; when one of R¹ and R¹⁰ is H, and the other is

then ring C is not a 5-membered heteroaromatic ring; when both R¹ and R¹⁰ are H, then ring A contains at least one nitrogen atom, and is not a 5- or 6-membered ring; when one of R¹ and R¹⁰ is H, and the other is

then ring C is not a 5-membered heteroaromatic ring; and when one of R¹ and R¹⁰ is H, and the other is FI or acetyl, then ring D is absent; R^(1a) and R^(1b) are each independently selected from the group consisting of H, halogen, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶, —C₁₋₆ alkylene-OR⁵ and —O—C₁₋₆ alkylene-NR⁵R⁶, provided that when one of R^(1a) and R^(1b) is n-propyl, the other is not H; or R^(1a) and R^(1b) together with the atom to which they are attached form a 3- to 12-membered heterocycle or heteroaromatic ring; R², R³, R⁴, R⁷, R⁸, R⁹ and R¹⁰, at each occurrence, are each independently selected from the group consisting of H, halogen, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶, —C₁₋₆ alkylene-O(P═O)(OH)₂ and —O—C₁₋₆ alkylene-NR⁵R⁶; the above alkyl, alkylene, alkenyl, alkynyl, cyclic hydrocarbyl, hydrocarbon ring, heterocyclyl, heterocycle, aryl, aromatic ring, heteroaryl, heteroaromatic ring and aralkyl, at each occurrence, are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, oxo, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₆ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, ═N—OR⁵, —C(═NH)NH₂, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶ and —O—C₁₋₆ alkylene-NR⁵R⁶, and the alkyl, cyclic hydrocarbyl, heterocyclyl, aryl, heteroaryl and aralkyl are further optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, oxo, amino, cyano, nitro, C₁₋₆ alkyl, C₃₋₆ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl; R⁵ and R⁶, at each occurrence, are each independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl; m, at each occurrence, is each independently an integer selected from 0, 1, 2 and 3; n is an integer selected from 0, 1 and 2; i is an integer selected from 0, 1 and 2; and g is an integer selected from 0, 1, 2, 3 and
 4. 20. The compound according to claim 19, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein X and Y are each independently selected from the group consisting of a direct bond, C(═O), O, S, S(═O), S(═O)₂, NH and NCH₃, and at least one of X and Y is a direct bond, provided that at least one of X and Y is not a direct bond.
 21. The compound according to claim 19, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein

the above group is attached to X at either of the two positions labeled # or ##, and is attached to R¹ at the other position, wherein:

represents either a single or a double bond, and the adjacent bonds are not double bonds simultaneously; Z¹, Z², Z³, Z⁴, Z⁵, Z⁶, Z⁷, Z⁸ and Z⁹, at each occurrence, are each independently selected from the group consisting of C, CR⁹, C(R⁹)₂, CR¹⁰, C(R¹⁰)₂, C(═O), N, NR⁹, NR¹⁰, O and S; and j is 0, 1, 2, 3 or 4; provided that at most two groups among Z¹-Z⁹ are simultaneously C(═O), and the atom attached to X is not a nitrogen atom; R⁹ and R¹⁰, at each occurrence, are each independently selected from the group consisting of halogen, methyl, ethyl, propyl, vinyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, monofluoromethyl, difluoromethyl, trifluoromethyl, —CH₂CHF₂, acetyl, —OCH₃, —CH₂OH, —CH₂OCH₃, —CH₂CH₂OCH₃, —CH₂—O(P═O)(OH)₂,

and —CH₂CH₂—N(CH₃)₂
 22. The compound according to claim 19, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein

R⁷ and R⁸, at each occurrence, are each independently selected from the group consisting of F, Cl, Br, I, cyano, —N(CH₃)₂, methyl, ethyl, propyl, methoxy, trifluoromethyl, phenyl, —CH₂-Ph, —NH-Ph, —O-Ph, —CH₂OCH₃, —CH₂NH₂, —CH₂—NHCH₃, —C(═O)CH₃, —C(═O)OH, —C(═O)OCH₂CH₃, —C(═O)NH₂, —O—CH₂CH₂—N(CH₃)₂ and —CH₂CH₂—N(CH₃)₂
 23. The compound according to claim 19, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein ring E is

R³ and R⁴, at each occurrence, are each independently selected from the group consisting of H, F, Cl, Br, I, —OH, methyl, ethyl, propyl, methoxy, —NH₂, —N(CH₃)₂, and —O-ethylene-N(CH₃)₂.
 24. The compound according to claim 19, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein R¹ is selected from the group consisting of methyl, —CH₂OH,

—C(═O)CF₃, —C(═O)CH₂CF₃, —C(═O)CH₂CN, —C(═O)OCH₃, —C(═O)OC(CH₃)₃,

—S(═O)₂CH₂CH₃,

—C(═O)CH₂N(CH₃)₂,


25. The compound according to claim 19, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein R^(1a) and R^(1b) are each independently selected from the group consisting of H, methyl, —CF₃, ethyl, —CH₂CF₃, —CH₂CH₂CF₃, —CH(CH₃)CF₃, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -ethylene-O-methyl, —CH₂CN, —CH₂CH₂CN, —CH₂CH₂OH,

or R^(1a) and R^(1b) together with the atom to which they are attached form a group selected from the group consisting of:


26. The compound according to claim 19, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein the compound has a structure selected from the group consisting of the following formulae:

wherein: Z is selected from the group consisting of O, S(═O)_(i) and NR; ring A′ and ring B′ are each independently selected from the group consisting of saturated or partially unsaturated 3- to 10-membered heterocycles and 5- to 14-membered heteroaromatic rings, and at most 2 ring members in the heterocycle are C(═O); provided that when ring B′ is a heterocycle containing a nitrogen atom, ring B′ is not attached to X via the nitrogen atom; R^(7′) is selected from the group consisting of H, halogen, —NH₂, —OH, C₁₋₆ alkyl and —OR⁵; R¹¹ is selected from the group consisting of H, halogen, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶ and —O—C₁₋₆ alkylene-NR⁵R⁶; and each of the remaining groups is as defined in claim
 19. 27. The compound according to claim 19, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein the compound has the structure of formula (XVII) or formula (XVIF):

wherein: R is selected from the group consisting of H and C₁₋₆ alkyl; ring D is selected from the group consisting of a saturated or partially unsaturated 3- to 10-membered heterocycle, C₆₋₁₀ aryl and a 5- to 10-membered heteroaromatic ring; R² is selected from the group consisting of H and C₁₋₆ alkyl; R³, R⁴, R⁷, R^(7′) and R⁸, at each occurrence, are each independently selected from the group consisting of H, halogen, —NH₂, —OH, C₁₋₆ alkyl and —OR⁵; R⁹ and R¹⁰, at each occurrence, are each independently selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵ and —C₁₋₆ alkylene-O(P═O)(OH)₂; wherein any of the above alkyl, alkenyl, cyclic hydrocarbyl, heterocyclyl, aryl, heteroaryl, heteroaromatic ring and aralkyl, at each occurrence, are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C₁₋₆ alkyl and —OR⁵; R⁵ and R⁶, at each occurrence, are each independently selected from the group consisting of H, C₁₋₆ alkyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl and C₆₋₁₂ aralkyl; m, at each occurrence, is independently an integer selected from 0, 1, 2 and 3; and n is an integer selected from 0, 1 and
 2. 28. The compound according to claim 19, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein the compound is selected from the group consisting of: No. Structural Formula TDI01102

TDI01103

TDI01104

TDI01105

TDI01106

TDI01107

TDI01108

TDI01109

TDI01110

TDI01111

TDI01112

TDI01113

TDI01114

TDI01115

TDI01116

TDI01117

TDI01118

TDI01119

TDI01120

TDI01121

TDI01122

TDI01127

TDI01128

TDI01129

TDI01130

TDI01131

TDI01132

TDI01133

TDI01134

TDI01135

TDI01136

TDI01139

TDI01140

TDI01141

TDI01142

TDI01143

TDI01144

TDI01145

TDI01146

TDI01147

TDI01148

TDI01149

TDI01150

TDI01151

TDI01152

TDI01153

TDI01154

TDI01155

TDI01156

TDI01157

TDI01158

TDI01159

TDI01160

TDI01161

TDI01162

TDI01163

TDI01164

TDI01165

TDI01166

TDI01167

TDI01168

TDI01169

TDI01171

TDI01172

TDI01173

TDI01174

TDI01175

TDI01176

TDI01177

TDI01178

TDI01179

TDI01180

TDI01181

TDI01182

TDI01183

TDI01184

TDI01185

TDI01186

TDI01187

TDI01188

TDI01189

TDI01190

TDI01191

TDI01192

TDI01193

TDI01194

TDI01195

TDI01196

TDI01197

TDI01198

TDI01199

TDI01200

TDI01201

TDI01209

TDI01211

TDI01212

TDI01213

TDI01214

TDI01215

TDI01216

TDI01217

TDI01218

TDI01219

TDI01220

TDI01211

TDI01222

TDI01223

TDI01224

TDI01225

TDI01226

TDI01227

TDI01228

TDI01229

TDI01230

TDI01231

TDI01232

TDI01233

TDI01234

TDI01235

TDI01236

TDI01237

TDI01238

TDI01239

TDI01240

TDI01241

TDI01242

TDI01243

TDI01244

TDI01245

TDI01246

TDI01247

TDI01248

TDI01249

TDI01250

TDI01251

TDI01253

TDI01254

TDI01255

TDI01256

TDI01257

TDI01258

TDI01259

TDI01260

TDI01261

TDI01262

TDI01263

TDI01264

TDI01265

TDI01266

TDI01267

TDI01268

TDI01271

TDI01272

TDI01273

TDI01274

TDI01275

TDI01276

TDI01277

TDI01278

TDI01280

TDI01281

TDI01282

TDI01283

TDI01285

TDI01286

TDI01287

TDI01288

TDI01289

TDI01290

TDI01291

TDI01292

TDI01294

TDI01295

TDI01296

TDI01297

TDI01298

TDI01299

TDI01300

TDI01310

TDI01311

TDI01312

TDI01314

TDI01315

TDI01316

TDI01317

TDI01318

TDI01319

TDI01320

TDI01321

TDI01322

TDI01323

TDI01324

TDI01325

TDI01326

TDI01327

TDI01328

TDI01329

TDI01330

TDI01331

TDI01332

TDI01333

TDI01334

TDI01335

TDI01336

TDI01337

TDI01338

TDI01339

TDI01340

TDI01341

TDI01342

TDI01343

TDI01344

TDI01345

TDI01346

TDI01347

TDI01348

TDI01348P-2

TDI01350

TDI01351

TDI01353

TDI01354

TDI01355

TDI01356

TDI01357

TDI01358

TDI01360

TDI01360P-1

TDI01361

TDI01362

TDI01363

TDI01364

TDI01365

TDI01366

TDI01367

TDI01368

TDI01369

TDI01370

TDI01371

TDI01372

TDI01373

TDI01374

TDI01375

TDI01376

TDI01379

TDI01380

TDI01381

TDI01382

TDI01383

TDI01384

TDI01385

TDI01386

TDI01387

TDI01388

TDI01389

TDI01399

TDI01391

TDI01392

TDI01393

TDI01394

TDI01395

TDI01396

TDI01397

TDI01398

TDI01399

TDI01400

TDI01402

TDI01344-2A

TDI01403

TDI01404

TDI01405

TDI01406

TDI01407

TDI01408

TDI01410

TDI01411

TDI01415

TDI01416

TDI01417

TDI01418

TDI01419

TDI01420

TDI01421

TDI01422

TDI01423

TDI01424

TDI01425

TDI01426

TDI01427

TDI01428

TDI01429

TDI01430

TDI01431

TDI01432

TDI01433

TDI01434

TDI01435

TDI01436

TDI01437

TDI01438

TDI01439

TDI01440

TDI01441

TDI01442

TDI01443

TDI01444

TDI01445

TDI01446

TDI01447

TDI01448

TDI01449

TDI01450

TDI01451

TDI01452

TDI01453

TDI01454

TDI01455

TDI01456

TDI01457

TDI01458

TDI01459

TDI01460

TDI01461

TDI01462

TDI01463

TDI01464

TDI01465

TDI01466

TDI01467

TDI01468

TDI01469

TDI01470

TDI01471

TDI01472

TDI01473

TDI01474

TDI01475

TDI01476

TDI01477

TDI01478

TDI01479

TDI01480

TDI01481

TDI01482

TDI01483

TDI01484

TDI01485

TDI01486

TDI01487

TDI01488

TDI01489

TDI01490

TDI01491

TDI01492

TDI01493

TDI01494

TDI01495

TDI01496

TDI01497

TDI01498

TDI01499

TDI01500

TDI01501

TDI01502

TDI01503

TDI01504

TDI01505

TDI01506

TDI01507

TDI01508

TDI01509

TDI01510

TDI01511

TDI01512

TD101513

TDI01514

TDI01515

TDI01516

TDI01517

TDI01518

TDI01519

TDI01520

TDI01521

TDI01522

TDI01523

TDI01524

TDI01525

TDI01526

TDI01529

TDI01530

TDI01531

TDI01532

TDI01533

TDI01534

TDI01535

TDI01536

TDI01537

TDI01538

TDI01543

TDI01544

TDI01545

TDI01546

TDI01547

TDI01550

TDI01551

TDI01552

TDI-1553

TDI01554

TDI01555

TDI01556

TDI01557

TDI01557B

TDI01558

TDI01559

TDI01560

TDI01561

TDI01562

TDI01563

TDI01564

TDI01565

TDI01566

TDI01567

TDI01567B

TDI01567C

TDI01569

TDI01570

TDI01571

TDI01571B

TDI01572

TDI01573

TDI01574

TDI01575

TDI01578

TDI01579

TDI01580

TDI01581

TDI01582

TDI01583

TDI01584

TDI01585

TDI01586

TDI01587

TDI01588

TDI01589

TDI01590

TDI01591

TDI01592

TDI01593

TDI01594

TDI01594B

TDI01596

TDI01596B

TDI01597

TDI01597B

TDI01598

TDI01609

TDI01611

TDI01613

TDI01615

TDI01617

TDI01618A

TDI01620

TDI01621

TDI01622

TDI01623

TDI01628

TDI01633

TDI01634

TDI01653

TDI01654

TDI01655

TDI01656

TDI01657

TDI01658

TDI01659

TDI01662

TDI01665

TDI01666

TDI01667

TDI01668

TDI01670

TDI01672

TDI01673

TDI01674

TDI01675

TDI01676

TDI01678

TDI01681

TDI01682

TDI01683

TDI01684

TDI01689

TDI01690

TDI01691

TDI01692

TDI01693

TDI01694

TDI01695

TDI01698

TDI01706

TDI01708

TDI01709

TDI01710

TDI01712

TDI01714

TDI01715

TDI01721

TDI01801

TDI01802

TDI01803

TDI01804

TDI01806

TDI01807

TDI01808

TDI01809

TDI01810

TDI01811

TDI01812

TDI01813

TDI01814

TDI01815

TDI01816

TDI01816B

TDI01818

TDI01819

TDI01820

TDI01821

TDI01822

TDI01823

TDI01824

TDI01825

TDI01825B

TDI01825C

TDI01826

TDI01827

TDI01829

TDI01829B

TDI01829C

TDI01830

TDI01831

TDI01832

TDI01833

TDI01834

TDI01835

TDI01836

TDI01837

TDI01838

TDI01839

TDI01840

TDI01841

TDI01842

TDI01842B

TDI01843

TDI01844

TDI01845

TDI01846

TDI01847

TDI01847B

TDI01848

TDI01849

TDI01849B

TDI01850

TDI01851

TDI01852

TDI01853

TDI01854

TDI01855

TDI01856

TDI01861

TDI01862

TDI01863

TDI01864

TDI01865

TDI01867

TDI01868

TDI01869

TDI01870

TDI01871

TDI01872

TDI01873

TDI01874

TDI01875

TDI01876

TDI01876B

TDI01877

TDI01878

TDI01879

TDI01880

TDI01881

TDI01882

TDI01883

TDI01884

TDI01885

TDI01886

TDI01887

TDI01888

TDI01890

TDI01891

TDI01892

TDI01893

TDI01894

TDI01898

TDI01898B

TDI01899

TDI01900

TDI01901

TDI01902

TDI01903

TDI01904

TDI01905

TDI01906

TDI01907

TDI01908

TDI01909

TDI01910

TDI01911

TDI01912

TDI01913

TDI01914

TDI01915

TDI01916

TDI01917

TDI01918

TDI01919

TDI01920

TDI01921

TDI01923

TDI01924

TDI01925

TDI01926

TDI01927

TDI01928

TDI01929

TDI01930

TDI01931

TDI01932

TDI01933

TDI01934

TDI01935

TDI01936

TDI01937B

TDI01938

TDI01939

TDI01940

TDI01941

TDI01942

TDI01943

TDI01944

TDI01945

TDI01946

TDI01947

TDI01948

TDI01949

TDI01950

TDI01951

TDI01952

TDI01953

TDI01954

TDI01955

TDI01956

TDI01957

TDI01958

TDI01959

TDI01960

TDI01962

TDI01965

TDI01966

TDI01967

TDI01968A

TDI01968B

TDI01969

TDI01972

TDI01973

TDI01974

TDI01975

TDI01976

TDI01978

TDI01979

TDI01989

TDI01990

TDI01991

TDI01995

TDI01996

TDI01998

and TDI01999


29. A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the compound according to claim 19 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound.
 30. A method of inhibiting a Rho-associated protein kinase (ROCK), preferably ROCK2, comprising administering an effective amount of the compound according to claim 19 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof to a subject in need thereof.
 31. A method for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK), comprising administering an effective amount of the compound according to claim 19 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, to a subject in need thereof, wherein the disease is selected from an autoimmune disorder selected from rheumatoid arthritis, systemic lupus erythematosus (SLE; lupus), psoriasis, Crohn's disease, atopic dermatitis, eczema, and graft-versus-host disease (GVHD); a cardiovascular disorder selected from hypertension, atherosclerosis, restenosis, cardiac hypertrophy, cerebral ischemia, cerebral vasospasm, or erectile dysfunction); inflammation (associated with or comprising asthma, cardiovascular inflammation, ulcerative colitis, and renal inflammation); a central nervous system disorder selected from neuronal degeneration or spinal cord injury; or a central nervous system disorder selected from Huntington's disease, Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), or multiple sclerosis; an arterial thrombotic disorder selected from platelet aggregation, and leukocyte aggregation; a fibrotic disorder selected from liver fibrosis, lung fibrosis, and kidney fibrosis; a neoplastic disease or cancer; a metabolic syndrome; insulin resistance; hyperinsulinemia; type 2 diabetes; glucose intolerance; osteoporosis; an ocular disorder selected from ocular hypertension, age related macular degeneration (AMD), choroidal neovascularization (CNV), diabetic macular edema (DME), iris neovascularization, uveitis, glaucoma (including primary open-angle glaucoma, acute angle-closure glaucoma, pigmentary glaucoma, congenital glaucoma, normal tension glaucoma, secondary glaucoma or neo vascular glaucoma), or retinitis of prematurity (ROP).
 32. A method for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK), comprising administering an effective amount of the compound according to claim 19 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof to a subject in need thereof, wherein the disease is selected from lupus nephritis, atherosclerosis, rheumatoid arthritis (RA), hemangioma, angiofibroma, lung fibrosis, psoriasis, corneal graft rejection, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, Crohn's disease, autoimmune nephritis, primary biliary cirrhosis, acute pancreatitis, allograft rejection, allergic inflammation, contact dermatitis, delayed hypersensitivity, inflammatory bowel disease, septic shock, osteoporosis, osteoarthritis, neuronal inflammation, Osier-Weber syndrome, restenosis, fungal infection, parasitic infection and viral infection.
 33. A method for the preparation of a compound of Formula (II), wherein the method comprises the following steps:

wherein: R² is H; Hal¹ and Hal² are same or different halogens; PG¹ is a carboxy protecting group; PG² is H or an amino protecting group; R^(a) and R^(a′), at each occurrence, are each independently selected from the group consisting of H and C₁₋₆ alkyl; or R^(a) and R^(a′) together with the group to which they are attached form a 5- to 10-membered ring system; the remaining groups are as defined in claim 19; the reaction conditions for each step are as follows: step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst, to obtain compound b-1; step 2: reacting compound b-1 with compound REG-1 under the catalysis of a palladium catalyst, to obtain compound c-1; and step 3: reacting compound c-1 with compound REG-2, to obtain the compound of Formula (II); alternatively, the method comprises the following steps:

wherein each of the groups is as defined above; the reaction conditions for each step are as follows: step 1: reacting compound a-2 with compound REG-2, to obtain compound b-2; step 2: reacting compound b-2 with a boric acid or borate under the catalysis of a palladium catalyst, to obtain compound c-2; and step 3: reacting compound c-2 with compound REG-1 under the catalysis of a palladium catalyst, to obtain the compound of Formula (II); or alternatively, the method comprises the following steps:

wherein each of the groups is as defined above; the reaction conditions for each step are as follows: step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst, to obtain compound b-1; step 2: deprotecting compound b-1 under a condition corresponding to PG¹, to obtain compound c-3; step 3: reacting compound c-3 with compound REG-2, to obtain compound d-3; and step 4: reacting compound d-3 with compound REG-1 under the catalysis of a palladium catalyst, to obtain the compound of Formula (II).
 34. A method for the preparation of a compound of Formula (XII), wherein the method comprises the following steps:

wherein: R² is H; Hal¹ and Hal² are same or different halogens; PG¹ is a carboxy protecting group; PG² is H or an amino protecting group; R^(a) and R^(a′), at each occurrence, are each independently selected from the group consisting of H and C₁₋₆ alkyl; or R^(a) and R^(a′) together with the group to which they are attached form a 5- to 10-membered ring system; the remaining groups are as defined in claim 19; the reaction conditions for each step are as follows: step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst, to obtain compound b-1; step 2: reacting compound b-1 with compound REG-1′ under the catalysis of a palladium catalyst, to obtain compound c-1′; and step 3: reacting compound c-1′ with compound REG-2′, to obtain the compound of Formula (XII).
 35. A method for the preparation of a compound of Formula (XIII), wherein the

wherein: R² is H; Hal¹ and Hal² are same or different halogens; PG¹ is a carboxy protecting group; PG² is H or an amino protecting group; R^(a) and R^(a′), at each occurrence, are each independently selected from the group consisting of H and C₁₋₆ alkyl; or R^(a) and R^(a′) together with the group to which they are attached form a 5- to 10-membered ring system; the remaining groups are as defined in claim 19; the reaction conditions for each step are as follows: step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst, to obtain compound b-1; step 2: reacting compound b-1 with compound REG-1 under the catalysis of a palladium catalyst, to obtain compound c-1; and step 3: reacting compound c-1 with compound REG-2′, to obtain the compound of Formula (XIII).
 36. A method for the preparation of a compound of Formula (XIV), wherein the method comprises the following steps:

wherein: R² is H; Hal¹ and Hal² are same or different halogens; PG¹ is a carboxy protecting group; PG² is FI or an amino protecting group; R^(a) and R^(a′), at each occurrence, are each independently selected from the group consisting of H and C₁₋₆ alkyl; or R^(a) and R^(a′) together with the group to which they are attached form a 5- to 10-membered ring system; the remaining groups are as defined in claim 19; the reaction conditions for each step are as follows: step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst, to obtain compound b-1; step 2: reacting compound b-1 with compound REG-1′ under the catalysis of a palladium catalyst, to obtain compound c-1′; and step 3: reacting compound c-1′ with compound REG-2, to obtain the compound of Formula (XIV); or alternatively, the method comprises the following steps:

wherein each of the groups is as defined above; the reaction conditions for each step are as follows: step 1: reacting compound a-2 with compound REG-2, to obtain compound b-2; step 2: reacting compound b-2 with a boric acid or borate under the catalysis of a palladium catalyst, to obtain compound c-2; and step 3: reacting compound c-2 with compound REG-1′ under the catalysis of a palladium catalyst, to obtain the compound of Formula (XIV); or alternatively, the method comprises the following steps:

wherein each of the groups is as defined above; the reaction conditions for each step are as follows: step 1: reacting compound a-1 with a boric acid or borate under the catalysis of a palladium catalyst, to obtain compound b-1; step 2: deprotecting compound b-1 under a condition corresponding to PG¹, to obtain compound c-3; step 3: reacting compound c-3 with compound REG-2, to obtain compound d-3; and step 4: reacting compound d-3 with compound REG-1′ under the catalysis of a palladium catalyst, to obtain the compound of Formula (XIV).
 37. The compound according to claim 21, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein Z¹, Z², Z³, Z⁴, Z⁵, Z⁶, Z⁷, Z⁸ and Z⁹, at each occurrence, are each independently selected from the group consisting of C, CH, CF, CCl, CCH₃, CH₂, C(CH₃)₂, C—OCH₃, C(═O), N, NH, NCH₃, NCH₂CH₃, NCH(CH₃)₂, NCH═CH₂, NCH₂F, NCHF₂, NCH₂CHF₂, NC(═O)CH₃, NCH₂OH, NCH₂OMe, NCH₂CH₂OMe, NCH₂—O(P═O)(OH)₂,

NCH₂CH₂—N(CH₃)₂, O and S.
 38. The compound according to claim 21, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein

the above group is attached to X at either of the two positions labeled # or ##, and is attached to R¹ at the other position, wherein:

represents either a single or a double bond, and the adjacent bonds are not double bonds simultaneously; Z¹, Z², Z³, Z⁴, Z⁵, Z⁶, Z⁷, Z⁸ and Z⁹, at each occurrence, are each independently selected from the group consisting of C, CR⁹, C(R⁹)₂, CR¹⁰, C(R¹⁰)₂, C(═O), N, NR⁹, NR¹⁰, O and S; and j is 0, 1, 2, 3 or 4; provided that at most two groups among Z¹-Z⁹ are simultaneously C(═O), and the atom attached to X is not a nitrogen atom.
 39. The compound according to claim 38, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein Z¹, Z², Z³, Z⁴, Z⁵, Z⁶, Z⁷, Z⁸ and Z⁹, at each occurrence, are each independently selected from the group consisting of C, CH, CF, CCl, CCH₃, CH₂, C(CH₃)₂, C—OCH₃, C(═O), N, NH, NCH₃, NCH₂CH₃, NCH(CH₃)₂, NCH═CH₂, NCH₂F, NCHF₂, NCH₂CHF₂, NC(═O)CH₃, NCH₂OH, NCH₂OMe, NCH₂CH₂OMe, NCH₂—O(P═O)(OH)₂,

NCH₂CH₂—N(CH₃)₂, O and S.
 40. The compound according to claim 21, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein at least one of ring A and ring B is selected from the group consisting of saturated or partially unsaturated 3- to 10-membered heterocycle and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the heterocycle are C(═O).
 41. The compound according to claim 21, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein

wherein ring A′ and ring B′ are each independently selected from the group consisting of saturated or partially unsaturated 3- to 10-membered heterocycle and 5- to 14-membered heteroaromatic ring, and at most 2 ring members in the heterocycle are C(═O); provided that when ring B′ is a heterocycle containing a nitrogen atom, ring B′ is not attached to X via the nitrogen atom.
 42. The compound according to claim 41, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein


43. The compound according to claim 41, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein


44. The compound according to claim 21, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein

is selected from the group consisting of

the above group is attached to X at either of the two positions labeled # or ##, and is attached to R¹ at the other position, provided that the atom attached to X is not a nitrogen atom.
 45. The compound according to claim 22, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein

the above group is attached to Y at either of the two positions labeled * or **, and is attached to X at the other position, wherein:

represents either a single or a double bond, and the adjacent bonds are not double bonds simultaneously; V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸ and V⁹, at each occurrence, are each independently selected from the group consisting of C, CR⁷, C(R⁷)₂, CR⁸, C(R⁸)₂, C(═O), N, NR⁷, NR⁸, O and S; and k is 0, 1, 2, 3 or 4; provided that at most two groups among V¹-V⁹ are simultaneously C(═O).
 46. The compound according to claim 22, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein

the above group is attached to Y at either of the two positions labeled * or **, and is attached to X at the other position, wherein:

represents either a single or a double bond, and the adjacent bonds are not double bonds simultaneously; V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸ and V⁹, at each occurrence, are each independently selected from the group consisting of C, CR⁷, C(R⁷)₂, CR⁸, C(R⁸)₂, C(═O), N, NR⁷, NR⁸, O and S; and k is 0, 1, 2, 3 or 4; provided that at most two groups among V¹-V⁹ are simultaneously C(═O).
 47. The compound according to claim 45, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸ and V⁹, at each occurrence, are each independently selected from the group consisting of C, CH, CF, CCl, CCN, CCH₃, C—OCH₃, CCF₃, C—CH₂-Ph, C—NH-Ph, C—O-Ph, C—CH₂OCH₃, C—CH₂—NHCH₃, C—N(CH₃)₂, C—CH₂NH₂, C—C(═O)OH, C—C(═O)OCH₂CH₃, C—C(═O)NH₂, —CO—CH₂CH₂—N(CH₃)₂, CH₂, C(═O), N, NH, NCH₃, N—C(═O)CH₃, N-Ph, —N—CH₂CH₂—N(CH₃)₂, O and S.
 48. The compound according to claim 46, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸ and V⁹, at each occurrence, are each independently selected from the group consisting of C, CH, CF, CCl, CCN, CCH₃, C—OCH₃, CCF₃, C—CH₂-Ph, C—NH-Ph, C—O-Ph, C—CH₂OCH₃, C—CH₂—NHCH₃, C—N(CH₃)₂, C—CH₂NH₂, C—C(═O)OH, C—C(═O)OCH₂CH₃, C—C(═O)NH₂, —CO—CH₂CH₂—N(CH₃)₂, CH₂, C(═O), N, NH, NCH₃, N—C(═O)CH₃, N-Ph, —N—CH₂CH₂—N(CH₃)₂, O and S.
 49. The compound according to claim 22, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein


50. The compound according to claim 22, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein


51. The compound according to claim 22, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein

is selected from the group consisting of

the above group is attached to Y at either of the two positions labeled * or **, and is attached to X at the other position.
 52. The compound according to claim 23, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein ring E is


53. The compound according to claim 23, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein ring E is selected from the group consisting of


54. The compound according to claim 24, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein

wherein R¹¹ is selected from the group consisting of H, halogen, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶ and —O—C₁₋₆, alkylene-NR⁵R⁶.
 55. The compound according to claim 24, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein R¹ is selected from the group consisting of

wherein R¹¹ is selected from the group consisting of H, halogen, amino, cyano, nitro, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cyclic hydrocarbyl, 3- to 10-membered heterocyclyl, C₆₋₁₀ aryl, 5- to 14-membered heteroaryl, C₆₋₁₂ aralkyl, —C(═O)R⁵, —OC(═O)R⁵, —C(═O)OR⁵, —OR⁵, —SR⁵, —S(═O)R⁵, —S(═O)₂R⁵, —S(═O)₂NR⁵R⁶, —NR⁵R⁶, —C(═O)NR⁵R⁶, —NR⁵—C(═O)R⁶, —NR⁵—C(═O)OR⁶, —NR⁵—S(═O)₂—R⁶, —NR⁵—C(═O)—NR⁵R⁶, —C₁₋₆ alkylene-NR⁵R⁶ and —O—C₁₋₆ alkylene-NR⁵R⁶.
 56. The compound according to claim 25, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein R^(1a) and R^(1b) together with the atom to which they are attached form a group selected from the group consisting of


57. The compound according to claim 27, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, or an isotopically labeled compound thereof, wherein ring D is selected from the group consisting of

phenyl ring, N-methylpyrrole ring, furan ring and thiophene ring.
 58. The method of claim 31, wherein the cancer is selected from lymphoma, carcinoma, squamous cell cancer, small-cell lung cancer, pituitary cancer, esophageal cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, liver cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, prostate cancer, vulval cancer, thyroid cancer, brain cancer, endometrial cancer, testis cancer, cholangiocarcinoma, gallbladder carcinoma, gastric cancer, melanoma, head and neck cancer, leukemia, astrocytoma, soft tissue sarcoma, sarcoma, and blastoma. 